{"PMC7292936": [], "de1c5a16a75d5c28d9e3a9be2e928406fee458e4": [["TRIM25 is an E3 ubiquitin ligase enzyme that is involved in various cellular processes, including regulation of the innate immune response against viruses.", [["cellular", "ANATOMY", 68, 76], ["TRIM25", "GENE_OR_GENE_PRODUCT", 0, 6], ["E3", "GENE_OR_GENE_PRODUCT", 13, 15], ["cellular", "CELL", 68, 76], ["TRIM25", "PROTEIN", 0, 6], ["E3 ubiquitin ligase enzyme", "PROTEIN", 13, 39], ["an E3 ubiquitin ligase enzyme", "TEST", 10, 39], ["various cellular processes", "PROBLEM", 60, 86], ["viruses", "PROBLEM", 147, 154], ["ubiquitin ligase", "OBSERVATION", 16, 32], ["cellular processes", "OBSERVATION", 68, 86]]], ["TRIM25-mediated ubiquitination of the cytosolic pattern recognition receptor RIG-I is an essential step for initiation of the intracellular antiviral response and has been thoroughly documented.", [["cytosolic", "ANATOMY", 38, 47], ["intracellular", "ANATOMY", 126, 139], ["TRIM25", "GENE_OR_GENE_PRODUCT", 0, 6], ["RIG-I", "GENE_OR_GENE_PRODUCT", 77, 82], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["TRIM25", "PROTEIN", 0, 6], ["cytosolic pattern recognition receptor", "PROTEIN", 38, 76], ["RIG-I", "PROTEIN", 77, 82], ["TRIM25", "TREATMENT", 0, 6], ["the intracellular antiviral response", "TREATMENT", 122, 158], ["antiviral response", "OBSERVATION", 140, 158]]], ["In recent years, however, additional roles of TRIM25 in early innate immunity are emerging, including negative regulation of RIG-I, activation of the melanoma differentiationassociated protein 5-mitochondrial antiviral signaling protein-TRAF6 antiviral axis and modulation of p53 levels and activity.", [["mitochondrial", "ANATOMY", 195, 208], ["TRIM25", "GENE_OR_GENE_PRODUCT", 46, 52], ["RIG-I", "GENE_OR_GENE_PRODUCT", 125, 130], ["melanoma differentiationassociated protein 5", "GENE_OR_GENE_PRODUCT", 150, 194], ["mitochondrial", "CELLULAR_COMPONENT", 195, 208], ["TRAF6", "GENE_OR_GENE_PRODUCT", 237, 242], ["p53", "GENE_OR_GENE_PRODUCT", 276, 279], ["TRIM25", "PROTEIN", 46, 52], ["RIG-I", "PROTEIN", 125, 130], ["melanoma differentiationassociated protein 5", "PROTEIN", 150, 194], ["mitochondrial antiviral signaling protein", "PROTEIN", 195, 236], ["TRAF6", "PROTEIN", 237, 242], ["p53", "PROTEIN", 276, 279], ["TRIM25", "TREATMENT", 46, 52], ["the melanoma differentiationassociated protein", "TEST", 146, 192], ["mitochondrial antiviral signaling protein", "TEST", 195, 236], ["TRAF6 antiviral axis", "TREATMENT", 237, 257], ["p53 levels", "TEST", 276, 286], ["melanoma", "OBSERVATION", 150, 158], ["antiviral axis", "OBSERVATION", 243, 257], ["p53 levels", "OBSERVATION", 276, 286]]], ["In addition, the ability of TRIM25 to bind RNA may uncover new mechanisms by which this molecule regulates intracellular signaling and/ or RNA virus replication.", [["intracellular", "ANATOMY", 107, 120], ["TRIM25", "GENE_OR_GENE_PRODUCT", 28, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 120], ["TRIM25", "PROTEIN", 28, 34], ["TRIM25", "TREATMENT", 28, 34], ["this molecule regulates intracellular signaling", "PROBLEM", 83, 130], ["RNA virus replication", "PROBLEM", 139, 160]]]], "PMC7176030": [["SARS-CoV: the first highly pathogenic human CoV outbreak of the 21st century ::: IntroductionAs mentioned above, in 2002, an outbreak of a new disease (SARS) was described for which a novel CoV, known as SARS-CoV, was identified as the etiologic agent [27, 28].", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 152, 156], ["SARS-CoV", "DISEASE", 204, 212], ["SARS-CoV", "ORGANISM", 0, 8], ["human", "ORGANISM", 38, 43], ["CoV", "ORGANISM", 44, 47], ["CoV", "ORGANISM", 190, 193], ["SARS-CoV", "ORGANISM", 204, 212], ["human", "SPECIES", 38, 43], ["SARS-CoV", "SPECIES", 0, 8], ["human CoV", "SPECIES", 38, 47], ["SARS-CoV", "SPECIES", 204, 212], ["a new disease (SARS)", "PROBLEM", 137, 157], ["a novel CoV", "PROBLEM", 182, 193], ["SARS-CoV", "PROBLEM", 204, 212], ["human CoV", "OBSERVATION", 38, 47], ["new", "OBSERVATION_MODIFIER", 139, 142], ["disease", "OBSERVATION", 143, 150]]], ["The disease reached pandemic proportions, as it spread to 29 countries on five continents, causing a total of 8096 laboratory-confirmed cases of SARS with 774 deaths by August 2003, when aggressive public health intervention measures managed to contain a potential pandemic (Fig. 3A).SARS-CoV: the first highly pathogenic human CoV outbreak of the 21st century ::: IntroductionThe first known case of SARS, caused by the novel CoV, was represented by a 45-year-old man in November 2002 in the city of Foshan, Guangdong Province, China [29, 30].", [["SARS", "DISEASE", 145, 149], ["deaths", "DISEASE", 159, 165], ["SARS", "DISEASE", 284, 288], ["SARS", "DISEASE", 401, 405], ["SARS-CoV", "ORGANISM", 284, 292], ["human", "ORGANISM", 322, 327], ["CoV", "ORGANISM", 328, 331], ["CoV", "ORGANISM", 427, 430], ["man", "ORGANISM", 465, 468], ["human", "SPECIES", 322, 327], ["man", "SPECIES", 465, 468], ["SARS-CoV", "SPECIES", 284, 292], ["human CoV", "SPECIES", 322, 331], ["The disease", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 145, 149], ["aggressive public health intervention measures", "TREATMENT", 187, 233], ["SARS", "PROBLEM", 401, 405], ["disease", "OBSERVATION", 4, 11], ["SARS", "OBSERVATION", 401, 405]]], ["The mysterious respiratory disease, which in the future would be called SARS, had high fever (>38\u00b0C), followed by dry cough and rapid progression to respiratory failure as clinical manifestations (Fig. 2B) [31, 32].", [["respiratory", "ANATOMY", 15, 26], ["respiratory", "ANATOMY", 149, 160], ["respiratory disease", "DISEASE", 15, 34], ["SARS", "DISEASE", 72, 76], ["fever", "DISEASE", 87, 92], ["dry cough", "DISEASE", 114, 123], ["respiratory failure", "DISEASE", 149, 168], ["The mysterious respiratory disease", "PROBLEM", 0, 34], ["SARS", "PROBLEM", 72, 76], ["high fever", "PROBLEM", 82, 92], ["dry cough", "PROBLEM", 114, 123], ["respiratory failure", "PROBLEM", 149, 168], ["mysterious", "OBSERVATION_MODIFIER", 4, 14], ["respiratory disease", "OBSERVATION", 15, 34], ["cough", "OBSERVATION", 118, 123], ["respiratory failure", "OBSERVATION", 149, 168]]], ["Consequently, a clinical picture of atypical pneumonia was noted; however, the detection of the new infectious agent, which was being transmitted from human to human, did not occur until several months later.", [["pneumonia", "DISEASE", 45, 54], ["human", "ORGANISM", 151, 156], ["human", "ORGANISM", 160, 165], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 160, 165], ["atypical pneumonia", "PROBLEM", 36, 54], ["the new infectious agent", "PROBLEM", 92, 116], ["atypical", "OBSERVATION_MODIFIER", 36, 44], ["pneumonia", "OBSERVATION", 45, 54], ["new", "OBSERVATION_MODIFIER", 96, 99], ["infectious", "OBSERVATION", 100, 110]]], ["Thus, it was only in April 2003 that the World Health Organization (WHO) announced that the SARS epidemic was caused by a new pathogen, a member of the CoV family never seen before in humans [33, 34].SARS-CoV: the first highly pathogenic human CoV outbreak of the 21st century ::: IntroductionInitial SARS cases were restricted to China until February 21, 2003, when an elderly doctor who was treating patients with \u201catypical pneumonia\u201d in Guangdong traveled to Hong Kong and stayed at a hotel in the Kowloon district.", [["SARS", "DISEASE", 92, 96], ["SARS", "DISEASE", 200, 204], ["SARS", "DISEASE", 301, 305], ["pneumonia", "DISEASE", 426, 435], ["CoV", "ORGANISM", 152, 155], ["humans", "ORGANISM", 184, 190], ["SARS-CoV", "ORGANISM", 200, 208], ["human", "ORGANISM", 238, 243], ["CoV", "ORGANISM", 244, 247], ["patients", "ORGANISM", 402, 410], ["humans", "SPECIES", 184, 190], ["human", "SPECIES", 238, 243], ["patients", "SPECIES", 402, 410], ["humans", "SPECIES", 184, 190], ["SARS-CoV", "SPECIES", 200, 208], ["human CoV", "SPECIES", 238, 247], ["the SARS epidemic", "PROBLEM", 88, 105], ["a new pathogen", "PROBLEM", 120, 134], ["IntroductionInitial SARS cases", "PROBLEM", 281, 311], ["atypical pneumonia", "PROBLEM", 417, 435], ["atypical", "OBSERVATION_MODIFIER", 417, 425], ["pneumonia", "OBSERVATION", 426, 435]]], ["It was at this hotel that some guests were infected and, as a result of the movement of these infected individuals, SARS-CoV spread to a considerable part of the world [27].", [["SARS", "DISEASE", 116, 120], ["SARS-CoV", "ORGANISM", 116, 124], ["SARS-CoV", "SPECIES", 116, 124], ["these infected individuals", "PROBLEM", 88, 114], ["SARS", "PROBLEM", 116, 120], ["infected", "OBSERVATION", 43, 51], ["infected", "OBSERVATION", 94, 102]]], ["The doctor was admitted to a local hospital with symptoms of acute respiratory disease and later died of the disease.", [["respiratory", "ANATOMY", 67, 78], ["acute respiratory disease", "DISEASE", 61, 86], ["symptoms", "PROBLEM", 49, 57], ["acute respiratory disease", "PROBLEM", 61, 86], ["the disease", "PROBLEM", 105, 116], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["respiratory disease", "OBSERVATION", 67, 86], ["disease", "OBSERVATION", 109, 116]]], ["It is recognized that from this index case, seven other people who were on the same floor in the hotel were directly affected by SARS.", [["SARS", "DISEASE", 129, 133], ["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["Practically all of these people were foreign visitors, including three visitors from Singapore, one visitor from Vietnam, and two visitors from Canada.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["Soon after returning to their countries, these infected visitors triggered outbreaks in their places of origin.", [["infected", "OBSERVATION", 47, 55], ["origin", "ANATOMY_MODIFIER", 104, 110]]], ["However, the high speed of the scientific response in understanding this new viral disease was unmatched and contributed to the success of SARS containment.SARS-CoV: the first highly pathogenic human CoV outbreak of the 21st century ::: IntroductionWith the discovery of a novel CoV responsible for the SARS epidemic, new questions need to be clarified as to which animal is the definitive host of this virus.", [["viral disease", "DISEASE", 77, 90], ["SARS", "DISEASE", 139, 143], ["SARS", "DISEASE", 156, 160], ["SARS", "DISEASE", 303, 307], ["SARS-CoV", "ORGANISM", 156, 164], ["human", "ORGANISM", 194, 199], ["CoV", "ORGANISM", 200, 203], ["CoV", "ORGANISM", 279, 282], ["human", "SPECIES", 194, 199], ["SARS-CoV", "SPECIES", 156, 164], ["human CoV", "SPECIES", 194, 203], ["this new viral disease", "PROBLEM", 68, 90], ["SARS containment", "TREATMENT", 139, 155], ["a novel CoV", "PROBLEM", 271, 282], ["the SARS epidemic", "PROBLEM", 299, 316], ["this virus", "PROBLEM", 398, 408]]], ["Could any animal have acted as an intermediate host involving the transmission of the virus to humans?", [["humans", "ORGANISM", 95, 101], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 95, 101]]], ["To solve this puzzle, it was necessary to return to the initial cases of SARS.", [["SARS", "DISEASE", 73, 77], ["SARS", "PROBLEM", 73, 77]]], ["However, in the first retrospectively identified case of SARS in the city of Foshan, it was unclear where and how the man had contracted the disease, but it was known that he had not traveled for weeks but had been exposed to different animals and had prepared chicken, domestic cat, and snake for family consumption [29].", [["SARS", "DISEASE", 57, 61], ["man", "ORGANISM", 118, 121], ["chicken", "ORGANISM", 261, 268], ["cat", "ORGANISM", 279, 282], ["man", "SPECIES", 118, 121], ["chicken", "SPECIES", 261, 268], ["cat", "SPECIES", 279, 282], ["chicken", "SPECIES", 261, 268], ["SARS", "PROBLEM", 57, 61], ["the disease", "PROBLEM", 137, 148], ["disease", "OBSERVATION", 141, 148]]], ["Additionally, at the beginning of the SARS epidemic, similar to the first case, the disease afflicted restaurant workers who handled wild mammals as exotic foods [28, 35].", [["SARS", "DISEASE", 38, 42], ["the SARS epidemic", "PROBLEM", 34, 51]]], ["Subsequently, SARS-CoV and/or anti-SARS-CoV antibodies were found in masked palm civets (Paguma larvata) and in animals that were being handled in a market [26, 36].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 30, 43], ["palm", "ORGANISM_SUBDIVISION", 76, 80], ["Paguma larvata", "ORGANISM", 89, 103], ["SARS-CoV and/or anti-SARS-CoV antibodies", "PROTEIN", 14, 54], ["Paguma larvata", "SPECIES", 89, 103], ["SARS-CoV", "SPECIES", 14, 22], ["anti-SARS-CoV", "SPECIES", 30, 43], ["palm civets", "SPECIES", 76, 87], ["Paguma larvata", "SPECIES", 89, 103], ["SARS", "PROBLEM", 14, 18], ["anti-SARS", "TEST", 30, 39], ["CoV antibodies", "TEST", 40, 54]]], ["However, it was only later that studies showed that populations of palm civets on farms were negative for SARS-CoV, while those in markets populations showed positive results (i.e., had a higher SARS-CoV antibody prevalence), suggesting that market animals were probably intermediate hosts and were possibly infected from another source in the markets [26, 37, 38].", [["SARS", "DISEASE", 106, 110], ["palm", "ORGANISM_SUBDIVISION", 67, 71], ["SARS-CoV", "ORGANISM", 106, 114], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 195, 203], ["palm civets", "TEST", 67, 78], ["SARS", "PROBLEM", 106, 110], ["CoV", "PROBLEM", 111, 114], ["a higher SARS", "PROBLEM", 186, 199], ["CoV antibody prevalence", "TEST", 200, 223], ["intermediate hosts", "OBSERVATION", 271, 289], ["possibly", "UNCERTAINTY", 299, 307], ["infected", "OBSERVATION", 308, 316]]], ["Subsequent studies showed that several CoVs were endemic in bats, including a CoV closely related to SARS-CoV.", [["SARS", "DISEASE", 101, 105], ["CoVs", "GENE_OR_GENE_PRODUCT", 39, 43], ["CoV", "ORGANISM", 78, 81], ["SARS-CoV", "ORGANISM", 101, 109], ["SARS-CoV", "SPECIES", 101, 109], ["Subsequent studies", "TEST", 0, 18], ["several CoVs", "PROBLEM", 31, 43], ["a CoV", "PROBLEM", 76, 81], ["SARS", "PROBLEM", 101, 105], ["several", "OBSERVATION_MODIFIER", 31, 38], ["CoVs", "OBSERVATION_MODIFIER", 39, 43], ["endemic", "OBSERVATION_MODIFIER", 49, 56]]], ["These findings suggest that bats are the natural host of all strains of CoV [19, 22, 39\u201341].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionMERS-CoV is a human CoV that causes SARS-like disease in the Middle East.", [["CoV respiratory infection", "DISEASE", 131, 156], ["SARS-like disease", "DISEASE", 209, 226], ["bats", "ORGANISM", 28, 32], ["CoV", "ORGANISM", 72, 75], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["CoV", "ORGANISM", 131, 134], ["human", "ORGANISM", 187, 192], ["CoV", "ORGANISM", 193, 196], ["human", "SPECIES", 187, 192], ["MERS-CoV", "SPECIES", 92, 100], ["human CoV", "SPECIES", 187, 196], ["CoV respiratory infection", "PROBLEM", 131, 156], ["a human CoV", "PROBLEM", 185, 196], ["SARS", "PROBLEM", 209, 213], ["disease", "PROBLEM", 219, 226], ["CoV", "OBSERVATION_MODIFIER", 131, 134], ["respiratory infection", "OBSERVATION", 135, 156], ["SARS", "OBSERVATION", 209, 213], ["Middle", "ANATOMY_MODIFIER", 234, 240], ["East", "ANATOMY_MODIFIER", 241, 245]]], ["The first reported case of the virus was in a 60-year-old Saudi man who had a 7-day history of fever, cough, sputum, and shortness of breath and was admitted to a private hospital in Jeddah, Saudi Arabia, on June 13, 2012, and died 11 days after admission to the hospital [42].", [["sputum", "ANATOMY", 109, 115], ["fever", "DISEASE", 95, 100], ["cough", "DISEASE", 102, 107], ["shortness of breath", "DISEASE", 121, 140], ["man", "ORGANISM", 64, 67], ["man", "SPECIES", 64, 67], ["the virus", "PROBLEM", 27, 36], ["fever", "PROBLEM", 95, 100], ["cough", "PROBLEM", 102, 107], ["sputum", "PROBLEM", 109, 115], ["shortness of breath", "PROBLEM", 121, 140], ["fever", "OBSERVATION", 95, 100], ["cough", "OBSERVATION", 102, 107]]], ["A few months later, on September 12 of the same year, a 49-year-old man was transferred from Qatar with acute renal failure and bilateral pneumonia.", [["renal", "ANATOMY", 110, 115], ["acute renal failure", "DISEASE", 104, 123], ["pneumonia", "DISEASE", 138, 147], ["man", "ORGANISM", 68, 71], ["renal", "ORGAN", 110, 115], ["man", "SPECIES", 68, 71], ["acute renal failure", "PROBLEM", 104, 123], ["bilateral pneumonia", "PROBLEM", 128, 147], ["few", "OBSERVATION_MODIFIER", 2, 5], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["renal", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123], ["bilateral", "ANATOMY_MODIFIER", 128, 137], ["pneumonia", "OBSERVATION", 138, 147]]], ["Molecular tests of patient samples performed in the same month detected a viral genome highly similar to that described in the case of the Saudi Arabian patient [43].", [["samples", "ANATOMY", 27, 34], ["patient", "ORGANISM", 19, 26], ["patient", "ORGANISM", 153, 160], ["viral genome", "DNA", 74, 86], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 153, 160], ["Molecular tests of patient samples", "TEST", 0, 34], ["a viral genome", "PROBLEM", 72, 86], ["viral genome", "OBSERVATION", 74, 86]]], ["The people who had had close contact with the patient, including health professionals, family and friends, were followed up until ten days after the last contact with the patient in an attempt to better understand the form of dissemination and viral contagion.", [["viral contagion", "DISEASE", 244, 259], ["people", "ORGANISM", 4, 10], ["patient", "ORGANISM", 46, 53], ["patient", "ORGANISM", 171, 178], ["people", "SPECIES", 4, 10], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 171, 178], ["dissemination and viral contagion", "PROBLEM", 226, 259], ["viral contagion", "OBSERVATION", 244, 259]]], ["Thus, 64 people were followed for ten days after their last contact with the hospitalized patient, and there was no confirmed evidence of continuous person-to-person transmission, despite active extensive contact tracking [43, 44].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionHealth authorities were alerted to the circulation of the novel CoV, classified in November 2012 as a new \u03b2-CoV closely related to the CoVs HKU4 and HKU5 present in bats [42].", [["CoV respiratory infection", "DISEASE", 270, 295], ["people", "ORGANISM", 9, 15], ["patient", "ORGANISM", 90, 97], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 231, 239], ["CoV", "ORGANISM", 270, 273], ["CoV", "ORGANISM", 376, 379], ["\u03b2-CoV", "ORGANISM", 418, 423], ["CoVs", "GENE_OR_GENE_PRODUCT", 447, 451], ["HKU4", "GENE_OR_GENE_PRODUCT", 452, 456], ["HKU5", "GENE_OR_GENE_PRODUCT", 461, 465], ["CoVs HKU4", "DNA", 447, 456], ["HKU5", "DNA", 461, 465], ["people", "SPECIES", 9, 15], ["patient", "SPECIES", 90, 97], ["person", "SPECIES", 149, 155], ["MERS-CoV", "SPECIES", 231, 239], ["\u03b2-CoV", "SPECIES", 418, 423], ["CoV respiratory infection", "PROBLEM", 270, 295], ["the CoVs HKU4", "PROBLEM", 443, 456], ["CoV", "OBSERVATION_MODIFIER", 270, 273], ["respiratory infection", "OBSERVATION", 274, 295]]], ["In December 2012, the European Center for Disease Prevention and Control (ECDC) established a list of countries at risk that included Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Palestine, Oman, Qatar, Saudi Arabia, Syria, the United Arab Emirates, and Yemen [45].", [["Disease Prevention", "TREATMENT", 42, 60]]], ["Subsequently, in May 2013, viral infection was identified in a French patient who had a severe respiratory disease.", [["respiratory", "ANATOMY", 95, 106], ["viral infection", "DISEASE", 27, 42], ["respiratory disease", "DISEASE", 95, 114], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["viral infection", "PROBLEM", 27, 42], ["a severe respiratory disease", "PROBLEM", 86, 114], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infection", "OBSERVATION", 33, 42], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["respiratory disease", "OBSERVATION", 95, 114]]], ["The male patient had been in the United Arab Emirates and had recently returned to France.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16]]], ["A protocol for monitoring contacts close to the patient was adopted, as well as for tracking individuals who had traveled together to the United Arab Emirates, to detect possible other cases and to prevent human-to-human transmission.", [["patient", "ORGANISM", 48, 55], ["human", "ORGANISM", 206, 211], ["human", "ORGANISM", 215, 220], ["patient", "SPECIES", 48, 55], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 215, 220], ["A protocol", "TREATMENT", 0, 10]]], ["The contact screening identified a secondary case in a patient admitted to the same hospital room, thereby confirming the person-to-person transmission of the disease [46].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionCases of the disease continued to be identified, and as of June 2013, 55 confirmed cases had been reported, with a mortality rate of 56% due to the 31 deaths caused by the virus.", [["CoV respiratory infection", "DISEASE", 211, 236], ["deaths", "DISEASE", 404, 410], ["patient", "ORGANISM", 55, 62], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 172, 180], ["CoV", "ORGANISM", 211, 214], ["patient", "SPECIES", 55, 62], ["person", "SPECIES", 122, 128], ["MERS-CoV", "SPECIES", 172, 180], ["The contact screening", "TEST", 0, 21], ["CoV respiratory infection", "PROBLEM", 211, 236], ["the disease", "PROBLEM", 262, 273], ["a mortality rate", "TEST", 366, 382], ["the virus", "PROBLEM", 421, 430], ["CoV", "OBSERVATION_MODIFIER", 211, 214], ["respiratory infection", "OBSERVATION", 215, 236], ["disease", "OBSERVATION", 266, 273], ["virus", "OBSERVATION", 425, 430]]], ["The reported cases occurred in different regions: 45 cases were in countries in the Middle East (Saudi Arabia, Jordan, Qatar, and the United Arab Emirates), eight were in Europe (France, Italy, and the United Kingdom) and two were in Africa (Tunisia) [47].", [["Middle", "ANATOMY_MODIFIER", 84, 90]]], ["Viral infection was the topic at the Sixty-Sixth World Health Assembly in Geneva, Switzerland, with the statement that \u201cthe novel coronavirus is a threat to the whole world\u201d, mainly because of a lack of information related to the virus [48].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionIn early 2014, there was an abrupt increase in the number of MERS-CoV infections in the Jeddah region of Saudi Arabia, the location of the first reported case of the disease.", [["Viral infection", "DISEASE", 0, 15], ["coronavirus", "DISEASE", 130, 141], ["CoV respiratory infection", "DISEASE", 280, 305], ["MERS-CoV infections", "DISEASE", 383, 402], ["coronavirus", "ORGANISM", 130, 141], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 241, 249], ["CoV", "ORGANISM", 280, 283], ["MERS-CoV", "ORGANISM", 383, 391], ["MERS-CoV", "SPECIES", 241, 249], ["MERS-CoV", "SPECIES", 383, 391], ["Viral infection", "PROBLEM", 0, 15], ["the novel coronavirus", "PROBLEM", 120, 141], ["the virus", "PROBLEM", 226, 235], ["CoV respiratory infection", "PROBLEM", 280, 305], ["an abrupt increase", "PROBLEM", 347, 365], ["CoV infections", "PROBLEM", 388, 402], ["the disease", "PROBLEM", 484, 495], ["infection", "OBSERVATION", 6, 15], ["CoV", "OBSERVATION_MODIFIER", 280, 283], ["respiratory infection", "OBSERVATION", 284, 305], ["abrupt", "OBSERVATION_MODIFIER", 350, 356], ["increase", "OBSERVATION_MODIFIER", 357, 365], ["number", "OBSERVATION_MODIFIER", 373, 379], ["CoV infections", "OBSERVATION", 388, 402], ["disease", "OBSERVATION", 488, 495]]], ["A total of 255 cases were identified from January 1 to January 16, with an average age of 45 years among patients, with person-to-person transmission identified mainly in people who had contact with a health unit in the region [49].", [["patients", "ORGANISM", 105, 113], ["people", "ORGANISM", 171, 177], ["patients", "SPECIES", 105, 113], ["person", "SPECIES", 120, 126], ["person", "SPECIES", 130, 136], ["people", "SPECIES", 171, 177]]], ["Two cases of the infection were identified in the Netherlands after two individuals from the same family returned from a pilgrimage to Medina and Mecca (Saudi Arabia), both aged 70 and over [50].", [["infection", "DISEASE", 17, 26], ["the infection", "PROBLEM", 13, 26], ["infection", "OBSERVATION", 17, 26]]], ["In April 2014, the first case of infection in Malaysia was identified in a male patient over the age of 50.", [["infection", "DISEASE", 33, 42], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["infection", "PROBLEM", 33, 42], ["infection", "OBSERVATION", 33, 42]]], ["The patient had traveled to Saudi Arabia days before to make a pilgrimage.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a pilgrimage", "TREATMENT", 61, 73]]], ["There were no positive cases in their close contacts [51].", [["no", "UNCERTAINTY", 11, 13], ["positive", "OBSERVATION_MODIFIER", 14, 22]]], ["The first reported case of MERS-CoV infection in the USA was from an individual who had traveled to Saudi Arabia.", [["MERS-CoV infection", "DISEASE", 27, 45], ["MERS-CoV", "ORGANISM", 27, 35], ["MERS-CoV", "SPECIES", 27, 35], ["MERS", "PROBLEM", 27, 31], ["CoV infection", "PROBLEM", 32, 45], ["infection", "OBSERVATION", 36, 45]]], ["The number of cases of the disease continued to rise.", [["the disease", "PROBLEM", 23, 34], ["disease", "OBSERVATION", 27, 34]]], ["As of May 2014, more than 570 cases had been reported to WHO, with at least 173 deaths [53].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionMERS-CoV continued to spread across countries, and the first case of the virus in South Korea was reported on May 20, 2015.", [["deaths", "DISEASE", 80, 86], ["CoV respiratory infection", "DISEASE", 131, 156], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["CoV", "ORGANISM", 131, 134], ["MERS-CoV", "SPECIES", 92, 100], ["CoV respiratory infection", "PROBLEM", 131, 156], ["IntroductionMERS", "TEST", 161, 177], ["CoV", "PROBLEM", 178, 181], ["the virus", "PROBLEM", 242, 251], ["CoV", "OBSERVATION_MODIFIER", 131, 134], ["respiratory infection", "OBSERVATION", 135, 156]]], ["On May 28, a 44-year-old traveler from South Korea was admitted to a hospital in China.", [["traveler", "ORGANISM", 25, 33]]], ["MERS-CoV infection was confirmed on May 29, marking the first case confirmed in the laboratory in China.", [["MERS-CoV infection", "DISEASE", 0, 18], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["CoV infection", "PROBLEM", 5, 18], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18]]], ["Fear of a new pandemic grew [55].MERS-CoV: another worrying outbreak of CoV respiratory infection ::: IntroductionAccording to WHO, since April 2012, 2519 laboratory-confirmed cases of MERS-CoV infection had been reported by January 2020.", [["CoV respiratory infection", "DISEASE", 72, 97], ["MERS-CoV infection", "DISEASE", 185, 203], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["CoV", "ORGANISM", 72, 75], ["MERS-CoV", "ORGANISM", 185, 193], ["MERS-CoV", "SPECIES", 33, 41], ["MERS-CoV", "SPECIES", 185, 193], ["CoV respiratory infection", "PROBLEM", 72, 97], ["MERS", "PROBLEM", 185, 189], ["CoV infection", "PROBLEM", 190, 203], ["new", "OBSERVATION_MODIFIER", 10, 13], ["CoV", "OBSERVATION_MODIFIER", 72, 75], ["respiratory infection", "OBSERVATION", 76, 97], ["infection", "OBSERVATION", 194, 203]]], ["The lethality rate is 34.3%, with 866 confirmed deaths, the majority occurring in Saudi Arabia (2121 cases, including 788 deaths, with a lethality rate of 37.1%) (Fig. 3B) [56].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionSurprisingly, at the end of December 2019, an outbreak of mysterious pneumonia occurred in Wuhan City, Hubei Province, China [57, 58].", [["deaths", "DISEASE", 48, 54], ["deaths", "DISEASE", 122, 128], ["SARS", "DISEASE", 177, 181], ["pneumonia", "DISEASE", 319, 328], ["SARS-CoV-2", "ORGANISM", 177, 187], ["CoV", "ORGANISM", 221, 224], ["The lethality rate", "TEST", 0, 18], ["a lethality rate", "TEST", 135, 151], ["a novel virus", "PROBLEM", 195, 208], ["mysterious pneumonia", "PROBLEM", 308, 328], ["mysterious", "OBSERVATION_MODIFIER", 308, 318], ["pneumonia", "OBSERVATION", 319, 328]]], ["It was observed that the etiologic agent of the disease was a novel CoV, previously designated 2019-nCoV by WHO and, more recently, SARS-CoV-2 by the International Committee for Taxonomy of Viruses [59, 60].", [["CoV", "ORGANISM", 68, 71], ["the disease", "PROBLEM", 44, 55], ["SARS", "TEST", 132, 136], ["CoV", "TEST", 137, 140], ["disease", "OBSERVATION", 48, 55]]], ["Consequently, China has been the epicenter of the emergence of the disease called COVID-19 (Coronavirus disease 2019), which WHO characterized the COVID-19 on March 11, 2020 as a pandemic [61, 62].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionFor the initial cases of COVID-19, it was observed that many patients, before falling ill, were exposed to wild animals at a wholesale seafood market in Huanan (Wuhan, China), a place where birds, bats, snakes, and other farm animals were traded [57, 63].", [["Coronavirus disease", "DISEASE", 92, 111], ["SARS", "DISEASE", 197, 201], ["SARS-CoV-2", "ORGANISM", 197, 207], ["CoV", "ORGANISM", 241, 244], ["patients", "ORGANISM", 331, 339], ["birds", "ORGANISM", 460, 465], ["snakes", "ORGANISM_SUBDIVISION", 473, 479], ["patients", "SPECIES", 331, 339], ["COVID", "TEST", 82, 87], ["Coronavirus disease", "PROBLEM", 92, 111], ["the COVID", "TEST", 143, 152], ["a novel virus", "PROBLEM", 215, 228], ["COVID", "TEST", 295, 300]]], ["In this scenario, a zoonotic origin of these initial cases was suggested; however, the transmission from person to person was soon recognized due to the various cases of COVID-19 within families and among people who did not go to the Huanan market.", [["people", "ORGANISM", 205, 211], ["person", "SPECIES", 105, 111], ["person", "SPECIES", 115, 121], ["people", "SPECIES", 205, 211]]], ["Already in January 2020, the disease spread rapidly inside and outside Hubei Province, and even other countries.", [["the disease spread", "PROBLEM", 25, 43], ["disease", "OBSERVATION", 29, 36], ["spread", "OBSERVATION_MODIFIER", 37, 43], ["rapidly", "OBSERVATION_MODIFIER", 44, 51]]], ["As of April 17, 2020, a total of 2,114,269 cases of COVID-19 were confirmed worldwide.", [["COVID", "TEST", 52, 57]]], ["Internationally, cases have been reported in 203 countries, areas or territories on five continents (Fig. 4) [64].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionIn case series studies, the clinical characteristics of patients diagnosed with COVID-19 were observed (Fig. 2B).", [["SARS", "DISEASE", 114, 118], ["SARS-CoV-2", "ORGANISM", 114, 124], ["CoV", "ORGANISM", 158, 161], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["a novel virus", "PROBLEM", 132, 145], ["IntroductionIn case series studies", "TEST", 175, 209], ["COVID", "TEST", 267, 272]]], ["Initially, Huang et al. reported that 66% (27/41) of patients admitted to Jinyintan Hospital (Wuhan, China) had a history of exposure to the wholesale seafood market in Huanan [65].", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Later, Chen et al. found that 49% (49/99) of the patients admitted to Jinyintan Hospital had a history of exposure to the same market [66].", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Subsequently, with the addition of the studies by Wang et al. [67], Yang et al. [68], and Tian et al. [69], the following clinical characteristics of a total of 689 patients were observed: fever (85%, 587/689), cough (58%, 401/689), myalgia or fatigue (29%, 199/689), sputum production (29%, 96/328), dyspnea (17%, 116/689), pharyngitis (13%, 50/386), dizziness (9%, 13/138), headache (7%, 50/689), hemoptysis (5%, 2/41), diarrhea (7%, 28/427), nausea and vomiting (4.4%, 17/386), rhinorrhea (4%, 9/248), and abdominal pain (2%; 3/138) [65\u201369].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionIn the clinical characteristics of patients infected with SARS-CoV-2, it is noted that most patients have relatively moderate symptoms and a good prognosis.", [["sputum", "ANATOMY", 268, 274], ["abdominal", "ANATOMY", 509, 518], ["fever", "DISEASE", 189, 194], ["cough", "DISEASE", 211, 216], ["myalgia", "DISEASE", 233, 240], ["fatigue", "DISEASE", 244, 251], ["sputum production", "DISEASE", 268, 285], ["dyspnea", "DISEASE", 301, 308], ["pharyngitis", "DISEASE", 325, 336], ["dizziness", "DISEASE", 352, 361], ["headache", "DISEASE", 376, 384], ["hemoptysis", "DISEASE", 399, 409], ["diarrhea", "DISEASE", 422, 430], ["nausea", "DISEASE", 445, 451], ["vomiting", "DISEASE", 456, 464], ["rhinorrhea", "DISEASE", 481, 491], ["abdominal pain", "DISEASE", 509, 523], ["SARS", "DISEASE", 544, 548], ["SARS", "DISEASE", 675, 679], ["patients", "ORGANISM", 165, 173], ["abdominal", "ORGANISM_SUBDIVISION", 509, 518], ["SARS-CoV-2", "ORGANISM", 544, 554], ["CoV", "ORGANISM", 588, 591], ["patients", "ORGANISM", 652, 660], ["SARS-CoV-2", "ORGANISM", 675, 685], ["patients", "ORGANISM", 709, 717], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 652, 660], ["patients", "SPECIES", 709, 717], ["SARS-CoV", "SPECIES", 675, 683], ["the studies", "TEST", 35, 46], ["fever", "PROBLEM", 189, 194], ["cough", "PROBLEM", 211, 216], ["myalgia", "PROBLEM", 233, 240], ["fatigue", "PROBLEM", 244, 251], ["sputum production", "TEST", 268, 285], ["dyspnea", "PROBLEM", 301, 308], ["pharyngitis", "PROBLEM", 325, 336], ["dizziness", "PROBLEM", 352, 361], ["headache", "PROBLEM", 376, 384], ["hemoptysis", "PROBLEM", 399, 409], ["diarrhea", "PROBLEM", 422, 430], ["nausea", "PROBLEM", 445, 451], ["vomiting", "PROBLEM", 456, 464], ["rhinorrhea", "PROBLEM", 481, 491], ["abdominal pain", "PROBLEM", 509, 523], ["a novel virus", "PROBLEM", 562, 575], ["relatively moderate symptoms", "PROBLEM", 723, 751], ["pharyngitis", "OBSERVATION", 325, 336], ["hemoptysis", "OBSERVATION", 399, 409], ["rhinorrhea", "OBSERVATION", 481, 491], ["abdominal", "ANATOMY", 509, 518], ["moderate", "OBSERVATION_MODIFIER", 734, 742], ["symptoms", "OBSERVATION", 743, 751]]], ["However, individuals with moderate clinical status can progress to severe cases, including organ dysfunction (shock, SARS, acute cardiac injury, and acute kidney injury), and many deaths have been reported [67].", [["organ", "ANATOMY", 91, 96], ["cardiac", "ANATOMY", 129, 136], ["kidney", "ANATOMY", 155, 161], ["organ dysfunction", "DISEASE", 91, 108], ["shock", "DISEASE", 110, 115], ["SARS", "DISEASE", 117, 121], ["acute cardiac injury", "DISEASE", 123, 143], ["acute kidney injury", "DISEASE", 149, 168], ["deaths", "DISEASE", 180, 186], ["organ", "ORGAN", 91, 96], ["cardiac", "ORGAN", 129, 136], ["kidney", "ORGAN", 155, 161], ["moderate clinical status", "PROBLEM", 26, 50], ["severe cases", "PROBLEM", 67, 79], ["organ dysfunction", "PROBLEM", 91, 108], ["shock", "PROBLEM", 110, 115], ["SARS", "PROBLEM", 117, 121], ["acute cardiac injury", "PROBLEM", 123, 143], ["acute kidney injury", "PROBLEM", 149, 168], ["moderate", "OBSERVATION_MODIFIER", 26, 34], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["cardiac", "ANATOMY", 129, 136], ["injury", "OBSERVATION", 137, 143], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["kidney", "ANATOMY", 155, 161], ["injury", "OBSERVATION", 162, 168]]], ["Recent European Centre for Disease Prevention and Control situation reports show that in total, there were 145,144 deaths, with most deaths confirmed in USA (33,284) Italy (22,172), Spain (19,130), France (17,920) and United Kingdon (13,729).", [["deaths", "DISEASE", 115, 121], ["deaths", "DISEASE", 133, 139], ["Disease", "PROBLEM", 27, 34]]], ["Thus, the current COVID-19 pandemic had already exceeded the number of cases and deaths from SARS and MERS combined [64].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionAt the time, the pathophysiology of severe cases of SARS-CoV-2 infection, as well as SARS-CoV and MERS-CoV, were not fully understood.", [["deaths", "DISEASE", 81, 87], ["SARS", "DISEASE", 93, 97], ["SARS", "DISEASE", 121, 125], ["SARS-CoV-2 infection", "DISEASE", 246, 266], ["SARS-CoV-2", "ORGANISM", 121, 131], ["CoV", "ORGANISM", 165, 168], ["SARS-CoV-2", "ORGANISM", 246, 256], ["SARS-CoV", "ORGANISM", 279, 287], ["MERS-CoV", "ORGANISM", 292, 300], ["SARS-CoV-2", "SPECIES", 246, 256], ["SARS-CoV", "SPECIES", 279, 287], ["MERS-CoV", "SPECIES", 292, 300], ["SARS", "PROBLEM", 93, 97], ["a novel virus", "PROBLEM", 139, 152], ["SARS", "PROBLEM", 246, 250], ["CoV", "PROBLEM", 251, 254], ["2 infection", "PROBLEM", 255, 266], ["SARS", "PROBLEM", 279, 283], ["severe", "OBSERVATION_MODIFIER", 230, 236], ["infection", "OBSERVATION", 257, 266]]], ["However, the first studies have shown that the \u2018cytokine storm\u2019 factor was associated with a greater severity of COVID-19, which was also seen in infections by SARS and MERS CoVs.", [["infections", "DISEASE", 146, 156], ["SARS", "DISEASE", 160, 164], ["COVID-19", "GENE_OR_GENE_PRODUCT", 113, 121], ["cytokine", "PROTEIN", 48, 56], ["the first studies", "TEST", 9, 26], ["COVID", "TEST", 113, 118], ["infections", "PROBLEM", 146, 156], ["SARS", "PROBLEM", 160, 164], ["MERS CoVs", "PROBLEM", 169, 178], ["infections", "OBSERVATION", 146, 156]]], ["Increased amounts of proinflammatory cytokines (e.g., IL1B, IFN\u03b3, IP10 and MCP1) were observed in the serum.", [["serum", "ANATOMY", 102, 107], ["IL1B", "GENE_OR_GENE_PRODUCT", 54, 58], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 60, 64], ["IP10", "GENE_OR_GENE_PRODUCT", 66, 70], ["MCP1", "GENE_OR_GENE_PRODUCT", 75, 79], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["proinflammatory cytokines", "PROTEIN", 21, 46], ["IL1B", "PROTEIN", 54, 58], ["IFN\u03b3", "PROTEIN", 60, 64], ["IP10", "PROTEIN", 66, 70], ["MCP1", "PROTEIN", 75, 79], ["proinflammatory cytokines", "PROBLEM", 21, 46], ["IL1B", "TEST", 54, 58], ["IFN\u03b3", "TEST", 60, 64], ["IP10", "TEST", 66, 70], ["MCP1", "TEST", 75, 79], ["amounts", "OBSERVATION_MODIFIER", 10, 17], ["proinflammatory cytokines", "OBSERVATION", 21, 46]]], ["Additionally, the involvement of the cytokine storm factor in the severity of the disease was corroborated by the observation that patients who needed to be admitted to the intensive care unit (ICU) had higher concentrations of cytokines (GCSF, IP10, MCP1, MIP1A and TNF\u03b1) than patients who did not require ICU admission.", [["patients", "ORGANISM", 131, 139], ["GCSF", "GENE_OR_GENE_PRODUCT", 239, 243], ["IP10", "GENE_OR_GENE_PRODUCT", 245, 249], ["MCP1", "GENE_OR_GENE_PRODUCT", 251, 255], ["MIP1A", "GENE_OR_GENE_PRODUCT", 257, 262], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 267, 271], ["patients", "ORGANISM", 278, 286], ["cytokine storm factor", "PROTEIN", 37, 58], ["cytokines", "PROTEIN", 228, 237], ["GCSF", "PROTEIN", 239, 243], ["IP10", "PROTEIN", 245, 249], ["MCP1", "PROTEIN", 251, 255], ["MIP1A", "PROTEIN", 257, 262], ["TNF\u03b1", "PROTEIN", 267, 271], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 278, 286], ["the cytokine storm factor", "PROBLEM", 33, 58], ["the disease", "PROBLEM", 78, 89], ["cytokines (GCSF", "TREATMENT", 228, 243], ["IP10", "TEST", 245, 249], ["MCP1", "TEST", 251, 255], ["cytokine storm", "OBSERVATION", 37, 51], ["disease", "OBSERVATION", 82, 89]]], ["Presently, in addition to increased secretion of T helper-1 cytokines, increases in secretion of T helper-2 cytokines (e.g., IL4 and IL10) were observed [65].", [["T helper-1", "GENE_OR_GENE_PRODUCT", 49, 59], ["T helper-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["IL4", "GENE_OR_GENE_PRODUCT", 125, 128], ["IL10", "GENE_OR_GENE_PRODUCT", 133, 137], ["T helper-1 cytokines", "PROTEIN", 49, 69], ["T helper-2 cytokines", "PROTEIN", 97, 117], ["IL4", "PROTEIN", 125, 128], ["IL10", "PROTEIN", 133, 137], ["increased secretion of T helper", "PROBLEM", 26, 57], ["IL4 and IL10)", "TREATMENT", 125, 138], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["increases", "OBSERVATION_MODIFIER", 71, 80]]], ["Based on this background, further studies are needed to characterize the response profiles of the immune system in SARS-CoV-2 infection and to better elucidate the mechanism of pathogenesis.SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionAlthough the general population is susceptible to SARS-CoV-2, a higher incidence has been observed in elderly males, especially those with chronic diseases, including diabetes, hypertension, and cardiovascular diseases [65\u201367].", [["cardiovascular", "ANATOMY", 458, 472], ["SARS-CoV-2 infection", "DISEASE", 115, 135], ["SARS", "DISEASE", 190, 194], ["SARS", "DISEASE", 313, 317], ["chronic diseases", "DISEASE", 402, 418], ["diabetes", "DISEASE", 430, 438], ["hypertension", "DISEASE", 440, 452], ["cardiovascular diseases", "DISEASE", 458, 481], ["SARS-CoV-2", "ORGANISM", 115, 125], ["SARS-CoV-2", "ORGANISM", 190, 200], ["CoV", "ORGANISM", 234, 237], ["SARS-CoV-2", "ORGANISM", 313, 323], ["cardiovascular", "ANATOMICAL_SYSTEM", 458, 472], ["SARS-CoV-2", "SPECIES", 115, 125], ["SARS-CoV", "SPECIES", 313, 321], ["further studies", "TEST", 26, 41], ["the immune system", "TEST", 94, 111], ["SARS", "PROBLEM", 115, 119], ["CoV-2 infection", "PROBLEM", 120, 135], ["pathogenesis", "PROBLEM", 177, 189], ["a novel virus", "PROBLEM", 208, 221], ["chronic diseases", "PROBLEM", 402, 418], ["diabetes", "PROBLEM", 430, 438], ["hypertension", "PROBLEM", 440, 452], ["cardiovascular diseases", "PROBLEM", 458, 481], ["pathogenesis", "OBSERVATION", 177, 189], ["chronic", "OBSERVATION_MODIFIER", 402, 409], ["diseases", "OBSERVATION", 410, 418], ["diabetes", "OBSERVATION", 430, 438], ["hypertension", "OBSERVATION", 440, 452], ["cardiovascular", "ANATOMY", 458, 472]]], ["In this context, the most recent case series study involving 138 patients with COVID-19 found an average age of 56 years in this group.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["COVID", "TEST", 79, 84]]], ["The researchers also noted that patients referred to the ICU were older than patients without the need for referral to the ICU (average age, 66 years vs. 51 years) [67].", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 77, 85]]], ["An additional study by Chen et al. gave similar results, showing that viral infection is more likely to affect elderly men with comorbidities [66].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionApproximately 120 days after the beginning of the COVID-19 epidemic in China, in the emerging COVID-19 pandemic in Italy, France, Iran, Spain, Germany, USA, and the United Kingdom, a large number of cases (2,114,269) and a low mortality rate (~6%) compared to SARS (~10%) and MERS (34.3%) were observed [64].", [["viral infection", "DISEASE", 70, 85], ["SARS", "DISEASE", 147, 151], ["SARS", "DISEASE", 480, 484], ["men", "ORGANISM", 119, 122], ["SARS-CoV-2", "ORGANISM", 147, 157], ["CoV", "ORGANISM", 191, 194], ["men", "SPECIES", 119, 122], ["An additional study", "TEST", 0, 19], ["viral infection", "PROBLEM", 70, 85], ["comorbidities", "PROBLEM", 128, 141], ["a novel virus", "PROBLEM", 165, 178], ["the COVID", "TEST", 266, 275], ["a low mortality rate", "PROBLEM", 441, 461], ["SARS", "TEST", 480, 484], ["MERS", "TEST", 496, 500], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 76, 85], ["large", "OBSERVATION_MODIFIER", 403, 408], ["low", "OBSERVATION_MODIFIER", 443, 446]]], ["Faced with this scenario, there is a concern that individuals with mild symptoms may spread the virus more easily due to not seeking medical attention [70].", [["mild symptoms", "PROBLEM", 67, 80], ["the virus", "PROBLEM", 92, 101]]], ["In addition, another factor of concern regarding the high rate of spread of the virus is related to the recent transmission of the virus in asymptomatic individuals in Germany [71].", [["the virus", "PROBLEM", 76, 85], ["the virus", "PROBLEM", 127, 136]]], ["Additionally, the large number of SARS-CoV-2 cases suggests that this virus may have acquired the ability to undergo efficient human-to-human transmission, including the ability to bind to human cells.", [["cells", "ANATOMY", 195, 200], ["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["human", "ORGANISM", 127, 132], ["human", "ORGANISM", 136, 141], ["human", "ORGANISM", 189, 194], ["cells", "CELL", 195, 200], ["human cells", "CELL_TYPE", 189, 200], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 189, 194], ["SARS-CoV", "SPECIES", 34, 42], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 189, 194], ["this virus", "PROBLEM", 65, 75], ["large", "OBSERVATION_MODIFIER", 18, 23], ["number", "OBSERVATION_MODIFIER", 24, 30]]], ["It also suggests that the route of transmission of the virus is via saliva, directly or indirectly, even among patients without a cough or other respiratory symptoms, and shows how contagious SARS-CoV-2 is [10, 70, 72].SARS-CoV-2: again a novel virus and now the CoV pandemic ::: IntroductionIn sum, with the efforts of scientists, professionals, and health authorities and the urgency to contain the COVID-19 pandemic, impressive results have been achieved in a short time.", [["respiratory", "ANATOMY", 145, 156], ["cough", "DISEASE", 130, 135], ["respiratory symptoms", "DISEASE", 145, 165], ["SARS", "DISEASE", 192, 196], ["SARS", "DISEASE", 219, 223], ["saliva", "ORGANISM_SUBSTANCE", 68, 74], ["patients", "ORGANISM", 111, 119], ["SARS-CoV-2", "ORGANISM", 219, 229], ["CoV", "ORGANISM", 263, 266], ["patients", "SPECIES", 111, 119], ["the virus", "PROBLEM", 51, 60], ["a cough", "PROBLEM", 128, 135], ["other respiratory symptoms", "PROBLEM", 139, 165], ["CoV", "TEST", 197, 200], ["a novel virus", "PROBLEM", 237, 250], ["the urgency", "PROBLEM", 374, 385], ["the COVID", "TEST", 397, 406], ["virus", "OBSERVATION", 55, 60]]], ["Among these results, the following stand out: the determination and availability to the public of several full-genome sequences of SARS-CoV-2 isolates from clinical specimens, and the efforts by the CDC of China and other institutions that are conducting drug screening for viral pneumonia and developing a vaccine for SARS-CoV-2 [73\u201377].", [["specimens", "ANATOMY", 165, 174], ["viral pneumonia", "DISEASE", 274, 289], ["SARS", "DISEASE", 319, 323], ["SARS-CoV-2", "ORGANISM", 131, 141], ["SARS-CoV-2", "ORGANISM", 319, 329], ["SARS-CoV", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 319, 327], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["clinical specimens", "TEST", 156, 174], ["drug screening", "TEST", 255, 269], ["viral pneumonia", "PROBLEM", 274, 289], ["a vaccine", "TREATMENT", 305, 314], ["SARS", "TEST", 319, 323], ["CoV", "TEST", 324, 327], ["pneumonia", "OBSERVATION", 280, 289]]], ["Another factor that has given rise to hope of preventing, or containment, of the COVID-19 epidemic in China and South Korea concerns the rapid isolation of symptomatic individuals and those suspected of having the disease, including self-isolation of those with mild symptoms, in addition to the constant surveillance of people closest to suspected cases.", [["people", "ORGANISM", 321, 327], ["people", "SPECIES", 321, 327], ["the COVID", "TEST", 77, 86], ["symptomatic individuals", "PROBLEM", 156, 179], ["the disease", "PROBLEM", 210, 221], ["mild symptoms", "PROBLEM", 262, 275], ["disease", "OBSERVATION", 214, 221]]], ["In this context, South Korea has been a model in combating the spread of the dissemination SARS-CoV-2 infection because the country quickly stabilized its COVID-19 outbreak at the beginning of the spread of virus through widespread rigorous quarantine measures and the opening of drive-through up testing centers.", [["SARS-CoV-2 infection", "DISEASE", 91, 111], ["SARS-CoV-2", "ORGANISM", 91, 101], ["CoV-2", "SPECIES", 96, 101], ["SARS-CoV-2", "SPECIES", 91, 101], ["the dissemination SARS", "PROBLEM", 73, 95], ["CoV-2 infection", "PROBLEM", 96, 111], ["its COVID", "PROBLEM", 151, 160], ["virus", "PROBLEM", 207, 212], ["rigorous quarantine measures", "TREATMENT", 232, 260]]], ["The great challenge of containing the spread of SARS-CoV-2 requires the joint effort of people throughout the world and will involve the immediate application of WHO recommendations for basic preventive measures against the novel CoV and rapid and accurate diagnosis for containment and clinical management.", [["SARS", "DISEASE", 48, 52], ["SARS-CoV-2", "ORGANISM", 48, 58], ["people", "ORGANISM", 88, 94], ["CoV", "ORGANISM", 230, 233], ["people", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 48, 56], ["CoV", "SPECIES", 230, 233], ["SARS", "PROBLEM", 48, 52], ["basic preventive measures", "TREATMENT", 186, 211], ["clinical management", "TREATMENT", 287, 306], ["great", "OBSERVATION_MODIFIER", 4, 9], ["joint", "ANATOMY", 72, 77]]], ["In addition, new advances in applied research involving the disease will be necessary to contain the acceleration of the COVID-19 pandemic.", [["the disease", "PROBLEM", 56, 67], ["the COVID", "TEST", 117, 126], ["pandemic", "PROBLEM", 130, 138], ["new", "OBSERVATION_MODIFIER", 13, 16], ["disease", "OBSERVATION", 60, 67]]]], "PMC7370267": [["BackgroundIn December 2019, a new beta coronavirus (CoV) was first detected in Wuhan, Hubei Providence of China, causing clusters of unknown pneumonia patients.", [["pneumonia", "DISEASE", 141, 150], ["beta coronavirus", "ORGANISM", 34, 50], ["CoV", "ORGANISM", 52, 55], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["beta coronavirus", "SPECIES", 34, 50], ["CoV", "SPECIES", 52, 55], ["a new beta coronavirus (CoV", "PROBLEM", 28, 55], ["unknown pneumonia patients", "PROBLEM", 133, 159], ["pneumonia", "OBSERVATION", 141, 150]]], ["It spread rapidly throughout Hubei and then to other provinces and abroad.", [["spread", "OBSERVATION_MODIFIER", 3, 9], ["rapidly", "OBSERVATION_MODIFIER", 10, 17]]], ["The novel coronavirus has been named SARS-CoV-2 by the International Committee on Taxonomy of Viruses and the disease it causes has been named \u201ccoronavirus disease 2019\u201d (COVID-19) [2].", [["coronavirus", "DISEASE", 10, 21], ["coronavirus disease", "DISEASE", 144, 163], ["coronavirus", "ORGANISM", 10, 21], ["coronavirus", "SPECIES", 10, 21], ["The novel coronavirus", "PROBLEM", 0, 21], ["CoV", "TEST", 42, 45], ["Viruses", "PROBLEM", 94, 101], ["the disease", "PROBLEM", 106, 117], ["coronavirus disease", "PROBLEM", 144, 163], ["COVID", "TEST", 171, 176], ["coronavirus", "OBSERVATION", 10, 21], ["Viruses", "OBSERVATION", 94, 101], ["disease", "OBSERVATION", 110, 117]]], ["As of Apr 12th, 2020, the global number of confirmed cases of COVID-19 has surpassed 1,600,000, including more than 100,000 deaths due to acute respiratory failure or other related complications [3].BackgroundCurrently, the minority of the population of China has been infected, which leaves the majority of China susceptible to infection.", [["respiratory", "ANATOMY", 144, 155], ["COVID", "DISEASE", 62, 67], ["deaths", "DISEASE", 124, 130], ["acute respiratory failure", "DISEASE", 138, 163], ["infection", "DISEASE", 329, 338], ["COVID", "TEST", 62, 67], ["acute respiratory failure", "PROBLEM", 138, 163], ["other related complications", "PROBLEM", 167, 194], ["infected", "PROBLEM", 269, 277], ["infection", "PROBLEM", 329, 338], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["respiratory failure", "OBSERVATION", 144, 163], ["minority", "OBSERVATION_MODIFIER", 224, 232], ["population", "OBSERVATION_MODIFIER", 240, 250], ["infected", "OBSERVATION", 269, 277], ["majority", "OBSERVATION_MODIFIER", 296, 304], ["infection", "OBSERVATION", 329, 338]]], ["Beijing, the capital of China, which has a population of 21 million residents including 8 millions of migrants at particular risk.", [["capital", "ANATOMY_MODIFIER", 13, 20], ["China", "ANATOMY", 24, 29]]], ["To prevent further spread, the Chinese government announced the lockdown (forced quarantine or in-and-outflow restriction) of Wuhan City on Jan 23rd before the upcoming spring festival during which massive population movements were expected to take place.", [["spread", "OBSERVATION_MODIFIER", 19, 25], ["massive", "OBSERVATION_MODIFIER", 198, 205], ["population movements", "OBSERVATION", 206, 226]]], ["Since it is of vital importance to get knowledge of basic epidemiological parameter values from data of real-world in mega-cities, we report the epidemiological and virological findings of 602 cases with SARS-CoV-2 infection and the outbreak response conducted in Beijing from Jan 1st to Apr 3rd 2020.Outbreak response ::: MethodsProtocols for COVID-19 diagnosis and treatment, surveillance, epidemiological investigation, management of close contacts, and laboratory testing were formulated, and relevant surveillance activities and epidemiological investigations conducted.", [["SARS-CoV-2 infection", "DISEASE", 204, 224], ["CoV-2", "ORGANISM", 209, 214], ["CoV-", "SPECIES", 209, 213], ["SARS-CoV-2", "SPECIES", 204, 214], ["SARS", "PROBLEM", 204, 208], ["CoV-2 infection", "PROBLEM", 209, 224], ["COVID", "TEST", 344, 349], ["treatment", "TREATMENT", 367, 376], ["surveillance", "TEST", 378, 390], ["epidemiological investigation", "TEST", 392, 421], ["management", "TREATMENT", 423, 433], ["laboratory testing", "TEST", 457, 475], ["surveillance activities", "TEST", 506, 529], ["epidemiological investigations", "TEST", 534, 564]]], ["All individuals with suspected SARS-CoV-2 infection were isolated in designated hospitals for treatment.", [["SARS-CoV-2 infection", "DISEASE", 31, 51], ["SARS-CoV-2", "ORGANISM", 31, 41], ["CoV-", "SPECIES", 36, 40], ["SARS-CoV-2", "SPECIES", 31, 41], ["suspected SARS", "PROBLEM", 21, 35], ["CoV", "PROBLEM", 36, 39], ["2 infection", "PROBLEM", 40, 51], ["treatment", "TREATMENT", 94, 103], ["SARS", "OBSERVATION", 31, 35], ["infection", "OBSERVATION", 42, 51]]], ["The epidemiological investigation, contact tracing, and quarantine were conducted by the Centers for Disease Prevention and Control (CDCs) at district level or municipal level.", [["The epidemiological investigation", "TEST", 0, 33], ["contact tracing", "TEST", 35, 50], ["quarantine", "TREATMENT", 56, 66], ["Disease Prevention", "TREATMENT", 101, 119]]], ["Without any efficient personal protective equipment, a person who had contact within one meter with a confirmed case after onset of symptoms was defined as close contact.", [["person", "SPECIES", 55, 61], ["symptoms", "PROBLEM", 132, 140]]], ["The definition changed on Feb 10th in accordance with the WHO guidelines [4], from the onset to 4 days prior to symptoms, given evidence of presymptomatic transmission.", [["symptoms", "PROBLEM", 112, 120], ["presymptomatic transmission", "PROBLEM", 140, 167]]], ["Besides traditional contact tracing, big data and artificial intelligence (AI) were used to strengthen contact tracing.", [["traditional contact tracing", "TEST", 8, 35], ["artificial intelligence (AI", "TREATMENT", 50, 77]]], ["For enhanced surveillance to detect COVID-19 in influenza-like illness (ILI) cases, all samples from ILI cases reported in routine influenza virological surveillance system [5] were tested for SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (Real-time RT-PCR) since January 28th.Case definitions ::: MethodsThe case definitions of suspected and confirmed cases of COVID-19 were based on the protocol released by the NHCPRC [6].", [["samples", "ANATOMY", 88, 95], ["COVID-19", "CHEMICAL", 36, 44], ["influenza-like illness", "DISEASE", 48, 70], ["ILI", "DISEASE", 72, 75], ["COVID-19", "DNA", 36, 44], ["SARS-CoV", "SPECIES", 193, 201], ["enhanced surveillance", "TEST", 4, 25], ["COVID", "TEST", 36, 41], ["influenza", "PROBLEM", 48, 57], ["all samples", "TEST", 84, 95], ["ILI cases", "TEST", 101, 110], ["SARS", "TEST", 193, 197], ["CoV", "TEST", 198, 201], ["polymerase chain reaction", "PROBLEM", 242, 267], ["Methods", "TREATMENT", 327, 334], ["COVID", "TEST", 391, 396]]], ["Some modifications in case definitions were made according to recent studies in China.", [["recent studies", "TEST", 62, 76]]], ["Among all confirmed cases, mild cases were defined cases without evidence of pneumonia, and moderate cases as those with pneumonia but no oxygen therapy required.", [["pneumonia", "DISEASE", 77, 86], ["pneumonia", "DISEASE", 121, 130], ["oxygen", "CHEMICAL", 138, 144], ["oxygen", "CHEMICAL", 138, 144], ["oxygen", "SIMPLE_CHEMICAL", 138, 144], ["mild cases", "PROBLEM", 27, 37], ["pneumonia", "PROBLEM", 77, 86], ["moderate cases", "PROBLEM", 92, 106], ["pneumonia", "PROBLEM", 121, 130], ["oxygen therapy", "TREATMENT", 138, 152], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["without evidence of", "UNCERTAINTY", 57, 76], ["pneumonia", "OBSERVATION", 77, 86], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["pneumonia", "OBSERVATION", 121, 130], ["no", "UNCERTAINTY", 135, 137], ["oxygen therapy", "OBSERVATION", 138, 152]]], ["Severe cases were defined as those with dyspnea, respiratory frequency \u2265 30/min, blood oxygen saturation \u2264 93%, PaO2/FiO2 ratio < 300, and/or lung infiltrates > 50% within 24\u201348 h.", [["respiratory", "ANATOMY", 49, 60], ["blood", "ANATOMY", 81, 86], ["lung", "ANATOMY", 142, 146], ["dyspnea", "DISEASE", 40, 47], ["oxygen", "CHEMICAL", 87, 93], ["oxygen", "CHEMICAL", 87, 93], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["oxygen", "SIMPLE_CHEMICAL", 87, 93], ["lung", "ORGAN", 142, 146], ["Severe cases", "PROBLEM", 0, 12], ["dyspnea", "PROBLEM", 40, 47], ["respiratory frequency", "TEST", 49, 70], ["blood oxygen saturation", "TEST", 81, 104], ["PaO2", "TEST", 112, 116], ["FiO2 ratio", "TEST", 117, 127], ["lung infiltrates", "PROBLEM", 142, 158], ["lung", "ANATOMY", 142, 146], ["infiltrates", "OBSERVATION", 147, 158]]], ["Critical cases were those that exhibited respiratory failure, septic shock, and/or multiple organ dysfunction/failure.Case definitions ::: MethodsAsymptomatic laboratory-confirmed cases were defined a person who were positive for SARS-CoV-2 while showing no clinical symptoms and signs.Data collection ::: MethodsThe demographic and epidemiological information, clinical symptoms and outcomes were obtained using a standardized questionnaire by interviewing patients and/or their family members/relatives, attending doctors and other health care providers, supplemented by patient medical records [7].", [["respiratory", "ANATOMY", 41, 52], ["organ", "ANATOMY", 92, 97], ["respiratory failure", "DISEASE", 41, 60], ["septic shock", "DISEASE", 62, 74], ["organ dysfunction", "DISEASE", 92, 109], ["SARS", "DISEASE", 230, 234], ["organ", "ORGAN", 92, 97], ["patients", "ORGANISM", 458, 466], ["patient", "ORGANISM", 573, 580], ["person", "SPECIES", 201, 207], ["patients", "SPECIES", 458, 466], ["patient", "SPECIES", 573, 580], ["SARS-CoV", "SPECIES", 230, 238], ["respiratory failure", "PROBLEM", 41, 60], ["septic shock", "PROBLEM", 62, 74], ["multiple organ dysfunction", "PROBLEM", 83, 109], ["failure", "PROBLEM", 110, 117], ["MethodsAsymptomatic laboratory", "TEST", 139, 169], ["SARS", "PROBLEM", 230, 234], ["CoV", "TEST", 235, 238], ["clinical symptoms", "PROBLEM", 258, 275], ["Methods", "TREATMENT", 306, 313], ["clinical symptoms", "PROBLEM", 362, 379], ["respiratory failure", "OBSERVATION", 41, 60], ["septic shock", "OBSERVATION", 62, 74], ["multiple", "OBSERVATION_MODIFIER", 83, 91], ["organ", "ANATOMY", 92, 97], ["dysfunction", "OBSERVATION", 98, 109], ["failure", "OBSERVATION", 110, 117]]], ["All data were checked by two public health professionals.Laboratory testing ::: MethodsUpper and lower respiratory tract specimens, urine, blood, stool, and sputum specimens were obtained from patients.", [["lower respiratory tract specimens", "ANATOMY", 97, 130], ["urine", "ANATOMY", 132, 137], ["blood", "ANATOMY", 139, 144], ["stool", "ANATOMY", 146, 151], ["sputum specimens", "ANATOMY", 157, 173], ["tract specimens", "ORGANISM_SUBSTANCE", 115, 130], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["stool", "ORGANISM_SUBSTANCE", 146, 151], ["sputum specimens", "ORGANISM_SUBSTANCE", 157, 173], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["All data", "TEST", 0, 8], ["Laboratory testing", "TEST", 57, 75], ["MethodsUpper and lower respiratory tract specimens", "TEST", 80, 130], ["urine, blood, stool, and sputum specimens", "TEST", 132, 173], ["lower", "ANATOMY_MODIFIER", 97, 102], ["respiratory tract", "ANATOMY", 103, 120], ["stool", "ANATOMY", 146, 151]]], ["For all RNA extractions, RNA was extracted from 200 \u03bcL of sample and eluted in 90 \u03bcL elution buffer by KingFisher Flex Purification System (Thermo Fisher, USA).", [["sample", "ANATOMY", 58, 64], ["all RNA extractions", "TREATMENT", 4, 23], ["RNA extractions", "OBSERVATION", 8, 23]]], ["The real-time RT-PCR assay was performed by TaqMan Fast Virus 1-Step Master Mix (ThermoFisher) in ABI 7500 fast system (ABI, USA).", [["The real-time RT-PCR assay", "TEST", 0, 26], ["ABI", "TEST", 98, 101]]], ["0.5 \u03bcM of forward primer, 0.5 \u03bcM of reverse primer, 0.25 \u03bcM of probe, and 5 \u03bcl of RNA sample were mixed in a 25 \u03bcL monoplex quantitative RT-PCR reaction.", [["sample", "ANATOMY", 86, 92], ["forward primer", "DNA", 10, 24], ["reverse primer", "DNA", 36, 50], ["RNA sample", "RNA", 82, 92], ["forward primer", "TREATMENT", 10, 24], ["reverse primer", "TREATMENT", 36, 50], ["RNA sample", "TEST", 82, 92]]], ["The primer and probe were generated following the national guideline [7], and the reaction condition was set according to the manufacturer\u2019s protocol.", [["The primer and probe", "TREATMENT", 0, 20], ["the reaction condition", "PROBLEM", 78, 100]]], ["Cases testing positive for both target genes (open reading frame 1ab and nucleocapsid protein) were determined as laboratory-confirmed cases.", [["open reading frame 1", "GENE_OR_GENE_PRODUCT", 46, 66], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 73, 93], ["target genes", "DNA", 32, 44], ["open reading frame 1ab", "DNA", 46, 68], ["nucleocapsid protein", "PROTEIN", 73, 93], ["Cases testing", "TEST", 0, 13], ["both target genes", "PROBLEM", 27, 44], ["nucleocapsid protein", "TEST", 73, 93]]], ["Upper and lower respiratory tract specimens from confirmed cases were used for viral genome sequencing.", [["lower respiratory tract specimens", "ANATOMY", 10, 43], ["lower respiratory tract specimens", "CANCER", 10, 43], ["Upper and lower respiratory tract specimens", "TEST", 0, 43], ["viral genome sequencing", "PROBLEM", 79, 102], ["lower", "ANATOMY_MODIFIER", 10, 15], ["respiratory tract", "ANATOMY", 16, 33]]], ["Next-generation sequencing (NGS) was achieved based on a metagenomics strategy followed by Illumina sequencing (Illumina Inc., San Diego, CA, USA).", [["Next-generation sequencing (NGS", "TREATMENT", 0, 31], ["a metagenomics strategy", "TREATMENT", 55, 78], ["Illumina sequencing", "TEST", 91, 110]]], ["Output data were assembled by a viral genome-targeted assembly pipeline with a homology search E-value of 1e\u2212 10.", [["viral genome", "DNA", 32, 44], ["Output data", "TEST", 0, 11], ["a viral genome", "PROBLEM", 30, 44], ["a homology search E-value", "TEST", 77, 102], ["viral genome", "OBSERVATION", 32, 44]]], ["Full genome sequences used in the current study are available on request.", [["the current study", "TEST", 30, 47]]], ["Sequence alignment was achieved by MAFFT [8].", [["Sequence alignment", "TEST", 0, 18]]], ["The Neighbor-Joining (N-J) method with a bootstrap of 1000 was used for phylogenetic analysis.Statistical analysis ::: MethodsWe used descriptive statistical methods to analyze the epidemiological characteristics of confirmed cases with SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 237, 257], ["CoV-2", "ORGANISM", 242, 247], ["SARS-CoV-2", "SPECIES", 237, 247], ["The Neighbor-Joining (N-J) method", "TREATMENT", 0, 33], ["a bootstrap", "TREATMENT", 39, 50], ["phylogenetic analysis", "TEST", 72, 93], ["SARS", "PROBLEM", 237, 241], ["CoV-2 infection", "PROBLEM", 242, 257], ["infection", "OBSERVATION", 248, 257]]], ["Monte Carlo approach was applied to simulate 1000 times and estimate the average incubation period and its confidential interval.", [["Monte Carlo approach", "TREATMENT", 0, 20]]], ["Data analysis was performed using SPSS statistical software package version 20.0 (IBM SPSS Inc., Chicago, IL, USA) and GraphPad Prism version 7.0 (GraphPad Software., San Diego, CA, USA).", [["Data analysis", "TEST", 0, 13], ["SPSS statistical software package version", "TEST", 34, 75], ["IBM SPSS", "TEST", 82, 90], ["GraphPad Prism version", "TEST", 119, 141]]], ["All statistical tests were 2-sided, and statistical significance was set at P value less than 0.05.Ethics approval ::: MethodsData collection and analysis of cases and close contacts were determined by the NHCPRC to be part of a continual public health outbreak investigation, and as such was granted exemption from the institutional review board.Epidemiological characteristics of confirmed cases ::: ResultsFrom Jan 1st 2020 to Apr 3rd 2020, respiratory specimens from 7432 suspected cases were tested for SARS-CoV-2, of which 602 (8.1%) were positive.", [["respiratory specimens", "ANATOMY", 444, 465], ["respiratory specimens", "CANCER", 444, 465], ["SARS-CoV-2", "ORGANISM", 508, 518], ["SARS-CoV-2", "SPECIES", 508, 518], ["All statistical tests", "TEST", 0, 21], ["MethodsData collection", "TEST", 119, 141], ["respiratory specimens", "TEST", 444, 465], ["SARS", "TEST", 508, 512], ["CoV", "TEST", 513, 516]]], ["Among the laboratory-confirmed SARS-CoV-2 infections, 585 were confirmed case-patients with symptoms and signs and 17 were asymptomatic COVID-19 cases.", [["SARS-CoV-2 infections", "DISEASE", 31, 52], ["SARS-CoV-2", "ORGANISM", 31, 41], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV-2 infections", "PROBLEM", 36, 52], ["symptoms", "PROBLEM", 92, 100], ["signs", "TEST", 105, 110], ["asymptomatic COVID", "TEST", 123, 141]]], ["The proportion of asymptomatic infection was 2.8% (95% CI: 1.5\u20134.2).Epidemiological characteristics of confirmed cases ::: ResultsThe epidemic curve in Beijing by date of confirmation and onset is shown in Fig. 1a.", [["infection", "DISEASE", 31, 40], ["asymptomatic infection", "PROBLEM", 18, 40], ["CI", "TEST", 55, 57], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["infection", "OBSERVATION", 31, 40]]], ["The number of infection rapidly grew to Jan 30th and peaked between Jan 31st and Feb 1st.", [["infection", "DISEASE", 14, 23], ["infection", "PROBLEM", 14, 23], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 14, 23]]], ["The infections steadily declined between Jan 30th and Feb 18th.", [["infections", "DISEASE", 4, 14], ["The infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14]]]], "PMC7184942": [["El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHTras el primer brote de COVID-19 en Wuhan en diciembre de 2019, donde las autoridades chinas confirmaron 41 casos detectados entre el 8 de diciembre y el 2 de enero de 2020, la ciudad dej\u00f3 de informar casos hasta el 19 de enero, cuando se confirmaron 17 casos m\u00e1s.", [["Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHTras el primer brote de COVID-19 en Wuhan en diciembre de 2019", "SPECIES", 3, 134], ["impacto del COVID", "TREATMENT", 28, 45]]], ["La r\u00e1pida expansi\u00f3n de la enfermedad hizo que la Organizaci\u00f3n Mundial de la Salud, el 30 de enero de 2020, la declarara una emergencia sanitaria a nivel internacional.", [["La r\u00e1pida", "TEST", 0, 9]]], ["En esa fecha, la enfermedad se hab\u00eda detectado en todas las provincias de China continental y se informaban casos en otros 15 pa\u00edses.", [["la enfermedad", "TEST", 14, 27]]], ["El 11 de marzo la enfermedad se hallaba en m\u00e1s de 100 territorios a nivel mundial y fue reconocida como una pandemia por la OMS.", [["OMS", "DISEASE", 124, 127], ["El", "TEST", 0, 2]]], ["A nivel mundial Estados Unidos, Espa\u00f1a e Italia son los pa\u00edses con m\u00e1s casos diagnosticados y con la cifra m\u00e1s alta de muertos.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHEl primer paciente en Espa\u00f1a con coronavirus se conoci\u00f3 el pasado 31 de enero.", [["Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHEl primer paciente en Espa\u00f1a con coronavirus se conoci\u00f3 el pasado 31 de enero", "SPECIES", 130, 276], ["El Virus", "PROBLEM", 127, 135], ["impacto del COVID", "TREATMENT", 155, 172], ["en las personas con VIHEl primer paciente", "TREATMENT", 176, 217], ["en Espa\u00f1a con coronavirus se conoci\u00f3 el pasado", "TREATMENT", 218, 264]]], ["Fue un paciente alem\u00e1n ingresado en la isla de La Gomera (Islas Canarias).", [["Fue un paciente", "TEST", 0, 15]]], ["Nueve d\u00edas despu\u00e9s se detect\u00f3 otro caso coronavirus Covid-19 en la Palma.", [["Nueve", "TEST", 0, 5], ["otro", "TEST", 30, 34], ["caso", "TEST", 35, 39], ["coronavirus", "TEST", 40, 51], ["Covid", "TEST", 52, 57]]], ["Pero no fue hasta el 24 de febrero cuando el virus salt\u00f3 a la pen\u00ednsula, detect\u00e1ndose los primeros casos en la Comunidad de Madrid, Catalu\u00f1a y la Comunidad Valenciana.", [["fue hasta el", "TEST", 8, 20], ["la pen\u00ednsula", "ANATOMY", 59, 71]]], ["La mala noticia es que ya 16,353 personas han fallecido por el COVID-19 en Espa\u00f1a [1].El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHSeg\u00fan el \u00cdndice de Competitividad elaborado por el Foro Econ\u00f3mico Mundial relativo al a\u00f1o 2019, Espa\u00f1a es el pa\u00eds con la mejor sanidad del mundo, un privilegio que comparte con Singapur, Hong Kong y Jap\u00f3n, todos ellos con la m\u00e1xima puntuaci\u00f3n obtenible [2].", [["mala noticia es que ya 16,353 personas han fallecido por el COVID-19 en Espa\u00f1a", "SPECIES", 3, 81], ["Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHSeg\u00fan el \u00cdndice de Competitividad elaborado por el Foro Econ\u00f3mico Mundial relativo al a\u00f1o 2019", "SPECIES", 89, 252], ["el COVID", "TEST", 60, 68], ["impacto del COVID", "TREATMENT", 114, 131]]], ["Largas jornadas de trabajo sin descanso y con insuficientes equipos de protecci\u00f3n individual han dejado un panorama de miles de profesionales sanitarios contagiados y agotados f\u00edsica y mentalmente.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHPero si el sistema sanitario espa\u00f1ol es tan bueno, \u00bfqu\u00e9 explica la explosi\u00f3n de casos de COVID-19 y su gran extensi\u00f3n en tan poco tiempo?", [["Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHPero si el sistema sanitario espa\u00f1ol es tan bueno, \u00bfqu\u00e9 explica la explosi\u00f3n de casos de COVID-19 y su gran extensi\u00f3n en tan poco tiempo", "SPECIES", 200, 405], ["impacto del COVID", "TREATMENT", 225, 242], ["en las personas con VIHPero si el sistema sanitario espa\u00f1ol es tan bueno", "TREATMENT", 246, 318], ["\u00bfqu\u00e9 explica la explosi\u00f3n de casos de COVID", "TREATMENT", 320, 363]]], ["Al igual que otros pa\u00edses como Italia y Estados Unidos se comenz\u00f3 a realizar tests diagn\u00f3sticos a la poblaci\u00f3n demasiado tarde y solo en casos donde la sintomatolog\u00eda ya era acusada.", [["a la poblaci\u00f3n demasiado", "TREATMENT", 96, 120]]], ["Eso hizo que este virus fuera capaz de infectar a tantas personas sin disparar las alarmas de las autoridades sanitarias al comienzo de la epidemia.", [["Eso", "TEST", 0, 3], ["la epidemia", "OBSERVATION", 136, 147]]], ["Seguramente a la r\u00e1pida extensi\u00f3n pudo contribuir tambi\u00e9n el car\u00e1cter latino y mediterr\u00e1neo de los espa\u00f1oles, una poblaci\u00f3n que gusta de la cercan\u00eda social, la celebraci\u00f3n de fiestas, la vida en la calle y el contacto f\u00edsico a trav\u00e9s de besos y abrazos.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHPero adem\u00e1s de estas razones, hubo otras dos que tuvieron un impacto muy negativo, y que tienen que ver con algunos rasgos de este coronavirus.", [["este coronavirus", "DISEASE", 451, 467], ["este coronavirus", "ORGANISM", 451, 467], ["a la r\u00e1pida", "TREATMENT", 12, 23], ["impacto del COVID", "TREATMENT", 281, 298], ["en las personas con VIHPero adem\u00e1s", "TREATMENT", 302, 336], ["hubo otras dos", "TREATMENT", 355, 369]]], ["El primero es su largo periodo de incubaci\u00f3n: de 2 a 14 d\u00edas hasta que se muestran los s\u00edntomas en el caso de que lleguen a aparecer y de 5 a 7 d\u00edas desde que aparecen los primeros s\u00edntomas hasta que los pacientes desarrollan s\u00edntomas m\u00e1s graves.", [["graves", "PROBLEM", 239, 245]]], ["Desafortunadamente, el comienzo de la epidemia de COVID-19 en Espa\u00f1a coincidi\u00f3 con la presencia entre la poblaci\u00f3n de estas enfermedades caracter\u00edsticas del invierno por lo que un alto porcentaje de personas que ya estaban infectadas, no lo sospecharon y nunca llegaron a ir a un centro de salud, aunque estaban contribuyendo a extender el virus.", [["Desafortunadamente", "CHEMICAL", 0, 18], ["Desafortunadamente", "CHEMICAL", 0, 18], ["Desafortunadamente", "SIMPLE_CHEMICAL", 0, 18], ["Desafortunadamente", "PROBLEM", 0, 18], ["en Espa\u00f1a coincidi\u00f3 con la presencia entre la poblaci\u00f3n", "TREATMENT", 59, 114], ["a extender el virus", "PROBLEM", 326, 345]]], ["De hecho, har\u00e1n falta semanas o quiz\u00e1s meses hasta que sepamos cu\u00e1ntos espa\u00f1oles han pasado ya el COVID-19 pero probablemente sean millones.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHEste inicio de la epidemia hizo que el 14 de marzo el gobierno de Espa\u00f1a declarara el estado de alarma durante quince d\u00edas, el m\u00e1ximo que permite la Constituci\u00f3n Espa\u00f1ola.", [["COVID", "TEST", 180, 185]]], ["Pero posteriormente el Congreso de los Diputados ha prorrogado dos veces este estado de alarma que estar\u00e1 vigente hasta el 26 de abril aunque lo m\u00e1s probable es que haya que volver a prorrogarlo.", [["prorrogarlo", "CHEMICAL", 183, 194]]], ["El estado de alarma, entre otras medidas, obliga al confinamiento de la poblaci\u00f3n en sus hogares, pudiendo salir solo para acudir a los servicios sanitarios en el caso de que sea imprescindible, comprar en supermercados o farmacias e ir a trabajar en el caso de que se trabaje en las actividades consideradas esenciales para la sociedad.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHMuerte, sufrimiento, miedo, soledad, desolaci\u00f3n,\u2026 el COVID-19 ha provocado un efecto devastador en la sociedad espa\u00f1ola.", [["impacto del COVID", "TREATMENT", 365, 382], ["sufrimiento", "TREATMENT", 417, 428], ["miedo", "TREATMENT", 430, 435], ["soledad", "TREATMENT", 437, 444], ["desolaci\u00f3n", "TREATMENT", 446, 456], ["\u2026 el COVID", "TREATMENT", 457, 467]]], ["Hac\u00eda muchas d\u00e9cadas, probablemente desde la Guerra Civil Espa\u00f1ola entre 1936 y 1939 que la sociedad espa\u00f1ola no sufr\u00eda tanto y de una manera tan generalizada.", [["Hac\u00eda muchas d\u00e9cadas, probablemente desde la Guerra Civil Espa\u00f1ola entre 1936 y 1939 que la sociedad espa\u00f1ola no sufr\u00eda tanto y de una manera tan generalizada", "SPECIES", 0, 158]]], ["Los fallecidos se han contado por miles y se ha llegado a una situaci\u00f3n en la que ya es una alegr\u00eda saber que solo 500 personas han fallecido en un solo d\u00eda por el coronavirus, como si cada muerte no fuera un drama.", [["Los fallecidos se han contado por miles y se ha llegado a una situaci\u00f3n en la que ya es una alegr\u00eda saber que solo 500 personas han fallecido en un solo d\u00eda por el coronavirus", "SPECIES", 0, 175], ["un drama", "OBSERVATION", 206, 214]]], ["Pero lo peor es que este virus, que est\u00e1 asolando nuestro pa\u00eds y gran parte del mundo, est\u00e1 siendo cruel en lo social, obligando a las personas a encerrarse en sus casas, impidiendo que los seres queridos se abracen entre s\u00ed, forzando a mantener las distancias porque cada persona se ha convertido en una amenaza para los dem\u00e1s y no nos est\u00e1 dejando ni acompa\u00f1ar a nuestros muertos en su entierro.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHEste efecto de la epidemia todav\u00eda puede ser m\u00e1s dif\u00edcil de sobrellevar en Espa\u00f1a donde los v\u00ednculos familiares son muy fuertes, la vida social muy intensa y existe una necesidad de expresar f\u00edsicamente los afectos.", [["impacto del COVID", "TREATMENT", 425, 442]]], ["Por ello, las heridas emocionales de esta crisis necesitar\u00e1n mucho tiempo para ser curadas y es posible que, cuando todo esto pase, la sociedad espa\u00f1ola sea otra muy distinta.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHComo sucede en toda crisis y cat\u00e1strofe, la poblaci\u00f3n m\u00e1s vulnerable est\u00e1 siendo la m\u00e1s afectada, concretamente las personas de m\u00e1s de 60 a\u00f1os, con enfermedades cardiovasculares e hipertensi\u00f3n arterial, diabetes, enfermedades pulmonares cr\u00f3nicas, c\u00e1ncer, inmunodepresi\u00f3n, embarazo y tambi\u00e9n las personas que viven o trabajan en instituciones cerradas, con especial atenci\u00f3n a las personas mayores que viven en residencias.", [["diabetes", "DISEASE", 450, 458], ["COVID", "TEST", 215, 220], ["la poblaci\u00f3n", "TEST", 288, 300], ["diabetes", "PROBLEM", 450, 458], ["enfermedades pulmonares cr\u00f3nicas", "PROBLEM", 460, 492], ["arterial", "ANATOMY", 440, 448], ["diabetes", "OBSERVATION", 450, 458]]], ["Las personas que viven con el VIH en Espa\u00f1a se encuentran entre ese colectivo.", [["Las personas que viven con el VIH en Espa\u00f1a se encuentran entre ese colectivo", "SPECIES", 0, 77]]], ["Desde nuestro grupo de investigaci\u00f3n Salusex y a trav\u00e9s de nuestro contacto con Organizaciones No Gubernamentales que trabajan en el \u00e1mbito del VIH, hemos podido comprobar que estas personas se est\u00e1n sintiendo m\u00e1s amenazadas durante esta crisis.", [["esta crisis", "PROBLEM", 233, 244]]], ["Est\u00e1n experimentando altos niveles de miedo, ansiedad y estr\u00e9s por la posibilidad de contagiarse con un virus que les pueda matar, por el desconocimiento de c\u00f3mo puede influir el SARS-CoV-2 al tener el VIH.", [["al tener el VIH", "TREATMENT", 190, 205]]], ["Pero tambi\u00e9n est\u00e1n preocupados por el acceso a los tratamientos.", [["Pero tambi\u00e9n est\u00e1n preocupados", "TREATMENT", 0, 30]]], ["No saben si ante el estado de alarma y de sobresaturaci\u00f3n y desbordamiento de los centros sanitarios, pueden ir a la farmacia del hospital para recoger sus antirretrovirales, si deben ir a la consulta m\u00e9dica o si resulta peligroso hacerlo y es mejor quedarse en sus casas.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHAunque todav\u00eda se desconoce mucho de este virus, los datos nos indican que hasta la fecha las personas con VIH con un n\u00famero de linfocitos por encima de 200 CD4, tienen el mismo riesgo y la misma evoluci\u00f3n que las personas que no tienen VIH [3].", [["impacto del COVID", "TREATMENT", 300, 317], ["tienen el mismo riesgo y la misma", "TREATMENT", 506, 539]]], ["La receta farmace\u00fatica se est\u00e1 activando generalmente sin pasar presencialmente por consulta, la consulta de enfermedades infecciosas se suele hacer online en la mayor\u00eda de los casos, y se facilita el tratamiento para mas tiempo en algunos casos.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHAnte esta situaci\u00f3n, es importante que las personas con VIH tengan informaci\u00f3n adecuada y no est\u00e9n ni excesivamente alarmados ni tampoco confiados, es decir, conseguir que tengan una adecuada conducta de enfermedad y especialmente una buena adherencia al tratamiento.", [["impacto del COVID", "TREATMENT", 274, 291]]], ["Es importante que las personas con VIH sepan que frente a la amenaza del COVID-19 la vulnerabilidad se la dar\u00e1 su estado de salud global, no el VIH.", [["a la amenaza del COVID", "TREATMENT", 56, 78]]], ["El que tengan un temor excesivo e irracional puede hacer que algunas personas con VIH inicien un tratamiento antirretroviral determinado o lo modifiquen sin motivo, tomando otros f\u00e1rmacos o aumentando la dosis peligrosamente.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHDesde Salusex estamos comprobando que existe mucha desinformaci\u00f3n y algo muy importante, algunas personas se est\u00e1n dedicando a extender fake news que pueden hacer mucho da\u00f1o a toda la poblaci\u00f3n y a \u00e9sta en particular.", [["impacto del COVID", "TREATMENT", 253, 270]]], ["Algunas de las m\u00e1s curiosas aseguran que el contagio es menor en climas c\u00e1lidos; que el fr\u00edo y la nive matan el virus; que los mosquitos pueden transmitirlo; que la vacuna contra la gripe, los antibi\u00f3ticos, los ba\u00f1os de agua caliente, las soluciones salinas para limpiar la nariz, o incluso comer ajo previenen el contagio; y que las l\u00e1mparas ultravioleta o rociar el cuerpo con alcohol o cloro mata al virus aunque ya haya entrado en el organismo.", [["alcohol", "CHEMICAL", 379, 386]]], ["Las fake news, al igual que sucedi\u00f3 con el negacionismo en la pandemia del VIH, constituye una irresponsabilidad social, un delito sanitario y una segunda epidemia donde la mentira resulta tan peligrosa como la extensi\u00f3n f\u00edsica del virus.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHAl margen de la adherencia al tratamiento antirretroviral, aunque no disponemos todav\u00eda de datos emp\u00edricos publicados, es bastante probable que la situaci\u00f3n de confinamiento est\u00e9 teniendo algunos beneficios en los h\u00e1bitos de salud de algunas personas con VIH, especialmente en aquellas que tienen un consumo abusivo del alcohol y de otras drogas, que habr\u00edan disminuido su accesibilidad.", [["impacto del COVID", "TREATMENT", 266, 283], ["en las personas con VIHAl margen de la adherencia al tratamiento antirretroviral", "TREATMENT", 287, 367], ["del virus", "OBSERVATION", 228, 237]]], ["Y tambi\u00e9n el n\u00famero de reinfecciones al no poder entrar en contacto f\u00edsico con otras personas fuera de su hogar.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHPor lo que respecta a los colectivos que pueden estar en una mayor situaci\u00f3n de riesgo frente al VIH por sus pr\u00e1cticas sexuales, a\u00fan no disponemos de datos cient\u00edficos sobre cu\u00e1l puede ser el efecto del confinamiento en estas pr\u00e1cticas.", [["impacto del COVID", "TREATMENT", 140, 157]]], ["Tambi\u00e9n el contacto sexual con trabajadores del sexo y las relaciones r\u00e1pidas a partir de las apps de contactos.", [["Tambi\u00e9n el", "TREATMENT", 0, 10]]], ["Y lo mismo sucede con las actividades sexuales de riesgo asociadas al consumo de alcohol y otras drogas en el marco de fiestas o grandes eventos sociales.", [["alcohol", "CHEMICAL", 81, 88]]], ["No obstante, es posible que algunas personas que ni siquiera est\u00e1n realizando pr\u00e1cticas de riesgo para el VIH, est\u00e9n tomando innecesariamente la PrEP pensando que va a ser efectiva contra el COVID-19.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHAlgunos datos provisionales de un estudio que nuestro grupo de investigaci\u00f3n Salusex est\u00e1 realizando sobre los efectos de esta epidemia en la conducta sexual de los espa\u00f1oles nos indican que en general ha disminuido la frecuencia sexual en los heterosexuales y se ha incrementado en la poblaci\u00f3n no heterosexual, pero en esta afirmaci\u00f3n se engloba todo tipo de actividad sexual incluida la masturbaci\u00f3n y el sexo online, que ha aumentado en personas de cualquier orientaci\u00f3n sexual.", [["est\u00e9n tomando innecesariamente la PrEP pensando que va a ser efectiva contra el COVID-19.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas", "SPECIES", 111, 264], ["obstante", "PROBLEM", 3, 11], ["COVID", "TEST", 191, 196], ["impacto del COVID", "TREATMENT", 228, 245], ["que ha aumentado", "TREATMENT", 693, 709]]], ["Pero en lo que no hay diferencias es en que m\u00e1s de un tercio considera que su vida sexual ha empeorado con esta epidemia.El Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHSin ninguna duda, para toda la poblaci\u00f3n espa\u00f1ola habr\u00e1 un antes y un despu\u00e9s del COVID-19.", [["Virus que cambi\u00f3 Espa\u00f1a: impacto del COVID-19 en las personas con VIHSin ninguna duda, para toda la poblaci\u00f3n espa\u00f1ola habr\u00e1 un antes y un despu\u00e9s del COVID-19", "SPECIES", 124, 283], ["El Virus", "TEST", 121, 129], ["COVID", "TEST", 161, 166], ["del COVID", "TEST", 271, 280]]], ["Pero tambi\u00e9n puede ser una buena ocasi\u00f3n para hacernos m\u00e1s resilientes, para sacar lo mejor de nosotros mismos y realizar aprendizajes valiosos, como darnos cuenta de que la salud es un bien colectivo; la importancia de la solidaridad y la empat\u00eda; la crueldad que supone cualquier estigma, algo de lo que las personas con VIH desgraciadamente saben mucho; el tesoro que supone nuestra poblaci\u00f3n m\u00e1s mayor a la que tanto le debemos; la importancia de tener una robusta sanidad p\u00fablica y de cuidar de nuestros profesionales sanitarios, que est\u00e1n siendo aplaudidos como h\u00e9roes durante esta crisis; el valor y la fragilidad de la vida y el deber moral de disfrutarla; y el privilegio que supone poder demostrar nuestro afecto con un abrazo.", [["esta crisis", "PROBLEM", 583, 594]]]], "PMC7366960": [["IntroductionIn December 2019, a new pneumonia case emerged in the Wuhan, Hubei province of China which had an association with the novel CoronaVirus (2019-nCoV)[1].", [["pneumonia", "DISEASE", 36, 45], ["a new pneumonia", "PROBLEM", 30, 45], ["the novel CoronaVirus", "PROBLEM", 127, 148], ["new", "OBSERVATION_MODIFIER", 32, 35], ["pneumonia", "OBSERVATION", 36, 45]]], ["Thereafter, on the 20th February 2020, the first patient was diagnosed with COVID-19 in Italy leading to a widespread throughout the country[2] and all over the word.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["COVID", "TEST", 76, 81], ["widespread", "OBSERVATION_MODIFIER", 107, 117]]], ["Clinical features vary from mild to critical symptomatic infection, mainly acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 81, 92], ["infection", "DISEASE", 57, 66], ["acute respiratory distress syndrome", "DISEASE", 75, 110], ["mild to critical symptomatic infection", "PROBLEM", 28, 66], ["acute respiratory distress syndrome", "PROBLEM", 75, 110], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["critical", "OBSERVATION_MODIFIER", 36, 44], ["symptomatic", "OBSERVATION_MODIFIER", 45, 56], ["infection", "OBSERVATION", 57, 66], ["mainly", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory distress syndrome", "OBSERVATION", 81, 110]]], ["Different organs, other than lung, can be involved by COVID-19 infection such as intestine, heart, kidney and brain[3], [4].Case reportA 64-year-old man with an history of hypertension entered in middle March 2020 the emergency department for cough and fever started 5 days before.", [["organs", "ANATOMY", 10, 16], ["lung", "ANATOMY", 29, 33], ["intestine", "ANATOMY", 81, 90], ["heart", "ANATOMY", 92, 97], ["kidney", "ANATOMY", 99, 105], ["brain", "ANATOMY", 110, 115], ["COVID-19", "CHEMICAL", 54, 62], ["infection", "DISEASE", 63, 72], ["hypertension", "DISEASE", 172, 184], ["cough", "DISEASE", 243, 248], ["fever", "DISEASE", 253, 258], ["organs", "ORGAN", 10, 16], ["lung", "ORGAN", 29, 33], ["COVID-19", "ORGANISM", 54, 62], ["intestine", "ORGAN", 81, 90], ["heart", "ORGAN", 92, 97], ["kidney", "ORGAN", 99, 105], ["brain", "ORGAN", 110, 115], ["man", "ORGANISM", 149, 152], ["man", "SPECIES", 149, 152], ["COVID", "TEST", 54, 59], ["19 infection such as intestine, heart, kidney and brain", "PROBLEM", 60, 115], ["hypertension", "PROBLEM", 172, 184], ["cough", "PROBLEM", 243, 248], ["fever", "PROBLEM", 253, 258], ["organs", "ANATOMY", 10, 16], ["lung", "ANATOMY", 29, 33], ["infection", "OBSERVATION", 63, 72], ["intestine", "ANATOMY", 81, 90], ["heart", "ANATOMY", 92, 97], ["kidney", "ANATOMY", 99, 105], ["brain", "ANATOMY", 110, 115], ["hypertension", "OBSERVATION", 172, 184], ["cough", "OBSERVATION", 243, 248], ["fever", "OBSERVATION", 253, 258]]], ["At hospital entrance (day 0), he performed complete blood exam, nasopharyngeal swab for COVID-19 and a computerized tomography (CT) of the thorax.", [["blood", "ANATOMY", 52, 57], ["nasopharyngeal swab", "ANATOMY", 64, 83], ["thorax", "ANATOMY", 139, 145], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 64, 83], ["thorax", "ORGAN", 139, 145], ["complete blood exam", "TEST", 43, 62], ["nasopharyngeal swab", "TEST", 64, 83], ["COVID", "TEST", 88, 93], ["a computerized tomography (CT) of the thorax", "TEST", 101, 145], ["nasopharyngeal", "ANATOMY", 64, 78], ["thorax", "ANATOMY", 139, 145]]], ["The blood exams showed white blood cells 6920/\u00b5L, with 1620/\u00b5L lymphocytes, ferritin 3602ng/mL, d-dimer 581 \u00b5g/L, LDH 892 U/L, a PaO2 59.1 mmHg in room air i.e., a ratio between partial pressure of oxygen and fraction of inspired oxygen (PaO2/FiO2) 281 mmHg.", [["blood", "ANATOMY", 4, 9], ["white blood cells", "ANATOMY", 23, 40], ["lymphocytes", "ANATOMY", 63, 74], ["oxygen", "CHEMICAL", 198, 204], ["oxygen", "CHEMICAL", 230, 236], ["oxygen", "CHEMICAL", 198, 204], ["oxygen", "CHEMICAL", 230, 236], ["FiO2", "CHEMICAL", 243, 247], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["blood cells", "CELL", 29, 40], ["lymphocytes", "CELL", 63, 74], ["ferritin", "GENE_OR_GENE_PRODUCT", 76, 84], ["oxygen", "SIMPLE_CHEMICAL", 198, 204], ["oxygen", "SIMPLE_CHEMICAL", 230, 236], ["white blood cells", "CELL_TYPE", 23, 40], ["ferritin", "PROTEIN", 76, 84], ["The blood exams", "TEST", 0, 15], ["white blood cells", "TEST", 23, 40], ["\u00b5L", "TEST", 46, 48], ["lymphocytes", "TEST", 63, 74], ["ferritin", "TEST", 76, 84], ["d-dimer", "TEST", 96, 103], ["\u00b5g", "TEST", 108, 110], ["LDH", "TEST", 114, 117], ["U/L", "TEST", 122, 125], ["a PaO2", "TEST", 127, 133], ["a ratio", "TEST", 162, 169], ["partial pressure of oxygen", "TREATMENT", 178, 204], ["inspired oxygen", "TREATMENT", 221, 236], ["PaO2", "TEST", 238, 242], ["FiO2", "TEST", 243, 247], ["pressure", "OBSERVATION_MODIFIER", 186, 194], ["oxygen", "OBSERVATION_MODIFIER", 198, 204]]], ["Nasopharyngeal swab was positive for COVID-19 and the CT-scan indicated bilateral interstitial pneumonia.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["interstitial", "ANATOMY", 82, 94], ["interstitial pneumonia", "DISEASE", 82, 104], ["Nasopharyngeal swab", "ORGANISM_SUBSTANCE", 0, 19], ["Nasopharyngeal swab", "TEST", 0, 19], ["COVID", "TEST", 37, 42], ["the CT-scan", "TEST", 50, 61], ["bilateral interstitial pneumonia", "PROBLEM", 72, 104], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["interstitial", "ANATOMY_MODIFIER", 82, 94], ["pneumonia", "OBSERVATION", 95, 104]]], ["He was prescribed hydroxychloroquine and Darunavir/Cobicistat and admitted to the hospital.Case reportOn day 2, his respiratory conditions deteriorated and on day 3 the patient was intubated.", [["respiratory", "ANATOMY", 116, 127], ["hydroxychloroquine", "CHEMICAL", 18, 36], ["Darunavir", "CHEMICAL", 41, 50], ["Cobicistat", "CHEMICAL", 51, 61], ["hydroxychloroquine", "CHEMICAL", 18, 36], ["Darunavir", "CHEMICAL", 41, 50], ["Cobicistat", "CHEMICAL", 51, 61], ["He", "ORGANISM", 0, 2], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 18, 36], ["Darunavir", "SIMPLE_CHEMICAL", 41, 50], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["hydroxychloroquine", "TREATMENT", 18, 36], ["Darunavir", "TREATMENT", 41, 50], ["Cobicistat", "TREATMENT", 51, 61], ["his respiratory conditions", "PROBLEM", 112, 138], ["intubated", "TREATMENT", 181, 190], ["respiratory", "ANATOMY", 116, 127]]], ["On the same day, low molecular weight heparin (LMWH) for deep vein thrombosis prophylaxis was started and increased to a therapeutic range on day 9.", [["deep vein", "ANATOMY", 57, 66], ["heparin", "CHEMICAL", 38, 45], ["LMWH", "CHEMICAL", 47, 51], ["deep vein thrombosis", "DISEASE", 57, 77], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 17, 45], ["LMWH", "SIMPLE_CHEMICAL", 47, 51], ["deep vein", "MULTI-TISSUE_STRUCTURE", 57, 66], ["low molecular weight heparin (LMWH", "TREATMENT", 17, 51], ["deep vein thrombosis prophylaxis", "TREATMENT", 57, 89], ["deep", "ANATOMY_MODIFIER", 57, 61], ["vein", "ANATOMY", 62, 66], ["thrombosis", "OBSERVATION", 67, 77]]], ["Patient was subjected to 3 cycles of prono-supination of about 18 hours in deep sedation and intermittent muscle paralysis.", [["muscle", "ANATOMY", 106, 112], ["muscle paralysis", "DISEASE", 106, 122], ["Patient", "ORGANISM", 0, 7], ["muscle", "ORGAN", 106, 112], ["Patient", "SPECIES", 0, 7], ["prono-supination", "TREATMENT", 37, 53], ["deep sedation", "TREATMENT", 75, 88], ["intermittent muscle paralysis", "PROBLEM", 93, 122], ["deep", "ANATOMY_MODIFIER", 75, 79], ["muscle", "ANATOMY", 106, 112], ["paralysis", "OBSERVATION", 113, 122]]], ["On day 11, PaO2/FiO2 ameliorated, about 200 mmHg and patient started to be ventilated in an assisted mode; deep sedation with propofol and midazolam was stopped and analgo-sedation with low dose of remifentanil 0.01 \u00b5g/kg/min and dexmedetomidine 0.4 \u00b5g/kg/h started.", [["propofol", "CHEMICAL", 126, 134], ["midazolam", "CHEMICAL", 139, 148], ["remifentanil", "CHEMICAL", 198, 210], ["dexmedetomidine", "CHEMICAL", 230, 245], ["FiO2", "CHEMICAL", 16, 20], ["propofol", "CHEMICAL", 126, 134], ["midazolam", "CHEMICAL", 139, 148], ["remifentanil", "CHEMICAL", 198, 210], ["dexmedetomidine", "CHEMICAL", 230, 245], ["patient", "ORGANISM", 53, 60], ["propofol", "SIMPLE_CHEMICAL", 126, 134], ["midazolam", "SIMPLE_CHEMICAL", 139, 148], ["dexmedetomidine", "SIMPLE_CHEMICAL", 230, 245], ["patient", "SPECIES", 53, 60], ["PaO2/FiO2", "TEST", 11, 20], ["ventilated", "TREATMENT", 75, 85], ["an assisted mode", "TREATMENT", 89, 105], ["deep sedation", "TREATMENT", 107, 120], ["propofol", "TREATMENT", 126, 134], ["midazolam", "TREATMENT", 139, 148], ["analgo", "TREATMENT", 165, 171], ["sedation", "TREATMENT", 172, 180], ["remifentanil", "TREATMENT", 198, 210], ["dexmedetomidine", "TREATMENT", 230, 245], ["ventilated", "OBSERVATION", 75, 85]]], ["On day 14, as patient was still unconscious, tracheotomy was performed.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["unconscious", "PROBLEM", 32, 43], ["tracheotomy", "TREATMENT", 45, 56], ["tracheotomy", "OBSERVATION", 45, 56]]], ["The electroencephalogram revealed anteriorly prominent theta and delta patterns while the head CT-Scan showed some cortical-subcortical blood-related hyperdensities in the bilateral fronto-parietal and right occipital lobes, leading to suspicion of subacute embolic strokes, encephalitis or cerebral vasculitis.", [["head", "ANATOMY", 90, 94], ["cortical", "ANATOMY", 115, 123], ["blood", "ANATOMY", 136, 141], ["bilateral fronto-parietal", "ANATOMY", 172, 197], ["right occipital lobes", "ANATOMY", 202, 223], ["cerebral", "ANATOMY", 291, 299], ["embolic strokes", "DISEASE", 258, 273], ["encephalitis", "DISEASE", 275, 287], ["cerebral vasculitis", "DISEASE", 291, 310], ["head", "ORGANISM_SUBDIVISION", 90, 94], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["fronto-parietal", "CANCER", 182, 197], ["occipital lobes", "MULTI-TISSUE_STRUCTURE", 208, 223], ["cerebral vasculitis", "PATHOLOGICAL_FORMATION", 291, 310], ["The electroencephalogram", "TEST", 0, 24], ["anteriorly prominent theta and delta patterns", "PROBLEM", 34, 79], ["the head CT-Scan", "TEST", 86, 102], ["some cortical-subcortical blood-related hyperdensities in the bilateral fronto-parietal and right occipital lobes", "PROBLEM", 110, 223], ["subacute embolic strokes", "PROBLEM", 249, 273], ["encephalitis", "PROBLEM", 275, 287], ["cerebral vasculitis", "PROBLEM", 291, 310], ["anteriorly", "ANATOMY_MODIFIER", 34, 44], ["prominent theta", "OBSERVATION", 45, 60], ["delta patterns", "OBSERVATION", 65, 79], ["head", "ANATOMY", 90, 94], ["cortical", "ANATOMY_MODIFIER", 115, 123], ["subcortical blood", "OBSERVATION", 124, 141], ["hyperdensities", "OBSERVATION", 150, 164], ["bilateral", "ANATOMY_MODIFIER", 172, 181], ["fronto", "ANATOMY_MODIFIER", 182, 188], ["parietal", "ANATOMY_MODIFIER", 189, 197], ["right occipital lobes", "ANATOMY", 202, 223], ["subacute", "OBSERVATION_MODIFIER", 249, 257], ["embolic", "OBSERVATION_MODIFIER", 258, 265], ["strokes", "OBSERVATION", 266, 273], ["encephalitis", "OBSERVATION", 275, 287], ["cerebral", "ANATOMY", 291, 299], ["vasculitis", "OBSERVATION", 300, 310]]], ["The neurological examination revealed: tetraplegia with bilateral mute plantar response, reactive mid-size pupils, presence of corneal, photomotor, oculocephalic reflexes, no meningeal signs.", [["neurological", "ANATOMY", 4, 16], ["plantar", "ANATOMY", 71, 78], ["corneal", "ANATOMY", 127, 134], ["photomotor", "ANATOMY", 136, 146], ["oculocephalic", "ANATOMY", 148, 161], ["meningeal", "ANATOMY", 175, 184], ["tetraplegia", "DISEASE", 39, 50], ["plantar", "ORGANISM_SUBDIVISION", 71, 78], ["corneal", "TISSUE", 127, 134], ["The neurological examination", "TEST", 0, 28], ["tetraplegia", "PROBLEM", 39, 50], ["bilateral mute plantar response", "PROBLEM", 56, 87], ["oculocephalic reflexes", "TEST", 148, 170], ["meningeal signs", "PROBLEM", 175, 190], ["tetraplegia", "OBSERVATION", 39, 50], ["bilateral", "ANATOMY_MODIFIER", 56, 65], ["plantar", "ANATOMY", 71, 78], ["reactive", "OBSERVATION_MODIFIER", 89, 97], ["corneal", "ANATOMY", 127, 134], ["no", "UNCERTAINTY", 172, 174], ["meningeal", "ANATOMY", 175, 184], ["signs", "OBSERVATION", 185, 190]]], ["GCS was 6 (E4 V1 M1).", [["GCS", "DISEASE", 0, 3], ["GCS", "TEST", 0, 3]]], ["Furthermore, the magnetic resonance imaging (MRI) showed some signal restriction of the cortex in a parietal and parieto-occipital region and at the pons level suggesting both signs of cortical inflammation and ischemia in the subacute phase (Figure 1).", [["cortex", "ANATOMY", 88, 94], ["parietal", "ANATOMY", 100, 108], ["parieto-occipital region", "ANATOMY", 113, 137], ["pons", "ANATOMY", 149, 153], ["cortical", "ANATOMY", 185, 193], ["cortical inflammation", "DISEASE", 185, 206], ["ischemia", "DISEASE", 211, 219], ["cortex", "CANCER", 88, 94], ["parietal", "MULTI-TISSUE_STRUCTURE", 100, 108], ["pons", "ORGAN", 149, 153], ["cortical", "TISSUE", 185, 193], ["the magnetic resonance imaging", "TEST", 13, 43], ["MRI", "TEST", 45, 48], ["some signal restriction of the cortex", "PROBLEM", 57, 94], ["cortical inflammation", "PROBLEM", 185, 206], ["ischemia in the subacute phase", "PROBLEM", 211, 241], ["signal restriction", "OBSERVATION", 62, 80], ["cortex", "ANATOMY_MODIFIER", 88, 94], ["parietal", "ANATOMY_MODIFIER", 100, 108], ["parieto", "ANATOMY_MODIFIER", 113, 120], ["occipital", "ANATOMY_MODIFIER", 121, 130], ["region", "ANATOMY_MODIFIER", 131, 137], ["pons", "ANATOMY", 149, 153], ["both", "OBSERVATION_MODIFIER", 171, 175], ["signs", "OBSERVATION_MODIFIER", 176, 181], ["cortical", "ANATOMY_MODIFIER", 185, 193], ["inflammation", "OBSERVATION", 194, 206], ["ischemia", "OBSERVATION", 211, 219], ["subacute", "OBSERVATION_MODIFIER", 227, 235], ["phase", "OBSERVATION_MODIFIER", 236, 241]]], ["On the lumbar puncture examination performed on day 22, his cerebrospinal fluid (CSF) was faint yellow, with a cell count of 2/\u03bcL, glicemia 117mg/dL, raised proteins to 91.5 mg/dL (normal values below 45).", [["lumbar", "ANATOMY", 7, 13], ["cerebrospinal fluid", "ANATOMY", 60, 79], ["cell", "ANATOMY", 111, 115], ["lumbar puncture", "MULTI-TISSUE_STRUCTURE", 7, 22], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 60, 79], ["CSF", "ORGANISM_SUBSTANCE", 81, 84], ["cell", "CELL", 111, 115], ["the lumbar puncture examination", "TEST", 3, 34], ["his cerebrospinal fluid (CSF", "TEST", 56, 84], ["faint yellow", "PROBLEM", 90, 102], ["a cell count", "TEST", 109, 121], ["\u03bcL", "TEST", 127, 129], ["glicemia", "TEST", 131, 139], ["raised proteins", "TEST", 150, 165], ["lumbar", "ANATOMY", 7, 13], ["cerebrospinal", "ANATOMY", 60, 73], ["fluid", "OBSERVATION", 74, 79]]], ["CSF array of respiratory and herpers viruses were negative as well as COVID-19 RT-PCR, while nasopharyngeal swab was still positive for COVID-19.", [["respiratory", "ANATOMY", 13, 24], ["nasopharyngeal swab", "ANATOMY", 93, 112], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["herpers viruses", "ORGANISM", 29, 44], ["nasopharyngeal swab", "CANCER", 93, 112], ["COVID-19", "DNA", 136, 144], ["CSF array", "TEST", 0, 9], ["respiratory and herpers viruses", "TEST", 13, 44], ["COVID", "TEST", 70, 75], ["RT-PCR", "TEST", 79, 85], ["nasopharyngeal swab", "TEST", 93, 112], ["COVID", "TEST", 136, 141], ["respiratory", "ANATOMY", 13, 24], ["nasopharyngeal", "ANATOMY", 93, 107]]], ["To exclude an embolic genesis despite negative blood culture, a transesophageal echocardiography was performed.Case reportA panel of common autoantibodies including anti-nuclear antibodies (ANA), extractable nuclear antigens antibodies (ENA), anti double strain DNA antibodies, anti neutrophil cytoplasmic antibodies was negative.", [["blood", "ANATOMY", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["anti-nuclear antibodies", "GENE_OR_GENE_PRODUCT", 165, 188], ["ANA", "GENE_OR_GENE_PRODUCT", 190, 193], ["extractable nuclear antigens antibodies", "GENE_OR_GENE_PRODUCT", 196, 235], ["DNA", "CELLULAR_COMPONENT", 262, 265], ["anti neutrophil cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 278, 316], ["common autoantibodies", "PROTEIN", 133, 154], ["anti-nuclear antibodies", "PROTEIN", 165, 188], ["ANA", "PROTEIN", 190, 193], ["extractable nuclear antigens antibodies", "PROTEIN", 196, 235], ["ENA", "PROTEIN", 237, 240], ["anti double strain DNA antibodies", "PROTEIN", 243, 276], ["anti neutrophil cytoplasmic antibodies", "PROTEIN", 278, 316], ["an embolic genesis", "PROBLEM", 11, 29], ["blood culture", "TEST", 47, 60], ["a transesophageal echocardiography", "TEST", 62, 96], ["common autoantibodies", "PROBLEM", 133, 154], ["anti-nuclear antibodies", "TEST", 165, 188], ["ANA)", "TEST", 190, 194], ["extractable nuclear antigens antibodies", "TEST", 196, 235], ["ENA", "TEST", 237, 240], ["anti double strain DNA antibodies", "TEST", 243, 276], ["anti neutrophil cytoplasmic antibodies", "TEST", 278, 316], ["embolic", "OBSERVATION", 14, 21]]], ["Only a slight alteration of lupus anticoagulant (DRVTT) was detected but without anti cardiolipin or anti Beta2-glycoprotein detection, suggesting a false positivity as expected in critical care patients[5].", [["lupus", "DISEASE", 28, 33], ["cardiolipin", "CHEMICAL", 86, 97], ["lupus anticoagulant", "GENE_OR_GENE_PRODUCT", 28, 47], ["DRVTT", "CANCER", 49, 54], ["cardiolipin", "SIMPLE_CHEMICAL", 86, 97], ["Beta2-glycoprotein", "GENE_OR_GENE_PRODUCT", 106, 124], ["patients", "ORGANISM", 195, 203], ["lupus anticoagulant", "PROTEIN", 28, 47], ["DRVTT", "PROTEIN", 49, 54], ["anti cardiolipin", "PROTEIN", 81, 97], ["anti Beta2", "PROTEIN", 101, 111], ["glycoprotein", "PROTEIN", 112, 124], ["patients", "SPECIES", 195, 203], ["lupus anticoagulant", "TREATMENT", 28, 47], ["anti cardiolipin", "TREATMENT", 81, 97], ["anti Beta2-glycoprotein detection", "TREATMENT", 101, 134], ["a false positivity", "PROBLEM", 147, 165], ["slight", "OBSERVATION_MODIFIER", 7, 13], ["alteration", "OBSERVATION_MODIFIER", 14, 24], ["lupus anticoagulant", "OBSERVATION", 28, 47], ["false positivity", "OBSERVATION", 149, 165]]], ["Interestingly complement fractions were very low, with C3 reduced to 10 mg/dl (normal values 10-40 ng/dl) and C4 to 4 ng/dl (normal values 90-180 ng/dl) and elevated serum beta 2 microglobulin 3080 ng/ml (normal values 900-2000 ng/ml), VES 95 mm/h (normal values 0-10 mm/h), with low level of C reactive protein 4.85mg/dl (normal values 0.00-1.00 mg/dl) and procalcitonin 0.11 ng/ml.Case reportAccording to these laboratory findings with no history of systemic autoimmune disease, a central nervous system (CNS) vasculitis was suspected.", [["serum", "ANATOMY", 166, 171], ["central nervous system", "ANATOMY", 483, 505], ["CNS", "ANATOMY", 507, 510], ["systemic autoimmune disease", "DISEASE", 452, 479], ["central nervous system (CNS) vasculitis", "DISEASE", 483, 522], ["serum", "ORGANISM_SUBSTANCE", 166, 171], ["beta 2 microglobulin", "GENE_OR_GENE_PRODUCT", 172, 192], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 293, 311], ["central nervous system", "ANATOMICAL_SYSTEM", 483, 505], ["CNS", "ANATOMICAL_SYSTEM", 507, 510], ["C3", "PROTEIN", 55, 57], ["C reactive protein", "PROTEIN", 293, 311], ["Interestingly complement fractions", "TEST", 0, 34], ["C3", "TEST", 55, 57], ["C4", "TEST", 110, 112], ["elevated serum beta", "PROBLEM", 157, 176], ["microglobulin", "TEST", 179, 192], ["VES", "TEST", 236, 239], ["low level of C reactive protein", "PROBLEM", 280, 311], ["procalcitonin", "TREATMENT", 358, 371], ["systemic autoimmune disease", "PROBLEM", 452, 479], ["a central nervous system (CNS) vasculitis", "PROBLEM", 481, 522], ["no history of", "UNCERTAINTY", 438, 451], ["systemic", "OBSERVATION_MODIFIER", 452, 460], ["autoimmune", "OBSERVATION", 461, 471], ["central", "ANATOMY_MODIFIER", 483, 490], ["nervous system", "ANATOMY", 491, 505], ["CNS", "ANATOMY", 507, 510], ["vasculitis", "OBSERVATION", 512, 522]]], ["Therefore, intra-venous immunoglobulins at 30g/die for 5 days and thereafter metilprednisolone 1g /die for 5 days, were administered.", [["intra-venous", "ANATOMY", 11, 23], ["metilprednisolone", "CHEMICAL", 77, 94], ["metilprednisolone", "CHEMICAL", 77, 94], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 24, 39], ["intra-venous immunoglobulins", "TREATMENT", 11, 39], ["metilprednisolone", "TREATMENT", 77, 94]]], ["On day 36, the patient appeared awake but unresponsive, he randomly tracked the examiner if speaking, and withdrew the left leg to pain.", [["left leg", "ANATOMY", 119, 127], ["pain", "DISEASE", 131, 135], ["patient", "ORGANISM", 15, 22], ["leg", "ORGANISM_SUBDIVISION", 124, 127], ["patient", "SPECIES", 15, 22], ["unresponsive", "PROBLEM", 42, 54], ["pain", "PROBLEM", 131, 135], ["left", "ANATOMY_MODIFIER", 119, 123], ["leg", "ANATOMY", 124, 127]]], ["The remaining neurological examination was unchanged, and GCS was 9 (E4 V1 M4).", [["neurological", "ANATOMY", 14, 26], ["GCS", "DISEASE", 58, 61], ["The remaining neurological examination", "TEST", 0, 38], ["GCS", "TEST", 58, 61], ["unchanged", "OBSERVATION_MODIFIER", 43, 52]]], ["MRI detected a significant reduction of the pons ischemia (Figure 2).DiscussionCNS vasculitides affect small- and medium-sized arteries of the CNS, and are rare conditions both as primary angiitis of central nervous system (PACNS) and in other systemic vasculitis[6].", [["pons", "ANATOMY", 44, 48], ["arteries", "ANATOMY", 127, 135], ["CNS", "ANATOMY", 143, 146], ["primary angiitis", "ANATOMY", 180, 196], ["central nervous system", "ANATOMY", 200, 222], ["PACNS", "ANATOMY", 224, 229], ["reduction of the pons ischemia", "DISEASE", 27, 57], ["vasculitides", "DISEASE", 83, 95], ["primary angiitis of central nervous system", "DISEASE", 180, 222], ["PACNS", "DISEASE", 224, 229], ["vasculitis", "DISEASE", 253, 263], ["pons", "ORGANISM_SUBDIVISION", 44, 48], ["arteries", "MULTI-TISSUE_STRUCTURE", 127, 135], ["CNS", "ANATOMICAL_SYSTEM", 143, 146], ["central nervous system", "ANATOMICAL_SYSTEM", 200, 222], ["PACNS", "CANCER", 224, 229], ["MRI", "TEST", 0, 3], ["the pons ischemia", "PROBLEM", 40, 57], ["rare conditions", "PROBLEM", 156, 171], ["primary angiitis of central nervous system", "PROBLEM", 180, 222], ["other systemic vasculitis", "PROBLEM", 238, 263], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["pons", "ANATOMY", 44, 48], ["ischemia", "OBSERVATION", 49, 57], ["small", "OBSERVATION_MODIFIER", 103, 108], ["sized", "OBSERVATION_MODIFIER", 121, 126], ["arteries", "ANATOMY", 127, 135], ["CNS", "ANATOMY", 143, 146], ["primary", "OBSERVATION_MODIFIER", 180, 187], ["angiitis", "OBSERVATION", 188, 196], ["central", "ANATOMY_MODIFIER", 200, 207], ["nervous system", "ANATOMY", 208, 222], ["systemic", "ANATOMY", 244, 252], ["vasculitis", "OBSERVATION", 253, 263]]], ["Viral infections, such as Varicella zoster, West Nile, HIV and HCV viruses can trigger CNS vasculitis and PACNS[7].", [["CNS", "ANATOMY", 87, 90], ["Viral infections", "DISEASE", 0, 16], ["Varicella zoster", "DISEASE", 26, 42], ["West Nile, HIV and HCV viruses", "DISEASE", 44, 74], ["vasculitis", "DISEASE", 91, 101], ["PACNS", "DISEASE", 106, 111], ["Viral", "ORGANISM", 0, 5], ["Varicella zoster", "ORGANISM", 26, 42], ["West Nile", "ORGANISM", 44, 53], ["HIV", "ORGANISM", 55, 58], ["HCV viruses", "ORGANISM", 63, 74], ["CNS vasculitis", "PATHOLOGICAL_FORMATION", 87, 101], ["Varicella zoster", "SPECIES", 26, 42], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["HCV", "SPECIES", 63, 66], ["Viral infections", "PROBLEM", 0, 16], ["Varicella zoster", "PROBLEM", 26, 42], ["HIV", "PROBLEM", 55, 58], ["HCV viruses", "PROBLEM", 63, 74], ["CNS vasculitis", "PROBLEM", 87, 101], ["infections", "OBSERVATION", 6, 16], ["Varicella zoster", "OBSERVATION", 26, 42], ["CNS", "ANATOMY", 87, 90], ["vasculitis", "OBSERVATION", 91, 101]]], ["SARS-CoV-2 infection in ICU has been associated to severe neurological dysfunctions and non-specific findings at brain MRI as for critical illness\u2013related encephalopathy[3].", [["neurological", "ANATOMY", 58, 70], ["brain", "ANATOMY", 113, 118], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["neurological dysfunctions", "DISEASE", 58, 83], ["encephalopathy", "DISEASE", 155, 169], ["SARS-CoV-2", "ORGANISM", 0, 10], ["brain", "ORGAN", 113, 118], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["severe neurological dysfunctions", "PROBLEM", 51, 83], ["non-specific findings", "PROBLEM", 88, 109], ["brain MRI", "TEST", 113, 122], ["critical illness\u2013related encephalopathy", "PROBLEM", 130, 169], ["infection", "OBSERVATION", 11, 20], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["encephalopathy", "OBSERVATION", 155, 169]]], ["Moreover several mechanisms of CNS damage for by SARS-Cov-2 have been proposed including an inflammatory response mediated by cytokines such as interleukin-6[8].ConclusionIn this case, the severe neurological dysfunction after SARS-Cov-2 acute respiratory distress syndrome, the pattern and load of CNS lesions at MRI, CSF findings, the clinical improvement after steroids altogether suggest the diagnosis of CNS vasculitis triggered by SARS-Cov-2 infection.", [["CNS", "ANATOMY", 31, 34], ["neurological", "ANATOMY", 196, 208], ["respiratory", "ANATOMY", 244, 255], ["CNS lesions", "ANATOMY", 299, 310], ["CNS", "ANATOMY", 409, 412], ["CNS damage", "DISEASE", 31, 41], ["neurological dysfunction", "DISEASE", 196, 220], ["SARS", "DISEASE", 227, 231], ["respiratory distress syndrome", "DISEASE", 244, 273], ["steroids", "CHEMICAL", 364, 372], ["vasculitis", "DISEASE", 413, 423], ["SARS", "DISEASE", 437, 441], ["infection", "DISEASE", 448, 457], ["steroids", "CHEMICAL", 364, 372], ["CNS", "ANATOMICAL_SYSTEM", 31, 34], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["interleukin-6[8", "GENE_OR_GENE_PRODUCT", 144, 159], ["CNS lesions", "PATHOLOGICAL_FORMATION", 299, 310], ["CNS vasculitis", "PATHOLOGICAL_FORMATION", 409, 423], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 437, 447], ["cytokines", "PROTEIN", 126, 135], ["interleukin", "PROTEIN", 144, 155], ["CNS damage", "PROBLEM", 31, 41], ["SARS", "PROBLEM", 49, 53], ["an inflammatory response", "PROBLEM", 89, 113], ["the severe neurological dysfunction", "PROBLEM", 185, 220], ["SARS", "PROBLEM", 227, 231], ["Cov", "PROBLEM", 232, 235], ["2 acute respiratory distress syndrome", "PROBLEM", 236, 273], ["CNS lesions", "PROBLEM", 299, 310], ["MRI", "TEST", 314, 317], ["CSF findings", "TEST", 319, 331], ["steroids", "TREATMENT", 364, 372], ["CNS vasculitis", "PROBLEM", 409, 423], ["SARS", "PROBLEM", 437, 441], ["Cov-2 infection", "PROBLEM", 442, 457], ["CNS", "ANATOMY", 31, 34], ["damage", "OBSERVATION", 35, 41], ["inflammatory", "OBSERVATION", 92, 104], ["severe", "OBSERVATION_MODIFIER", 189, 195], ["neurological", "OBSERVATION_MODIFIER", 196, 208], ["dysfunction", "OBSERVATION", 209, 220], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["respiratory distress", "OBSERVATION", 244, 264], ["CNS", "ANATOMY", 299, 302], ["lesions", "OBSERVATION", 303, 310], ["CNS", "ANATOMY", 409, 412], ["vasculitis", "OBSERVATION", 413, 423], ["infection", "OBSERVATION", 448, 457]]], ["Physicians should be aware of this additional severe complication associated with COVID-19.Declarations of interestnone.Fundingnone.", [["interestnone", "CHEMICAL", 107, 119], ["Fundingnone", "CHEMICAL", 120, 131], ["COVID-19", "CHEMICAL", 82, 90], ["interestnone", "CHEMICAL", 107, 119], ["interestnone", "SIMPLE_CHEMICAL", 107, 119], ["this additional severe complication", "PROBLEM", 30, 65], ["COVID", "TEST", 82, 87], ["interestnone", "TREATMENT", 107, 119], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["complication", "OBSERVATION", 53, 65]]]], "PMC7368152": [["IntroductionCoronaviruses (CoV) are a group of non-segmented positive single-stranded RNA, with size up to 32 kb, belonging to the Coronaviridae family and Nidovirales order [1,2].", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoV", "ORGANISM", 27, 30], ["non-segmented positive single-stranded RNA", "RNA", 47, 89], ["CoV", "SPECIES", 27, 30], ["non-segmented positive single-stranded RNA", "PROBLEM", 47, 89], ["stranded RNA", "OBSERVATION_MODIFIER", 77, 89], ["size", "OBSERVATION_MODIFIER", 96, 100], ["32 kb", "OBSERVATION_MODIFIER", 107, 112]]], ["Seventeen coronaviruses can infect humans.", [["coronaviruses", "ORGANISM", 10, 23], ["humans", "ORGANISM", 35, 41], ["humans", "SPECIES", 35, 41], ["humans", "SPECIES", 35, 41], ["Seventeen coronaviruses", "PROBLEM", 0, 23], ["coronaviruses", "OBSERVATION", 10, 23]]], ["Typically, this infection presents slight symptoms, like a common cold.", [["infection", "DISEASE", 16, 25], ["this infection", "PROBLEM", 11, 25], ["slight symptoms", "PROBLEM", 35, 50], ["a common cold", "PROBLEM", 57, 70], ["infection", "OBSERVATION", 16, 25], ["slight", "OBSERVATION_MODIFIER", 35, 41]]], ["However, among them, three cause the same symptoms but with higher intensity and are also responsible for atypically severe pneumonia complications, which increases their mortality compared to other viruses [[1], [2], [3], [4], [5]].IntroductionIn the last two decades, three CoV outbreaks have spread widely, becoming world pandemics.", [["pneumonia", "DISEASE", 124, 133], ["[[1], [2], [3], [4], [5]]", "SIMPLE_CHEMICAL", 207, 232], ["CoV", "ORGANISM", 276, 279], ["the same symptoms", "PROBLEM", 33, 50], ["atypically severe pneumonia complications", "PROBLEM", 106, 147], ["IntroductionIn", "TREATMENT", 233, 247], ["three CoV outbreaks", "PROBLEM", 270, 289], ["responsible for", "UNCERTAINTY", 90, 105], ["atypically", "OBSERVATION_MODIFIER", 106, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["pneumonia", "OBSERVATION", 124, 133], ["spread", "OBSERVATION_MODIFIER", 295, 301], ["widely", "OBSERVATION_MODIFIER", 302, 308]]], ["The first began in the winter of 2002 in China, where viral pneumonia caused by CoVs resulted in severe acute respiratory syndrome coronavirus (SARS-CoV-1), officially infecting 8906 people in 26 countries and leading to 774 deaths [6,7].", [["viral pneumonia", "DISEASE", 54, 69], ["CoVs", "CHEMICAL", 80, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 104, 142], ["SARS", "DISEASE", 144, 148], ["deaths", "DISEASE", 225, 231], ["SARS-CoV-1", "ORGANISM", 144, 154], ["people", "ORGANISM", 183, 189], ["CoV-1", "SPECIES", 149, 154], ["people", "SPECIES", 183, 189], ["severe acute respiratory syndrome coronavirus", "SPECIES", 97, 142], ["SARS-CoV-1", "SPECIES", 144, 154], ["viral pneumonia", "PROBLEM", 54, 69], ["CoVs", "PROBLEM", 80, 84], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 97, 142], ["pneumonia", "OBSERVATION", 60, 69], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory syndrome coronavirus", "OBSERVATION", 110, 142]]], ["The second was 2012 in Saudi Arabia, called Middle East respiratory syndrome coronavirus (MERS-CoV), which led to death of 37% of infected patients.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 44, 88], ["death", "DISEASE", 114, 119], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 44, 88], ["MERS-CoV", "ORGANISM", 90, 98], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Middle East respiratory syndrome coronavirus", "SPECIES", 44, 88], ["MERS-CoV", "SPECIES", 90, 98], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 44, 88], ["Middle", "ANATOMY_MODIFIER", 44, 50], ["respiratory syndrome", "ANATOMY", 56, 76]]], ["MERS-CoV spread to 27 countries, infecting 2254 people and causing 800 deaths worldwide [6,8].IntroductionThe third outbreak is ongoing, a pandemic situation that started in December 2019 in China.", [["deaths", "DISEASE", 71, 77], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["MERS-CoV", "SPECIES", 0, 8], ["a pandemic situation", "PROBLEM", 137, 157]]], ["Patients developed new severe pneumonia (COVID-19) caused by SARS-CoV-2.COVID-19.", [["pneumonia", "DISEASE", 30, 39], ["SARS", "DISEASE", 61, 65], ["Patients", "ORGANISM", 0, 8], ["COVID-19", "DNA", 72, 80], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 61, 69], ["new severe pneumonia", "PROBLEM", 19, 39], ["COVID", "TEST", 41, 46], ["COVID", "TEST", 72, 77], ["new", "OBSERVATION_MODIFIER", 19, 22], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["pneumonia", "OBSERVATION", 30, 39]]], ["The disease spread rapidly to 210 countries, at this writing infecting almost 5 million people and causing around 362 thousand deaths [9,10], figures that are rising steeply.", [["deaths", "DISEASE", 127, 133], ["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["The disease spread", "PROBLEM", 0, 18], ["disease", "OBSERVATION", 4, 11]]], ["The origin of SARS-CoV-2 is obscure.", [["SARS", "DISEASE", 14, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["origin", "ANATOMY_MODIFIER", 4, 10], ["SARS", "OBSERVATION", 14, 18], ["CoV", "OBSERVATION_MODIFIER", 19, 22]]], ["Although there are similarities between SARS-CoV-2 and bat SARS-CoV-like coronaviruses, the progenitor is hard identify [3,11,12].IntroductionGenome sequence data has revealed at least 70% similarity between SARS-CoV-1 and SARS-CoV-2 [3,[12], [13], [14]].", [["progenitor", "ANATOMY", 92, 102], ["SARS-CoV-2", "ORGANISM", 40, 50], ["bat SARS-CoV-like coronaviruses", "ORGANISM", 55, 86], ["progenitor", "CELL", 92, 102], ["[12], [13], [14]]", "SIMPLE_CHEMICAL", 237, 254], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV-like coronaviruses", "SPECIES", 59, 86], ["SARS-CoV-1", "SPECIES", 208, 218], ["SARS-CoV", "SPECIES", 223, 231], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["bat SARS", "TEST", 55, 63], ["coronaviruses", "PROBLEM", 73, 86], ["IntroductionGenome sequence data", "TEST", 130, 162], ["SARS", "TEST", 208, 212], ["CoV", "TEST", 213, 216], ["SARS", "TEST", 223, 227], ["CoV", "TEST", 228, 231], ["coronaviruses", "OBSERVATION", 73, 86]]], ["Both coronaviruses share the same entry path in human cells, but with particularities.", [["cells", "ANATOMY", 54, 59], ["coronaviruses", "ORGANISM", 5, 18], ["human", "ORGANISM", 48, 53], ["cells", "CELL", 54, 59], ["human cells", "CELL_TYPE", 48, 59], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["coronaviruses", "OBSERVATION", 5, 18], ["human cells", "OBSERVATION", 48, 59]]], ["SARS-CoV-1 and SARS-CoV-2 possess a membrane-bound trimeric spike (S) protein, which has a receptor-binding domain (RBD) able to interact with Angiotensin I Converting Enzyme 2 (ACE2) receptor in human cells [7,15].", [["membrane", "ANATOMY", 36, 44], ["cells", "ANATOMY", 202, 207], ["SARS", "DISEASE", 0, 4], ["Angiotensin", "CHEMICAL", 143, 154], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["Angiotensin I Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 143, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["human", "ORGANISM", 196, 201], ["cells", "CELL", 202, 207], ["SARS-CoV-2", "DNA", 15, 25], ["membrane-bound trimeric spike (S) protein", "PROTEIN", 36, 77], ["receptor-binding domain", "PROTEIN", 91, 114], ["RBD", "PROTEIN", 116, 119], ["Angiotensin I Converting Enzyme 2 (ACE2) receptor", "PROTEIN", 143, 192], ["human cells", "CELL_TYPE", 196, 207], ["human", "SPECIES", 196, 201], ["SARS-CoV-1", "SPECIES", 0, 10], ["SARS-CoV", "SPECIES", 15, 23], ["human", "SPECIES", 196, 201], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "PROBLEM", 15, 19], ["CoV", "TEST", 20, 23], ["a membrane-bound trimeric spike (S) protein", "PROBLEM", 34, 77], ["a receptor-binding domain (RBD)", "PROBLEM", 89, 120], ["Angiotensin I Converting Enzyme 2 (ACE2) receptor in human cells", "TREATMENT", 143, 207]]], ["Despite the similarities, the S protein from SARS-CoV-2 has modifications in the RBD sequence that enhance the affinity with ACE2 of humans.", [["SARS-CoV-2", "ORGANISM", 45, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["humans", "ORGANISM", 133, 139], ["S protein", "PROTEIN", 30, 39], ["RBD sequence", "DNA", 81, 93], ["ACE2", "PROTEIN", 125, 129], ["humans", "SPECIES", 133, 139], ["SARS-CoV", "SPECIES", 45, 53], ["humans", "SPECIES", 133, 139], ["the S protein", "TEST", 26, 39], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["the RBD sequence", "TEST", 77, 93]]], ["Indeed, the SARS-CoV-2 S protein has a 20-fold higher affinity with human ACE2 than the S protein from SARS-CoV-1, leading to faster spread from human to human [3,7,[13], [14], [15]].IntroductionAs yet there are no drugs for clinical treatment or vaccines to prevent human infection by SARS-CoV-2.", [["infection", "DISEASE", 273, 282], ["SARS", "DISEASE", 286, 290], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 12, 24], ["human", "ORGANISM", 68, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 103, 113], ["human", "ORGANISM", 145, 150], ["human", "ORGANISM", 154, 159], ["3,7,[13], [14], [15]]", "SIMPLE_CHEMICAL", 161, 182], ["human", "ORGANISM", 267, 272], ["SARS-CoV-2", "ORGANISM", 286, 296], ["SARS-CoV-2 S protein", "PROTEIN", 12, 32], ["human ACE2", "PROTEIN", 68, 78], ["S protein", "PROTEIN", 88, 97], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 267, 272], ["SARS-CoV", "SPECIES", 12, 20], ["human", "SPECIES", 68, 73], ["SARS-CoV-1", "SPECIES", 103, 113], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 267, 272], ["SARS-CoV", "SPECIES", 286, 294], ["the SARS", "TEST", 8, 16], ["CoV", "TEST", 17, 20], ["S protein", "TEST", 23, 32], ["human ACE2", "TEST", 68, 78], ["the S protein", "TEST", 84, 97], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["drugs", "TREATMENT", 215, 220], ["clinical treatment", "TREATMENT", 225, 243], ["vaccines", "TREATMENT", 247, 255], ["human infection", "PROBLEM", 267, 282], ["infection", "OBSERVATION", 273, 282]]], ["Drug repositioning seems to be a faster method to find an effective medicine to treat clinical symptoms of COVID-19 [16].", [["COVID", "DISEASE", 107, 112], ["COVID-19", "CHEMICAL", 107, 115], ["Drug repositioning", "TREATMENT", 0, 18], ["a faster method", "TREATMENT", 31, 46], ["an effective medicine", "TREATMENT", 55, 76], ["clinical symptoms", "PROBLEM", 86, 103], ["COVID", "TEST", 107, 112]]], ["However, in this chaotic scenario, computational screening and molecular docking (MD) are promising alternatives to find a new or existing drug to treat symptoms of COVID-19.", [["COVID-19", "CHEMICAL", 165, 173], ["computational screening", "TEST", 35, 58], ["symptoms", "PROBLEM", 153, 161], ["COVID", "TEST", 165, 170]]], ["In all those MD analyses, a common target has been tested, the SARS-CoV-2 S protein, because it is essential to the entry in cells to start the infection process [[17], [18], [19], [20], [21]].IntroductionHere we report a MD study using eight antimicrobial peptides (Mo-CBP3-PepI, Mo-CBP3-PepII, Mo-CBP3-PepIII [22,23], RcAlb-PepI, RcAlb-PepII, RcAlb-PepIII [24], PepGAT and PepKAA [25] (unpublished data)) that target the SARS-CoV-2 S protein.", [["cells", "ANATOMY", 125, 130], ["infection", "DISEASE", 144, 153], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 63, 75], ["cells", "CELL", 125, 130], ["[17], [18], [19], [20]", "SIMPLE_CHEMICAL", 163, 185], ["[21]", "SIMPLE_CHEMICAL", 187, 191], ["CBP3", "GENE_OR_GENE_PRODUCT", 270, 274], ["PepI", "GENE_OR_GENE_PRODUCT", 275, 279], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 281, 294], ["Mo-CBP3-PepIII", "GENE_OR_GENE_PRODUCT", 296, 310], ["RcAlb-PepI", "SIMPLE_CHEMICAL", 320, 330], ["RcAlb-PepII", "SIMPLE_CHEMICAL", 332, 343], ["PepGAT", "SIMPLE_CHEMICAL", 364, 370], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 423, 435], ["SARS-CoV-2 S protein", "PROTEIN", 63, 83], ["CBP3", "PROTEIN", 270, 274], ["PepI", "PROTEIN", 275, 279], ["Mo-CBP3", "PROTEIN", 281, 288], ["PepII", "PROTEIN", 289, 294], ["Mo-CBP3", "PROTEIN", 296, 303], ["PepIII", "PROTEIN", 304, 310], ["RcAlb", "PROTEIN", 320, 325], ["PepI", "PROTEIN", 326, 330], ["RcAlb", "PROTEIN", 332, 337], ["PepII", "PROTEIN", 338, 343], ["RcAlb", "PROTEIN", 345, 350], ["PepIII", "PROTEIN", 351, 357], ["PepGAT", "DNA", 364, 370], ["SARS-CoV-2 S protein", "PROTEIN", 423, 443], ["the SARS", "TEST", 59, 67], ["CoV", "TEST", 68, 71], ["the infection process", "PROBLEM", 140, 161], ["a MD study", "TEST", 220, 230], ["eight antimicrobial peptides", "TREATMENT", 237, 265], ["CBP3", "TEST", 270, 274], ["PepI", "TREATMENT", 275, 279], ["Mo-CBP3", "TREATMENT", 281, 288], ["PepII", "TREATMENT", 289, 294], ["Mo-CBP3", "TREATMENT", 296, 303], ["PepIII", "TREATMENT", 304, 310], ["RcAlb", "TREATMENT", 320, 325], ["PepI", "TREATMENT", 326, 330], ["RcAlb", "TREATMENT", 332, 337], ["PepII", "TREATMENT", 338, 343], ["RcAlb", "TREATMENT", 345, 350], ["PepIII", "TREATMENT", 351, 357], ["PepGAT", "TREATMENT", 364, 370], ["PepKAA", "TREATMENT", 375, 381], ["the SARS", "TEST", 419, 427], ["CoV", "TEST", 428, 431], ["infection", "OBSERVATION", 144, 153]]], ["With different affinities, all peptides interact with the RBD from the SARS-CoV-2 S protein.", [["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 71, 83], ["RBD", "PROTEIN", 58, 61], ["SARS-CoV-2 S protein", "PROTEIN", 71, 91], ["different affinities", "PROBLEM", 5, 25], ["the RBD", "PROBLEM", 54, 61], ["the SARS", "TEST", 67, 75], ["CoV", "TEST", 76, 79]]], ["By interacting with SARS-CoV-2 S protein, peptides change its native conformation, inducing incorrect interaction with the ACE2 receptor and thus blocking the entry of SARS-CoV-2 into the cell.", [["cell", "ANATOMY", 188, 192], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 20, 32], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 123, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 168, 178], ["cell", "CELL", 188, 192], ["SARS-CoV-2 S protein", "PROTEIN", 20, 40], ["ACE2 receptor", "PROTEIN", 123, 136], ["SARS-CoV-2", "PROTEIN", 168, 178], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["peptides", "PROBLEM", 42, 50], ["the ACE2 receptor", "TREATMENT", 119, 136], ["CoV", "TEST", 173, 176], ["cell", "ANATOMY", 188, 192]]], ["The MD results suggest peptides as potential alternative molecules to be used against SARS-CoV-2.", [["SARS", "DISEASE", 86, 90], ["SARS-CoV-2", "ORGANISM", 86, 96], ["SARS-CoV", "SPECIES", 86, 94], ["alternative molecules", "TREATMENT", 45, 66], ["SARS", "PROBLEM", 86, 90]]], ["To the best of our knowledge, this is the first study to employ synthetic peptides as drugs to target spike protein from SARS-CoV-2.Three-dimensional (3D) structures ::: MethodologyThe 3D structures of Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII were the same reported by Oliveira et al. [22].", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["Mo-CBP3-PepI", "SIMPLE_CHEMICAL", 202, 214], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 216, 229], ["Mo-CBP3-PepIII", "GENE_OR_GENE_PRODUCT", 235, 249], ["spike protein", "PROTEIN", 102, 115], ["Mo-CBP3", "PROTEIN", 202, 209], ["PepI", "PROTEIN", 210, 214], ["Mo-CBP3", "PROTEIN", 216, 223], ["PepII", "PROTEIN", 224, 229], ["Mo-CBP3", "PROTEIN", 235, 242], ["PepIII", "PROTEIN", 243, 249], ["SARS-CoV", "SPECIES", 121, 129], ["synthetic peptides", "TREATMENT", 64, 82], ["drugs", "TREATMENT", 86, 91], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["Mo-CBP3", "TEST", 202, 209], ["PepI", "TREATMENT", 210, 214], ["Mo-CBP3", "TEST", 216, 223], ["PepII", "TREATMENT", 224, 229], ["Mo-CBP3", "TREATMENT", 235, 242], ["PepIII", "TREATMENT", 243, 249]]], ["The 3D structures of RcAlb-PepI, RcAlb-PepII, RcAlb-PepIII were the same as employed by Dias et al. [24].", [["RcAlb-PepI", "SIMPLE_CHEMICAL", 21, 31], ["RcAlb-PepII", "GENE_OR_GENE_PRODUCT", 33, 44], ["RcAlb-PepIII", "GENE_OR_GENE_PRODUCT", 46, 58], ["RcAlb", "PROTEIN", 21, 26], ["PepI", "PROTEIN", 27, 31], ["RcAlb", "PROTEIN", 33, 38], ["PepII", "PROTEIN", 39, 44], ["RcAlb", "PROTEIN", 46, 51], ["PepIII", "PROTEIN", 52, 58], ["RcAlb", "TEST", 21, 26], ["PepI", "TREATMENT", 27, 31], ["RcAlb", "TEST", 33, 38], ["PepII", "TREATMENT", 39, 44], ["RcAlb-PepIII", "TREATMENT", 46, 58]]], ["The 3D structures of PepGAT and PepKAA were the same as employed by Souza et al. [25].", [["PepGAT", "GENE_OR_GENE_PRODUCT", 21, 27], ["PepKAA", "SIMPLE_CHEMICAL", 32, 38], ["PepGAT", "PROTEIN", 21, 27], ["PepKAA", "PROTEIN", 32, 38], ["PepGAT and PepKAA", "TREATMENT", 21, 38]]], ["The 3D structure files of SARS-CoV-2 Spike protein (open state, PDB: 6VYB; closed state, PDB: 6VXX) and human ACE2 (ACE2; PDB: 1R42) were downloaded from Protein Data Bank (PDB, https://www.rcsb.org/).Bioinformatic analyses of antiviral potential of synthetic peptides ::: MethodologyBioinformatics was employed to evaluate whether the peptides presented any antiviral potential.", [["SARS", "DISEASE", 26, 30], ["human", "ORGANISM", 104, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["SARS-CoV-2 Spike protein", "PROTEIN", 26, 50], ["open state", "PROTEIN", 52, 62], ["6VYB", "PROTEIN", 69, 73], ["closed state", "PROTEIN", 75, 87], ["PDB", "PROTEIN", 89, 92], ["6VXX", "PROTEIN", 94, 98], ["human ACE2", "PROTEIN", 104, 114], ["ACE2", "PROTEIN", 116, 120], ["PDB: 1R42", "PROTEIN", 122, 131], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["Spike protein", "TEST", 37, 50], ["Bioinformatic analyses", "TEST", 201, 223], ["MethodologyBioinformatics", "TREATMENT", 273, 298], ["the peptides", "PROBLEM", 332, 344], ["PDB", "ANATOMY", 173, 176]]], ["We used the free server iAMPPred (http://cabgrid.res.in:8080/amppred/).Molecular docking (MD) assays ::: MethodologyBlind molecular docking assays were carried out in two systems.", [["Blind molecular docking assays", "TEST", 116, 146]]], ["First, the molecular docking experiments involved synthetic peptides (ligands) against SARS-CoV-2 spike glycoprotein in the open state (6VYB) and closed state (6VXX).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 87, 97], ["SARS-CoV-2 spike glycoprotein", "PROTEIN", 87, 116], ["6VXX", "PROTEIN", 160, 164], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95]]], ["Second, SARS-CoV-2 spike-peptide complexes were tested by molecular docking against the ACE2 human receptor.", [["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["human", "ORGANISM", 93, 98], ["ACE2 human receptor", "PROTEIN", 88, 107], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["SARS", "TEST", 8, 12], ["CoV", "TEST", 13, 16], ["peptide complexes", "PROBLEM", 25, 42], ["the ACE2 human receptor", "TREATMENT", 84, 107]]], ["It is also used for the study of inhibitor-enzyme, peptide-protein, and inhibitor-protein complexes, additionally allowing the analysis and choice of the most appropriate scoring scheme for the complex in this study [[27], [28], [29]].Molecular docking (MD) assays ::: MethodologyThe GPU option was selected because it uses more specific computer graphic units of the Massachusetts Green High-Performance Computing Center (MGHPC).", [["[27], [28], [29]]", "SIMPLE_CHEMICAL", 217, 234], ["inhibitor-enzyme", "PROTEIN", 33, 49], ["protein complexes", "PROTEIN", 82, 99], ["the study", "TEST", 20, 29], ["inhibitor-enzyme", "TEST", 33, 49], ["peptide-protein", "TEST", 51, 66], ["inhibitor-protein complexes", "TEST", 72, 99], ["the analysis", "TEST", 123, 135], ["this study", "TEST", 205, 215], ["The GPU option", "TREATMENT", 280, 294]]], ["The best complexes generated by molecular docking studies were analyzed in terms of interface energy and interaction between surface residues, and for models with a high number of members.", [["surface", "ANATOMY", 125, 132], ["molecular docking studies", "TEST", 32, 57]]], ["The first 12 models of the balanced energy parameter were used for the analysis of waste and interface energy, and models with less than 20 anchored structures were excluded from the analysis.", [["the balanced energy parameter", "TREATMENT", 23, 52], ["the analysis of waste and interface energy", "TEST", 67, 109], ["the analysis", "TEST", 179, 191]]], ["The models were also selected from the analysis of the PIPER energy in the center of the cluster, that is, the structure that has the largest number of neighboring structures in the center of the cluster, as well as from the analysis of the structure that had the lowest energy of the cluster.Minimization and equilibration by molecular dynamics simulation ::: MethodologyTo reach a higher stabilized state, the six systems of interest (S protein closed:: ACE2; S protein open::ACE2; S protein closed::Mo-CBP3-PepII::ACE2; S protein open::Mo-CBP3-PepII::ACE2; S protein closed::PepKAA:: ACE2; and S protein open::PepKAA:: ACE2) were minimized and equilibrated using Gromacs version 2018.4 [30].", [["ACE2", "GENE_OR_GENE_PRODUCT", 456, 460], ["ACE2", "GENE_OR_GENE_PRODUCT", 478, 482], ["S protein", "GENE_OR_GENE_PRODUCT", 484, 493], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 502, 515], ["ACE2", "GENE_OR_GENE_PRODUCT", 517, 521], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 539, 552], ["ACE2", "GENE_OR_GENE_PRODUCT", 554, 558], ["S protein", "GENE_OR_GENE_PRODUCT", 560, 569], ["PepKAA", "GENE_OR_GENE_PRODUCT", 578, 584], ["ACE2", "GENE_OR_GENE_PRODUCT", 587, 591], ["S protein", "GENE_OR_GENE_PRODUCT", 597, 606], ["PepKAA", "GENE_OR_GENE_PRODUCT", 613, 619], ["ACE2", "GENE_OR_GENE_PRODUCT", 622, 626], ["S protein", "PROTEIN", 437, 446], ["ACE2", "PROTEIN", 456, 460], ["S protein", "PROTEIN", 462, 471], ["ACE2", "PROTEIN", 478, 482], ["S protein", "PROTEIN", 484, 493], ["Mo-", "PROTEIN", 502, 505], ["CBP3", "PROTEIN", 505, 509], ["PepII", "PROTEIN", 510, 515], ["ACE2", "PROTEIN", 517, 521], ["S protein", "PROTEIN", 523, 532], ["Mo-CBP3", "PROTEIN", 539, 546], ["PepII", "PROTEIN", 547, 552], ["ACE2", "PROTEIN", 554, 558], ["S protein", "PROTEIN", 560, 569], ["PepKAA", "PROTEIN", 578, 584], ["ACE2", "PROTEIN", 587, 591], ["S protein", "PROTEIN", 597, 606], ["PepKAA", "PROTEIN", 613, 619], ["ACE2", "PROTEIN", 622, 626], ["the analysis", "TEST", 35, 47], ["a higher stabilized state", "PROBLEM", 381, 406], ["ACE2", "TEST", 456, 460], ["ACE2", "TEST", 478, 482], ["CBP3", "TEST", 505, 509], ["ACE2", "TEST", 517, 521], ["Mo-CBP3", "TEST", 539, 546], ["ACE2", "TEST", 554, 558], ["ACE2", "TEST", 587, 591], ["ACE2", "TEST", 622, 626], ["PIPER energy", "OBSERVATION", 55, 67], ["cluster", "OBSERVATION_MODIFIER", 89, 96], ["largest", "OBSERVATION_MODIFIER", 134, 141], ["number", "OBSERVATION_MODIFIER", 142, 148], ["neighboring structures", "OBSERVATION", 152, 174], ["center", "OBSERVATION_MODIFIER", 182, 188], ["cluster", "OBSERVATION_MODIFIER", 196, 203], ["lowest", "OBSERVATION_MODIFIER", 264, 270], ["energy", "OBSERVATION_MODIFIER", 271, 277], ["cluster", "OBSERVATION_MODIFIER", 285, 292]]], ["Initially, the topology was recorded using the OPLS-AA/L all-atom force field [31,32], after a cubic box was created with 2 nm from the box edge.", [["the OPLS", "TEST", 43, 51], ["a cubic box", "TREATMENT", 93, 104], ["box edge", "OBSERVATION", 136, 144]]], ["The box solvation was done with the SPC/E water model.", [["The box solvation", "TEST", 0, 17], ["the SPC/E water model", "TREATMENT", 32, 53]]], ["The systems were neutralized and Na+ and Cl\u2212 ions were added at a concentration of 0.15 M. The minimization was carried out until reaching negative potential energy and maximum force under 1000 kJ mol\u22121 nm\u22121.", [["Na", "CHEMICAL", 33, 35], ["Cl\u2212", "CHEMICAL", 41, 44], ["Na+", "CHEMICAL", 33, 36], ["Cl\u2212", "CHEMICAL", 41, 44], ["Na+", "SIMPLE_CHEMICAL", 33, 36], ["Cl\u2212 ions", "SIMPLE_CHEMICAL", 41, 49], ["Na", "TEST", 33, 35], ["Cl\u2212 ions", "PROBLEM", 41, 49]]], ["Finally, the equilibration of temperature and pressure was performed for 100 ps.Analysis of the complexes interface ::: MethodologyThe database for structural analysis of 3D structures PDBdum (EMBL - EBI; http://www.ebi.ac.uk/pdbsum) was used to analyze the general content of the interface region resulting from the molecular docking tests.", [["the equilibration of temperature", "TEST", 9, 41], ["pressure", "TEST", 46, 54], ["structural analysis", "TEST", 148, 167], ["the molecular docking tests", "TEST", 313, 340]]], ["The Ligplot software was used to generate the 2D figures with the hydrogen bonds and the hydrophobic interactions, and the Pymol software was used to generate the figures with 3D structures [28].", [["hydrogen", "CHEMICAL", 66, 74], ["the hydrogen bonds", "TREATMENT", 62, 80], ["the Pymol software", "TEST", 119, 137]]], ["The Pymol software, in addition to being used to visualize the molecular structure of models, was also used to identify molecular interactions between complexes, identify polar and non-polar interactions, and perform the alignment of structures.", [["The Pymol software", "TEST", 0, 18], ["polar", "OBSERVATION_MODIFIER", 171, 176], ["non-polar interactions", "OBSERVATION", 181, 203]]], ["PyMol was also used to calculate RMSD and generate the score for the overlapping of structures.Refinement and validation of structures ::: MethodologyThe complex structures generated by the molecular docking tests were refined by the Galaxy Refine Complex, a tool belonging to the molecular interaction server GalaxyWEB.", [["GalaxyWEB", "SIMPLE_CHEMICAL", 310, 319], ["Galaxy Refine Complex", "PROTEIN", 234, 255], ["GalaxyWEB", "PROTEIN", 310, 319], ["the molecular docking tests", "TEST", 186, 213], ["complex", "OBSERVATION_MODIFIER", 154, 161]]], ["All 3D structures were validated for steric impediment by the MolProbity and PROCHECK servers.Antiviral potential of synthetic peptides ::: ResultsBefore molecular docking analyses, the peptides were analyzed in an antiviral sever to evaluate whether or not they had antiviral potential.", [["molecular docking analyses", "TEST", 154, 180], ["the peptides", "TREATMENT", 182, 194], ["synthetic peptides", "OBSERVATION", 117, 135]]], ["We only considered peptides that were at least 70% antiviral to be promising.", [["peptides", "PROBLEM", 19, 27]]], ["Among all peptides tested, only four that criterion: Mo-CBP3-PepI, Mo-CBP3-PepII, RcAlb-PepIII, and PepKAA, respectively with 70, 85, 84, 74% being antiviral (Supplementary Table 1).Interaction of SARS-Cov-2 spike glycoprotein with human ACE2 receptor ::: ResultsThe subunits and domains of spike protein are represented in Fig. 1, in which their two conformational states are also observed: the closed state (Fig. 1A) and the open state (Fig. 1B).", [["Mo-CBP3-PepI", "GENE_OR_GENE_PRODUCT", 53, 65], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 67, 80], ["RcAlb-PepIII", "GENE_OR_GENE_PRODUCT", 82, 94], ["PepKAA", "GENE_OR_GENE_PRODUCT", 100, 106], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 197, 207], ["human", "ORGANISM", 232, 237], ["ACE2", "GENE_OR_GENE_PRODUCT", 238, 242], ["Mo-CBP3", "PROTEIN", 53, 60], ["PepI", "PROTEIN", 61, 65], ["Mo-CBP3", "PROTEIN", 67, 74], ["PepII", "PROTEIN", 75, 80], ["RcAlb", "PROTEIN", 82, 87], ["PepIII", "PROTEIN", 88, 94], ["PepKAA", "PROTEIN", 100, 106], ["SARS-Cov-2 spike glycoprotein", "PROTEIN", 197, 226], ["human ACE2 receptor", "PROTEIN", 232, 251], ["spike protein", "PROTEIN", 291, 304], ["Fig. 1B", "PROTEIN", 439, 446], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["all peptides", "TEST", 6, 18], ["Mo-CBP3", "TEST", 53, 60], ["PepI", "TEST", 61, 65], ["Mo-CBP3", "TEST", 67, 74], ["PepII", "TEST", 75, 80], ["RcAlb", "TEST", 82, 87], ["PepIII", "TREATMENT", 88, 94], ["PepKAA", "TEST", 100, 106], ["antiviral (Supplementary Table", "TREATMENT", 148, 178], ["SARS", "PROBLEM", 197, 201], ["The subunits", "TREATMENT", 263, 275], ["spike protein", "PROBLEM", 291, 304], ["Fig", "OBSERVATION_MODIFIER", 324, 327]]], ["As expected, in the open state (Fig. 1B) the receptor-binding domain (RBD) responsible for interacting with the human ACE2 receptor was positioned outside the structure, favoring interaction with ACE2 (Fig. 1B).", [["human", "ORGANISM", 112, 117], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 118, 131], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 202, 209], ["receptor-binding domain", "PROTEIN", 45, 68], ["RBD", "PROTEIN", 70, 73], ["human ACE2 receptor", "PROTEIN", 112, 131], ["ACE2", "PROTEIN", 196, 200], ["Fig. 1B", "PROTEIN", 202, 209], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["the human ACE2 receptor", "TREATMENT", 108, 131]]], ["Additionally, it the S1 and S2 domains of spike protein, which are respectively responsible for the S1 domain's interaction with human ACE2 and viral and cell membrane fusion before entrance (Fig. 1A and B) [7].", [["cell membrane", "ANATOMY", 154, 167], ["S2", "GENE_OR_GENE_PRODUCT", 28, 30], ["human", "ORGANISM", 129, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["cell membrane", "CELLULAR_COMPONENT", 154, 167], ["S1 and S2 domains", "PROTEIN", 21, 38], ["spike protein", "PROTEIN", 42, 55], ["S1 domain", "PROTEIN", 100, 109], ["human ACE2", "PROTEIN", 129, 139], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["spike protein", "PROBLEM", 42, 55], ["the S1 domain's interaction", "PROBLEM", 96, 123], ["human ACE2", "TREATMENT", 129, 139], ["viral and cell membrane fusion", "TREATMENT", 144, 174], ["S1", "ANATOMY", 21, 23], ["S2", "ANATOMY", 28, 30], ["spike protein", "OBSERVATION", 42, 55], ["cell membrane fusion", "OBSERVATION", 154, 174]]], ["The results of blind molecular docking assays performed by Cluspro 2.0 revealed that in both closed (Fig. 1C) and open (Fig. 1D) state, the spike protein can interact with ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["spike protein", "PROTEIN", 140, 153], ["ACE2", "PROTEIN", 172, 176], ["blind molecular docking assays", "TEST", 15, 45], ["Cluspro", "TEST", 59, 66], ["open (Fig. 1D)", "TREATMENT", 114, 128]]], ["Fig. 1D insert is a zoom view of the interaction between spike protein and ACE2 receptor.Interaction of SARS-Cov-2 spike glycoprotein with human ACE2 receptor ::: ResultsThe interface region of the spike protein in the open state with ACE2 had the lowest energy among all the models generated, with the lowest binding energy (LBE), \u22121032.0 kJ\u00b7mol\u22121.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 75, 88], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["human", "ORGANISM", 139, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 235, 239], ["spike protein", "PROTEIN", 57, 70], ["ACE2 receptor", "PROTEIN", 75, 88], ["SARS-Cov-2 spike glycoprotein", "PROTEIN", 104, 133], ["human ACE2 receptor", "PROTEIN", 139, 158], ["spike protein", "PROTEIN", 198, 211], ["ACE2", "PROTEIN", 235, 239], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["1D insert", "TREATMENT", 5, 14], ["ACE2 receptor", "TREATMENT", 75, 88], ["SARS", "PROBLEM", 104, 108], ["the spike protein", "TEST", 194, 211], ["ACE2", "TEST", 235, 239], ["interface", "OBSERVATION_MODIFIER", 174, 183], ["region", "OBSERVATION_MODIFIER", 184, 190], ["spike", "OBSERVATION_MODIFIER", 198, 203]]], ["Thus it was used as a control for the analysis of the interaction between peptides and spike protein.", [["spike protein", "PROTEIN", 87, 100], ["the analysis", "TEST", 34, 46], ["the interaction between peptides", "PROBLEM", 50, 82], ["spike protein", "PROBLEM", 87, 100]]], ["In the closed state, spike protein binds to a different region of ACE2 with an LBE of \u2212899.0 kJ\u00b7mol\u22121 and interaction with 33 members.", [["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["spike protein", "PROTEIN", 21, 34], ["ACE2", "PROTEIN", 66, 70], ["spike protein binds", "PROBLEM", 21, 40], ["an LBE", "TEST", 76, 82]]], ["This model correlates with the literature data for the ACE2 region (31\u201341 interaction with spike protein; Uniprot: Q9BYF1 [33]), demonstrating the importance of open conformational state for binding with ACE2 and onset of infection (Fig. 1C).Interaction of SARS-Cov-2 spike glycoprotein with human ACE2 receptor ::: ResultsThese results confirm the predictions identified by [33], who suggested that spike protein must be in the open conformation to interact with the PD domain of ACE2 on the cell surface.", [["cell surface", "ANATOMY", 493, 505], ["infection", "DISEASE", 222, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 257, 267], ["human", "ORGANISM", 292, 297], ["ACE2", "GENE_OR_GENE_PRODUCT", 298, 302], ["ACE2", "GENE_OR_GENE_PRODUCT", 481, 485], ["cell surface", "CELLULAR_COMPONENT", 493, 505], ["ACE2 region", "PROTEIN", 55, 66], ["spike protein", "PROTEIN", 91, 104], ["ACE2", "PROTEIN", 204, 208], ["SARS-Cov-2 spike glycoprotein", "PROTEIN", 257, 286], ["human ACE2 receptor", "PROTEIN", 292, 311], ["spike protein", "PROTEIN", 400, 413], ["PD domain", "PROTEIN", 468, 477], ["ACE2", "PROTEIN", 481, 485], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["the ACE2 region", "PROBLEM", 51, 66], ["ACE2", "TREATMENT", 204, 208], ["infection", "PROBLEM", 222, 231], ["SARS", "PROBLEM", 257, 261], ["spike protein", "PROBLEM", 400, 413], ["the PD domain of ACE2 on the cell surface", "TREATMENT", 464, 505], ["infection", "OBSERVATION", 222, 231]]], ["The spike glycoprotein must expose the RBD domain for the interaction to occur, because in the closed conformational state, the ACE2 recognition motifs (RBDs) are buried at the interface between the proteins.Molecular docking of SARS-Cov-2 S protein with peptides ::: ResultsThe molecular docking experiments were performed using the eight peptides against spike protein in both open (Fig. 2) and closed (Fig. 3) states.", [["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 229, 239], ["spike glycoprotein", "PROTEIN", 4, 22], ["RBD domain", "PROTEIN", 39, 49], ["ACE2 recognition motifs", "PROTEIN", 128, 151], ["RBDs", "PROTEIN", 153, 157], ["SARS-Cov-2 S protein", "PROTEIN", 229, 249], ["spike protein", "PROTEIN", 357, 370], ["The spike glycoprotein", "PROBLEM", 0, 22], ["SARS", "TEST", 229, 233], ["Cov", "TEST", 234, 237], ["The molecular docking experiments", "TEST", 275, 308], ["the eight peptides", "TREATMENT", 330, 348], ["spike protein", "PROBLEM", 357, 370]]], ["MD assays with the open state of spike protein showed that Mo-CBP3-PepI, Mo-CBP3-PepII, Mo-CBP3-PepIII, RcAlb-PepI, RcAlb-PepII and PepGAT interact with the S1 domain (Fig. 2A\u2013E, G).", [["Mo-CBP3-PepI", "GENE_OR_GENE_PRODUCT", 59, 71], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 73, 86], ["Mo-CBP3-PepIII", "GENE_OR_GENE_PRODUCT", 88, 102], ["RcAlb-PepI", "GENE_OR_GENE_PRODUCT", 104, 114], ["RcAlb-PepII", "GENE_OR_GENE_PRODUCT", 116, 127], ["PepGAT", "GENE_OR_GENE_PRODUCT", 132, 138], ["2A\u2013E", "SIMPLE_CHEMICAL", 173, 177], ["spike protein", "PROTEIN", 33, 46], ["Mo-CBP3", "PROTEIN", 59, 66], ["PepI", "PROTEIN", 67, 71], ["Mo-CBP3", "PROTEIN", 73, 80], ["PepII", "PROTEIN", 81, 86], ["Mo-CBP3", "PROTEIN", 88, 95], ["PepIII", "PROTEIN", 96, 102], ["RcAlb", "PROTEIN", 104, 109], ["PepI", "PROTEIN", 110, 114], ["RcAlb", "PROTEIN", 116, 121], ["PepII", "PROTEIN", 122, 127], ["PepGAT", "PROTEIN", 132, 138], ["S1 domain", "PROTEIN", 157, 166], ["spike protein", "TEST", 33, 46], ["Mo-CBP3", "TEST", 59, 66], ["PepI", "TEST", 67, 71], ["Mo-CBP3", "TEST", 73, 80], ["PepII", "TREATMENT", 81, 86], ["Mo-CBP3", "TREATMENT", 88, 95], ["PepIII", "TREATMENT", 96, 102], ["RcAlb", "TREATMENT", 104, 109], ["PepI", "TREATMENT", 110, 114], ["RcAlb", "TREATMENT", 116, 121], ["PepII", "TREATMENT", 122, 127], ["PepGAT", "TREATMENT", 132, 138]]], ["In contrast, RcAlb-PepIII and PepKAA interacted with the S2 domain (Fig. 2F and H).", [["RcAlb-PepIII", "GENE_OR_GENE_PRODUCT", 13, 25], ["PepKAA", "GENE_OR_GENE_PRODUCT", 30, 36], ["RcAlb", "PROTEIN", 13, 18], ["PepIII", "PROTEIN", 19, 25], ["PepKAA", "PROTEIN", 30, 36], ["S2 domain", "PROTEIN", 57, 66], ["RcAlb", "TEST", 13, 18], ["PepIII", "TREATMENT", 19, 25], ["PepKAA", "TREATMENT", 30, 36]]], ["Similar results were found out during the MD assays with peptides against the closed state of spike protein (Fig. 3).", [["spike protein", "PROTEIN", 94, 107], ["the MD assays", "TEST", 38, 51], ["peptides", "TREATMENT", 57, 65], ["spike protein", "PROBLEM", 94, 107]]], ["Only one difference was observed: in this model, RcAlb-PepIII interacted with the S1 domain of the spike protein instead of S2 as in the open state (Fig. 3G).Molecular docking of SARS-Cov-2 S protein with peptides ::: ResultsThe number of hydrogen bonds and hydrophobic interactions of the peptides and spike protein suggests their strong interaction, in both open (Table 1) and closed (Table 2) states.", [["hydrogen", "CHEMICAL", 239, 247], ["hydrogen", "CHEMICAL", 239, 247], ["RcAlb-PepIII", "GENE_OR_GENE_PRODUCT", 49, 61], ["S2", "GENE_OR_GENE_PRODUCT", 124, 126], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 179, 189], ["RcAlb", "PROTEIN", 49, 54], ["PepIII", "PROTEIN", 55, 61], ["S1 domain", "PROTEIN", 82, 91], ["spike protein", "PROTEIN", 99, 112], ["S2", "PROTEIN", 124, 126], ["SARS-Cov-2 S protein", "PROTEIN", 179, 199], ["spike protein", "PROTEIN", 303, 316], ["RcAlb", "TEST", 49, 54], ["PepIII", "TREATMENT", 55, 61], ["SARS", "TEST", 179, 183], ["Cov", "TEST", 184, 187], ["hydrogen bonds", "TREATMENT", 239, 253], ["the peptides", "TREATMENT", 286, 298], ["spike protein", "TEST", 303, 316], ["one", "OBSERVATION_MODIFIER", 5, 8], ["difference", "OBSERVATION", 9, 19], ["hydrogen bonds", "OBSERVATION", 239, 253], ["hydrophobic interactions", "OBSERVATION", 258, 282], ["strong", "OBSERVATION_MODIFIER", 332, 338]]], ["Our results revealed distinct behaviors of peptides when in contact with spike protein.", [["spike protein", "PROTEIN", 73, 86], ["distinct behaviors of peptides", "PROBLEM", 21, 51], ["spike protein", "PROBLEM", 73, 86], ["distinct", "OBSERVATION_MODIFIER", 21, 29]]], ["Among the peptides that interacted with the S1 domain, Mo-CBP3-PepII presented the lowest binding energy, of \u2212814.4 kJ\u00b7mol\u22121 (Table 1), and the highest number of interactions (185), of which 170 were hydrophobic interactions and 15 were hydrogen bonds in the open state, and 173 were hydrophobic interactions and 12 were hydrogen bonds in the closed state (Table 1, Table 2).Stable and balanced structures ::: ResultsAll structures were minimized with potential energy of about \u22122.5 \u00d7 10\u22127 after 5500 energy minimization steps and maximum force of less than 1000 kJ mol\u22121 nm\u22121 (Fig. 4A).", [["Mo-CBP3", "CHEMICAL", 55, 62], ["PepII", "CHEMICAL", 63, 68], ["hydrogen", "CHEMICAL", 237, 245], ["hydrogen", "CHEMICAL", 321, 329], ["Mo-CBP3-PepII", "GENE_OR_GENE_PRODUCT", 55, 68], ["S1 domain", "PROTEIN", 44, 53], ["Mo-CBP3", "PROTEIN", 55, 62], ["PepII", "PROTEIN", 63, 68], ["Mo-CBP3", "TEST", 55, 62], ["hydrogen bonds", "TEST", 237, 251], ["highest", "OBSERVATION_MODIFIER", 144, 151]]], ["The minimized structures occurred at the equilibrium of temperature.", [["The minimized structures", "PROBLEM", 0, 24]]], ["From 5 to 100 ps, the temperature of all complexes was balanced at 300 K, with small variations (Fig. 4B).", [["the temperature", "TEST", 18, 33], ["small variations (Fig. 4B", "PROBLEM", 79, 104], ["small", "OBSERVATION_MODIFIER", 79, 84], ["variations", "OBSERVATION_MODIFIER", 85, 95]]], ["Finally, with variable pressure and density it was possible to observe equilibrium after 5 ps and continuing stability until 100 ps.", [["5 ps", "TREATMENT", 89, 93], ["density", "OBSERVATION", 36, 43]]], ["The pressure and density equilibrium were achieved at about 0 bar and 1015 kg m\u22123, respectively (Fig. 4C and D).", [["The pressure and density equilibrium", "TEST", 0, 36], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["density", "OBSERVATION_MODIFIER", 17, 24], ["equilibrium", "OBSERVATION_MODIFIER", 25, 36]]], ["The final stable complexes were used in the subsequent analyses.Interaction of SARS-Cov-2 S protein with peptides ::: Results", [["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["SARS-Cov-2 S protein", "PROTEIN", 79, 99], ["the subsequent analyses", "TEST", 40, 63], ["SARS", "TEST", 79, 83], ["Cov", "TEST", 84, 87], ["stable", "OBSERVATION_MODIFIER", 10, 16]]]], "297848f6922ed4a206bd99462ef143fe40a7c253": [["1 From The Codman Shoulder Society: 1", [["Shoulder", "ANATOMY", 18, 26], ["Society", "OBSERVATION", 27, 34]]]], "a36ff9ac7a441a594c80f7f4bbfeebe918171fb9": [["The anti-tumor immune response and the immune profile of tumorsThe innate and the adaptive immune system work together to detect transformed cells and remove them before they form a tumor [1] .", [["tumors", "ANATOMY", 57, 63], ["immune system", "ANATOMY", 91, 104], ["cells", "ANATOMY", 141, 146], ["tumor", "ANATOMY", 182, 187], ["tumors", "DISEASE", 57, 63], ["tumor", "DISEASE", 182, 187], ["anti-tumor", "CANCER", 4, 14], ["tumors", "CANCER", 57, 63], ["cells", "CELL", 141, 146], ["tumor", "CANCER", 182, 187], ["transformed cells", "CELL_LINE", 129, 146], ["tumors", "PROBLEM", 57, 63], ["a tumor", "PROBLEM", 180, 187], ["anti-tumor immune", "OBSERVATION", 4, 21], ["tumors", "OBSERVATION", 57, 63], ["tumor", "OBSERVATION", 182, 187]]], ["The anti-tumor response starts with the release of tumor associated antigens (TAA) from dying cancer cells and accompanying signal molecules, which attract and activate cells of the innate immune system [2, 3] .", [["tumor", "ANATOMY", 51, 56], ["cancer cells", "ANATOMY", 94, 106], ["cells", "ANATOMY", 169, 174], ["tumor", "DISEASE", 51, 56], ["TAA", "DISEASE", 78, 81], ["cancer", "DISEASE", 94, 100], ["anti-tumor", "CANCER", 4, 14], ["tumor", "CANCER", 51, 56], ["TAA", "SIMPLE_CHEMICAL", 78, 81], ["cancer cells", "CELL", 94, 106], ["cells", "CELL", 169, 174], ["tumor associated antigens", "PROTEIN", 51, 76], ["TAA", "PROTEIN", 78, 81], ["dying cancer cells", "CELL_TYPE", 88, 106], ["signal molecules", "PROTEIN", 124, 140], ["tumor associated antigens", "PROBLEM", 51, 76], ["dying cancer cells", "PROBLEM", 88, 106], ["accompanying signal molecules", "PROBLEM", 111, 140], ["tumor", "OBSERVATION", 51, 56], ["cancer cells", "OBSERVATION", 94, 106], ["signal molecules", "OBSERVATION", 124, 140]]], ["Whereas NK and \u03b3d-T cells can recognize and kill tumor cells directly, antigen presenting cells (APCs), such as DCs and macrophages, take up TAAs to activate the adaptive immune system [4, 5] .", [["NK", "ANATOMY", 8, 10], ["\u03b3d-T cells", "ANATOMY", 15, 25], ["tumor cells", "ANATOMY", 49, 60], ["antigen presenting cells", "ANATOMY", 71, 95], ["APCs", "ANATOMY", 97, 101], ["DCs", "ANATOMY", 112, 115], ["macrophages", "ANATOMY", 120, 131], ["tumor", "DISEASE", 49, 54], ["NK", "CELL", 8, 10], ["\u03b3d-T cells", "CELL", 15, 25], ["tumor cells", "CELL", 49, 60], ["antigen presenting cells", "CELL", 71, 95], ["APCs", "CELL", 97, 101], ["DCs", "CELL", 112, 115], ["macrophages", "CELL", 120, 131], ["TAAs", "GENE_OR_GENE_PRODUCT", 141, 145], ["NK and \u03b3d-T cells", "CELL_TYPE", 8, 25], ["tumor cells", "CELL_TYPE", 49, 60], ["antigen presenting cells", "CELL_TYPE", 71, 95], ["APCs", "CELL_TYPE", 97, 101], ["DCs", "CELL_TYPE", 112, 115], ["macrophages", "CELL_TYPE", 120, 131], ["kill tumor cells", "PROBLEM", 44, 60], ["macrophages", "PROBLEM", 120, 131]]], ["The maturation of APCs by the accompanying danger signal molecules determines the skewing to a preferred T helper cell (Th) 1 response.", [["APCs", "ANATOMY", 18, 22], ["T helper cell", "ANATOMY", 105, 118], ["APCs", "CELL", 18, 22], ["T helper cell", "CELL", 105, 118], ["Th) 1", "GENE_OR_GENE_PRODUCT", 120, 125], ["APCs", "CELL_TYPE", 18, 22], ["T helper cell", "CELL_TYPE", 105, 118]]], ["These Th1 signals constitute of pro-inflammatory cytokines, such as interleukin (IL)-12, type I interferons (IFNs) and tumor necrosis factor (TNF), and damageassociated molecular pattern molecules (DAMPs), such as nuclear protein HMGB1, heat-shock proteins and ATP, [3] .", [["nuclear", "ANATOMY", 214, 221], ["necrosis", "DISEASE", 125, 133], ["ATP", "CHEMICAL", 261, 264], ["ATP", "CHEMICAL", 261, 264], ["interleukin (IL)-12", "GENE_OR_GENE_PRODUCT", 68, 87], ["type I interferons", "GENE_OR_GENE_PRODUCT", 89, 107], ["IFNs", "GENE_OR_GENE_PRODUCT", 109, 113], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 119, 140], ["TNF", "GENE_OR_GENE_PRODUCT", 142, 145], ["damageassociated molecular pattern molecules", "GENE_OR_GENE_PRODUCT", 152, 196], ["DAMPs", "GENE_OR_GENE_PRODUCT", 198, 203], ["HMGB1", "GENE_OR_GENE_PRODUCT", 230, 235], ["heat-shock proteins", "GENE_OR_GENE_PRODUCT", 237, 256], ["ATP", "SIMPLE_CHEMICAL", 261, 264], ["pro-inflammatory cytokines", "PROTEIN", 32, 58], ["interleukin (IL)-12", "PROTEIN", 68, 87], ["type I interferons", "PROTEIN", 89, 107], ["IFNs", "PROTEIN", 109, 113], ["tumor necrosis factor", "PROTEIN", 119, 140], ["TNF", "PROTEIN", 142, 145], ["damageassociated molecular pattern molecules", "PROTEIN", 152, 196], ["DAMPs", "PROTEIN", 198, 203], ["nuclear protein", "PROTEIN", 214, 229], ["HMGB1", "PROTEIN", 230, 235], ["heat-shock proteins", "PROTEIN", 237, 256], ["pro-inflammatory cytokines", "PROBLEM", 32, 58], ["interleukin (IL)", "TREATMENT", 68, 84], ["type I interferons (IFNs)", "PROBLEM", 89, 114], ["tumor necrosis factor", "PROBLEM", 119, 140], ["TNF", "TEST", 142, 145], ["damageassociated molecular pattern molecules (DAMPs)", "PROBLEM", 152, 204], ["nuclear protein HMGB1", "TEST", 214, 235], ["shock proteins", "TREATMENT", 242, 256], ["ATP", "TEST", 261, 264], ["pro-inflammatory cytokines", "OBSERVATION", 32, 58], ["tumor", "OBSERVATION_MODIFIER", 119, 124], ["necrosis", "OBSERVATION", 125, 133]]], ["The Th1 cytokines stimulate the generation of tumor specific cytotoxic CD8+ T cells (CTLs), which are crucial effector cells in the antitumor response [6] .", [["tumor", "ANATOMY", 46, 51], ["cytotoxic CD8+ T cells", "ANATOMY", 61, 83], ["CTLs", "ANATOMY", 85, 89], ["cells", "ANATOMY", 119, 124], ["antitumor", "ANATOMY", 132, 141], ["tumor", "DISEASE", 46, 51], ["tumor", "CANCER", 46, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["CTLs", "CELL", 85, 89], ["cells", "CELL", 119, 124], ["antitumor", "CANCER", 132, 141], ["Th1 cytokines", "PROTEIN", 4, 17], ["tumor specific cytotoxic CD8+ T cells", "CELL_TYPE", 46, 83], ["CTLs", "CELL_TYPE", 85, 89], ["effector cells", "CELL_TYPE", 110, 124], ["The Th1 cytokines", "TREATMENT", 0, 17], ["CTLs", "TEST", 85, 89], ["tumor", "OBSERVATION", 46, 51], ["cytotoxic CD8", "OBSERVATION", 61, 74], ["effector cells", "OBSERVATION", 110, 124]]], ["Subsequently, effector T cells, including T helper cells and CTLs, are attracted to the tumor site via a gradient of T cell attracting chemokines, including chemokine (C-C motif) ligand 2 (CCL2), CCL5/ RANTES, chemokine (C-X-C motif) ligand 9 (CXCL9), and CXCL10 [7] .", [["effector T cells", "ANATOMY", 14, 30], ["T helper cells", "ANATOMY", 42, 56], ["CTLs", "ANATOMY", 61, 65], ["tumor site", "ANATOMY", 88, 98], ["T cell", "ANATOMY", 117, 123], ["tumor", "DISEASE", 88, 93], ["effector T cells", "CELL", 14, 30], ["T helper cells", "CELL", 42, 56], ["CTLs", "CELL", 61, 65], ["tumor", "CANCER", 88, 93], ["T cell", "CELL", 117, 123], ["C-C motif) ligand 2", "GENE_OR_GENE_PRODUCT", 168, 187], ["CCL2", "GENE_OR_GENE_PRODUCT", 189, 193], ["CCL5", "GENE_OR_GENE_PRODUCT", 196, 200], ["RANTES", "GENE_OR_GENE_PRODUCT", 202, 208], ["C-X-C motif) ligand 9", "GENE_OR_GENE_PRODUCT", 221, 242], ["CXCL9", "GENE_OR_GENE_PRODUCT", 244, 249], ["CXCL10", "GENE_OR_GENE_PRODUCT", 256, 262], ["effector T cells", "CELL_TYPE", 14, 30], ["T helper cells", "CELL_TYPE", 42, 56], ["CTLs", "CELL_TYPE", 61, 65], ["chemokines", "PROTEIN", 135, 145], ["chemokine (C-C motif) ligand 2", "PROTEIN", 157, 187], ["CCL2", "PROTEIN", 189, 193], ["CCL5", "PROTEIN", 196, 200], ["RANTES", "PROTEIN", 202, 208], ["chemokine", "PROTEIN", 210, 219], ["C-X-C motif) ligand 9", "PROTEIN", 221, 242], ["CXCL9", "PROTEIN", 244, 249], ["CXCL10", "PROTEIN", 256, 262], ["effector T cells", "PROBLEM", 14, 30], ["T helper cells", "TREATMENT", 42, 56], ["CTLs", "TEST", 61, 65], ["T cell attracting chemokines", "TREATMENT", 117, 145], ["chemokine (C-C motif) ligand", "TREATMENT", 157, 185], ["CCL2", "TEST", 189, 193], ["CCL5", "TEST", 196, 200], ["RANTES", "TEST", 202, 208], ["chemokine", "TEST", 210, 219], ["C", "TEST", 221, 222], ["motif) ligand", "TEST", 227, 240], ["CXCL9", "TEST", 244, 249], ["CXCL10", "TEST", 256, 262], ["tumor", "OBSERVATION", 88, 93]]], ["At the site, CTLs recognize and kill tumor cells mediated by MHCI-T cell receptor interactions.", [["CTLs", "ANATOMY", 13, 17], ["tumor cells", "ANATOMY", 37, 48], ["T cell", "ANATOMY", 66, 72], ["tumor", "DISEASE", 37, 42], ["CTLs", "CELL", 13, 17], ["tumor cells", "CELL", 37, 48], ["MHCI-T cell receptor", "GENE_OR_GENE_PRODUCT", 61, 81], ["CTLs", "CELL_TYPE", 13, 17], ["tumor cells", "CELL_TYPE", 37, 48], ["MHCI", "PROTEIN", 61, 65], ["kill tumor cells", "PROBLEM", 32, 48]]], ["If the immune system succeeds in destruction of the beginning tumor, the host remains free of cancer.The anti-tumor immune response and the immune profile of tumorsIn some cases, tumor cells are reprogrammed to evade the immune system resulting in an equilibrium between dying tumor cells and tumor cells surviving the immune attack.", [["immune system", "ANATOMY", 7, 20], ["tumor", "ANATOMY", 62, 67], ["cancer", "ANATOMY", 94, 100], ["tumors", "ANATOMY", 158, 164], ["tumor cells", "ANATOMY", 179, 190], ["immune system", "ANATOMY", 221, 234], ["tumor cells", "ANATOMY", 277, 288], ["tumor cells", "ANATOMY", 293, 304], ["tumor", "DISEASE", 62, 67], ["cancer", "DISEASE", 94, 100], ["tumors", "DISEASE", 158, 164], ["tumor", "DISEASE", 179, 184], ["tumor", "DISEASE", 277, 282], ["tumor", "DISEASE", 293, 298], ["tumor", "CANCER", 62, 67], ["cancer", "CANCER", 94, 100], ["anti-tumor", "CANCER", 105, 115], ["tumors", "CANCER", 158, 164], ["tumor cells", "CELL", 179, 190], ["tumor cells", "CELL", 277, 288], ["tumor cells", "CELL", 293, 304], ["tumor cells", "CELL_TYPE", 179, 190], ["dying tumor cells", "CELL_TYPE", 271, 288], ["tumor cells", "CELL_TYPE", 293, 304], ["destruction", "PROBLEM", 33, 44], ["the beginning tumor", "PROBLEM", 48, 67], ["cancer", "PROBLEM", 94, 100], ["tumors", "PROBLEM", 158, 164], ["tumor cells", "PROBLEM", 179, 190], ["an equilibrium between dying tumor cells", "PROBLEM", 248, 288], ["tumor cells", "PROBLEM", 293, 304], ["beginning", "OBSERVATION_MODIFIER", 52, 61], ["tumor", "OBSERVATION", 62, 67], ["cancer", "OBSERVATION", 94, 100], ["anti-tumor immune", "OBSERVATION", 105, 122], ["tumors", "OBSERVATION", 158, 164], ["tumor cells", "OBSERVATION", 179, 190], ["tumor cells", "OBSERVATION", 277, 288], ["tumor cells", "OBSERVATION", 293, 304], ["immune attack", "OBSERVATION", 319, 332]]], ["As a consequence, a selection of immunosuppressive or less immunogenic tumor cell variants is introduced, which cannot be eliminated by the immune system [8] .", [["tumor cell", "ANATOMY", 71, 81], ["tumor", "DISEASE", 71, 76], ["tumor cell", "CELL", 71, 81], ["immunogenic tumor cell variants", "CELL_LINE", 59, 90], ["immunosuppressive", "TREATMENT", 33, 50], ["less immunogenic tumor cell variants", "PROBLEM", 54, 90], ["immunosuppressive", "OBSERVATION_MODIFIER", 33, 50], ["less", "OBSERVATION_MODIFIER", 54, 58], ["immunogenic", "OBSERVATION_MODIFIER", 59, 70], ["tumor cell variants", "OBSERVATION", 71, 90]]], ["These tumor cells establish a tumor microenvironment (TME), in which the function of anti-tumor immune cells is attenuated ( Fig. 1 ) [9] .", [["tumor cells", "ANATOMY", 6, 17], ["tumor", "ANATOMY", 30, 35], ["anti-tumor immune cells", "ANATOMY", 85, 108], ["tumor", "DISEASE", 6, 11], ["tumor", "DISEASE", 30, 35], ["tumor cells", "CELL", 6, 17], ["tumor", "CANCER", 30, 35], ["anti-tumor immune cells", "CELL", 85, 108], ["tumor cells", "CELL_TYPE", 6, 17], ["anti-tumor immune cells", "CELL_TYPE", 85, 108], ["These tumor cells", "PROBLEM", 0, 17], ["a tumor microenvironment", "PROBLEM", 28, 52], ["anti-tumor immune cells", "TREATMENT", 85, 108], ["tumor cells", "OBSERVATION", 6, 17], ["tumor", "OBSERVATION", 30, 35], ["anti-tumor immune cells", "OBSERVATION", 85, 108]]], ["First of all, tumor cells and stromal cells (endothelial and epithelial cells and fibroblasts) produce factors such as transforming growth factor-\u03b2 (TGF\u03b2), prostaglandin E2 (PGE2) and IL-10, that disrupt APC maturation in the TME [3, 7, 9] .", [["tumor cells", "ANATOMY", 14, 25], ["stromal cells", "ANATOMY", 30, 43], ["endothelial", "ANATOMY", 45, 56], ["epithelial cells", "ANATOMY", 61, 77], ["fibroblasts", "ANATOMY", 82, 93], ["tumor", "DISEASE", 14, 19], ["prostaglandin E2", "CHEMICAL", 156, 172], ["PGE2", "CHEMICAL", 174, 178], ["prostaglandin E2", "CHEMICAL", 156, 172], ["PGE2", "CHEMICAL", 174, 178], ["tumor cells", "CELL", 14, 25], ["stromal cells", "CELL", 30, 43], ["endothelial", "CELL", 45, 56], ["epithelial cells", "CELL", 61, 77], ["fibroblasts", "CELL", 82, 93], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 119, 147], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 149, 153], ["prostaglandin E2", "SIMPLE_CHEMICAL", 156, 172], ["PGE2", "SIMPLE_CHEMICAL", 174, 178], ["IL-10", "GENE_OR_GENE_PRODUCT", 184, 189], ["APC", "GENE_OR_GENE_PRODUCT", 204, 207], ["tumor cells", "CELL_TYPE", 14, 25], ["stromal cells", "CELL_TYPE", 30, 43], ["endothelial and epithelial cells", "CELL_TYPE", 45, 77], ["fibroblasts", "CELL_TYPE", 82, 93], ["transforming growth factor-\u03b2", "PROTEIN", 119, 147], ["TGF\u03b2", "PROTEIN", 149, 153], ["prostaglandin E2", "PROTEIN", 156, 172], ["PGE2", "PROTEIN", 174, 178], ["IL", "PROTEIN", 184, 186], ["APC", "CELL_TYPE", 204, 207], ["all, tumor cells", "PROBLEM", 9, 25], ["stromal cells", "PROBLEM", 30, 43], ["epithelial cells", "PROBLEM", 61, 77], ["fibroblasts) produce factors", "PROBLEM", 82, 110], ["transforming growth factor", "PROBLEM", 119, 145], ["TGF", "TEST", 149, 152], ["prostaglandin E2 (PGE2", "TREATMENT", 156, 178], ["IL", "TREATMENT", 184, 186], ["tumor cells", "OBSERVATION", 14, 25], ["stromal cells", "OBSERVATION", 30, 43], ["endothelial", "ANATOMY", 45, 56], ["epithelial cells", "OBSERVATION", 61, 77]]], ["As a result, DCs isolated from the TME often display a partly matured, immune suppressive phenotype and secrete cytokines that induce non-favorable Th2 responses [7] .", [["DCs", "ANATOMY", 13, 16], ["TME", "ANATOMY", 35, 38], ["DCs", "CELL", 13, 16], ["DCs", "CELL_TYPE", 13, 16], ["cytokines", "PROTEIN", 112, 121], ["immune suppressive phenotype", "PROBLEM", 71, 99], ["secrete cytokines", "TEST", 104, 121]]], ["Secondly, tumors inhibit infiltration of effector T cells by repressing the production of T cell attracting chemokines CXCL9/10 and modification of CCL2 [7, 10] .The anti-tumor immune response and the immune profile of tumorsThirdly, effector T cells that can infiltrate the tumor are attenuated by expression of several immunosuppressive molecules and persistent exposure to tumor antigens.", [["tumors", "ANATOMY", 10, 16], ["effector T cells", "ANATOMY", 41, 57], ["T cell", "ANATOMY", 90, 96], ["tumors", "ANATOMY", 219, 225], ["effector T cells", "ANATOMY", 234, 250], ["tumor", "ANATOMY", 275, 280], ["tumor", "ANATOMY", 376, 381], ["tumors", "DISEASE", 10, 16], ["tumors", "DISEASE", 219, 225], ["tumor", "DISEASE", 275, 280], ["tumor", "DISEASE", 376, 381], ["tumors", "CANCER", 10, 16], ["effector T cells", "CELL", 41, 57], ["T cell", "CELL", 90, 96], ["CXCL9", "GENE_OR_GENE_PRODUCT", 119, 124], ["10", "GENE_OR_GENE_PRODUCT", 125, 127], ["CCL2", "GENE_OR_GENE_PRODUCT", 148, 152], ["anti-tumor", "CANCER", 166, 176], ["tumors", "CANCER", 219, 225], ["effector T cells", "CELL", 234, 250], ["tumor", "CANCER", 275, 280], ["tumor", "CANCER", 376, 381], ["effector T cells", "CELL_TYPE", 41, 57], ["chemokines", "PROTEIN", 108, 118], ["CXCL9", "PROTEIN", 119, 124], ["CCL2", "PROTEIN", 148, 152], ["effector T cells", "CELL_TYPE", 234, 250], ["immunosuppressive molecules", "PROTEIN", 321, 348], ["tumor antigens", "PROTEIN", 376, 390], ["tumors inhibit infiltration of effector T cells", "PROBLEM", 10, 57], ["CXCL9", "TEST", 119, 124], ["CCL2", "TEST", 148, 152], ["tumors", "PROBLEM", 219, 225], ["effector T cells", "PROBLEM", 234, 250], ["infiltrate the tumor", "PROBLEM", 260, 280], ["several immunosuppressive molecules", "PROBLEM", 313, 348], ["persistent exposure to tumor antigens", "PROBLEM", 353, 390], ["tumors", "OBSERVATION", 10, 16], ["infiltration", "OBSERVATION_MODIFIER", 25, 37], ["effector T cells", "OBSERVATION", 41, 57], ["anti-tumor immune", "OBSERVATION", 166, 183], ["tumors", "OBSERVATION", 219, 225], ["tumor", "OBSERVATION", 275, 280], ["several", "OBSERVATION_MODIFIER", 313, 320], ["immunosuppressive molecules", "OBSERVATION", 321, 348], ["persistent", "OBSERVATION_MODIFIER", 353, 363], ["tumor", "OBSERVATION", 376, 381]]], ["As a result, T helper cells and CTLs isolated from the TME often present an exhausted phenotype, characterized by high level expression of immune checkpoint receptors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) [10] .", [["T helper cells", "ANATOMY", 13, 27], ["CTLs", "ANATOMY", 32, 36], ["TME", "ANATOMY", 55, 58], ["T helper cells", "CELL", 13, 27], ["CTLs", "CELL", 32, 36], ["cytotoxic T-lymphocyte-associated protein 4", "GENE_OR_GENE_PRODUCT", 175, 218], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 220, 226], ["programmed cell death protein 1", "GENE_OR_GENE_PRODUCT", 232, 263], ["PD-1", "GENE_OR_GENE_PRODUCT", 265, 269], ["T helper cells", "CELL_TYPE", 13, 27], ["CTLs", "CELL_TYPE", 32, 36], ["immune checkpoint receptors", "PROTEIN", 139, 166], ["cytotoxic T-lymphocyte-associated protein 4 (CTLA-4", "PROTEIN", 175, 226], ["programmed cell death protein 1", "PROTEIN", 232, 263], ["CTLs", "TEST", 32, 36], ["an exhausted phenotype", "PROBLEM", 73, 95], ["immune checkpoint receptors", "PROBLEM", 139, 166], ["cytotoxic T", "TEST", 175, 186], ["lymphocyte", "TEST", 187, 197], ["protein", "TEST", 209, 216], ["CTLA", "TEST", 220, 224], ["programmed cell death protein", "TEST", 232, 261], ["PD", "TEST", 265, 267]]], ["Ligation of these receptors with their ligands expressed on tumor and stromal cells, but also immunosuppressed APCs, leads to inhibition of the tumor specific T cell response.", [["tumor", "ANATOMY", 60, 65], ["stromal cells", "ANATOMY", 70, 83], ["APCs", "ANATOMY", 111, 115], ["tumor", "ANATOMY", 144, 149], ["T cell", "ANATOMY", 159, 165], ["tumor", "DISEASE", 60, 65], ["tumor", "DISEASE", 144, 149], ["tumor", "CELL", 60, 65], ["stromal cells", "CELL", 70, 83], ["APCs", "CELL", 111, 115], ["tumor", "CANCER", 144, 149], ["T cell", "CELL", 159, 165], ["tumor and stromal cells", "CELL_TYPE", 60, 83], ["immunosuppressed APCs", "CELL_TYPE", 94, 115], ["Ligation", "TREATMENT", 0, 8], ["their ligands", "PROBLEM", 33, 46], ["tumor", "PROBLEM", 60, 65], ["stromal cells", "PROBLEM", 70, 83], ["immunosuppressed APCs", "PROBLEM", 94, 115], ["the tumor", "PROBLEM", 140, 149], ["tumor", "OBSERVATION", 60, 65], ["stromal cells", "OBSERVATION", 70, 83], ["tumor", "OBSERVATION", 144, 149], ["cell response", "OBSERVATION", 161, 174]]], ["Fourthly, regulatory immune cells such as CD4+ regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) are recruited to the tumor site.", [["immune cells", "ANATOMY", 21, 33], ["CD4+ regulatory T cells", "ANATOMY", 42, 65], ["Tregs", "ANATOMY", 67, 72], ["myeloid derived suppressor cells", "ANATOMY", 78, 110], ["MDSCs", "ANATOMY", 112, 117], ["tumor site", "ANATOMY", 140, 150], ["tumor", "DISEASE", 140, 145], ["immune cells", "CELL", 21, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["Tregs", "CELL", 67, 72], ["myeloid derived suppressor cells", "CELL", 78, 110], ["MDSCs", "CELL", 112, 117], ["tumor", "CANCER", 140, 145], ["regulatory immune cells", "CELL_TYPE", 10, 33], ["CD4", "PROTEIN", 42, 45], ["regulatory T cells", "CELL_TYPE", 47, 65], ["Tregs", "CELL_TYPE", 67, 72], ["myeloid derived suppressor cells", "CELL_TYPE", 78, 110], ["MDSCs", "CELL_TYPE", 112, 117], ["regulatory immune cells", "PROBLEM", 10, 33], ["CD4+ regulatory T cells", "PROBLEM", 42, 65], ["myeloid derived suppressor cells (MDSCs)", "TREATMENT", 78, 118], ["immune cells", "OBSERVATION", 21, 33], ["myeloid", "ANATOMY", 78, 85], ["suppressor cells", "OBSERVATION", 94, 110], ["tumor", "OBSERVATION", 140, 145]]], ["Similar to tumor cells, Tregs secrete IL-10, Indoleamine 2,3-dioxygenase (IDO) and TGF-\u03b2, leading to further attenuation of the T cell response [7, 11] .", [["tumor cells", "ANATOMY", 11, 22], ["Tregs", "ANATOMY", 24, 29], ["T cell", "ANATOMY", 128, 134], ["tumor", "DISEASE", 11, 16], ["Indoleamine", "CHEMICAL", 45, 56], ["tumor cells", "CELL", 11, 22], ["Tregs", "CELL", 24, 29], ["IL-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["Indoleamine 2,3-dioxygenase", "GENE_OR_GENE_PRODUCT", 45, 72], ["IDO", "GENE_OR_GENE_PRODUCT", 74, 77], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 83, 88], ["T cell", "CELL", 128, 134], ["tumor cells", "CELL_TYPE", 11, 22], ["Tregs", "CELL_TYPE", 24, 29], ["IL-10", "PROTEIN", 38, 43], ["Indoleamine 2,3-dioxygenase", "PROTEIN", 45, 72], ["IDO", "PROTEIN", 74, 77], ["TGF-\u03b2", "PROTEIN", 83, 88], ["tumor cells", "TEST", 11, 22], ["Tregs secrete IL", "TEST", 24, 40], ["Indoleamine", "TREATMENT", 45, 56], ["TGF", "TEST", 83, 86], ["tumor cells", "OBSERVATION", 11, 22]]], ["Furthermore, Tregs consume IL-2, which is indispensable for T cell activation [7] .", [["Tregs", "ANATOMY", 13, 18], ["T cell", "ANATOMY", 60, 66], ["Tregs", "CELL", 13, 18], ["IL-2", "GENE_OR_GENE_PRODUCT", 27, 31], ["T cell", "CELL", 60, 66], ["Tregs", "CELL_TYPE", 13, 18], ["IL-2", "PROTEIN", 27, 31]]], ["MDSCs contribute to the suppression of effector T cells through production of arginase and nitric oxide, which deprives T cells from amino acids necessary for proliferation [12] .The anti-tumor immune response and the immune profile of tumorsDespite all these evasion mechanisms, CTLs and Th1 T helper cells are still considered to be the most crucial effector cells in anti-tumor immunity and their infiltration into the TME is associated with good prognosis in various types of cancer [13] .", [["MDSCs", "ANATOMY", 0, 5], ["effector T cells", "ANATOMY", 39, 55], ["T cells", "ANATOMY", 120, 127], ["tumors", "ANATOMY", 236, 242], ["CTLs", "ANATOMY", 280, 284], ["Th1 T helper cells", "ANATOMY", 289, 307], ["cells", "ANATOMY", 361, 366], ["anti-tumor", "ANATOMY", 370, 380], ["cancer", "ANATOMY", 480, 486], ["nitric oxide", "CHEMICAL", 91, 103], ["amino acids", "CHEMICAL", 133, 144], ["tumors", "DISEASE", 236, 242], ["cancer", "DISEASE", 480, 486], ["nitric oxide", "CHEMICAL", 91, 103], ["amino acids", "CHEMICAL", 133, 144], ["MDSCs", "CELL", 0, 5], ["effector T cells", "CELL", 39, 55], ["arginase", "GENE_OR_GENE_PRODUCT", 78, 86], ["nitric oxide", "SIMPLE_CHEMICAL", 91, 103], ["T cells", "CELL", 120, 127], ["amino acids", "AMINO_ACID", 133, 144], ["anti-tumor", "CANCER", 183, 193], ["tumors", "CANCER", 236, 242], ["CTLs", "CELL", 280, 284], ["Th1 T helper cells", "CELL", 289, 307], ["effector cells", "CELL", 352, 366], ["anti-tumor", "CANCER", 370, 380], ["cancer", "CANCER", 480, 486], ["MDSCs", "CELL_TYPE", 0, 5], ["effector T cells", "CELL_TYPE", 39, 55], ["arginase", "PROTEIN", 78, 86], ["T cells", "CELL_TYPE", 120, 127], ["CTLs", "CELL_TYPE", 280, 284], ["Th1 T helper cells", "CELL_TYPE", 289, 307], ["effector cells", "CELL_TYPE", 352, 366], ["effector T cells", "PROBLEM", 39, 55], ["production of arginase", "TREATMENT", 64, 86], ["nitric oxide", "TREATMENT", 91, 103], ["amino acids", "TREATMENT", 133, 144], ["proliferation", "PROBLEM", 159, 172], ["tumors", "PROBLEM", 236, 242], ["CTLs", "TEST", 280, 284], ["cancer", "PROBLEM", 480, 486], ["tumors", "OBSERVATION", 236, 242], ["cancer", "OBSERVATION", 480, 486]]], ["Proper activation of these cells is key for an effective antitumor response and the abundance of mechanisms used by tumors to suppress these cells offers many targets for cancer immunotherapy strategies.The anti-tumor immune response and the immune profile of tumorsAt the moment, multiple strategies to target the TME are being explored.", [["cells", "ANATOMY", 27, 32], ["antitumor", "ANATOMY", 57, 66], ["tumors", "ANATOMY", 116, 122], ["cells", "ANATOMY", 141, 146], ["cancer", "ANATOMY", 171, 177], ["tumors", "ANATOMY", 260, 266], ["tumors", "DISEASE", 116, 122], ["cancer", "DISEASE", 171, 177], ["tumors", "DISEASE", 260, 266], ["cells", "CELL", 27, 32], ["antitumor", "CANCER", 57, 66], ["tumors", "CANCER", 116, 122], ["cells", "CELL", 141, 146], ["cancer", "CANCER", 171, 177], ["anti-tumor", "CANCER", 207, 217], ["tumors", "CANCER", 260, 266], ["these cells", "PROBLEM", 21, 32], ["an effective antitumor response", "PROBLEM", 44, 75], ["tumors", "PROBLEM", 116, 122], ["these cells", "PROBLEM", 135, 146], ["cancer immunotherapy strategies", "TREATMENT", 171, 202], ["tumors", "PROBLEM", 260, 266], ["anti-tumor immune", "OBSERVATION", 207, 224], ["tumors", "OBSERVATION", 260, 266]]], ["Recent successes have led to the FDA approval of checkpoint inhibitors anti-CTLA-4 (clinical responses in 10-15% of treated patients) and anti-PD1 (clinical responses in 30-40% of patients) for treatment of melanoma [14, 15] .", [["melanoma", "ANATOMY", 207, 215], ["anti-CTLA-4", "CHEMICAL", 71, 82], ["melanoma", "DISEASE", 207, 215], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 71, 82], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 180, 188], ["melanoma", "CANCER", 207, 215], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 180, 188], ["checkpoint inhibitors anti-CTLA", "TREATMENT", 49, 80], ["anti-PD1", "TREATMENT", 138, 146], ["melanoma", "PROBLEM", 207, 215], ["melanoma", "OBSERVATION", 207, 215]]], ["Clinical trials have shown that dual, synergistic blockage improved antitumor responses against melanoma, indicating that it might take more than one approach to induce powerful and long lasting anti-tumor immunity [16, 17] .", [["antitumor", "ANATOMY", 68, 77], ["melanoma", "ANATOMY", 96, 104], ["melanoma", "DISEASE", 96, 104], ["antitumor", "CANCER", 68, 77], ["melanoma", "CANCER", 96, 104], ["anti-tumor", "CANCER", 195, 205], ["Clinical trials", "TEST", 0, 15], ["dual, synergistic blockage", "PROBLEM", 32, 58], ["melanoma", "PROBLEM", 96, 104], ["melanoma", "OBSERVATION", 96, 104]]], ["However, systemic administration of these checkpoint inhibitors, as well as other immunotherapies, often coincides with severe immune-related adverse effects similar to autoimmune diseases [16, 17] .", [["autoimmune diseases", "DISEASE", 169, 188], ["these checkpoint inhibitors", "TREATMENT", 36, 63], ["other immunotherapies", "TREATMENT", 76, 97], ["severe immune-related adverse effects", "PROBLEM", 120, 157], ["autoimmune diseases", "PROBLEM", 169, 188]]], ["A promising treatment option to potentially overcome this obstacle is oncolytic virotherapy.Oncolytic viral therapyOncolytic virotherapy is an approach that uses oncolytic viruses (OVs), either with natural tropism for neoplastic cells or genetically modified to enhance selectivity for tumor cells [18, 19] .", [["neoplastic cells", "ANATOMY", 219, 235], ["tumor cells", "ANATOMY", 287, 298], ["tumor", "DISEASE", 287, 292], ["oncolytic viruses", "ORGANISM", 162, 179], ["OVs", "CANCER", 181, 184], ["neoplastic cells", "CELL", 219, 235], ["tumor cells", "CELL", 287, 298], ["neoplastic cells", "CELL_TYPE", 219, 235], ["tumor cells", "CELL_TYPE", 287, 298], ["A promising treatment option", "TREATMENT", 0, 28], ["oncolytic virotherapy", "TREATMENT", 70, 91], ["Oncolytic viral therapyOncolytic virotherapy", "TREATMENT", 92, 136], ["an approach", "TREATMENT", 140, 151], ["oncolytic viruses (OVs", "TREATMENT", 162, 184], ["neoplastic cells", "PROBLEM", 219, 235], ["tumor cells", "PROBLEM", 287, 298], ["therapyOncolytic virotherapy", "OBSERVATION", 108, 136]]], ["Tumor cells often lack an adequate antiviral response, making them more susceptible to OV infection than healthy cells.", [["Tumor cells", "ANATOMY", 0, 11], ["OV", "ANATOMY", 87, 89], ["cells", "ANATOMY", 113, 118], ["infection", "DISEASE", 90, 99], ["Tumor cells", "CELL", 0, 11], ["cells", "CELL", 113, 118], ["Tumor cells", "CELL_TYPE", 0, 11], ["healthy cells", "CELL_TYPE", 105, 118], ["OV", "SPECIES", 87, 89], ["Tumor cells", "PROBLEM", 0, 11], ["OV infection than healthy cells", "PROBLEM", 87, 118], ["adequate", "OBSERVATION_MODIFIER", 26, 34], ["antiviral response", "OBSERVATION", 35, 53], ["infection", "OBSERVATION", 90, 99]]], ["The viral infection leads to tumor regression through two distinct mechanisms: direct killing of tumor cells by replication dependent induced cell death and promotion of an antitumor response towards all tumor cells, including non-infected cells, by inducing immunogenic cell death.", [["tumor", "ANATOMY", 29, 34], ["tumor cells", "ANATOMY", 97, 108], ["cell", "ANATOMY", 142, 146], ["antitumor", "ANATOMY", 173, 182], ["tumor cells", "ANATOMY", 204, 215], ["cells", "ANATOMY", 240, 245], ["cell", "ANATOMY", 271, 275], ["viral infection", "DISEASE", 4, 19], ["tumor", "DISEASE", 29, 34], ["tumor", "DISEASE", 97, 102], ["death", "DISEASE", 147, 152], ["tumor", "DISEASE", 204, 209], ["death", "DISEASE", 276, 281], ["tumor", "CANCER", 29, 34], ["tumor cells", "CELL", 97, 108], ["cell", "CELL", 142, 146], ["antitumor", "CANCER", 173, 182], ["tumor cells", "CELL", 204, 215], ["cells", "CELL", 240, 245], ["cell", "CELL", 271, 275], ["tumor cells", "CELL_TYPE", 97, 108], ["tumor cells", "CELL_TYPE", 204, 215], ["non-infected cells", "CELL_TYPE", 227, 245], ["The viral infection", "PROBLEM", 0, 19], ["tumor regression", "PROBLEM", 29, 45], ["tumor cells", "PROBLEM", 97, 108], ["replication dependent induced cell death", "PROBLEM", 112, 152], ["an antitumor response", "PROBLEM", 170, 191], ["all tumor cells", "PROBLEM", 200, 215], ["non-infected cells", "PROBLEM", 227, 245], ["immunogenic cell death", "PROBLEM", 259, 281], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19], ["tumor", "OBSERVATION", 29, 34], ["distinct", "OBSERVATION_MODIFIER", 58, 66], ["tumor", "OBSERVATION", 97, 102], ["cell death", "OBSERVATION", 142, 152], ["tumor cells", "OBSERVATION", 204, 215], ["non-infected cells", "OBSERVATION", 227, 245], ["immunogenic cell death", "OBSERVATION", 259, 281]]], ["Types of immunogenic cell death, such as immunogenic apoptosis, necrosis and autophagic cell death, are characterized by the release of TAAs in combination with DAMPs and viral pathogen associated molecular patterns (PAMPs) [19] .", [["cell", "ANATOMY", 21, 25], ["autophagic cell", "ANATOMY", 77, 92], ["death", "DISEASE", 26, 31], ["necrosis", "DISEASE", 64, 72], ["death", "DISEASE", 93, 98], ["cell", "CELL", 21, 25], ["autophagic cell", "CELL", 77, 92], ["TAAs", "GENE_OR_GENE_PRODUCT", 136, 140], ["DAMPs", "GENE_OR_GENE_PRODUCT", 161, 166], ["viral pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 171, 215], ["TAAs", "PROTEIN", 136, 140], ["DAMPs", "PROTEIN", 161, 166], ["viral pathogen associated molecular patterns", "PROTEIN", 171, 215], ["PAMPs", "PROTEIN", 217, 222], ["immunogenic cell death", "PROBLEM", 9, 31], ["immunogenic apoptosis", "PROBLEM", 41, 62], ["necrosis", "PROBLEM", 64, 72], ["autophagic cell death", "PROBLEM", 77, 98], ["TAAs", "PROBLEM", 136, 140], ["DAMPs", "PROBLEM", 161, 166], ["viral pathogen", "PROBLEM", 171, 185], ["immunogenic cell death", "OBSERVATION", 9, 31], ["immunogenic apoptosis", "OBSERVATION", 41, 62], ["necrosis", "OBSERVATION", 64, 72], ["autophagic cell death", "OBSERVATION", 77, 98], ["TAAs", "OBSERVATION", 136, 140], ["viral pathogen", "OBSERVATION", 171, 185]]], ["Following the secretion of DAMPs and cytokines, more innate immune cells, such as macrophages, DCs, NK cells and neutrophils infiltrate the tumor environment.", [["immune cells", "ANATOMY", 60, 72], ["macrophages", "ANATOMY", 82, 93], ["DCs", "ANATOMY", 95, 98], ["NK cells", "ANATOMY", 100, 108], ["neutrophils", "ANATOMY", 113, 124], ["tumor", "ANATOMY", 140, 145], ["tumor", "DISEASE", 140, 145], ["DAMPs", "GENE_OR_GENE_PRODUCT", 27, 32], ["immune cells", "CELL", 60, 72], ["macrophages", "CELL", 82, 93], ["DCs", "CELL", 95, 98], ["NK cells", "CELL", 100, 108], ["neutrophils", "CELL", 113, 124], ["tumor", "CANCER", 140, 145], ["DAMPs", "PROTEIN", 27, 32], ["cytokines", "PROTEIN", 37, 46], ["immune cells", "CELL_TYPE", 60, 72], ["macrophages", "CELL_TYPE", 82, 93], ["DCs", "CELL_TYPE", 95, 98], ["NK cells", "CELL_TYPE", 100, 108], ["neutrophils", "CELL_TYPE", 113, 124], ["DAMPs", "PROBLEM", 27, 32], ["cytokines", "PROBLEM", 37, 46], ["macrophages", "PROBLEM", 82, 93], ["DCs", "PROBLEM", 95, 98], ["NK cells", "PROBLEM", 100, 108], ["neutrophils infiltrate the tumor environment", "PROBLEM", 113, 157], ["immune cells", "OBSERVATION", 60, 72], ["macrophages", "ANATOMY", 82, 93], ["NK cells", "OBSERVATION", 100, 108], ["neutrophils infiltrate", "OBSERVATION", 113, 135], ["tumor", "OBSERVATION", 140, 145]]], ["The immune stimulating cytokine secretion leads to maturation of APCs and hence presentation of TAAs and viral antigens to activate the adaptive immune system in the lymph nodes.", [["APCs", "ANATOMY", 65, 69], ["immune system", "ANATOMY", 145, 158], ["lymph nodes", "ANATOMY", 166, 177], ["APCs", "CELL", 65, 69], ["TAAs", "GENE_OR_GENE_PRODUCT", 96, 100], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 166, 177], ["cytokine", "PROTEIN", 23, 31], ["APCs", "CELL_TYPE", 65, 69], ["TAAs", "PROTEIN", 96, 100], ["viral antigens", "PROTEIN", 105, 119], ["The immune stimulating cytokine secretion", "TREATMENT", 0, 41], ["TAAs", "PROBLEM", 96, 100], ["viral antigens", "PROBLEM", 105, 119], ["lymph nodes", "OBSERVATION", 166, 177]]], ["Cytotoxic T cells will start infiltrating the tumor again and specifically eliminate cancer cells.", [["Cytotoxic T cells", "ANATOMY", 0, 17], ["tumor", "ANATOMY", 46, 51], ["cancer cells", "ANATOMY", 85, 97], ["tumor", "DISEASE", 46, 51], ["cancer", "DISEASE", 85, 91], ["Cytotoxic T cells", "CELL", 0, 17], ["tumor", "CANCER", 46, 51], ["cancer cells", "CELL", 85, 97], ["Cytotoxic T cells", "CELL_TYPE", 0, 17], ["cancer cells", "CELL_TYPE", 85, 97], ["Cytotoxic T cells", "PROBLEM", 0, 17], ["infiltrating the tumor", "PROBLEM", 29, 51], ["cancer cells", "PROBLEM", 85, 97], ["tumor", "OBSERVATION", 46, 51], ["cancer cells", "OBSERVATION", 85, 97]]], ["Simultaneously, memory T cells are formed, which improves protection against new tumor challenges in mouse models [20, 21] .", [["memory T cells", "ANATOMY", 16, 30], ["tumor", "ANATOMY", 81, 86], ["tumor", "DISEASE", 81, 86], ["memory T cells", "CELL", 16, 30], ["tumor", "CANCER", 81, 86], ["mouse", "ORGANISM", 101, 106], ["memory T cells", "CELL_TYPE", 16, 30], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["new tumor challenges", "PROBLEM", 77, 97], ["tumor", "OBSERVATION", 81, 86]]], ["Therefore, it is evident that OV therapy can function as a 'kick start' for the antitumor immune response by providing TAAs in an immunogenic manner and inducing infiltration of immune cells.Oncolytic viral therapyRecently, the focus in the oncolytic virotherapy field has shifted from their oncolytic effect to their immune stimulatory effect.", [["antitumor", "ANATOMY", 80, 89], ["immune cells", "ANATOMY", 178, 190], ["OV", "SIMPLE_CHEMICAL", 30, 32], ["antitumor", "CANCER", 80, 89], ["TAAs", "GENE_OR_GENE_PRODUCT", 119, 123], ["immune cells", "CELL", 178, 190], ["immune cells", "CELL_TYPE", 178, 190], ["OV therapy", "TREATMENT", 30, 40], ["the antitumor immune response", "TREATMENT", 76, 105], ["TAAs", "TREATMENT", 119, 123], ["an immunogenic manner", "TREATMENT", 127, 148], ["infiltration of immune cells", "PROBLEM", 162, 190], ["Oncolytic viral therapyRecently", "TREATMENT", 191, 222], ["the oncolytic virotherapy field", "TREATMENT", 237, 268], ["their immune stimulatory effect", "TREATMENT", 312, 343], ["immune cells", "OBSERVATION", 178, 190]]], ["Recombinant OVs armed with immune modulators further enhance the activation of the immune system and overcome the immunosuppressive TME [18] .", [["immune system", "ANATOMY", 83, 96], ["OVs", "GENE_OR_GENE_PRODUCT", 12, 15], ["immune modulators", "TREATMENT", 27, 44], ["the immunosuppressive TME", "TREATMENT", 110, 135]]], ["The first armed OV approved by the FDA is oncolytic Herpes-Simplex-Virus (HSV)-1 expressing GM-CSF showing improvement of and stromal cells (pink) secrete immune suppressive molecules, which inhibit the maturation of APCs.", [["stromal cells", "ANATOMY", 126, 139], ["APCs", "ANATOMY", 217, 221], ["Herpes-Simplex-Virus", "DISEASE", 52, 72], ["GM", "CHEMICAL", 92, 94], ["oncolytic", "ORGANISM", 42, 51], ["Herpes-Simplex-Virus (HSV)-1", "ORGANISM", 52, 80], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 92, 98], ["stromal cells", "CELL", 126, 139], ["APCs", "CELL", 217, 221], ["CSF", "PROTEIN", 95, 98], ["stromal cells", "CELL_TYPE", 126, 139], ["immune suppressive molecules", "PROTEIN", 155, 183], ["APCs", "CELL_TYPE", 217, 221], ["Herpes-Simplex-Virus", "SPECIES", 52, 72], ["HSV", "SPECIES", 74, 77], ["oncolytic Herpes", "TEST", 42, 58], ["Simplex-Virus (HSV)", "TEST", 59, 78], ["GM-CSF", "TEST", 92, 98], ["stromal cells", "PROBLEM", 126, 139], ["secrete immune suppressive molecules", "PROBLEM", 147, 183], ["stromal cells", "OBSERVATION", 126, 139]]], ["Maturated APCs migrate to the lymph node to activate the adaptive immune system.", [["APCs", "ANATOMY", 10, 14], ["lymph node", "ANATOMY", 30, 40], ["immune system", "ANATOMY", 66, 79], ["APCs", "CELL", 10, 14], ["lymph node", "MULTI-TISSUE_STRUCTURE", 30, 40], ["immune system", "ANATOMICAL_SYSTEM", 66, 79], ["APCs", "CELL_TYPE", 10, 14], ["lymph node", "OBSERVATION", 30, 40]]], ["(B) As a result, activated T cells migrate to the tumor driven by a chemokine gradient.", [["T cells", "ANATOMY", 27, 34], ["tumor", "ANATOMY", 50, 55], ["tumor", "DISEASE", 50, 55], ["T cells", "CELL", 27, 34], ["tumor", "CANCER", 50, 55], ["activated T cells", "CELL_TYPE", 17, 34], ["chemokine", "PROTEIN", 68, 77], ["activated T cells", "TREATMENT", 17, 34], ["the tumor", "PROBLEM", 46, 55], ["a chemokine gradient", "TEST", 66, 86], ["tumor", "OBSERVATION", 50, 55]]], ["However, the secretion of chemokines is lowered in the tumor resulting in reduced T cell infiltration.", [["tumor", "ANATOMY", 55, 60], ["T cell", "ANATOMY", 82, 88], ["tumor", "DISEASE", 55, 60], ["tumor", "CANCER", 55, 60], ["T cell", "CELL", 82, 88], ["chemokines", "PROTEIN", 26, 36], ["the secretion of chemokines", "PROBLEM", 9, 36], ["the tumor", "PROBLEM", 51, 60], ["reduced T cell infiltration", "PROBLEM", 74, 101], ["chemokines", "OBSERVATION", 26, 36], ["lowered", "OBSERVATION_MODIFIER", 40, 47], ["tumor", "OBSERVATION", 55, 60], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["T cell infiltration", "OBSERVATION", 82, 101]]], ["(C) T cells that enter the TME to target the tumor cells are inhibited by immune suppressive receptors expressed by the tumor, stromal cell, but also immune suppressed APCs.", [["(C) T cells", "ANATOMY", 0, 11], ["tumor cells", "ANATOMY", 45, 56], ["tumor", "ANATOMY", 120, 125], ["stromal cell", "ANATOMY", 127, 139], ["APCs", "ANATOMY", 168, 172], ["tumor", "DISEASE", 45, 50], ["tumor", "DISEASE", 120, 125], ["C) T cells", "CELL", 1, 11], ["tumor cells", "CELL", 45, 56], ["tumor", "CELL", 120, 125], ["stromal cell", "CELL", 127, 139], ["APCs", "CELL", 168, 172], ["T cells", "CELL_TYPE", 4, 11], ["tumor cells", "CELL_TYPE", 45, 56], ["immune suppressive receptors", "PROTEIN", 74, 102], ["tumor, stromal cell", "CELL_TYPE", 120, 139], ["APCs", "CELL_TYPE", 168, 172], ["(C) T cells", "PROBLEM", 0, 11], ["the tumor cells", "PROBLEM", 41, 56], ["immune suppressive receptors", "TREATMENT", 74, 102], ["the tumor", "PROBLEM", 116, 125], ["stromal cell", "PROBLEM", 127, 139], ["tumor cells", "OBSERVATION", 45, 56], ["tumor", "OBSERVATION", 120, 125], ["stromal cell", "OBSERVATION", 127, 139]]], ["(D) Tregs and MDSCs are recruited to the TME, which secrete more immune suppressive molecules and inhibit the T cell response even further. melanoma treatment, but no cure yet (T-VEC) [22] .", [["Tregs", "ANATOMY", 4, 9], ["MDSCs", "ANATOMY", 14, 19], ["T cell", "ANATOMY", 110, 116], ["melanoma", "ANATOMY", 140, 148], ["melanoma", "DISEASE", 140, 148], ["D) Tregs", "CELL", 1, 9], ["MDSCs", "CELL", 14, 19], ["T cell", "CELL", 110, 116], ["melanoma", "CANCER", 140, 148], ["T-VEC", "CELL", 177, 182], ["Tregs", "CELL_TYPE", 4, 9], ["MDSCs", "CELL_TYPE", 14, 19], ["immune suppressive molecules", "PROTEIN", 65, 93], ["MDSCs", "TREATMENT", 14, 19], ["the T cell response", "PROBLEM", 106, 125], ["melanoma treatment", "TREATMENT", 140, 158], ["no", "UNCERTAINTY", 164, 166]]], ["Therefore, many more immune modulator armed OV therapies followed and their obstacles and opportunities have come to light.", [["OV", "MULTI-TISSUE_STRUCTURE", 44, 46], ["immune modulator armed OV therapies", "TREATMENT", 21, 56]]], ["This review will give an overview of the state-of-the-art therapies used in combination with immune modulators to treat cancer patients and give a hint on potential future directions.Immune therapyImmune therapies for treatment of cancer aim at overcoming the tumor immune suppressive environment and at increasing antitumor immunity.", [["cancer", "ANATOMY", 120, 126], ["cancer", "ANATOMY", 231, 237], ["tumor", "ANATOMY", 260, 265], ["antitumor", "ANATOMY", 315, 324], ["cancer", "DISEASE", 120, 126], ["cancer", "DISEASE", 231, 237], ["tumor", "DISEASE", 260, 265], ["cancer", "CANCER", 120, 126], ["patients", "ORGANISM", 127, 135], ["cancer", "CANCER", 231, 237], ["tumor", "CANCER", 260, 265], ["antitumor", "CANCER", 315, 324], ["patients", "SPECIES", 127, 135], ["the-art therapies", "TREATMENT", 50, 67], ["immune modulators", "TREATMENT", 93, 110], ["cancer patients", "PROBLEM", 120, 135], ["Immune therapy", "TREATMENT", 183, 197], ["Immune therapies", "TREATMENT", 197, 213], ["treatment", "TREATMENT", 218, 227], ["cancer", "PROBLEM", 231, 237], ["the tumor immune suppressive environment", "TREATMENT", 256, 296], ["increasing antitumor immunity", "TREATMENT", 304, 333], ["cancer", "OBSERVATION", 231, 237]]], ["Most immune therapies target directly or indirectly the inhibitory or stimulatory receptors on immune cells and are often based on monoclonal antibodies.", [["immune cells", "ANATOMY", 95, 107], ["immune cells", "CELL", 95, 107], ["inhibitory or stimulatory receptors", "PROTEIN", 56, 91], ["immune cells", "CELL_TYPE", 95, 107], ["monoclonal antibodies", "PROTEIN", 131, 152], ["Most immune therapies", "TREATMENT", 0, 21], ["immune cells", "TREATMENT", 95, 107], ["monoclonal antibodies", "TEST", 131, 152]]], ["Other therapies intend to restore the intratumoral balance of cytokines and chemokines into a more favorable inflammatory TME to attract and activate immune cells.", [["intratumoral", "ANATOMY", 38, 50], ["immune cells", "ANATOMY", 150, 162], ["immune cells", "CELL", 150, 162], ["cytokines", "PROTEIN", 62, 71], ["chemokines", "PROTEIN", 76, 86], ["immune cells", "CELL_TYPE", 150, 162], ["Other therapies", "TREATMENT", 0, 15], ["the intratumoral balance of cytokines", "TREATMENT", 34, 71], ["chemokines", "TREATMENT", 76, 86], ["a more favorable inflammatory TME", "PROBLEM", 92, 125]]], ["The most interesting noncellular therapies for combination with OV therapy for solid tumors are described below.CytokinesCytokines are key players in stimulating and regulating antitumor immune responses.", [["noncellular", "ANATOMY", 21, 32], ["solid tumors", "ANATOMY", 79, 91], ["antitumor", "ANATOMY", 177, 186], ["tumors", "DISEASE", 85, 91], ["OV", "SIMPLE_CHEMICAL", 64, 66], ["solid tumors", "CANCER", 79, 91], ["antitumor", "CANCER", 177, 186], ["Cytokines", "PROTEIN", 112, 121], ["Cytokines", "PROTEIN", 121, 130], ["interesting noncellular therapies", "TREATMENT", 9, 42], ["OV therapy", "TREATMENT", 64, 74], ["solid tumors", "PROBLEM", 79, 91], ["CytokinesCytokines", "PROBLEM", 112, 130], ["tumors", "OBSERVATION", 85, 91]]], ["For this reason, one of the first immune therapeutic approaches in cancer treatment was the administration of recombinant cytokines.", [["cancer", "ANATOMY", 67, 73], ["cancer", "DISEASE", 67, 73], ["cancer", "CANCER", 67, 73], ["recombinant cytokines", "PROTEIN", 110, 131], ["cancer treatment", "TREATMENT", 67, 83], ["recombinant cytokines", "TREATMENT", 110, 131], ["cancer", "OBSERVATION", 67, 73]]], ["As described before, the most essential cytokines in the antitumor response are IL-12, GM-CSF, IL-2 and IL-2-related cytokines IL-15 and IL-21, and they all stimulate different parts of the immune system [23] : GM-CSF recruits APCs to the TME [17] , IL-12 is normally expressed by APCs and stimulates polarization of T helper cells to a Th1 phenotype, IL-2 is a T cell growth factor and improves T cell expansion [9] , and the IL-2-related cytokines promote survival of T cells, but also play an important role in NK cell activation [23] .", [["antitumor", "ANATOMY", 57, 66], ["APCs", "ANATOMY", 227, 231], ["APCs", "ANATOMY", 281, 285], ["T helper cells", "ANATOMY", 317, 331], ["T cell", "ANATOMY", 362, 368], ["T cell", "ANATOMY", 396, 402], ["T cells", "ANATOMY", 470, 477], ["NK cell", "ANATOMY", 514, 521], ["GM", "CHEMICAL", 211, 213], ["antitumor", "CANCER", 57, 66], ["IL-12", "GENE_OR_GENE_PRODUCT", 80, 85], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 87, 93], ["IL-2", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-2", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL-15", "GENE_OR_GENE_PRODUCT", 127, 132], ["IL-21", "GENE_OR_GENE_PRODUCT", 137, 142], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 211, 217], ["APCs", "CELL", 227, 231], ["IL-12", "GENE_OR_GENE_PRODUCT", 250, 255], ["APCs", "CELL", 281, 285], ["T helper cells", "CELL", 317, 331], ["IL-2", "GENE_OR_GENE_PRODUCT", 352, 356], ["T cell", "CELL", 362, 368], ["T cell", "CELL", 396, 402], ["IL-2", "GENE_OR_GENE_PRODUCT", 427, 431], ["T cells", "CELL", 470, 477], ["NK cell", "CELL", 514, 521], ["cytokines", "PROTEIN", 40, 49], ["cytokines", "PROTEIN", 117, 126], ["IL-21", "PROTEIN", 137, 142], ["CSF", "PROTEIN", 214, 217], ["APCs", "CELL_TYPE", 227, 231], ["IL-12", "PROTEIN", 250, 255], ["APCs", "CELL_TYPE", 281, 285], ["T helper cells", "CELL_TYPE", 317, 331], ["IL-2", "PROTEIN", 352, 356], ["T cell growth factor", "PROTEIN", 362, 382], ["cytokines", "PROTEIN", 440, 449], ["T cells", "CELL_TYPE", 470, 477], ["IL", "TEST", 80, 82], ["GM", "TEST", 87, 89], ["CSF", "TEST", 90, 93], ["IL", "TEST", 95, 97], ["IL", "TEST", 104, 106], ["cytokines IL", "TEST", 117, 129], ["IL", "TEST", 137, 139], ["the immune system", "TEST", 186, 203], ["GM", "TEST", 211, 213], ["APCs", "TEST", 227, 231], ["the TME", "TEST", 235, 242], ["IL", "TEST", 250, 252], ["a Th1 phenotype", "TEST", 335, 350], ["IL", "TEST", 352, 354], ["a T cell growth factor", "PROBLEM", 360, 382], ["T cell expansion", "TEST", 396, 412], ["the IL", "TEST", 423, 429], ["T cells", "PROBLEM", 470, 477], ["cytokines", "OBSERVATION", 40, 49], ["NK cell", "OBSERVATION", 514, 521]]], ["Despite the their plethora of immune modulatory actions, cytokines have lost their popularity as a monotherapy, because of their low objective response rates and non-negligible side effects upon systemic administration [24, 25] .Inhibitory receptorsOne of the most promising immune therapeutics are checkpoint inhibitors.", [["cytokines", "PROTEIN", 57, 66], ["Inhibitory receptors", "PROTEIN", 229, 249], ["immune modulatory actions", "TREATMENT", 30, 55], ["cytokines", "TREATMENT", 57, 66], ["a monotherapy", "TREATMENT", 97, 110], ["their low objective response rates", "PROBLEM", 123, 157], ["non-negligible side effects", "PROBLEM", 162, 189], ["systemic administration", "TREATMENT", 195, 218], ["Inhibitory receptors", "TREATMENT", 229, 249], ["checkpoint inhibitors", "TREATMENT", 299, 320]]], ["Inhibitory receptors such as CTLA-4 and PD-1 act as checkpoints to avoid over activation and are expressed by T cells and inhibit the T cell activation in the lymph nodes and survival in the TME [26] .", [["T cells", "ANATOMY", 110, 117], ["T cell", "ANATOMY", 134, 140], ["lymph nodes", "ANATOMY", 159, 170], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 29, 35], ["PD-1", "GENE_OR_GENE_PRODUCT", 40, 44], ["T cells", "CELL", 110, 117], ["T cell", "CELL", 134, 140], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 159, 170], ["CTLA-4", "PROTEIN", 29, 35], ["PD-1", "PROTEIN", 40, 44], ["T cells", "CELL_TYPE", 110, 117], ["Inhibitory receptors", "TREATMENT", 0, 20], ["CTLA", "TEST", 29, 33], ["PD", "TREATMENT", 40, 42], ["the T cell activation", "PROBLEM", 130, 151], ["lymph nodes", "OBSERVATION", 159, 170]]], ["Several checkpoint inhibitors have been approved by the FDA of which the first were against CTLA-4 and PD-1.", [["CTLA-4", "GENE_OR_GENE_PRODUCT", 92, 98], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["Several checkpoint inhibitors", "TREATMENT", 0, 29], ["CTLA", "TEST", 92, 96], ["PD", "TEST", 103, 105], ["checkpoint inhibitors", "OBSERVATION", 8, 29]]], ["Treatment with these inhibitors results in reactivation of the suppressed immune cells [14, 15] .", [["immune cells", "ANATOMY", 74, 86], ["immune cells", "CELL", 74, 86], ["immune cells", "CELL_TYPE", 74, 86], ["these inhibitors", "TREATMENT", 15, 31], ["the suppressed immune cells", "PROBLEM", 59, 86]]], ["In addition, blocking of CTLA-4 can lead to depletion of Tregs [25] .", [["Tregs", "ANATOMY", 57, 62], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 25, 31], ["Tregs", "CELL", 57, 62], ["CTLA-4", "PROTEIN", 25, 31], ["Tregs", "CELL_TYPE", 57, 62], ["CTLA", "TEST", 25, 29], ["depletion of Tregs", "PROBLEM", 44, 62]]], ["Combinations of a-CTLA-4 antibody and a-PD-1 antibody have shown to increase responses to treatment of advanced melanoma.", [["melanoma", "ANATOMY", 112, 120], ["melanoma", "DISEASE", 112, 120], ["a-CTLA-4 antibody", "GENE_OR_GENE_PRODUCT", 16, 33], ["a-PD-1 antibody", "GENE_OR_GENE_PRODUCT", 38, 53], ["melanoma", "CANCER", 112, 120], ["a-CTLA-4 antibody", "PROTEIN", 16, 33], ["a-PD-1 antibody", "PROTEIN", 38, 53], ["a-CTLA", "TEST", 16, 22], ["antibody", "TEST", 25, 33], ["a-PD", "TEST", 38, 42], ["advanced melanoma", "PROBLEM", 103, 120], ["advanced", "OBSERVATION_MODIFIER", 103, 111], ["melanoma", "OBSERVATION", 112, 120]]], ["However, the frequency of severe immune-related adverse events was also enhanced in clinical studies (16.3 \u221227.3% in monotherapy group vs. 55% in combination therapy group) [16] .", [["severe immune-related adverse events", "PROBLEM", 26, 62], ["clinical studies", "TEST", 84, 100], ["monotherapy group", "TREATMENT", 117, 134], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["immune", "OBSERVATION", 33, 39]]], ["Another disadvantage of these therapies is the fact that tumors can become resistant towards checkpoint inhibitors [27] .", [["tumors", "ANATOMY", 57, 63], ["tumors", "DISEASE", 57, 63], ["tumors", "CANCER", 57, 63], ["these therapies", "TREATMENT", 24, 39], ["tumors", "PROBLEM", 57, 63], ["checkpoint inhibitors", "TREATMENT", 93, 114], ["tumors", "OBSERVATION", 57, 63]]], ["As a result, a variety of other co-inhibitory receptors, such as lymphocyte activation gene 3 (LAG-3) and T cell immunoglobulin and mucin receptor protein 3 (TIM-3), have recently been identified.", [["lymphocyte", "ANATOMY", 65, 75], ["lymphocyte activation gene 3", "GENE_OR_GENE_PRODUCT", 65, 93], ["LAG-3", "GENE_OR_GENE_PRODUCT", 95, 100], ["T cell immunoglobulin", "GENE_OR_GENE_PRODUCT", 106, 127], ["mucin receptor protein 3", "GENE_OR_GENE_PRODUCT", 132, 156], ["TIM-3", "GENE_OR_GENE_PRODUCT", 158, 163], ["co-inhibitory receptors", "PROTEIN", 32, 55], ["lymphocyte activation gene 3", "DNA", 65, 93], ["LAG-3", "DNA", 95, 100], ["T cell immunoglobulin", "PROTEIN", 106, 127], ["mucin receptor protein 3", "PROTEIN", 132, 156], ["TIM", "PROTEIN", 158, 161], ["other co-inhibitory receptors", "TREATMENT", 26, 55], ["lymphocyte activation gene", "TEST", 65, 91], ["LAG", "TEST", 95, 98], ["T cell immunoglobulin", "TEST", 106, 127], ["mucin receptor protein", "TEST", 132, 154]]], ["LAG-3 is normally activated by its ligand MHCII on APCs and indirectly reduces T cell proliferation [28] .", [["APCs", "ANATOMY", 51, 55], ["T cell", "ANATOMY", 79, 85], ["LAG-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHCII", "GENE_OR_GENE_PRODUCT", 42, 47], ["APCs", "CELL", 51, 55], ["T cell", "CELL", 79, 85], ["LAG-3", "PROTEIN", 0, 5], ["MHCII", "PROTEIN", 42, 47], ["APCs", "CELL_TYPE", 51, 55], ["LAG", "TEST", 0, 3], ["T cell proliferation", "PROBLEM", 79, 99], ["cell proliferation", "OBSERVATION", 81, 99]]], ["Interaction of TIM-3 with its ligand galectin-9, expressed by Tregs, induces cell death in Th1 cells [28] .", [["Tregs", "ANATOMY", 62, 67], ["cell", "ANATOMY", 77, 81], ["Th1 cells", "ANATOMY", 91, 100], ["death", "DISEASE", 82, 87], ["TIM-3", "GENE_OR_GENE_PRODUCT", 15, 20], ["galectin-9", "GENE_OR_GENE_PRODUCT", 37, 47], ["Tregs", "CELL", 62, 67], ["cell", "CELL", 77, 81], ["Th1 cells", "CELL", 91, 100], ["TIM-3", "PROTEIN", 15, 20], ["galectin-9", "PROTEIN", 37, 47], ["Tregs", "CELL_TYPE", 62, 67], ["Th1 cells", "CELL_TYPE", 91, 100], ["its ligand galectin", "TEST", 26, 45], ["cell death in Th1 cells", "PROBLEM", 77, 100], ["cell death", "OBSERVATION", 77, 87]]], ["Blockage of these inhibitory receptors can unleash potent antitumor CTL responses and are now in clinical or preclinical development [17, 28] .Co-stimulatory receptorsAgonistic antibodies are also in development to activate co-stimulatory receptors expressed by T cells, such as 4-1BB and OX40 [17] .Co-stimulatory receptorsStimulation of these two receptors by their ligands or monoclonal antibodies induces activation, proliferation and survival of T cells.", [["antitumor", "ANATOMY", 58, 67], ["T cells", "ANATOMY", 262, 269], ["T cells", "ANATOMY", 451, 458], ["antitumor", "CANCER", 58, 67], ["T cells", "CELL", 262, 269], ["4-1BB", "GENE_OR_GENE_PRODUCT", 279, 284], ["OX40", "GENE_OR_GENE_PRODUCT", 289, 293], ["T cells", "CELL", 451, 458], ["inhibitory receptors", "PROTEIN", 18, 38], ["Co-stimulatory receptors", "PROTEIN", 143, 167], ["Agonistic antibodies", "PROTEIN", 167, 187], ["co-stimulatory receptors", "PROTEIN", 224, 248], ["T cells", "CELL_TYPE", 262, 269], ["1BB", "PROTEIN", 281, 284], ["OX40", "PROTEIN", 289, 293], ["monoclonal antibodies", "PROTEIN", 379, 400], ["T cells", "CELL_TYPE", 451, 458], ["Blockage of these inhibitory receptors", "PROBLEM", 0, 38], ["Co-stimulatory receptorsAgonistic antibodies", "TEST", 143, 187], ["Co-stimulatory receptorsStimulation", "TREATMENT", 300, 335], ["monoclonal antibodies", "PROBLEM", 379, 400], ["T cells", "PROBLEM", 451, 458]]], ["Another interesting target is CD40, which is expressed on DCs.", [["DCs", "ANATOMY", 58, 61], ["CD40", "GENE_OR_GENE_PRODUCT", 30, 34], ["DCs", "CELL", 58, 61], ["CD40", "PROTEIN", 30, 34], ["DCs", "CELL_TYPE", 58, 61], ["CD40", "OBSERVATION", 30, 34]]], ["CD40 ligation with CD40L or therapeutic antibody stimulates DC maturation and presentation of antigens, which leads to efficient T cell priming [28] .", [["DC", "ANATOMY", 60, 62], ["T cell", "ANATOMY", 129, 135], ["CD40", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD40L", "GENE_OR_GENE_PRODUCT", 19, 24], ["DC", "CELL", 60, 62], ["T cell", "CELL", 129, 135], ["CD40", "PROTEIN", 0, 4], ["CD40L", "PROTEIN", 19, 24], ["therapeutic antibody", "PROTEIN", 28, 48], ["DC", "CELL_TYPE", 60, 62], ["antigens", "PROTEIN", 94, 102], ["CD40 ligation", "TREATMENT", 0, 13], ["CD40L", "TREATMENT", 19, 24], ["therapeutic antibody stimulates", "TREATMENT", 28, 59]]], ["More stimulatory co-receptors are explored today, such as B7.1 and GITR [29] [30] [31] , which might benefit the effect of current therapies.BiTEsAnother class of therapeutics constitute of dual specificity recombinant antibodies, also called bispecific T cell engagers (BiTEs), which have shown promise as anti-tumor therapeutics.", [["T cell", "ANATOMY", 254, 260], ["anti-tumor", "ANATOMY", 307, 317], ["BiTEs", "CHEMICAL", 141, 146], ["B7.1", "GENE_OR_GENE_PRODUCT", 58, 62], ["GITR", "GENE_OR_GENE_PRODUCT", 67, 71], ["T cell", "CELL", 254, 260], ["BiTEs", "SIMPLE_CHEMICAL", 271, 276], ["anti-tumor", "CANCER", 307, 317], ["stimulatory co-receptors", "PROTEIN", 5, 29], ["B7.1", "PROTEIN", 58, 62], ["GITR", "PROTEIN", 67, 71], ["recombinant antibodies", "PROTEIN", 207, 229], ["BiTEs", "PROTEIN", 271, 276], ["current therapies", "TREATMENT", 123, 140], ["dual specificity recombinant antibodies", "PROBLEM", 190, 229], ["anti-tumor therapeutics", "TREATMENT", 307, 330]]], ["These antibodies simultaneously bind to CTLs via the T cell receptor (TCR) and a tumor antigen expressed on the tumor cell resulting in bypassing MHC dependent antigen presentation [32] .", [["CTLs", "ANATOMY", 40, 44], ["T cell", "ANATOMY", 53, 59], ["tumor", "ANATOMY", 81, 86], ["tumor cell", "ANATOMY", 112, 122], ["tumor", "DISEASE", 81, 86], ["tumor", "DISEASE", 112, 117], ["CTLs", "CELL", 40, 44], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 53, 68], ["TCR", "GENE_OR_GENE_PRODUCT", 70, 73], ["tumor", "CANCER", 81, 86], ["tumor cell", "CELL", 112, 122], ["antibodies", "PROTEIN", 6, 16], ["CTLs", "CELL_TYPE", 40, 44], ["T cell receptor", "PROTEIN", 53, 68], ["TCR", "PROTEIN", 70, 73], ["tumor antigen", "PROTEIN", 81, 94], ["tumor cell", "CELL_TYPE", 112, 122], ["MHC", "PROTEIN", 146, 149], ["These antibodies", "TEST", 0, 16], ["CTLs", "TEST", 40, 44], ["a tumor antigen", "PROBLEM", 79, 94], ["the tumor cell", "PROBLEM", 108, 122], ["tumor", "OBSERVATION", 81, 86], ["tumor cell", "OBSERVATION", 112, 122]]], ["An example of such therapy is Blinatumomab, which engages the CTL to CD19+ tumor cells.", [["CTL", "ANATOMY", 62, 65], ["CD19+ tumor cells", "ANATOMY", 69, 86], ["Blinatumomab", "CHEMICAL", 30, 42], ["tumor", "DISEASE", 75, 80], ["Blinatumomab", "CHEMICAL", 30, 42], ["Blinatumomab", "SIMPLE_CHEMICAL", 30, 42], ["CTL", "CELL", 62, 65], ["CD19", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD19", "PROTEIN", 69, 73], ["tumor cells", "CELL_TYPE", 75, 86], ["such therapy", "TREATMENT", 14, 26], ["Blinatumomab", "PROBLEM", 30, 42], ["tumor cells", "PROBLEM", 75, 86], ["tumor cells", "OBSERVATION", 75, 86]]], ["Currently, it is approved by the FDA for treating acute lymphoblastic leukemia, which is an hematologic malignancy [32] .Combination of immune therapy and oncolytic virotherapyTherapeutic treatment of solid tumors could be enhanced by combination treatment of both immune and OV therapy.", [["acute lymphoblastic leukemia", "ANATOMY", 50, 78], ["hematologic malignancy", "ANATOMY", 92, 114], ["solid tumors", "ANATOMY", 201, 213], ["OV", "ANATOMY", 276, 278], ["acute lymphoblastic leukemia", "DISEASE", 50, 78], ["malignancy", "DISEASE", 104, 114], ["tumors", "DISEASE", 207, 213], ["acute lymphoblastic leukemia", "CANCER", 50, 78], ["solid tumors", "CANCER", 201, 213], ["OV", "MULTI-TISSUE_STRUCTURE", 276, 278], ["acute lymphoblastic leukemia", "PROBLEM", 50, 78], ["an hematologic malignancy", "PROBLEM", 89, 114], ["immune therapy", "TREATMENT", 136, 150], ["oncolytic virotherapy", "TREATMENT", 155, 176], ["Therapeutic treatment", "TREATMENT", 176, 197], ["solid tumors", "PROBLEM", 201, 213], ["both immune", "TREATMENT", 260, 271], ["OV therapy", "TREATMENT", 276, 286], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["lymphoblastic leukemia", "OBSERVATION", 56, 78], ["hematologic", "OBSERVATION_MODIFIER", 92, 103], ["malignancy", "OBSERVATION", 104, 114], ["immune therapy", "OBSERVATION", 136, 150], ["solid", "OBSERVATION_MODIFIER", 201, 206], ["tumors", "OBSERVATION", 207, 213]]], ["By introducing these discussed immune stimulators, checkpoint inhibitors and cytokines as immune modulators in viral vectors, adverse events can be reduced, resistance reverted and treatment responsiveness enhanced.Combination of OVs with cytokines and chemokinesSeveral viruses have been engineered to express different cytokines or chemokines.", [["OVs", "SIMPLE_CHEMICAL", 230, 233], ["cytokines", "PROTEIN", 77, 86], ["OVs", "PROTEIN", 230, 233], ["cytokines", "PROTEIN", 239, 248], ["chemokines", "PROTEIN", 253, 263], ["cytokines", "PROTEIN", 321, 330], ["chemokines", "PROTEIN", 334, 344], ["immune stimulators", "TREATMENT", 31, 49], ["checkpoint inhibitors", "TREATMENT", 51, 72], ["cytokines", "TREATMENT", 77, 86], ["immune modulators", "TREATMENT", 90, 107], ["viral vectors", "TREATMENT", 111, 124], ["adverse events", "PROBLEM", 126, 140], ["OVs", "TREATMENT", 230, 233], ["cytokines", "TREATMENT", 239, 248], ["chemokines", "TREATMENT", 253, 263]]], ["Cytokines and chemokines are attractive transgenes, because they are encoded by small genes and are in general easy to build in a viral genome.", [["Cytokines", "PROTEIN", 0, 9], ["chemokines", "PROTEIN", 14, 24], ["viral genome", "DNA", 130, 142], ["Cytokines", "TREATMENT", 0, 9], ["chemokines", "OBSERVATION", 14, 24], ["small genes", "OBSERVATION", 80, 91], ["viral genome", "OBSERVATION", 130, 142]]], ["Moreover, they often have pleiotropic effects, which means they can target different immune cells simultaneously [23, 32] .", [["immune cells", "ANATOMY", 85, 97], ["immune cells", "CELL", 85, 97], ["immune cells", "CELL_TYPE", 85, 97], ["pleiotropic effects", "PROBLEM", 26, 45]]], ["A complete overview of all cytokines and chemokines used in oncolytic virotherapy is given in Table 1 .GM-CSFThe most extensively studied transgene is the cytokine GM-CSF.", [["GM", "CHEMICAL", 103, 105], ["GM", "CHEMICAL", 164, 166], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 103, 109], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 164, 170], ["cytokines", "PROTEIN", 27, 36], ["chemokines", "PROTEIN", 41, 51], ["cytokine", "PROTEIN", 155, 163], ["GM", "PROTEIN", 164, 166], ["CSF", "PROTEIN", 167, 170], ["all cytokines", "TREATMENT", 23, 36], ["chemokines", "TREATMENT", 41, 51], ["oncolytic virotherapy", "TREATMENT", 60, 81], ["the cytokine GM", "TEST", 151, 166], ["CSF", "OBSERVATION", 106, 109]]], ["GM-CSF promotes DC recruitment and maturation.", [["DC", "ANATOMY", 16, 18], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["DC", "CELL", 16, 18], ["CSF", "PROTEIN", 3, 6], ["DC", "CELL_TYPE", 16, 18], ["CSF", "OBSERVATION", 3, 6], ["recruitment", "OBSERVATION_MODIFIER", 19, 30]]], ["GM-CSF has been successfully used to arm HSV and this armed virus has been approved by the FDA under the name of T-VEC for treatment of metastatic melanoma patients [22] .", [["T-VEC", "ANATOMY", 113, 118], ["metastatic melanoma", "ANATOMY", 136, 155], ["GM", "CHEMICAL", 0, 2], ["T-VEC", "CHEMICAL", 113, 118], ["melanoma", "DISEASE", 147, 155], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["HSV", "ORGANISM", 41, 44], ["T-VEC", "CELL", 113, 118], ["metastatic melanoma", "CANCER", 136, 155], ["patients", "ORGANISM", 156, 164], ["CSF", "PROTEIN", 3, 6], ["patients", "SPECIES", 156, 164], ["HSV", "SPECIES", 41, 44], ["CSF", "PROBLEM", 3, 6], ["arm HSV", "PROBLEM", 37, 44], ["this armed virus", "PROBLEM", 49, 65], ["metastatic melanoma", "PROBLEM", 136, 155], ["CSF", "OBSERVATION", 3, 6], ["arm", "ANATOMY", 37, 40], ["HSV", "OBSERVATION", 41, 44], ["metastatic", "OBSERVATION_MODIFIER", 136, 146], ["melanoma", "OBSERVATION", 147, 155]]], ["Besides HSV, other viruses have also been armed with GM-CSF [33, 34] .", [["GM", "CHEMICAL", 53, 55], ["HSV", "ORGANISM", 8, 11], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 53, 59], ["HSV", "SPECIES", 8, 11], ["HSV", "PROBLEM", 8, 11], ["other viruses", "PROBLEM", 13, 26], ["GM-CSF", "TEST", 53, 59], ["viruses", "OBSERVATION", 19, 26]]], ["Phase 1 clinical trials in patients with colorectal and hepatocellular carcinoma, neuroblastoma and Ewings sarcoma have proven the efficacy and safety of oncolytic vaccinia virus (VV) expressing GM-CSF (Pexa-Vec) [35] [36] [37] .", [["colorectal", "ANATOMY", 41, 51], ["hepatocellular carcinoma", "ANATOMY", 56, 80], ["neuroblastoma", "ANATOMY", 82, 95], ["Ewings sarcoma", "ANATOMY", 100, 114], ["colorectal and hepatocellular carcinoma", "DISEASE", 41, 80], ["neuroblastoma", "DISEASE", 82, 95], ["Ewings sarcoma", "DISEASE", 100, 114], ["GM", "CHEMICAL", 195, 197], ["patients", "ORGANISM", 27, 35], ["colorectal", "CANCER", 41, 51], ["hepatocellular carcinoma", "CANCER", 56, 80], ["neuroblastoma", "CANCER", 82, 95], ["Ewings sarcoma", "CANCER", 100, 114], ["oncolytic", "ORGANISM", 154, 163], ["vaccinia virus", "ORGANISM", 164, 178], ["VV", "ORGANISM", 180, 182], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 195, 201], ["Pexa-Vec", "SIMPLE_CHEMICAL", 203, 211], ["patients", "SPECIES", 27, 35], ["vaccinia virus", "SPECIES", 164, 178], ["VV", "SPECIES", 180, 182], ["colorectal and hepatocellular carcinoma", "PROBLEM", 41, 80], ["neuroblastoma", "PROBLEM", 82, 95], ["Ewings sarcoma", "PROBLEM", 100, 114], ["oncolytic vaccinia virus", "TREATMENT", 154, 178], ["colorectal", "ANATOMY", 41, 51], ["hepatocellular", "ANATOMY", 56, 70], ["carcinoma", "OBSERVATION", 71, 80]]], ["In addition, two different adenovirus serotypes expressing GM-CSF induced long term survival of patients with, amongst others, ovarian, colon, pancreatic and breast cancer, with no severe side effects [34, 38] .", [["ovarian", "ANATOMY", 127, 134], ["colon", "ANATOMY", 136, 141], ["pancreatic", "ANATOMY", 143, 153], ["breast cancer", "ANATOMY", 158, 171], ["GM", "CHEMICAL", 59, 61], ["ovarian, colon, pancreatic and breast cancer", "DISEASE", 127, 171], ["adenovirus", "ORGANISM", 27, 37], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 59, 65], ["patients", "ORGANISM", 96, 104], ["ovarian", "CANCER", 127, 134], ["colon", "CANCER", 136, 141], ["pancreatic", "CANCER", 143, 153], ["breast cancer", "CANCER", 158, 171], ["GM", "PROTEIN", 59, 61], ["CSF", "PROTEIN", 62, 65], ["patients", "SPECIES", 96, 104], ["two different adenovirus serotypes", "PROBLEM", 13, 47], ["ovarian, colon, pancreatic and breast cancer", "PROBLEM", 127, 171], ["severe side effects", "PROBLEM", 181, 200], ["long term", "OBSERVATION_MODIFIER", 74, 83], ["ovarian", "ANATOMY", 127, 134], ["colon", "ANATOMY", 136, 141], ["pancreatic", "ANATOMY", 143, 153], ["breast", "ANATOMY", 158, 164], ["cancer", "OBSERVATION", 165, 171], ["no", "UNCERTAINTY", 178, 180], ["severe", "OBSERVATION_MODIFIER", 181, 187]]], ["Biopsies obtained from these patients with different metastatic tumors showed increased infiltration of T-cells and macrophages, which also correlated with patient survival and hence the additive effect of GM-CSF as vectorized immune modulator [38] .IL-12IL-12 both activates and promotes survival of NK cells, but also Th1 effector cells [39, 40] .", [["Biopsies", "ANATOMY", 0, 8], ["metastatic tumors", "ANATOMY", 53, 70], ["T-cells", "ANATOMY", 104, 111], ["macrophages", "ANATOMY", 116, 127], ["NK cells", "ANATOMY", 301, 309], ["Th1 effector cells", "ANATOMY", 320, 338], ["tumors", "DISEASE", 64, 70], ["GM", "CHEMICAL", 206, 208], ["Biopsies", "CANCER", 0, 8], ["patients", "ORGANISM", 29, 37], ["tumors", "CANCER", 64, 70], ["T-cells", "CELL", 104, 111], ["macrophages", "CELL", 116, 127], ["patient", "ORGANISM", 156, 163], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 206, 212], ["NK cells", "CELL", 301, 309], ["Th1 effector cells", "CELL", 320, 338], ["T-cells", "CELL_TYPE", 104, 111], ["macrophages", "CELL_TYPE", 116, 127], ["CSF", "PROTEIN", 209, 212], ["NK cells", "CELL_TYPE", 301, 309], ["Th1 effector cells", "CELL_TYPE", 320, 338], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 156, 163], ["Biopsies", "TEST", 0, 8], ["different metastatic tumors", "PROBLEM", 43, 70], ["increased infiltration of T-cells", "PROBLEM", 78, 111], ["macrophages", "PROBLEM", 116, 127], ["GM-CSF", "TEST", 206, 212], ["NK cells", "PROBLEM", 301, 309], ["metastatic", "OBSERVATION_MODIFIER", 53, 63], ["tumors", "OBSERVATION", 64, 70], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["infiltration", "OBSERVATION", 88, 100], ["T-cells", "OBSERVATION_MODIFIER", 104, 111], ["macrophages", "ANATOMY", 116, 127], ["NK cells", "OBSERVATION", 301, 309]]], ["Several viruses have been armed with IL-12 and tested in different tumor models (Table 1) [41] [42] [43] [44] [45] [46] .", [["tumor", "ANATOMY", 67, 72], ["tumor", "DISEASE", 67, 72], ["IL-12", "GENE_OR_GENE_PRODUCT", 37, 42], ["tumor", "CANCER", 67, 72], ["[41] [42] [43] [44] [45] [46]", "SIMPLE_CHEMICAL", 90, 119], ["IL-12", "PROTEIN", 37, 42], ["Several viruses", "PROBLEM", 0, 15], ["IL", "TEST", 37, 39], ["different tumor models", "TEST", 57, 79], ["viruses", "OBSERVATION", 8, 15]]], ["HSV-IL-12 induces tumor infiltration of effector T cells, NK cells and APCs in neuroblastoma and glioma mouse models [43, 45] .", [["tumor", "ANATOMY", 18, 23], ["effector T cells", "ANATOMY", 40, 56], ["NK cells", "ANATOMY", 58, 66], ["APCs", "ANATOMY", 71, 75], ["neuroblastoma", "ANATOMY", 79, 92], ["glioma", "ANATOMY", 97, 103], ["tumor", "DISEASE", 18, 23], ["neuroblastoma", "DISEASE", 79, 92], ["glioma", "DISEASE", 97, 103], ["HSV", "ORGANISM", 0, 3], ["IL-12", "GENE_OR_GENE_PRODUCT", 4, 9], ["tumor", "CANCER", 18, 23], ["effector T cells", "CELL", 40, 56], ["NK cells", "CELL", 58, 66], ["APCs", "CELL", 71, 75], ["neuroblastoma", "CANCER", 79, 92], ["glioma", "CANCER", 97, 103], ["mouse", "ORGANISM", 104, 109], ["HSV-IL-12", "PROTEIN", 0, 9], ["effector T cells", "CELL_TYPE", 40, 56], ["NK cells", "CELL_TYPE", 58, 66], ["APCs", "CELL_TYPE", 71, 75], ["mouse", "SPECIES", 104, 109], ["HSV", "SPECIES", 0, 3], ["mouse", "SPECIES", 104, 109], ["HSV", "TEST", 0, 3], ["IL", "TEST", 4, 6], ["tumor infiltration", "PROBLEM", 18, 36], ["effector T cells", "PROBLEM", 40, 56], ["NK cells", "PROBLEM", 58, 66], ["APCs", "PROBLEM", 71, 75], ["neuroblastoma", "PROBLEM", 79, 92], ["glioma mouse models", "TEST", 97, 116], ["tumor infiltration", "OBSERVATION", 18, 36], ["effector T cells", "OBSERVATION", 40, 56], ["NK cells", "OBSERVATION", 58, 66], ["neuroblastoma", "OBSERVATION", 79, 92], ["glioma", "ANATOMY", 97, 103]]], ["When comparing HSV-IL-12 with HSV-GM-CSF, HSV-IL-12 was demonstrated most effective in tumor growth inhibition of injected tumors as well as metastases in a squamous cell carcinoma mouse model and a prostate cancer mouse model [47, 48] .", [["tumor", "ANATOMY", 87, 92], ["tumors", "ANATOMY", 123, 129], ["metastases", "ANATOMY", 141, 151], ["squamous cell carcinoma", "ANATOMY", 157, 180], ["prostate cancer", "ANATOMY", 199, 214], ["tumor", "DISEASE", 87, 92], ["tumors", "DISEASE", 123, 129], ["metastases", "DISEASE", 141, 151], ["squamous cell carcinoma", "DISEASE", 157, 180], ["prostate cancer", "DISEASE", 199, 214], ["HSV", "ORGANISM", 15, 18], ["IL-12", "GENE_OR_GENE_PRODUCT", 19, 24], ["HSV", "ORGANISM", 30, 33], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 34, 40], ["HSV", "ORGANISM", 42, 45], ["IL-12", "GENE_OR_GENE_PRODUCT", 46, 51], ["tumor", "CANCER", 87, 92], ["tumors", "CANCER", 123, 129], ["squamous cell carcinoma", "CANCER", 157, 180], ["mouse", "ORGANISM", 181, 186], ["prostate cancer", "CANCER", 199, 214], ["mouse", "ORGANISM", 215, 220], ["IL", "PROTEIN", 19, 21], ["CSF", "PROTEIN", 37, 40], ["IL", "PROTEIN", 46, 48], ["mouse", "SPECIES", 181, 186], ["mouse", "SPECIES", 215, 220], ["HSV", "SPECIES", 15, 18], ["HSV", "SPECIES", 30, 33], ["HSV", "SPECIES", 42, 45], ["mouse", "SPECIES", 181, 186], ["mouse", "SPECIES", 215, 220], ["HSV", "TEST", 15, 18], ["IL", "TEST", 19, 21], ["HSV", "TEST", 30, 33], ["CSF", "TEST", 37, 40], ["HSV", "TEST", 42, 45], ["IL", "TEST", 46, 48], ["injected tumors", "PROBLEM", 114, 129], ["metastases", "PROBLEM", 141, 151], ["a squamous cell carcinoma mouse model", "PROBLEM", 155, 192], ["a prostate cancer mouse model", "PROBLEM", 197, 226], ["CSF", "ANATOMY", 37, 40], ["most effective", "OBSERVATION_MODIFIER", 69, 83], ["tumor", "OBSERVATION", 87, 92], ["injected tumors", "OBSERVATION", 114, 129], ["metastases", "OBSERVATION", 141, 151], ["squamous cell carcinoma", "OBSERVATION", 157, 180], ["prostate", "ANATOMY", 199, 207], ["cancer", "OBSERVATION", 208, 214]]], ["In addition, mice were better protected against re- Table 1 Combination therapy of armed oncolytic viruses and immune modulators.Transgene Virus Tumor Additive immunologic effects ToxicityCytokines GM-CSF HSV [22, 48, 121] Adenocarcinoma [33] , Metastised (phase I) a [22, 34] Breast cancer [121] , Melanoma (phase I) a [121, 122] Improved peripheral blood mononuclear cell response [124] Grade 1 and 2 [22, 34] , AdV [34, 110, 122] CD3+ T cell infiltration [33] MV [33] Long-term immunity against rechallenge with tumor cells [33] VSV [123] NDV [124] IL-12Transgene Virus Tumor Additive immunologic effects ToxicityAdV [108] Neuroblastoma [45] , Glioma [43] , Prostate [48] , Squamous Cell Carcinoma [46, 47] , Melanoma [108] Infiltration of macrophages, T helper, CTL and NK cells [43, 45, 47, 48] No signs [44, 46, 47] HSV [30, [43] [44] [45] 47, 48] Improved survival [108] and protective against rechallenge [47] VSV [46] IL-2 NDV [52] [53] [54] [55] [56] Melanoma [54, 55] , Hepatoma [52, 53] , Squamous Cell Carcinoma [51] Infiltration of T helper and CTL [51] [52] [53] [54] [55] [56] No signs [53, 54] HSV [51] Immunity against rechallenge with tumor cells [51] [52] [53] [54]IL-15VSV [57] Colon carcinoma [57] , Melanoma [58, 127] Increase in tumor specific CTLs in the blood [57] IL-15 only detectable in tumor [58] NDV [58] I n filtration of T helper and CTL [58] , [126] IAV [125] Immunity against rechallenge with tumor cells [58] HSV [126] Increases survival in mouse model [58, 127] IAV [127] IFN-\u03b2 MV [61] Non-small cell lung cancer [128] , [129] , Improved survival mouse model [61] Not reported VV [128] Mesothelioma [61] , Pancreatic adenocarcinoma [59] VSV [129] NDV [59] IFN-\u03b3 NDV [55] Melanoma [55] , Mammary and colon carcinoma [62] Increased cytokine expression and improved DC maturation [62] Not Reported VSV [62] Increased T cell infiltration [55] Others: IL-18 [30] , [108] , IL-17 [130] , TNF [55] , MIP1a [131] , FLT3L [131] NDV [55] Improved T cell responses Not reported VSV [130] AdV [108] HSV [30] Chemokines: CCL5 [65] , CCL2 [67] , CCL19 [132] , CXCL11 [64] , [133] VV [65, 66, 122, 123] Colon carcinoma Improved DC maturation [65] Not reported HSV [67] Improved infiltration T helper cells and CTLs [64] , [65] , [132] , [133] Induces a Th2 response, but reverts to a Th1 response in combination with DC vaccination [65] Co-stimulatory ligands B7.1/CD80 HSV [84] Neuroblastoma [84] , Melanoma (patients) a [86] Immunity against rechallenge with tumor cells [84] Low grade [86] VV [ [75] , [108] No signs [75] , [108] AdV [74, 108] Decreased infiltration of Tregs [75] anti-PD1 or PD-L1IL-15MV [75] Melanoma Infiltration of T helper and CTL [75] , [83] No signs [75] VV [83] Decreased infiltration of Tregs [75] , [83] MYXV [81] Improved survival [81] (continued on next page) J.F. de Graaf et al.IL-15Cytokine and Growth Factor Reviews 41 (2018) [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] challenges with tumor cells in the HSV-IL-12 treated group, indicating the formation of a long term, anti-tumor response [47] .", [["Adenocarcinoma", "ANATOMY", 223, 237], ["Breast cancer", "ANATOMY", 277, 290], ["Melanoma", "ANATOMY", 299, 307], ["peripheral blood mononuclear cell", "ANATOMY", 340, 373], ["CD3+ T cell", "ANATOMY", 433, 444], ["tumor cells", "ANATOMY", 515, 526], ["Neuroblastoma", "ANATOMY", 626, 639], ["Glioma", "ANATOMY", 647, 653], ["Prostate", "ANATOMY", 661, 669], ["Squamous Cell Carcinoma", "ANATOMY", 677, 700], ["Melanoma", "ANATOMY", 712, 720], ["macrophages", "ANATOMY", 743, 754], ["T helper", "ANATOMY", 756, 764], ["CTL", "ANATOMY", 766, 769], ["NK cells", "ANATOMY", 774, 782], ["Melanoma", "ANATOMY", 961, 969], ["Hepatoma", "ANATOMY", 981, 989], ["Squamous Cell Carcinoma", "ANATOMY", 1001, 1024], ["tumor cells", "ANATOMY", 1154, 1165], ["Colon carcinoma", "ANATOMY", 1199, 1214], ["Melanoma", "ANATOMY", 1222, 1230], ["tumor", "ANATOMY", 1253, 1258], ["CTLs", "ANATOMY", 1268, 1272], ["blood", "ANATOMY", 1280, 1285], ["tumor", "ANATOMY", 1316, 1321], ["tumor cells", "ANATOMY", 1428, 1439], ["Non-small cell lung cancer", "ANATOMY", 1523, 1549], ["Mesothelioma", "ANATOMY", 1623, 1635], ["Pancreatic adenocarcinoma", "ANATOMY", 1643, 1668], ["Melanoma", "ANATOMY", 1708, 1716], ["Mammary", "ANATOMY", 1724, 1731], ["colon carcinoma", "ANATOMY", 1736, 1751], ["DC", "ANATOMY", 1800, 1802], ["T cell", "ANATOMY", 1851, 1857], ["T cell", "ANATOMY", 1974, 1980], ["Colon carcinoma", "ANATOMY", 2125, 2140], ["DC", "ANATOMY", 2150, 2152], ["T helper cells", "ANATOMY", 2213, 2227], ["DC", "ANATOMY", 2339, 2341], ["Neuroblastoma", "ANATOMY", 2401, 2414], ["Melanoma", "ANATOMY", 2422, 2430], ["tumor cells", "ANATOMY", 2483, 2494], ["Tregs", "ANATOMY", 2595, 2600], ["Melanoma", "ANATOMY", 2636, 2644], ["Tregs", "ANATOMY", 2738, 2743], ["tumor cells", "ANATOMY", 2960, 2971], ["GM", "CHEMICAL", 198, 200], ["Breast cancer", "DISEASE", 277, 290], ["Melanoma", "DISEASE", 299, 307], ["tumor", "DISEASE", 515, 520], ["Neuroblastoma", "DISEASE", 626, 639], ["Glioma", "DISEASE", 647, 653], ["Prostate [48]", "DISEASE", 661, 674], ["Squamous Cell Carcinoma", "DISEASE", 677, 700], ["Melanoma", "DISEASE", 712, 720], ["Melanoma", "DISEASE", 961, 969], ["Hepatoma", "DISEASE", 981, 989], ["Squamous Cell Carcinoma", "DISEASE", 1001, 1024], ["tumor", "DISEASE", 1154, 1159], ["Colon carcinoma", "DISEASE", 1199, 1214], ["Melanoma", "DISEASE", 1222, 1230], ["tumor", "DISEASE", 1253, 1258], ["tumor", "DISEASE", 1316, 1321], ["tumor", "DISEASE", 1428, 1433], ["Non-small cell lung cancer", "DISEASE", 1523, 1549], ["Mesothelioma", "DISEASE", 1623, 1635], ["Pancreatic adenocarcinoma", "DISEASE", 1643, 1668], ["Melanoma", "DISEASE", 1708, 1716], ["Mammary and colon carcinoma", "DISEASE", 1724, 1751], ["Colon carcinoma", "DISEASE", 2125, 2140], ["Neuroblastoma", "DISEASE", 2401, 2414], ["Melanoma", "DISEASE", 2422, 2430], ["tumor", "DISEASE", 2483, 2488], ["Melanoma", "DISEASE", 2636, 2644], ["tumor", "DISEASE", 2960, 2965], ["mice", "ORGANISM", 13, 17], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 198, 204], ["Breast cancer", "CANCER", 277, 290], ["Melanoma", "CANCER", 299, 307], ["peripheral blood mononuclear cell", "CELL", 340, 373], ["AdV", "ORGANISM", 414, 417], ["CD3", "GENE_OR_GENE_PRODUCT", 433, 436], ["tumor cells", "CELL", 515, 526], ["VSV", "ORGANISM", 532, 535], ["NDV", "ORGANISM", 542, 545], ["IL", "GENE_OR_GENE_PRODUCT", 552, 554], ["Tumor", "CANCER", 573, 578], ["ToxicityAdV [108] Neuroblastoma", "CANCER", 608, 639], ["Glioma", "CANCER", 647, 653], ["Prostate [48", "CANCER", 661, 673], ["Squamous Cell Carcinoma", "CANCER", 677, 700], ["macrophages", "CELL", 743, 754], ["T helper", "CELL", 756, 764], ["CTL", "CELL", 766, 769], ["NK cells", "CELL", 774, 782], ["HSV", "ORGANISM", 822, 825], ["VSV", "ORGANISM", 918, 921], ["IL-2", "GENE_OR_GENE_PRODUCT", 927, 931], ["NDV", "ORGANISM", 932, 935], ["Melanoma", "CANCER", 961, 969], ["Hepatoma", "CANCER", 981, 989], ["Squamous Cell Carcinoma", "CANCER", 1001, 1024], ["T helper", "GENE_OR_GENE_PRODUCT", 1046, 1054], ["CTL [51] [52] [53] [54] [55] [56", "SIMPLE_CHEMICAL", 1059, 1091], ["HSV", "ORGANISM", 1111, 1114], ["tumor cells", "CELL", 1154, 1165], ["[51] [52] [53] [54]IL-15VSV", "SIMPLE_CHEMICAL", 1166, 1193], ["Colon carcinoma", "CANCER", 1199, 1214], ["Melanoma", "CANCER", 1222, 1230], ["tumor", "CANCER", 1253, 1258], ["blood", "ORGANISM_SUBSTANCE", 1280, 1285], ["IL-15", "GENE_OR_GENE_PRODUCT", 1291, 1296], ["tumor", "CANCER", 1316, 1321], ["T helper", "GENE_OR_GENE_PRODUCT", 1354, 1362], ["tumor cells", "CELL", 1428, 1439], ["HSV", "ORGANISM", 1445, 1448], ["mouse", "ORGANISM", 1477, 1482], ["Non-small cell lung cancer", "CANCER", 1523, 1549], ["mouse", "ORGANISM", 1584, 1589], ["VV [128] Mesothelioma", "CANCER", 1614, 1635], ["Pancreatic adenocarcinoma", "CANCER", 1643, 1668], ["VSV", "ORGANISM", 1674, 1677], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 1693, 1698], ["Melanoma", "CANCER", 1708, 1716], ["Mammary", "CANCER", 1724, 1731], ["colon carcinoma", "CANCER", 1736, 1751], ["DC", "CELL", 1800, 1802], ["VSV", "ORGANISM", 1832, 1835], ["T cell", "CELL", 1851, 1857], ["IL-18", "GENE_OR_GENE_PRODUCT", 1884, 1889], ["IL-17", "GENE_OR_GENE_PRODUCT", 1905, 1910], ["TNF", "GENE_OR_GENE_PRODUCT", 1919, 1922], ["MIP1a", "GENE_OR_GENE_PRODUCT", 1930, 1935], ["T cell", "CELL", 1974, 1980], ["VSV", "ORGANISM", 2004, 2007], ["AdV", "ORGANISM", 2014, 2017], ["HSV", "ORGANISM", 2024, 2027], ["CCL5", "GENE_OR_GENE_PRODUCT", 2045, 2049], ["CCL2", "GENE_OR_GENE_PRODUCT", 2057, 2061], ["CCL19", "GENE_OR_GENE_PRODUCT", 2069, 2074], ["CXCL11", "GENE_OR_GENE_PRODUCT", 2083, 2089], ["Colon carcinoma", "CANCER", 2125, 2140], ["HSV", "ORGANISM", 2182, 2185], ["T helper cells", "CELL", 2213, 2227], ["CTLs", "CELL", 2232, 2236], ["[133]", "SIMPLE_CHEMICAL", 2259, 2264], ["B7.1", "GENE_OR_GENE_PRODUCT", 2382, 2386], ["CD80", "GENE_OR_GENE_PRODUCT", 2387, 2391], ["Melanoma", "CANCER", 2422, 2430], ["patients", "ORGANISM", 2432, 2440], ["tumor cells", "CELL", 2483, 2494], ["PD1", "GENE_OR_GENE_PRODUCT", 2611, 2614], ["PD-L1IL", "GENE_OR_GENE_PRODUCT", 2618, 2625], ["T helper", "GENE_OR_GENE_PRODUCT", 2661, 2669], ["Tregs", "CELL", 2738, 2743], ["IL-15Cytokine", "GENE_OR_GENE_PRODUCT", 2834, 2847], ["[28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39]", "SIMPLE_CHEMICAL", 2884, 2943], ["tumor cells", "CELL", 2960, 2971], ["HSV", "ORGANISM", 2979, 2982], ["IL-12", "GENE_OR_GENE_PRODUCT", 2983, 2988], ["anti-tumor", "CANCER", 3045, 3055], ["peripheral blood mononuclear cell", "CELL_TYPE", 340, 373], ["CD3", "PROTEIN", 433, 436], ["tumor cells", "CELL_TYPE", 515, 526], ["macrophages", "CELL_TYPE", 743, 754], ["T helper, CTL and NK cells", "CELL_TYPE", 756, 782], ["tumor cells", "CELL_TYPE", 1154, 1165], ["tumor specific CTLs", "CELL_TYPE", 1253, 1272], ["IL", "PROTEIN", 1291, 1293], ["T helper", "CELL_TYPE", 1354, 1362], ["tumor cells", "CELL_TYPE", 1428, 1439], ["IFN", "PROTEIN", 1509, 1512], ["IFN", "PROTEIN", 1693, 1696], ["cytokine", "PROTEIN", 1767, 1775], ["DC", "CELL_TYPE", 1800, 1802], ["TNF", "PROTEIN", 1919, 1922], ["Chemokines", "PROTEIN", 2033, 2043], ["CCL5", "PROTEIN", 2045, 2049], ["CCL2", "PROTEIN", 2057, 2061], ["CCL19", "PROTEIN", 2069, 2074], ["CXCL11", "PROTEIN", 2083, 2089], ["DC", "CELL_TYPE", 2150, 2152], ["T helper cells", "CELL_TYPE", 2213, 2227], ["CTLs", "CELL_TYPE", 2232, 2236], ["DC", "CELL_TYPE", 2339, 2341], ["B7.1", "PROTEIN", 2382, 2386], ["CD80", "PROTEIN", 2387, 2391], ["tumor cells", "CELL_TYPE", 2483, 2494], ["PD1", "PROTEIN", 2611, 2614], ["Tregs", "CELL_TYPE", 2738, 2743], ["IL", "PROTEIN", 2834, 2836], ["tumor cells", "CELL_TYPE", 2960, 2971], ["mice", "SPECIES", 13, 17], ["mouse", "SPECIES", 1477, 1482], ["mouse", "SPECIES", 1584, 1589], ["patients", "SPECIES", 2432, 2440], ["mice", "SPECIES", 13, 17], ["MV", "SPECIES", 463, 465], ["NDV", "SPECIES", 542, 545], ["NDV", "SPECIES", 1327, 1330], ["mouse", "SPECIES", 1477, 1482], ["MV", "SPECIES", 1515, 1517], ["mouse", "SPECIES", 1584, 1589], ["NDV", "SPECIES", 1684, 1687], ["NDV", "SPECIES", 1699, 1702], ["NDV", "SPECIES", 1956, 1959], ["armed oncolytic viruses", "TREATMENT", 83, 106], ["immune modulators", "TREATMENT", 111, 128], ["Transgene Virus Tumor", "PROBLEM", 129, 150], ["immunologic effects", "TEST", 160, 179], ["ToxicityCytokines", "TEST", 180, 197], ["GM", "TEST", 198, 200], ["CSF HSV", "TEST", 201, 208], ["Adenocarcinoma", "TEST", 223, 237], ["Metastised (phase I", "TEST", 245, 264], ["Breast cancer", "PROBLEM", 277, 290], ["Melanoma (phase I", "TEST", 299, 316], ["peripheral blood mononuclear cell response", "TEST", 340, 382], ["Grade", "TEST", 389, 394], ["AdV", "TEST", 414, 417], ["CD3", "TEST", 433, 436], ["T cell infiltration", "PROBLEM", 438, 457], ["MV", "TEST", 463, 465], ["Long-term immunity", "TREATMENT", 471, 489], ["tumor cells", "TEST", 515, 526], ["VSV", "TEST", 532, 535], ["NDV", "TEST", 542, 545], ["IL", "TEST", 552, 554], ["Virus Tumor", "PROBLEM", 567, 578], ["ToxicityAdV", "TEST", 608, 619], ["Neuroblastoma", "PROBLEM", 626, 639], ["Glioma", "PROBLEM", 647, 653], ["Squamous Cell Carcinoma", "PROBLEM", 677, 700], ["Melanoma", "PROBLEM", 712, 720], ["Infiltration of macrophages", "PROBLEM", 727, 754], ["CTL and NK cells", "TEST", 766, 782], ["signs", "TEST", 803, 808], ["HSV", "TEST", 822, 825], ["survival", "TEST", 863, 871], ["VSV", "TEST", 918, 921], ["IL", "TEST", 927, 929], ["NDV", "TEST", 932, 935], ["Melanoma", "TEST", 961, 969], ["Hepatoma", "TEST", 981, 989], ["Squamous Cell Carcinoma", "PROBLEM", 1001, 1024], ["Infiltration of T helper", "TEST", 1030, 1054], ["CTL", "TEST", 1059, 1062], ["signs", "TEST", 1096, 1101], ["HSV", "TEST", 1111, 1114], ["tumor cells", "TEST", 1154, 1165], ["IL", "TEST", 1185, 1187], ["Colon carcinoma", "PROBLEM", 1199, 1214], ["Melanoma", "PROBLEM", 1222, 1230], ["tumor specific CTLs", "TEST", 1253, 1272], ["the blood", "TEST", 1276, 1285], ["IL", "TEST", 1291, 1293], ["detectable in tumor", "PROBLEM", 1302, 1321], ["NDV", "TEST", 1327, 1330], ["I n filtration of T helper", "TEST", 1336, 1362], ["CTL", "TEST", 1367, 1370], ["tumor cells", "TEST", 1428, 1439], ["HSV", "TEST", 1445, 1448], ["survival in mouse model", "TEST", 1465, 1488], ["IAV", "TEST", 1499, 1502], ["IFN", "TEST", 1509, 1512], ["MV", "TEST", 1515, 1517], ["Non-small cell lung cancer", "PROBLEM", 1523, 1549], ["survival mouse model", "TEST", 1575, 1595], ["VV", "TEST", 1614, 1616], ["Mesothelioma", "PROBLEM", 1623, 1635], ["Pancreatic adenocarcinoma", "PROBLEM", 1643, 1668], ["VSV", "TEST", 1674, 1677], ["NDV", "TEST", 1684, 1687], ["IFN", "TEST", 1693, 1696], ["NDV", "PROBLEM", 1699, 1702], ["Melanoma", "PROBLEM", 1708, 1716], ["colon carcinoma", "PROBLEM", 1736, 1751], ["Increased cytokine expression", "PROBLEM", 1757, 1786], ["VSV", "TEST", 1832, 1835], ["Increased T cell infiltration", "PROBLEM", 1841, 1870], ["IL", "TEST", 1884, 1886], ["IL", "TEST", 1905, 1907], ["TNF", "TEST", 1919, 1922], ["MIP1a", "TEST", 1930, 1935], ["FLT3L", "TEST", 1944, 1949], ["NDV", "TEST", 1956, 1959], ["T cell responses", "TEST", 1974, 1990], ["VSV", "TEST", 2004, 2007], ["HSV", "TEST", 2024, 2027], ["CCL5", "TEST", 2045, 2049], ["CCL2", "TEST", 2057, 2061], ["CCL19", "TEST", 2069, 2074], ["CXCL11", "TEST", 2083, 2089], ["VV", "TEST", 2103, 2105], ["Colon carcinoma", "PROBLEM", 2125, 2140], ["DC maturation", "TEST", 2150, 2163], ["HSV", "TEST", 2182, 2185], ["CTLs", "TEST", 2232, 2236], ["a Th2 response", "TEST", 2273, 2287], ["DC vaccination", "TREATMENT", 2339, 2353], ["Co-stimulatory ligands", "TEST", 2359, 2381], ["HSV", "TEST", 2392, 2395], ["Neuroblastoma", "PROBLEM", 2401, 2414], ["Melanoma", "PROBLEM", 2422, 2430], ["tumor cells", "PROBLEM", 2483, 2494], ["Low grade", "PROBLEM", 2500, 2509], ["VV", "TEST", 2515, 2517], ["signs", "TEST", 2536, 2541], ["AdV", "TEST", 2555, 2558], ["Decreased infiltration", "PROBLEM", 2569, 2591], ["Tregs", "TEST", 2595, 2600], ["anti-PD1", "TEST", 2606, 2614], ["PD", "TEST", 2618, 2620], ["L1IL", "TEST", 2621, 2625], ["Melanoma Infiltration", "PROBLEM", 2636, 2657], ["CTL", "TEST", 2674, 2677], ["signs", "TEST", 2693, 2698], ["VV", "TEST", 2704, 2706], ["Decreased infiltration of Tregs", "PROBLEM", 2712, 2743], ["IL", "TEST", 2834, 2836], ["tumor cells", "PROBLEM", 2960, 2971], ["the HSV", "TEST", 2975, 2982], ["IL", "TEST", 2983, 2985], ["Adenocarcinoma", "OBSERVATION", 223, 237], ["Breast", "ANATOMY", 277, 283], ["cancer", "OBSERVATION", 284, 290], ["Melanoma", "OBSERVATION", 299, 307], ["peripheral", "ANATOMY_MODIFIER", 340, 350], ["blood", "ANATOMY", 351, 356], ["mononuclear cell", "OBSERVATION", 357, 373], ["Glioma", "ANATOMY", 647, 653], ["Prostate", "ANATOMY", 661, 669], ["Squamous Cell Carcinoma", "OBSERVATION", 677, 700], ["Melanoma", "OBSERVATION", 712, 720], ["macrophages", "ANATOMY", 743, 754], ["NK", "ANATOMY", 774, 776], ["Melanoma", "OBSERVATION", 961, 969], ["Hepatoma", "ANATOMY", 981, 989], ["Squamous Cell Carcinoma", "OBSERVATION", 1001, 1024], ["Colon", "ANATOMY", 1199, 1204], ["carcinoma", "OBSERVATION", 1205, 1214], ["tumor", "OBSERVATION", 1253, 1258], ["tumor", "OBSERVATION", 1316, 1321], ["Non-small cell", "OBSERVATION", 1523, 1537], ["lung", "ANATOMY", 1538, 1542], ["cancer", "OBSERVATION", 1543, 1549], ["Mesothelioma", "OBSERVATION", 1623, 1635], ["Pancreatic", "ANATOMY", 1643, 1653], ["adenocarcinoma", "OBSERVATION", 1654, 1668], ["Melanoma", "OBSERVATION", 1708, 1716], ["Mammary", "ANATOMY", 1724, 1731], ["colon", "ANATOMY", 1736, 1741], ["carcinoma", "OBSERVATION", 1742, 1751], ["Colon", "ANATOMY", 2125, 2130], ["carcinoma", "OBSERVATION", 2131, 2140], ["Melanoma", "OBSERVATION", 2422, 2430], ["Melanoma", "OBSERVATION", 2636, 2644], ["tumor cells", "OBSERVATION", 2960, 2971]]], ["Similarly, adenovirus armed with IL-12 showed improved tumor reduction compared to adenovirus armed with GM-CSF in a thyroid cancer rat model [49] .", [["tumor", "ANATOMY", 55, 60], ["thyroid cancer", "ANATOMY", 117, 131], ["tumor", "DISEASE", 55, 60], ["GM", "CHEMICAL", 105, 107], ["thyroid cancer", "DISEASE", 117, 131], ["adenovirus", "ORGANISM", 11, 21], ["IL-12", "GENE_OR_GENE_PRODUCT", 33, 38], ["tumor", "CANCER", 55, 60], ["adenovirus", "ORGANISM", 83, 93], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 105, 111], ["thyroid cancer", "CANCER", 117, 131], ["rat", "ORGANISM", 132, 135], ["IL-12", "PROTEIN", 33, 38], ["GM", "PROTEIN", 105, 107], ["CSF", "PROTEIN", 108, 111], ["rat", "SPECIES", 132, 135], ["IL", "TEST", 33, 35], ["improved tumor reduction", "PROBLEM", 46, 70], ["GM", "TEST", 105, 107], ["a thyroid cancer", "PROBLEM", 115, 131], ["tumor", "OBSERVATION", 55, 60], ["thyroid", "ANATOMY", 117, 124], ["cancer", "OBSERVATION", 125, 131]]], ["In conclusion, multiple studies demonstrate that OVs armed with IL-12 yield better anti-tumor effects than vectorized GM-CSF and can even be further improved by combining different immune modulators.IL-2 and IL-15IL-2 and IL-15 both signal via cytokine receptors of the common \u03b3 chain family and are important for the stimulation, proliferation and survival of T cells and NK cells [23, 50] .", [["T cells", "ANATOMY", 361, 368], ["NK cells", "ANATOMY", 373, 381], ["GM", "CHEMICAL", 118, 120], ["OVs", "SIMPLE_CHEMICAL", 49, 52], ["IL-12", "GENE_OR_GENE_PRODUCT", 64, 69], ["anti-tumor", "CANCER", 83, 93], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 118, 124], ["IL-2", "GENE_OR_GENE_PRODUCT", 199, 203], ["IL-15IL-2", "GENE_OR_GENE_PRODUCT", 208, 217], ["IL-15", "GENE_OR_GENE_PRODUCT", 222, 227], ["\u03b3 chain", "GENE_OR_GENE_PRODUCT", 277, 284], ["T cells", "CELL", 361, 368], ["NK cells", "CELL", 373, 381], ["IL", "PROTEIN", 64, 66], ["IL", "PROTEIN", 199, 201], ["IL-15", "PROTEIN", 222, 227], ["cytokine receptors", "PROTEIN", 244, 262], ["\u03b3 chain family", "PROTEIN", 277, 291], ["T cells", "CELL_TYPE", 361, 368], ["NK cells", "CELL_TYPE", 373, 381], ["multiple studies", "TEST", 15, 31], ["IL", "TEST", 64, 66], ["combining different immune modulators", "TREATMENT", 161, 198], ["IL", "TEST", 199, 201], ["IL", "TEST", 208, 210], ["IL", "TREATMENT", 222, 224], ["the stimulation", "TREATMENT", 314, 329], ["NK cells", "TEST", 373, 381], ["immune modulators", "OBSERVATION", 181, 198]]], ["Systemic treatment with IL-2 is associated with major adverse side effects in humans [24] .", [["IL-2", "GENE_OR_GENE_PRODUCT", 24, 28], ["humans", "ORGANISM", 78, 84], ["IL", "PROTEIN", 24, 26], ["humans", "SPECIES", 78, 84], ["humans", "SPECIES", 78, 84], ["Systemic treatment with IL", "TREATMENT", 0, 26], ["major adverse side effects in humans", "PROBLEM", 48, 84]]], ["Therefore, local delivery of IL-2 by OVs has been tested by several research groups [51] [52] [53] [54] [55] [56] .", [["[51] [52] [53] [54] [55]", "CHEMICAL", 84, 108], ["IL-2", "GENE_OR_GENE_PRODUCT", 29, 33], ["OVs", "SIMPLE_CHEMICAL", 37, 40], ["[51] [52] [53] [54] [55] [56]", "SIMPLE_CHEMICAL", 84, 113], ["IL", "PROTEIN", 29, 31], ["local delivery of IL", "TREATMENT", 11, 31]]], ["In these murine studies, reduced tumor growth and increased T cell infiltration of the tumors was reported.", [["tumor", "ANATOMY", 33, 38], ["T cell", "ANATOMY", 60, 66], ["tumors", "ANATOMY", 87, 93], ["tumor", "DISEASE", 33, 38], ["tumors", "DISEASE", 87, 93], ["murine", "ORGANISM", 9, 15], ["tumor", "CANCER", 33, 38], ["T cell", "CELL", 60, 66], ["tumors", "CANCER", 87, 93], ["murine", "SPECIES", 9, 15], ["these murine studies", "TEST", 3, 23], ["reduced tumor growth", "PROBLEM", 25, 45], ["increased T cell infiltration", "PROBLEM", 50, 79], ["the tumors", "PROBLEM", 83, 93], ["reduced", "OBSERVATION_MODIFIER", 25, 32], ["tumor", "OBSERVATION", 33, 38], ["growth", "OBSERVATION_MODIFIER", 39, 45], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["T cell infiltration", "OBSERVATION", 60, 79], ["tumors", "OBSERVATION", 87, 93]]], ["No distress was observed in mice and IL-2 production was limited to the tumor site, which might indicate less side-effects when administrated to humans [53] [54] [55] .", [["tumor site", "ANATOMY", 72, 82], ["tumor", "DISEASE", 72, 77], ["mice", "ORGANISM", 28, 32], ["IL-2", "GENE_OR_GENE_PRODUCT", 37, 41], ["tumor", "CANCER", 72, 77], ["humans", "ORGANISM", 145, 151], ["mice", "SPECIES", 28, 32], ["humans", "SPECIES", 145, 151], ["mice", "SPECIES", 28, 32], ["humans", "SPECIES", 145, 151], ["distress", "PROBLEM", 3, 11], ["the tumor site", "PROBLEM", 68, 82], ["distress", "OBSERVATION", 3, 11], ["tumor", "OBSERVATION", 72, 77]]], ["Also, mice were protected from re-challenge with tumor cells suggesting induction of long term tumor specific immunity and thus show promise as vectorized immune modulator [52] [53] [54] [55] .IL-2 and IL-15Despite the promising effects of IL-2, IL-15 showed to have several advantages over IL-2.", [["tumor cells", "ANATOMY", 49, 60], ["tumor", "ANATOMY", 95, 100], ["tumor", "DISEASE", 49, 54], ["tumor", "DISEASE", 95, 100], ["mice", "ORGANISM", 6, 10], ["tumor cells", "CELL", 49, 60], ["tumor", "CANCER", 95, 100], ["IL-2", "GENE_OR_GENE_PRODUCT", 193, 197], ["IL-15Despite", "GENE_OR_GENE_PRODUCT", 202, 214], ["IL-2", "GENE_OR_GENE_PRODUCT", 240, 244], ["IL-15", "GENE_OR_GENE_PRODUCT", 246, 251], ["IL-2", "GENE_OR_GENE_PRODUCT", 291, 295], ["tumor cells", "CELL_TYPE", 49, 60], ["IL", "PROTEIN", 193, 195], ["IL", "PROTEIN", 240, 242], ["IL-15", "PROTEIN", 246, 251], ["IL", "PROTEIN", 291, 293], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["tumor cells", "PROBLEM", 49, 60], ["long term tumor specific immunity", "PROBLEM", 85, 118], ["IL", "TEST", 193, 195], ["IL", "TREATMENT", 202, 204], ["IL", "TEST", 240, 242], ["IL", "TEST", 246, 248], ["tumor cells", "OBSERVATION", 49, 60]]], ["In contrast to IL-2, Il-15 can stimulate only NK and effector T-cells, whereas IL-2 has also the undesirable effect of stimulating Tregs [50] .", [["NK", "ANATOMY", 46, 48], ["effector T-cells", "ANATOMY", 53, 69], ["Tregs", "ANATOMY", 131, 136], ["IL-2", "GENE_OR_GENE_PRODUCT", 15, 19], ["Il-15", "GENE_OR_GENE_PRODUCT", 21, 26], ["NK", "CELL", 46, 48], ["effector T-cells", "CELL", 53, 69], ["IL-2", "GENE_OR_GENE_PRODUCT", 79, 83], ["Tregs", "CELL", 131, 136], ["IL", "PROTEIN", 15, 17], ["Il-15", "PROTEIN", 21, 26], ["NK and effector T-cells", "CELL_TYPE", 46, 69], ["IL-2", "PROTEIN", 79, 83], ["Tregs", "CELL_TYPE", 131, 136], ["IL", "TEST", 15, 17]]], ["Even though systemic treatment with IL-15 induces less toxic effects local expression of IL-15 mediated by armed Vescilular Stomatitus virus (VSV) enhanced anti-tumor activity compared to VSV treatment combined with systemic IL-15 in murine models [57] .", [["IL-15", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-15", "GENE_OR_GENE_PRODUCT", 89, 94], ["Vescilular Stomatitus virus", "ORGANISM", 113, 140], ["VSV", "ORGANISM", 142, 145], ["anti-tumor", "CANCER", 156, 166], ["VSV", "ORGANISM", 188, 191], ["IL-15", "GENE_OR_GENE_PRODUCT", 225, 230], ["murine", "ORGANISM", 234, 240], ["IL", "PROTEIN", 36, 38], ["IL-15", "PROTEIN", 89, 94], ["IL", "PROTEIN", 225, 227], ["Stomatitus virus", "SPECIES", 124, 140], ["murine", "SPECIES", 234, 240], ["Vescilular Stomatitus virus", "SPECIES", 113, 140], ["VSV", "SPECIES", 142, 145], ["VSV", "SPECIES", 188, 191], ["systemic treatment", "TREATMENT", 12, 30], ["IL", "TREATMENT", 36, 38], ["less toxic effects", "PROBLEM", 50, 68], ["IL", "TEST", 89, 91], ["armed Vescilular Stomatitus virus (VSV) enhanced anti-tumor activity", "PROBLEM", 107, 175], ["VSV treatment", "TREATMENT", 188, 201], ["systemic IL", "TREATMENT", 216, 227]]], ["Vectorization by NDV demonstrated that IL-15 induced more CTL infiltration and increased activation of tumor-specific effector cells resulting in improved survival rates compared to IL-2 in a melanoma mouse model [58] .", [["tumor", "ANATOMY", 103, 108], ["cells", "ANATOMY", 127, 132], ["melanoma", "ANATOMY", 192, 200], ["tumor", "DISEASE", 103, 108], ["melanoma", "DISEASE", 192, 200], ["NDV", "ORGANISM", 17, 20], ["IL-15", "GENE_OR_GENE_PRODUCT", 39, 44], ["tumor", "CANCER", 103, 108], ["cells", "CELL", 127, 132], ["IL-2", "GENE_OR_GENE_PRODUCT", 182, 186], ["melanoma", "CANCER", 192, 200], ["mouse", "ORGANISM", 201, 206], ["IL-15", "PROTEIN", 39, 44], ["tumor-specific effector cells", "CELL_TYPE", 103, 132], ["IL", "PROTEIN", 182, 184], ["mouse", "SPECIES", 201, 206], ["NDV", "SPECIES", 17, 20], ["mouse", "SPECIES", 201, 206], ["Vectorization", "TREATMENT", 0, 13], ["IL", "TEST", 39, 41], ["more CTL infiltration", "PROBLEM", 53, 74], ["increased activation of tumor", "PROBLEM", 79, 108], ["specific effector cells", "PROBLEM", 109, 132], ["improved survival rates", "PROBLEM", 146, 169], ["IL", "TEST", 182, 184], ["CTL infiltration", "OBSERVATION", 58, 74], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["tumor", "OBSERVATION", 103, 108], ["effector cells", "OBSERVATION", 118, 132], ["improved", "OBSERVATION_MODIFIER", 146, 154], ["survival", "OBSERVATION_MODIFIER", 155, 163]]], ["Altogether, these studies indicate that treatment with OVs expressing IL-15 is more efficient than systemic treatment with IL-15 or treatment with OVs expressing IL-2.Type I and II interferonsIFN-\u03b1/\u03b2 are important in antiviral responses, but also play a role in anti-cancer immunity by inducing DC maturation and CTL and NK cell activation [23, 32] .", [["DC", "ANATOMY", 295, 297], ["NK cell", "ANATOMY", 321, 328], ["OVs", "SIMPLE_CHEMICAL", 55, 58], ["IL-15", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-15", "GENE_OR_GENE_PRODUCT", 123, 128], ["OVs", "SIMPLE_CHEMICAL", 147, 150], ["IL-2", "GENE_OR_GENE_PRODUCT", 162, 166], ["Type I and II interferonsIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 167, 197], ["\u03b2", "GENE_OR_GENE_PRODUCT", 198, 199], ["anti-cancer", "CANCER", 262, 273], ["DC", "CELL", 295, 297], ["CTL", "CELL", 313, 316], ["NK cell", "CELL", 321, 328], ["IL-15", "PROTEIN", 70, 75], ["IL", "PROTEIN", 123, 125], ["IL-2", "PROTEIN", 162, 166], ["Type I and II interferonsIFN-\u03b1/\u03b2", "PROTEIN", 167, 199], ["DC", "CELL_TYPE", 295, 297], ["CTL", "CELL_TYPE", 313, 316], ["these studies", "TEST", 12, 25], ["OVs expressing IL", "TREATMENT", 55, 72], ["systemic treatment", "TREATMENT", 99, 117], ["IL", "TREATMENT", 123, 125], ["treatment", "TREATMENT", 132, 141], ["OVs expressing IL", "TREATMENT", 147, 164]]], ["In addition, they result in upregulation of MHC I expression on tumor cells and can have direct effect on cell proliferation.", [["tumor cells", "ANATOMY", 64, 75], ["cell", "ANATOMY", 106, 110], ["tumor", "DISEASE", 64, 69], ["MHC I", "GENE_OR_GENE_PRODUCT", 44, 49], ["tumor cells", "CELL", 64, 75], ["cell", "CELL", 106, 110], ["MHC I", "PROTEIN", 44, 49], ["tumor cells", "CELL_TYPE", 64, 75], ["MHC I expression on tumor cells", "PROBLEM", 44, 75], ["cell proliferation", "PROBLEM", 106, 124], ["tumor cells", "OBSERVATION", 64, 75], ["cell proliferation", "OBSERVATION", 106, 124]]], ["Only a few studies have investigated OVs armed with type I interferons [59] [60] [61] .", [["OVs", "SIMPLE_CHEMICAL", 37, 40], ["a few studies", "TEST", 5, 18]]], ["The direct anti-tumor effects of IFN-\u03b2 expressed by the measles virus (MV) and NDV has been demonstrated in immune deficient mouse models leading to some improvement of the viral therapy.", [["IFN-\u03b2", "CHEMICAL", 33, 38], ["anti-tumor", "CANCER", 11, 21], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["measles virus", "ORGANISM", 56, 69], ["NDV", "ORGANISM", 79, 82], ["mouse", "ORGANISM", 125, 130], ["IFN", "PROTEIN", 33, 36], ["\u03b2", "PROTEIN", 37, 38], ["measles virus", "SPECIES", 56, 69], ["NDV", "SPECIES", 79, 82], ["mouse", "SPECIES", 125, 130], ["measles virus", "SPECIES", 56, 69], ["MV", "SPECIES", 71, 73], ["NDV", "SPECIES", 79, 82], ["mouse", "SPECIES", 125, 130], ["IFN", "TREATMENT", 33, 36], ["the measles virus", "PROBLEM", 52, 69], ["NDV", "PROBLEM", 79, 82], ["immune deficient mouse models", "PROBLEM", 108, 137], ["the viral therapy", "TREATMENT", 169, 186], ["immune deficient", "OBSERVATION", 108, 124], ["improvement", "OBSERVATION_MODIFIER", 154, 165], ["viral therapy", "OBSERVATION", 173, 186]]], ["Buijs et al. showed that a virus expressing IFN-\u03b2 interfered with oncolytic NDV replication, whereas Willmon et al. and Li et al. found that viral IFN-\u03b2 expression did not interfere with VSV and MV replication [59] [60] [61] .", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["NDV", "ORGANISM", 76, 79], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 147, 152], ["VSV", "ORGANISM", 187, 190], ["IFN", "PROTEIN", 44, 47], ["\u03b2", "PROTEIN", 48, 49], ["IFN", "PROTEIN", 147, 150], ["\u03b2", "PROTEIN", 151, 152], ["NDV", "SPECIES", 76, 79], ["VSV", "SPECIES", 187, 190], ["MV", "SPECIES", 195, 197], ["a virus expressing IFN", "PROBLEM", 25, 47], ["oncolytic NDV replication", "TREATMENT", 66, 91], ["viral IFN", "PROBLEM", 141, 150], ["viral IFN", "OBSERVATION", 141, 150]]], ["However, the immune stimulating effect of virus mediated IFN-\u03b2 expression still needs to be assessed in an immunocompetent model to determine the potency of IFN-\u03b2 as transgene.Type I and II interferonsType II interferon (IFN-\u03b3) is an important Th1 effector cytokine, secreted by activated Th1 cells, CTLs and NK cells [23] .", [["Th1 cells", "ANATOMY", 289, 298], ["CTLs", "ANATOMY", 300, 304], ["NK cells", "ANATOMY", 309, 317], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 57, 62], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["Type I and II interferons", "GENE_OR_GENE_PRODUCT", 176, 201], ["Type II interferon", "GENE_OR_GENE_PRODUCT", 201, 219], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 221, 226], ["Th1 cells", "CELL", 289, 298], ["CTLs", "CELL", 300, 304], ["NK cells", "CELL", 309, 317], ["IFN", "PROTEIN", 57, 60], ["\u03b2", "PROTEIN", 61, 62], ["IFN", "PROTEIN", 157, 160], ["\u03b2", "PROTEIN", 161, 162], ["Type I and II interferons", "PROTEIN", 176, 201], ["Type II interferon", "PROTEIN", 201, 219], ["IFN", "PROTEIN", 221, 224], ["\u03b3", "PROTEIN", 225, 226], ["Th1 effector cytokine", "PROTEIN", 244, 265], ["activated Th1 cells", "CELL_TYPE", 279, 298], ["CTLs", "CELL_TYPE", 300, 304], ["NK cells", "CELL_TYPE", 309, 317], ["virus", "PROBLEM", 42, 47], ["Type I and II interferonsType II interferon (IFN", "TREATMENT", 176, 224]]], ["IFN-\u03b3 upregulates MHC I expression in tumor cells and promotes Th1 skewing via an autocrine loop [23] .", [["tumor cells", "ANATOMY", 38, 49], ["tumor", "DISEASE", 38, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHC I", "GENE_OR_GENE_PRODUCT", 18, 23], ["tumor cells", "CELL", 38, 49], ["Th1", "GENE_OR_GENE_PRODUCT", 63, 66], ["IFN", "PROTEIN", 0, 3], ["\u03b3", "PROTEIN", 4, 5], ["MHC I", "PROTEIN", 18, 23], ["tumor cells", "CELL_TYPE", 38, 49], ["expression in tumor cells", "PROBLEM", 24, 49], ["an autocrine loop", "TREATMENT", 79, 96], ["tumor cells", "OBSERVATION", 38, 49]]], ["A recent study describing VSV expressing IFN-\u03b3 suggested that this virus induces a stronger immune response by increasing MHC I antigen presentation on tumor cells, enhancing DC maturation and attracting T cells to the tumor site by inducing CCL2 expression in mice [62] .", [["tumor cells", "ANATOMY", 152, 163], ["DC", "ANATOMY", 175, 177], ["T cells", "ANATOMY", 204, 211], ["tumor site", "ANATOMY", 219, 229], ["tumor", "DISEASE", 152, 157], ["tumor", "DISEASE", 219, 224], ["VSV", "ORGANISM", 26, 29], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 41, 46], ["MHC I antigen", "GENE_OR_GENE_PRODUCT", 122, 135], ["tumor cells", "CELL", 152, 163], ["DC", "CELL", 175, 177], ["T cells", "CELL", 204, 211], ["tumor", "CANCER", 219, 224], ["CCL2", "GENE_OR_GENE_PRODUCT", 242, 246], ["mice", "ORGANISM", 261, 265], ["IFN-\u03b3", "PROTEIN", 41, 46], ["MHC I antigen", "PROTEIN", 122, 135], ["tumor cells", "CELL_TYPE", 152, 163], ["DC", "CELL_TYPE", 175, 177], ["T cells", "CELL_TYPE", 204, 211], ["CCL2", "PROTEIN", 242, 246], ["mice", "SPECIES", 261, 265], ["VSV", "SPECIES", 26, 29], ["mice", "SPECIES", 261, 265], ["A recent study", "TEST", 0, 14], ["this virus", "PROBLEM", 62, 72], ["tumor cells", "PROBLEM", 152, 163], ["enhancing DC maturation", "TREATMENT", 165, 188], ["attracting T cells to the tumor site", "PROBLEM", 193, 229], ["tumor cells", "OBSERVATION", 152, 163], ["tumor", "OBSERVATION", 219, 224]]], ["The authors did not observe any difference in viral replication, even though IFN-\u03b3 is also known for its antiviral activity.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 77, 82], ["IFN", "PROTEIN", 77, 80], ["\u03b3", "PROTEIN", 81, 82], ["viral replication", "PROBLEM", 46, 63], ["viral replication", "OBSERVATION", 46, 63], ["antiviral activity", "OBSERVATION", 105, 123]]], ["In another murine study, treatment with NDV-IFN-\u03b3 did not result in a significant beneficial effect compared to unarmed NDV [55] .Type I and II interferonsIn conclusion, arming OVs with IFN-\u03b3 has been shown to be effective, but efficacy may depend on the virus used.Effector cell attracting chemokinesInsufficient infiltration of effector lymphocytes in the tumor often correlates with low efficacy of T cell stimulating immunotherapies [7, 10] .", [["cell", "ANATOMY", 275, 279], ["effector lymphocytes", "ANATOMY", 330, 350], ["tumor", "ANATOMY", 358, 363], ["T cell", "ANATOMY", 402, 408], ["NDV-IFN-\u03b3", "CHEMICAL", 40, 49], ["IFN-\u03b3", "CHEMICAL", 186, 191], ["tumor", "DISEASE", 358, 363], ["murine", "ORGANISM", 11, 17], ["NDV", "ORGANISM", 40, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 44, 49], ["NDV", "ORGANISM", 120, 123], ["Type I and II interferons", "GENE_OR_GENE_PRODUCT", 130, 155], ["OVs", "SIMPLE_CHEMICAL", 177, 180], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 186, 191], ["Effector cell", "CELL", 266, 279], ["effector lymphocytes", "CELL", 330, 350], ["tumor", "CANCER", 358, 363], ["T cell", "CELL", 402, 408], ["IFN", "PROTEIN", 44, 47], ["Type I and II interferons", "PROTEIN", 130, 155], ["IFN", "PROTEIN", 186, 189], ["chemokines", "PROTEIN", 291, 301], ["effector lymphocytes", "CELL_TYPE", 330, 350], ["murine", "SPECIES", 11, 17], ["NDV", "SPECIES", 40, 43], ["NDV", "SPECIES", 120, 123], ["another murine study", "TEST", 3, 23], ["NDV", "TREATMENT", 40, 43], ["IFN", "TREATMENT", 44, 47], ["a significant beneficial effect", "PROBLEM", 68, 99], ["Type I and II interferons", "PROBLEM", 130, 155], ["IFN", "TREATMENT", 186, 189], ["the virus", "PROBLEM", 251, 260], ["Insufficient infiltration of effector lymphocytes", "PROBLEM", 301, 350], ["the tumor", "PROBLEM", 354, 363], ["T cell stimulating immunotherapies", "TREATMENT", 402, 436], ["infiltration", "OBSERVATION", 314, 326], ["effector lymphocytes", "OBSERVATION", 330, 350], ["tumor", "OBSERVATION", 358, 363], ["low efficacy", "OBSERVATION_MODIFIER", 386, 398]]], ["Therefore, OVs armed with chemokines, which attract effector cells, may improve antitumor efficacy in addition to the endogenous chemokine release upon viral infection.", [["effector cells", "ANATOMY", 52, 66], ["antitumor", "ANATOMY", 80, 89], ["viral infection", "DISEASE", 152, 167], ["OVs", "SIMPLE_CHEMICAL", 11, 14], ["cells", "CELL", 61, 66], ["antitumor", "CANCER", 80, 89], ["OVs", "PROTEIN", 11, 14], ["chemokines", "PROTEIN", 26, 36], ["effector cells", "CELL_TYPE", 52, 66], ["chemokine", "PROTEIN", 129, 138], ["chemokines", "TREATMENT", 26, 36], ["the endogenous chemokine release", "TREATMENT", 114, 146], ["viral infection", "PROBLEM", 152, 167], ["viral infection", "OBSERVATION", 152, 167]]], ["Important chemokines in the TME are CCL2, CCL5 (RANTES), CXCL9 and CXCL10, which attract Th1 cells and CTLs and CCL22, which attracts undesirable Tregs [63] .", [["Th1 cells", "ANATOMY", 89, 98], ["CTLs", "ANATOMY", 103, 107], ["Tregs", "ANATOMY", 146, 151], ["CCL2", "GENE_OR_GENE_PRODUCT", 36, 40], ["CCL5", "GENE_OR_GENE_PRODUCT", 42, 46], ["RANTES", "GENE_OR_GENE_PRODUCT", 48, 54], ["CXCL9", "GENE_OR_GENE_PRODUCT", 57, 62], ["CXCL10", "GENE_OR_GENE_PRODUCT", 67, 73], ["Th1 cells", "CELL", 89, 98], ["CTLs", "CELL", 103, 107], ["CCL22", "GENE_OR_GENE_PRODUCT", 112, 117], ["chemokines", "PROTEIN", 10, 20], ["CCL2", "PROTEIN", 36, 40], ["CCL5", "PROTEIN", 42, 46], ["RANTES", "PROTEIN", 48, 54], ["CXCL9", "PROTEIN", 57, 62], ["CXCL10", "PROTEIN", 67, 73], ["Th1 cells", "CELL_TYPE", 89, 98], ["CTLs", "CELL_TYPE", 103, 107], ["CCL22", "PROTEIN", 112, 117], ["Tregs", "CELL_TYPE", 146, 151], ["RANTES", "TEST", 48, 54], ["CXCL9", "TEST", 57, 62], ["CXCL10", "TEST", 67, 73], ["CTLs", "TEST", 103, 107], ["CCL22", "TEST", 112, 117], ["CCL2", "ANATOMY", 36, 40]]], ["Combination of OV therapy with a chemokine modulating cocktail, which induces production of CCL5 and CXCL10 while reducing CCL22, was shown to promote trafficking of T helper cells and CTLs to the TME and resulted in improved survival in a murine colon cancer model [64] .", [["T helper cells", "ANATOMY", 166, 180], ["CTLs", "ANATOMY", 185, 189], ["colon cancer", "ANATOMY", 247, 259], ["colon cancer", "DISEASE", 247, 259], ["OV", "SIMPLE_CHEMICAL", 15, 17], ["CCL5", "GENE_OR_GENE_PRODUCT", 92, 96], ["CXCL10", "GENE_OR_GENE_PRODUCT", 101, 107], ["CCL22", "GENE_OR_GENE_PRODUCT", 123, 128], ["T helper cells", "CELL", 166, 180], ["CTLs", "CELL", 185, 189], ["murine", "ORGANISM", 240, 246], ["colon cancer", "CANCER", 247, 259], ["chemokine", "PROTEIN", 33, 42], ["CCL5", "PROTEIN", 92, 96], ["CXCL10", "PROTEIN", 101, 107], ["CCL22", "PROTEIN", 123, 128], ["T helper cells", "CELL_TYPE", 166, 180], ["CTLs", "CELL_TYPE", 185, 189], ["murine", "SPECIES", 240, 246], ["OV therapy", "TREATMENT", 15, 25], ["a chemokine modulating cocktail", "TREATMENT", 31, 62], ["CXCL10", "TEST", 101, 107], ["CCL22", "TEST", 123, 128], ["CCL5", "ANATOMY", 92, 96], ["colon", "ANATOMY", 247, 252], ["cancer", "OBSERVATION", 253, 259]]], ["Administration of viruses armed with CCL5 or CCL2 both resulted in increased numbers of infiltrating Th1 cells in colon cancer and neuroblastoma [65] [66] [67] .", [["infiltrating Th1 cells", "ANATOMY", 88, 110], ["colon cancer", "ANATOMY", 114, 126], ["neuroblastoma", "ANATOMY", 131, 144], ["colon cancer", "DISEASE", 114, 126], ["neuroblastoma", "DISEASE", 131, 144], ["CCL5", "GENE_OR_GENE_PRODUCT", 37, 41], ["CCL2", "GENE_OR_GENE_PRODUCT", 45, 49], ["Th1 cells", "CELL", 101, 110], ["colon cancer", "CANCER", 114, 126], ["neuroblastoma", "CANCER", 131, 144], ["CCL5", "PROTEIN", 37, 41], ["CCL2", "PROTEIN", 45, 49], ["infiltrating Th1 cells", "CELL_TYPE", 88, 110], ["CCL5 or CCL2", "TREATMENT", 37, 49], ["infiltrating Th1 cells", "PROBLEM", 88, 110], ["colon cancer", "PROBLEM", 114, 126], ["neuroblastoma", "PROBLEM", 131, 144], ["viruses", "OBSERVATION", 18, 25], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["numbers", "OBSERVATION_MODIFIER", 77, 84], ["infiltrating", "OBSERVATION_MODIFIER", 88, 100], ["Th1 cells", "OBSERVATION", 101, 110], ["colon", "ANATOMY", 114, 119], ["cancer", "OBSERVATION", 120, 126]]], ["In conclusion, these studies have shown that the use of OVs armed with chemokines efficiently increased the infiltration of T cells into the tumor.", [["T cells", "ANATOMY", 124, 131], ["tumor", "ANATOMY", 141, 146], ["tumor", "DISEASE", 141, 146], ["OVs", "SIMPLE_CHEMICAL", 56, 59], ["T cells", "CELL", 124, 131], ["tumor", "CANCER", 141, 146], ["OVs", "PROTEIN", 56, 59], ["chemokines", "PROTEIN", 71, 81], ["T cells", "CELL_TYPE", 124, 131], ["these studies", "TEST", 15, 28], ["chemokines", "TREATMENT", 71, 81], ["the infiltration of T cells", "TREATMENT", 104, 131], ["the tumor", "PROBLEM", 137, 146], ["infiltration", "OBSERVATION", 108, 120], ["tumor", "OBSERVATION", 141, 146]]], ["However, none of the studies have assessed the infiltration of immune cells in distant tumors and tumor reduction has not been mentioned.Combination of OVs with blocking of co-inhibitory receptorsThe most popular immunotherapeutics are the checkpoint inhibitors, anti-CTLA-4 or anti-PD-1/PD-L1, yielding promising effects but coinciding with major adverse effects, as described above [68] .", [["immune cells", "ANATOMY", 63, 75], ["tumors", "ANATOMY", 87, 93], ["tumor", "ANATOMY", 98, 103], ["tumors", "DISEASE", 87, 93], ["tumor", "DISEASE", 98, 103], ["immune cells", "CELL", 63, 75], ["distant tumors", "CANCER", 79, 93], ["tumor", "CANCER", 98, 103], ["OVs", "SIMPLE_CHEMICAL", 152, 155], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 263, 274], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 278, 287], ["PD-L1", "GENE_OR_GENE_PRODUCT", 288, 293], ["immune cells", "CELL_TYPE", 63, 75], ["co-inhibitory receptors", "PROTEIN", 173, 196], ["the studies", "TEST", 17, 28], ["immune cells", "PROBLEM", 63, 75], ["distant tumors", "PROBLEM", 79, 93], ["tumor reduction", "TREATMENT", 98, 113], ["blocking of co-inhibitory receptors", "TREATMENT", 161, 196], ["the checkpoint inhibitors", "TREATMENT", 236, 261], ["anti-CTLA", "TEST", 263, 272], ["anti-PD", "TREATMENT", 278, 285], ["major adverse effects", "PROBLEM", 342, 363], ["infiltration", "OBSERVATION", 47, 59], ["immune cells", "OBSERVATION", 63, 75], ["distant", "OBSERVATION_MODIFIER", 79, 86], ["tumors", "OBSERVATION", 87, 93], ["tumor", "OBSERVATION", 98, 103], ["L1", "ANATOMY", 291, 293]]], ["In addition, some tumors are resistant to these immunotherapies, dependent on the immunogenicity of the tumor and the suppression of the anti-tumor immune responses in the TME [69] .", [["tumors", "ANATOMY", 18, 24], ["tumor", "ANATOMY", 104, 109], ["tumors", "DISEASE", 18, 24], ["tumor", "DISEASE", 104, 109], ["tumors", "CANCER", 18, 24], ["tumor", "CANCER", 104, 109], ["anti-tumor", "CANCER", 137, 147], ["some tumors", "PROBLEM", 13, 24], ["these immunotherapies", "TREATMENT", 42, 63], ["the tumor", "PROBLEM", 100, 109], ["some", "OBSERVATION_MODIFIER", 13, 17], ["tumors", "OBSERVATION", 18, 24], ["resistant", "OBSERVATION_MODIFIER", 29, 38], ["tumor", "OBSERVATION", 104, 109]]], ["Combination of systemic immunotherapeutics with localized OV therapy may enhance their therapeutic efficacy and may overcome tumor resistance and reduce immune related adverse effects.CTLA-4CTLA-4 is a checkpoint inhibitor that inhibits early stages of T cell activation in the lymph nodes, but also stimulates undesirable Treg functions [28, 68] .", [["OV", "ANATOMY", 58, 60], ["tumor", "ANATOMY", 125, 130], ["T cell", "ANATOMY", 253, 259], ["lymph nodes", "ANATOMY", 278, 289], ["Treg", "ANATOMY", 323, 327], ["tumor", "DISEASE", 125, 130], ["CTLA-4CTLA-4", "CHEMICAL", 184, 196], ["OV", "MULTI-TISSUE_STRUCTURE", 58, 60], ["tumor", "CANCER", 125, 130], ["CTLA-4CTLA-4", "GENE_OR_GENE_PRODUCT", 184, 196], ["T cell", "CELL", 253, 259], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 278, 289], ["Treg", "CELL", 323, 327], ["CTLA-4CTLA-4", "PROTEIN", 184, 196], ["systemic immunotherapeutics", "TREATMENT", 15, 42], ["localized OV therapy", "TREATMENT", 48, 68], ["tumor resistance", "PROBLEM", 125, 141], ["immune related adverse effects", "PROBLEM", 153, 183], ["CTLA", "TEST", 184, 188], ["a checkpoint inhibitor", "TREATMENT", 200, 222], ["T cell activation in the lymph nodes", "PROBLEM", 253, 289], ["tumor", "OBSERVATION", 125, 130], ["T cell activation", "OBSERVATION", 253, 270], ["lymph nodes", "OBSERVATION", 278, 289]]], ["Blockage of CTLA-4 signaling releases a brake on T cell activation and even depletes intratumoral Tregs [28] .", [["T cell", "ANATOMY", 49, 55], ["intratumoral Tregs", "ANATOMY", 85, 103], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 12, 18], ["T cell", "CELL", 49, 55], ["CTLA-4", "PROTEIN", 12, 18], ["intratumoral Tregs", "CELL_TYPE", 85, 103], ["Blockage of CTLA", "PROBLEM", 0, 16], ["a brake", "PROBLEM", 38, 45], ["T cell activation", "TEST", 49, 66], ["depletes", "OBSERVATION_MODIFIER", 76, 84], ["intratumoral Tregs", "OBSERVATION", 85, 103]]], ["Intratumoral administration of NDV combined with systemic treatment with anti-CTLA-4 (Ipilimumab) showed improved antitumor effect mediated by CTLs and NK cells in a murine melanoma model [70] .", [["Intratumoral", "ANATOMY", 0, 12], ["antitumor", "ANATOMY", 114, 123], ["CTLs", "ANATOMY", 143, 147], ["NK cells", "ANATOMY", 152, 160], ["melanoma", "ANATOMY", 173, 181], ["anti-CTLA-4", "CHEMICAL", 73, 84], ["Ipilimumab", "CHEMICAL", 86, 96], ["melanoma", "DISEASE", 173, 181], ["Ipilimumab", "CHEMICAL", 86, 96], ["NDV", "ORGANISM", 31, 34], ["anti-CTLA-4", "SIMPLE_CHEMICAL", 73, 84], ["Ipilimumab", "SIMPLE_CHEMICAL", 86, 96], ["antitumor", "CANCER", 114, 123], ["CTLs", "CELL", 143, 147], ["NK cells", "CELL", 152, 160], ["murine", "ORGANISM", 166, 172], ["melanoma", "CANCER", 173, 181], ["CTLs", "CELL_TYPE", 143, 147], ["NK cells", "CELL_TYPE", 152, 160], ["murine", "SPECIES", 166, 172], ["NDV", "SPECIES", 31, 34], ["Intratumoral administration of NDV", "TREATMENT", 0, 34], ["systemic treatment", "TREATMENT", 49, 67], ["anti-CTLA", "TREATMENT", 73, 82], ["Ipilimumab", "TREATMENT", 86, 96], ["improved antitumor effect", "PROBLEM", 105, 130], ["a murine melanoma model", "TREATMENT", 164, 187], ["NK cells", "OBSERVATION", 152, 160]]], ["Studies using combinations of systemic CTLA-4 blockade with other OVs (VV [71, 72] and VSV [20] ) showed prolonged survival in renal [71] , lung [72] and mammary [20] tumor models, long term protection to re-challenge with tumor cells [71, 72] , and even cured mice [20] .", [["renal", "ANATOMY", 127, 132], ["lung", "ANATOMY", 140, 144], ["mammary [20] tumor", "ANATOMY", 154, 172], ["tumor cells", "ANATOMY", 223, 234], ["tumor", "DISEASE", 167, 172], ["tumor", "DISEASE", 223, 228], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 39, 45], ["OVs", "SIMPLE_CHEMICAL", 66, 69], ["VSV", "ORGANISM", 87, 90], ["renal", "CANCER", 127, 132], ["lung", "ORGAN", 140, 144], ["mammary [20] tumor", "CANCER", 154, 172], ["tumor cells", "CELL", 223, 234], ["mice", "ORGANISM", 261, 265], ["tumor cells", "CELL_TYPE", 223, 234], ["mice", "SPECIES", 261, 265], ["VV", "SPECIES", 71, 73], ["mice", "SPECIES", 261, 265], ["systemic CTLA", "TREATMENT", 30, 43], ["4 blockade", "TREATMENT", 44, 54], ["VSV", "TEST", 87, 90], ["prolonged survival", "PROBLEM", 105, 123], ["tumor models", "PROBLEM", 167, 179], ["long term protection", "TREATMENT", 181, 201], ["tumor cells", "PROBLEM", 223, 234], ["renal", "ANATOMY", 127, 132], ["lung", "ANATOMY", 140, 144], ["mammary", "ANATOMY", 154, 161]]], ["Moreover, T-VEC combined with systemic CTLA-4 blockade has been evaluated for therapy in melanoma patients, which yielded a tumor growth control that was significantly greater than observed after both monotherapies [73] .", [["T-VEC", "ANATOMY", 10, 15], ["melanoma", "ANATOMY", 89, 97], ["tumor", "ANATOMY", 124, 129], ["T-VEC", "CHEMICAL", 10, 15], ["melanoma", "DISEASE", 89, 97], ["tumor", "DISEASE", 124, 129], ["T-VEC", "GENE_OR_GENE_PRODUCT", 10, 15], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 39, 45], ["melanoma", "CANCER", 89, 97], ["patients", "ORGANISM", 98, 106], ["tumor", "CANCER", 124, 129], ["patients", "SPECIES", 98, 106], ["systemic CTLA", "TREATMENT", 30, 43], ["4 blockade", "TREATMENT", 44, 54], ["therapy", "TREATMENT", 78, 85], ["a tumor growth control", "PROBLEM", 122, 144], ["melanoma", "OBSERVATION", 89, 97], ["tumor", "OBSERVATION", 124, 129]]], ["The incidence of severe adverse effects was similar to Ipilimumab monotherapy [68] , [73] .", [["Ipilimumab", "CHEMICAL", 55, 65], ["Ipilimumab", "CHEMICAL", 55, 65], ["Ipilimumab", "SIMPLE_CHEMICAL", 55, 65], ["severe adverse effects", "PROBLEM", 17, 39], ["Ipilimumab monotherapy", "TREATMENT", 55, 77], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["adverse", "OBSERVATION", 24, 31]]], ["Local expression of anti-CTLA-4 induced by administration of adenovirus armed with anti-CTLA-4 resulted in significantly higher concentrations of the antibody in the treated tumor, while plasma levels remained at concentrations indicated as safe in murine models [74] .", [["tumor", "ANATOMY", 174, 179], ["plasma", "ANATOMY", 187, 193], ["anti-CTLA-4", "CHEMICAL", 83, 94], ["tumor", "DISEASE", 174, 179], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 20, 31], ["adenovirus", "ORGANISM", 61, 71], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 83, 94], ["tumor", "CANCER", 174, 179], ["plasma", "ORGANISM_SUBSTANCE", 187, 193], ["murine", "ORGANISM", 249, 255], ["anti-CTLA-4", "PROTEIN", 20, 31], ["anti-CTLA-4", "PROTEIN", 83, 94], ["murine", "SPECIES", 249, 255], ["anti-CTLA", "TREATMENT", 20, 29], ["adenovirus", "TREATMENT", 61, 71], ["anti-CTLA", "TREATMENT", 83, 92], ["the antibody", "PROBLEM", 146, 158], ["the treated tumor", "PROBLEM", 162, 179], ["plasma levels", "TEST", 187, 200], ["treated", "OBSERVATION_MODIFIER", 166, 173], ["tumor", "OBSERVATION", 174, 179]]], ["However, Engeland et al. demonstrated that treatment with MV armed with anti-CTLA-4 was less efficient than intratumoral treatment with MV combined with systemic administration of anti-CTLA-4, presumably because the major site of action of CTLA-4 is in the lymph node and not in the periphery [75] .", [["lymph node", "ANATOMY", 257, 267], ["anti-CTLA-4", "CHEMICAL", 72, 83], ["anti-CTLA-4", "CHEMICAL", 180, 191], ["CTLA-4", "CHEMICAL", 240, 246], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 72, 83], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 180, 191], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 240, 246], ["lymph node", "MULTI-TISSUE_STRUCTURE", 257, 267], ["anti-CTLA", "PROTEIN", 72, 81], ["anti-CTLA-4", "PROTEIN", 180, 191], ["CTLA-4", "PROTEIN", 240, 246], ["MV", "SPECIES", 58, 60], ["MV", "SPECIES", 136, 138], ["MV", "TREATMENT", 58, 60], ["anti-CTLA", "TREATMENT", 72, 81], ["intratumoral treatment", "TREATMENT", 108, 130], ["MV", "TREATMENT", 136, 138], ["systemic administration of anti-CTLA", "TREATMENT", 153, 189], ["CTLA", "TEST", 240, 244], ["lymph node", "OBSERVATION", 257, 267], ["periphery", "ANATOMY_MODIFIER", 283, 292]]], ["Though local expression may lead to transient expression of the transgene in tumor draining lymph nodes, this study indicated that systemic anti-CTLA-4 therapy may be required for optimal responses.PD-1 and PD-L1With a completely different mechanism of action, PD-1 is also a checkpoint inhibitor expressed by effector T cells [68] .", [["tumor draining lymph nodes", "ANATOMY", 77, 103], ["effector T cells", "ANATOMY", 310, 326], ["tumor", "DISEASE", 77, 82], ["anti-CTLA-4", "CHEMICAL", 140, 151], ["tumor draining", "MULTI-TISSUE_STRUCTURE", 77, 91], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 92, 103], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 140, 151], ["PD-1", "GENE_OR_GENE_PRODUCT", 198, 202], ["PD-L1With", "GENE_OR_GENE_PRODUCT", 207, 216], ["PD-1", "GENE_OR_GENE_PRODUCT", 261, 265], ["effector T cells", "CELL", 310, 326], ["effector T cells", "CELL_TYPE", 310, 326], ["the transgene in tumor draining lymph nodes", "PROBLEM", 60, 103], ["this study", "TEST", 105, 115], ["systemic anti-CTLA-4 therapy", "TREATMENT", 131, 159], ["PD", "TEST", 198, 200], ["PD", "TREATMENT", 207, 209], ["PD", "TEST", 261, 263], ["a checkpoint inhibitor", "TREATMENT", 274, 296], ["tumor", "OBSERVATION_MODIFIER", 77, 82], ["draining", "OBSERVATION_MODIFIER", 83, 91], ["lymph nodes", "OBSERVATION", 92, 103]]], ["While CTLA-4 inhibits T cells in early activation stages in the lymph nodes, PD-1 signaling limits the function of activated T cells at later stages of the immune response taking place in tumors and tissues [68] .", [["T cells", "ANATOMY", 22, 29], ["lymph nodes", "ANATOMY", 64, 75], ["T cells", "ANATOMY", 125, 132], ["tumors", "ANATOMY", 188, 194], ["tissues", "ANATOMY", 199, 206], ["CTLA-4", "CHEMICAL", 6, 12], ["tumors", "DISEASE", 188, 194], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 6, 12], ["T cells", "CELL", 22, 29], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 64, 75], ["PD-1", "GENE_OR_GENE_PRODUCT", 77, 81], ["T cells", "CELL", 125, 132], ["tumors", "CANCER", 188, 194], ["tissues", "TISSUE", 199, 206], ["CTLA-4", "PROTEIN", 6, 12], ["T cells", "CELL_TYPE", 22, 29], ["activated T cells", "CELL_TYPE", 115, 132], ["CTLA", "TEST", 6, 10], ["T cells", "PROBLEM", 22, 29], ["early activation stages in the lymph nodes", "PROBLEM", 33, 75], ["PD", "TEST", 77, 79], ["activated T cells", "PROBLEM", 115, 132], ["lymph nodes", "OBSERVATION", 64, 75], ["immune response", "OBSERVATION", 156, 171], ["tumors", "OBSERVATION", 188, 194]]], ["Multiple OVs such as MV [76] , reovirus [77, 78] , and VSV [79, 80] , have been combined with systemic PD-1 blockade in treatment of murine glioblastoma [76] , melanoma [77, 78] , and acute myeloid leukemia [79] tumor models, resulting in enhanced influx of CTLs in the tumors and prolonged survival in mice.", [["OVs", "ANATOMY", 9, 12], ["glioblastoma", "ANATOMY", 140, 152], ["melanoma", "ANATOMY", 160, 168], ["acute myeloid leukemia", "ANATOMY", 184, 206], ["tumor", "ANATOMY", 212, 217], ["CTLs", "ANATOMY", 258, 262], ["tumors", "ANATOMY", 270, 276], ["glioblastoma", "DISEASE", 140, 152], ["melanoma", "DISEASE", 160, 168], ["acute myeloid leukemia", "DISEASE", 184, 206], ["tumor", "DISEASE", 212, 217], ["tumors", "DISEASE", 270, 276], ["reovirus", "ORGANISM", 31, 39], ["VSV", "ORGANISM", 55, 58], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["murine", "ORGANISM", 133, 139], ["glioblastoma", "CANCER", 140, 152], ["melanoma", "CANCER", 160, 168], ["acute myeloid leukemia", "CANCER", 184, 206], ["tumor", "CANCER", 212, 217], ["CTLs", "CELL", 258, 262], ["tumors", "CANCER", 270, 276], ["mice", "ORGANISM", 303, 307], ["CTLs", "CELL_TYPE", 258, 262], ["murine", "SPECIES", 133, 139], ["mice", "SPECIES", 303, 307], ["MV", "SPECIES", 21, 23], ["VSV", "SPECIES", 55, 58], ["mice", "SPECIES", 303, 307], ["MV", "TEST", 21, 23], ["reovirus", "TEST", 31, 39], ["VSV", "TEST", 55, 58], ["systemic PD", "TREATMENT", 94, 105], ["1 blockade", "TREATMENT", 106, 116], ["murine glioblastoma", "PROBLEM", 133, 152], ["melanoma", "PROBLEM", 160, 168], ["acute myeloid leukemia", "PROBLEM", 184, 206], ["tumor models", "TEST", 212, 224], ["enhanced influx of CTLs", "PROBLEM", 239, 262], ["the tumors", "PROBLEM", 266, 276], ["murine glioblastoma", "OBSERVATION", 133, 152], ["melanoma", "OBSERVATION", 160, 168], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["myeloid leukemia", "OBSERVATION", 190, 206], ["tumors", "OBSERVATION", 270, 276], ["prolonged", "OBSERVATION_MODIFIER", 281, 290], ["survival", "OBSERVATION_MODIFIER", 291, 299]]], ["Specifically CTLs and NK cells, but not T helper cells, were shown to mediate the beneficial effects [77, 79, 81] .PD-1 and PD-L1Moreover, a phase 1b clinical trial with the FDA approved T-VEC combined with PD-1 resulted in good response rates in patients [82] .", [["CTLs", "ANATOMY", 13, 17], ["NK cells", "ANATOMY", 22, 30], ["T helper cells", "ANATOMY", 40, 54], ["T-VEC", "CHEMICAL", 187, 192], ["CTLs", "CELL", 13, 17], ["NK cells", "CELL", 22, 30], ["T helper cells", "CELL", 40, 54], ["PD-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["T-VEC", "CELL", 187, 192], ["PD-1", "GENE_OR_GENE_PRODUCT", 207, 211], ["patients", "ORGANISM", 247, 255], ["CTLs", "CELL_TYPE", 13, 17], ["NK cells", "CELL_TYPE", 22, 30], ["T helper cells", "CELL_TYPE", 40, 54], ["patients", "SPECIES", 247, 255], ["PD", "TEST", 115, 117], ["PD", "TEST", 124, 126], ["the FDA", "TREATMENT", 170, 177], ["PD", "TREATMENT", 207, 209], ["NK cells", "OBSERVATION", 22, 30]]], ["Arming Myxoma Virus (MYXV) with anti-PD-1 did result in improved survival in mice as well [81] .", [["Arming Myxoma Virus", "ORGANISM", 0, 19], ["MYXV", "CANCER", 21, 25], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 32, 41], ["mice", "ORGANISM", 77, 81], ["anti-PD-1", "DNA", 32, 41], ["mice", "SPECIES", 77, 81], ["MYXV", "SPECIES", 21, 25], ["mice", "SPECIES", 77, 81], ["Arming Myxoma Virus", "PROBLEM", 0, 19], ["anti-PD", "TREATMENT", 32, 39], ["Myxoma", "OBSERVATION", 7, 13]]], ["However, local expression induced by administration of MV or VV armed with anti-PD-1 or anti-PD-L1 demonstrated to be as efficient as therapy with unarmed VV combined with systemic anti-PD-1/anti-PD-L1 treatment in murine tumor models [75, 83] .", [["tumor", "ANATOMY", 222, 227], ["anti-PD-1 or anti-PD-L1", "CHEMICAL", 75, 98], ["tumor", "DISEASE", 222, 227], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 75, 84], ["anti-PD-L1", "GENE_OR_GENE_PRODUCT", 88, 98], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 181, 190], ["PD-L1", "GENE_OR_GENE_PRODUCT", 196, 201], ["murine", "ORGANISM", 215, 221], ["tumor", "CANCER", 222, 227], ["anti-PD", "PROTEIN", 75, 82], ["anti-PD", "PROTEIN", 88, 95], ["murine", "SPECIES", 215, 221], ["MV", "SPECIES", 55, 57], ["VV", "SPECIES", 61, 63], ["VV", "SPECIES", 155, 157], ["MV", "TREATMENT", 55, 57], ["anti-PD", "TREATMENT", 75, 82], ["anti-PD-L1", "TREATMENT", 88, 98], ["unarmed VV", "TREATMENT", 147, 157], ["systemic anti-PD", "TREATMENT", 172, 188], ["anti-PD", "TREATMENT", 191, 198], ["L1 treatment", "TREATMENT", 199, 211], ["L1", "ANATOMY", 199, 201]]], ["In conclusion, these studies suggest that OVs combined with checkpoint inhibitors improve treatment, but the benefits of vectorization differ per oncolytic virus.Combination of OVs with activation of co-stimulatory receptors3.3.1.", [["OVs", "CHEMICAL", 42, 45], ["OVs", "SIMPLE_CHEMICAL", 42, 45], ["OVs", "CANCER", 177, 180], ["co-stimulatory receptors", "PROTEIN", 200, 224], ["these studies", "TEST", 15, 28], ["OVs", "PROBLEM", 42, 45], ["checkpoint inhibitors", "TREATMENT", 60, 81], ["treatment", "TREATMENT", 90, 99], ["vectorization", "TREATMENT", 121, 134], ["oncolytic virus", "PROBLEM", 146, 161], ["co-stimulatory receptors", "TEST", 200, 224]]], ["B7-1 B7-1 (CD80) is expressed by APCs and a potent co-stimulatory molecule for T cells.", [["APCs", "ANATOMY", 33, 37], ["T cells", "ANATOMY", 79, 86], ["B7-1 B7-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["CD80", "GENE_OR_GENE_PRODUCT", 11, 15], ["APCs", "CELL", 33, 37], ["T cells", "CELL", 79, 86], ["B7", "PROTEIN", 0, 2], ["B7", "PROTEIN", 5, 7], ["CD80", "PROTEIN", 11, 15], ["APCs", "CELL_TYPE", 33, 37], ["co-stimulatory molecule", "PROTEIN", 51, 74], ["T cells", "CELL_TYPE", 79, 86], ["B7", "TEST", 0, 2], ["B7", "TEST", 5, 7], ["CD80", "TEST", 11, 15], ["APCs", "TEST", 33, 37], ["T cells", "PROBLEM", 79, 86]]], ["B7-1 provides co-stimulation via interaction with CD28 on T cells, but inhibits T cells through interaction with CTLA-4 [28] .", [["T cells", "ANATOMY", 58, 65], ["T cells", "ANATOMY", 80, 87], ["B7-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD28", "GENE_OR_GENE_PRODUCT", 50, 54], ["T cells", "CELL", 58, 65], ["T cells", "CELL", 80, 87], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 113, 119], ["B7", "PROTEIN", 0, 2], ["CD28", "PROTEIN", 50, 54], ["T cells", "CELL_TYPE", 58, 65], ["T cells", "CELL_TYPE", 80, 87], ["CTLA", "PROTEIN", 113, 117], ["B7", "TEST", 0, 2], ["CTLA", "TEST", 113, 117]]], ["Nevertheless, several OVs armed with B7-1 have been tested in (pre)-clinical trials for the treatment of melanoma [41, [84] [85] [86] .", [["melanoma", "ANATOMY", 105, 113], ["melanoma", "DISEASE", 105, 113], ["B7-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["melanoma", "CANCER", 105, 113], ["B7", "PROTEIN", 37, 39], ["melanoma", "PROBLEM", 105, 113], ["melanoma", "OBSERVATION", 105, 113]]], ["Replication defective HSV expressing soluble B7-1 induced a prolonged tumor specific immune response in mice bearing neuroblastoma tumors [84] .", [["tumor", "ANATOMY", 70, 75], ["neuroblastoma tumors", "ANATOMY", 117, 137], ["tumor", "DISEASE", 70, 75], ["neuroblastoma tumors", "DISEASE", 117, 137], ["HSV", "ORGANISM", 22, 25], ["B7-1", "GENE_OR_GENE_PRODUCT", 45, 49], ["tumor", "CANCER", 70, 75], ["mice", "ORGANISM", 104, 108], ["neuroblastoma tumors", "CANCER", 117, 137], ["B7-1", "PROTEIN", 45, 49], ["mice", "SPECIES", 104, 108], ["HSV", "SPECIES", 22, 25], ["mice", "SPECIES", 104, 108], ["Replication defective", "PROBLEM", 0, 21], ["a prolonged tumor", "PROBLEM", 58, 75], ["mice bearing neuroblastoma tumors", "PROBLEM", 104, 137], ["tumor", "OBSERVATION", 70, 75], ["neuroblastoma tumors", "OBSERVATION", 117, 137]]], ["VV expressing B7-1 was eventually evaluated in melanoma patients, where the treatment was well tolerated, but only few patients responded [86] .", [["melanoma", "ANATOMY", 47, 55], ["melanoma", "DISEASE", 47, 55], ["VV", "ORGANISM", 0, 2], ["B7-1", "GENE_OR_GENE_PRODUCT", 14, 18], ["melanoma", "CANCER", 47, 55], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 119, 127], ["B7", "PROTEIN", 14, 16], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 119, 127], ["VV", "SPECIES", 0, 2], ["the treatment", "TREATMENT", 72, 85], ["melanoma", "OBSERVATION", 47, 55]]], ["Overall, OV expression of B7-1 seems to have additional benefits in combination with other transgenes, but not as a single transgene.4-1BB4-1BB is a surface protein primarily present on activated T cells and NK cells.", [["surface", "ANATOMY", 149, 156], ["T cells", "ANATOMY", 196, 203], ["NK cells", "ANATOMY", 208, 216], ["4-1BB4-1BB", "CHEMICAL", 133, 143], ["B7-1", "GENE_OR_GENE_PRODUCT", 26, 30], ["4-1BB4-1BB", "SIMPLE_CHEMICAL", 133, 143], ["T cells", "CELL", 196, 203], ["NK cells", "CELL", 208, 216], ["B7", "PROTEIN", 26, 28], ["1BB4", "PROTEIN", 135, 139], ["1BB", "PROTEIN", 140, 143], ["surface protein", "PROTEIN", 149, 164], ["activated T cells", "CELL_TYPE", 186, 203], ["NK cells", "CELL_TYPE", 208, 216], ["a surface protein", "TEST", 147, 164], ["NK cells", "OBSERVATION", 208, 216]]], ["4-1BB signaling promotes Th1 skewing over Th2, protects T cells from activation induced cell death and enhances cytotoxic activity of T cells and NK cells [28] .", [["T cells", "ANATOMY", 56, 63], ["cell", "ANATOMY", 88, 92], ["T cells", "ANATOMY", 134, 141], ["NK cells", "ANATOMY", 146, 154], ["death", "DISEASE", 93, 98], ["4-1BB", "CHEMICAL", 0, 5], ["4-1BB", "SIMPLE_CHEMICAL", 0, 5], ["Th1", "GENE_OR_GENE_PRODUCT", 25, 28], ["Th2", "GENE_OR_GENE_PRODUCT", 42, 45], ["T cells", "CELL", 56, 63], ["cell", "CELL", 88, 92], ["T cells", "CELL", 134, 141], ["NK cells", "CELL", 146, 154], ["1BB", "PROTEIN", 2, 5], ["Th2", "CELL_LINE", 42, 45], ["T cells", "CELL_TYPE", 56, 63], ["T cells", "CELL_TYPE", 134, 141], ["NK cells", "CELL_TYPE", 146, 154], ["activation induced cell death", "PROBLEM", 69, 98], ["enhances cytotoxic activity of T cells", "PROBLEM", 103, 141], ["NK cells", "TEST", 146, 154], ["cell death", "OBSERVATION", 88, 98], ["cytotoxic activity", "OBSERVATION", 112, 130]]], ["4-1BB signaling has been shown to be more potent in T cell activation compared to the CD28 co-stimulation by B7-1 [87] .", [["T cell", "ANATOMY", 52, 58], ["4-1BB", "SIMPLE_CHEMICAL", 0, 5], ["T cell", "CELL", 52, 58], ["CD28", "GENE_OR_GENE_PRODUCT", 86, 90], ["B7-1", "GENE_OR_GENE_PRODUCT", 109, 113], ["1BB", "PROTEIN", 2, 5], ["CD28", "PROTEIN", 86, 90], ["B7", "PROTEIN", 109, 111], ["T cell activation", "PROBLEM", 52, 69], ["the CD28 co-stimulation", "TREATMENT", 82, 105], ["B7", "TEST", 109, 111], ["more potent", "OBSERVATION_MODIFIER", 37, 48]]], ["A combination of oncolytic VV with systemic anti-4-1BB administration in a breast cancer model resulted in increased survival and tumor infiltration by CTLs compared to both monotherapies in patients (40% survival vs. 0% survival) [88] .", [["breast cancer", "ANATOMY", 75, 88], ["tumor", "ANATOMY", 130, 135], ["CTLs", "ANATOMY", 152, 156], ["anti-4-1BB", "CHEMICAL", 44, 54], ["breast cancer", "DISEASE", 75, 88], ["tumor", "DISEASE", 130, 135], ["VV", "ORGANISM", 27, 29], ["anti-4-1BB", "SIMPLE_CHEMICAL", 44, 54], ["breast cancer", "CANCER", 75, 88], ["tumor", "CANCER", 130, 135], ["CTLs", "CELL", 152, 156], ["patients", "ORGANISM", 191, 199], ["CTLs", "CELL_TYPE", 152, 156], ["patients", "SPECIES", 191, 199], ["VV", "SPECIES", 27, 29], ["oncolytic VV", "TREATMENT", 17, 29], ["systemic anti-4-1BB administration", "TREATMENT", 35, 69], ["a breast cancer model", "TREATMENT", 73, 94], ["increased survival", "PROBLEM", 107, 125], ["tumor infiltration", "PROBLEM", 130, 148], ["CTLs", "PROBLEM", 152, 156], ["both monotherapies", "TREATMENT", 169, 187], ["breast", "ANATOMY", 75, 81], ["cancer", "OBSERVATION", 82, 88], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["survival", "OBSERVATION_MODIFIER", 117, 125], ["tumor infiltration", "OBSERVATION", 130, 148]]], ["Local expression of 4-1BB ligand (4-1BBL) by oncolytic VV in mice has demonstrated to enhance tumor regression and this effect was enhanced even more in combination with lymph node depletion in order to slow down viral clearance [89] .", [["tumor", "ANATOMY", 94, 99], ["lymph node", "ANATOMY", 170, 180], ["tumor", "DISEASE", 94, 99], ["4-1BB ligand", "GENE_OR_GENE_PRODUCT", 20, 32], ["4-1BBL", "GENE_OR_GENE_PRODUCT", 34, 40], ["oncolytic VV", "ORGANISM", 45, 57], ["mice", "ORGANISM", 61, 65], ["tumor", "CANCER", 94, 99], ["lymph node", "MULTI-TISSUE_STRUCTURE", 170, 180], ["4-1BB ligand", "PROTEIN", 20, 32], ["mice", "SPECIES", 61, 65], ["VV", "SPECIES", 55, 57], ["mice", "SPECIES", 61, 65], ["tumor regression", "PROBLEM", 94, 110], ["lymph node depletion", "TREATMENT", 170, 190], ["slow down viral clearance", "PROBLEM", 203, 228], ["tumor", "OBSERVATION", 94, 99], ["lymph node depletion", "OBSERVATION", 170, 190]]], ["Local injection of the armed virus resulted in an improved CTL/Treg ratio in the TME.", [["Treg", "ANATOMY", 63, 67], ["Treg", "CELL", 63, 67], ["Local injection", "TREATMENT", 0, 15], ["the armed virus", "TREATMENT", 19, 34]]], ["In another study, vectorization of both IL-12 and 4-1BBL by adenovirus increased T helper, CTL and DC infiltration, which resulted in improved survival of the mice [42] .", [["T helper", "ANATOMY", 81, 89], ["DC", "ANATOMY", 99, 101], ["IL-12", "GENE_OR_GENE_PRODUCT", 40, 45], ["4-1BBL", "SIMPLE_CHEMICAL", 50, 56], ["adenovirus", "ORGANISM", 60, 70], ["T helper", "CELL", 81, 89], ["CTL", "CELL", 91, 94], ["DC", "CELL", 99, 101], ["mice", "ORGANISM", 159, 163], ["IL", "PROTEIN", 40, 42], ["DC", "CELL_TYPE", 99, 101], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 159, 163], ["another study", "TEST", 3, 16], ["vectorization", "TEST", 18, 31], ["IL", "TEST", 40, 42], ["adenovirus", "PROBLEM", 60, 70], ["CTL", "PROBLEM", 91, 94], ["DC infiltration", "PROBLEM", 99, 114], ["infiltration", "OBSERVATION", 102, 114], ["improved", "OBSERVATION_MODIFIER", 134, 142]]], ["In other murine models, DC vaccination combined with the armed adenovirus combined treatment yielded even better results and DCs showed enhanced migration to the tumor draining lymph node, where they activated T cells [42] .", [["DC", "ANATOMY", 24, 26], ["DCs", "ANATOMY", 125, 128], ["tumor", "ANATOMY", 162, 167], ["lymph node", "ANATOMY", 177, 187], ["T cells", "ANATOMY", 210, 217], ["tumor", "DISEASE", 162, 167], ["murine", "ORGANISM", 9, 15], ["DC", "CELL", 24, 26], ["adenovirus", "ORGANISM", 63, 73], ["DCs", "CELL", 125, 128], ["tumor", "CANCER", 162, 167], ["lymph node", "MULTI-TISSUE_STRUCTURE", 177, 187], ["T cells", "CELL", 210, 217], ["DC", "CELL_TYPE", 24, 26], ["DCs", "CELL_TYPE", 125, 128], ["T cells", "CELL_TYPE", 210, 217], ["murine", "SPECIES", 9, 15], ["DC vaccination", "TREATMENT", 24, 38], ["the armed adenovirus combined treatment", "TREATMENT", 53, 92], ["enhanced migration", "PROBLEM", 136, 154], ["the tumor draining lymph node", "PROBLEM", 158, 187], ["tumor", "OBSERVATION_MODIFIER", 162, 167], ["draining", "OBSERVATION_MODIFIER", 168, 176], ["lymph node", "OBSERVATION", 177, 187]]], ["These studies have shown that vectorization of this immune modulator in OVs enhances its therapeutic efficacy.CD40The maturation and activation status of DCs is often a limiting factor in the induction of antitumor immune responses.", [["OVs", "ANATOMY", 72, 75], ["DCs", "ANATOMY", 154, 157], ["antitumor", "ANATOMY", 205, 214], ["OVs", "SIMPLE_CHEMICAL", 72, 75], ["CD40", "GENE_OR_GENE_PRODUCT", 110, 114], ["DCs", "CELL", 154, 157], ["antitumor", "CANCER", 205, 214], ["CD40", "PROTEIN", 110, 114], ["DCs", "CELL_TYPE", 154, 157], ["These studies", "TEST", 0, 13], ["this immune modulator", "TREATMENT", 47, 68]]], ["Ligation of the CD40 receptor provides a strong activating signal to DCs, resulting in upregulation of MHC II and co-stimulatory molecules and production of IL-12, which is important for skewing of T cells towards a Th1 phenotype [28] .", [["DCs", "ANATOMY", 69, 72], ["T cells", "ANATOMY", 198, 205], ["CD40", "GENE_OR_GENE_PRODUCT", 16, 20], ["DCs", "CELL", 69, 72], ["MHC II", "GENE_OR_GENE_PRODUCT", 103, 109], ["IL-12", "GENE_OR_GENE_PRODUCT", 157, 162], ["T cells", "CELL", 198, 205], ["CD40 receptor", "PROTEIN", 16, 29], ["DCs", "CELL_TYPE", 69, 72], ["MHC II", "PROTEIN", 103, 109], ["co-stimulatory molecules", "PROTEIN", 114, 138], ["IL-12", "PROTEIN", 157, 162], ["T cells", "CELL_TYPE", 198, 205], ["Ligation", "TREATMENT", 0, 8], ["the CD40 receptor", "TREATMENT", 12, 29], ["production of IL", "TREATMENT", 143, 159], ["CD40", "ANATOMY", 16, 20]]], ["As DC activation takes place in the TME, treatment with OVs armed with a stimulatory CD40 antibody or CD40 ligand (CD40L) may lead to enhanced therapeutic efficacy.CD40Adenoviruses armed with CD40L have been tested in melanoma mouse models and patients with different types of cancer [90] [91] [92] .", [["DC", "ANATOMY", 3, 5], ["melanoma", "ANATOMY", 218, 226], ["cancer", "ANATOMY", 277, 283], ["melanoma", "DISEASE", 218, 226], ["cancer", "DISEASE", 277, 283], ["DC", "CELL", 3, 5], ["OVs", "SIMPLE_CHEMICAL", 56, 59], ["CD40", "GENE_OR_GENE_PRODUCT", 85, 89], ["CD40 ligand", "GENE_OR_GENE_PRODUCT", 102, 113], ["CD40L", "GENE_OR_GENE_PRODUCT", 115, 120], ["CD40Adenoviruses", "GENE_OR_GENE_PRODUCT", 164, 180], ["CD40L", "GENE_OR_GENE_PRODUCT", 192, 197], ["melanoma", "CANCER", 218, 226], ["mouse", "ORGANISM", 227, 232], ["patients", "ORGANISM", 244, 252], ["cancer", "CANCER", 277, 283], ["DC", "CELL_TYPE", 3, 5], ["CD40 antibody", "PROTEIN", 85, 98], ["CD40 ligand", "PROTEIN", 102, 113], ["CD40L", "PROTEIN", 115, 120], ["CD40Adenoviruses", "PROTEIN", 164, 180], ["CD40L", "PROTEIN", 192, 197], ["mouse", "SPECIES", 227, 232], ["patients", "SPECIES", 244, 252], ["mouse", "SPECIES", 227, 232], ["OVs", "TREATMENT", 56, 59], ["a stimulatory CD40 antibody", "TREATMENT", 71, 98], ["CD40 ligand (CD40L)", "TREATMENT", 102, 121], ["CD40L", "TREATMENT", 192, 197], ["cancer", "PROBLEM", 277, 283]]], ["Treatment with a CD40L expressing VV resulted in tumor growth inhibition and increased infiltration of effector T cells, NK cells, DCs in a melanoma mouse model.", [["tumor", "ANATOMY", 49, 54], ["effector T cells", "ANATOMY", 103, 119], ["NK cells", "ANATOMY", 121, 129], ["DCs", "ANATOMY", 131, 134], ["melanoma", "ANATOMY", 140, 148], ["tumor", "DISEASE", 49, 54], ["melanoma", "DISEASE", 140, 148], ["CD40L", "GENE_OR_GENE_PRODUCT", 17, 22], ["VV", "ORGANISM", 34, 36], ["tumor", "CANCER", 49, 54], ["effector T cells", "CELL", 103, 119], ["NK cells", "CELL", 121, 129], ["DCs", "CELL", 131, 134], ["melanoma", "CANCER", 140, 148], ["mouse", "ORGANISM", 149, 154], ["CD40L", "PROTEIN", 17, 22], ["effector T cells", "CELL_TYPE", 103, 119], ["NK cells", "CELL_TYPE", 121, 129], ["DCs", "CELL_TYPE", 131, 134], ["mouse", "SPECIES", 149, 154], ["VV", "SPECIES", 34, 36], ["mouse", "SPECIES", 149, 154], ["Treatment", "TREATMENT", 0, 9], ["a CD40L expressing VV", "TREATMENT", 15, 36], ["tumor growth inhibition", "PROBLEM", 49, 72], ["increased infiltration of effector T cells", "PROBLEM", 77, 119], ["NK cells", "PROBLEM", 121, 129], ["DCs", "PROBLEM", 131, 134], ["a melanoma mouse model", "TREATMENT", 138, 160], ["tumor", "OBSERVATION", 49, 54], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["infiltration", "OBSERVATION", 87, 99], ["effector T cells", "OBSERVATION", 103, 119], ["NK cells", "OBSERVATION", 121, 129], ["melanoma mouse model", "OBSERVATION", 140, 160]]], ["However, also numbers of Myeloid derived suppressor cells increased of which its effects are unknown [93] .", [["Myeloid derived suppressor cells", "ANATOMY", 25, 57], ["Myeloid derived suppressor cells", "CELL", 25, 57], ["Myeloid derived suppressor cells", "CELL_TYPE", 25, 57], ["Myeloid derived suppressor cells", "PROBLEM", 25, 57], ["Myeloid", "OBSERVATION", 25, 32], ["suppressor cells", "OBSERVATION", 41, 57]]], ["When evaluated in a clinical trial, patients showed disease control for 3-6 months and a systemic tumor specific immune response was induced [92] .OX40Similar to checkpoint inhibitors, more and more co-stimulatory targets, such as OX40 and GITR, are being discovered as anti-tumor targets.", [["tumor", "ANATOMY", 98, 103], ["anti-tumor", "ANATOMY", 270, 280], ["tumor", "DISEASE", 98, 103], ["patients", "ORGANISM", 36, 44], ["tumor", "CANCER", 98, 103], ["OX40", "GENE_OR_GENE_PRODUCT", 231, 235], ["GITR", "GENE_OR_GENE_PRODUCT", 240, 244], ["anti-tumor", "CANCER", 270, 280], ["OX40", "PROTEIN", 231, 235], ["GITR", "PROTEIN", 240, 244], ["patients", "SPECIES", 36, 44], ["disease control", "PROBLEM", 52, 67], ["a systemic tumor specific immune response", "PROBLEM", 87, 128], ["checkpoint inhibitors", "TREATMENT", 162, 183], ["tumor", "OBSERVATION", 98, 103]]], ["The OX40 receptor is expressed by activated T cells and induces the production of Th1 and Th2 cytokines upon interaction with OX40 ligand (OX40L) [28, 94] .", [["T cells", "ANATOMY", 44, 51], ["OX40", "GENE_OR_GENE_PRODUCT", 4, 8], ["T cells", "CELL", 44, 51], ["Th1", "GENE_OR_GENE_PRODUCT", 82, 85], ["Th2", "GENE_OR_GENE_PRODUCT", 90, 93], ["OX40 ligand", "GENE_OR_GENE_PRODUCT", 126, 137], ["OX40L", "GENE_OR_GENE_PRODUCT", 139, 144], ["OX40 receptor", "PROTEIN", 4, 17], ["activated T cells", "CELL_TYPE", 34, 51], ["Th1 and Th2 cytokines", "PROTEIN", 82, 103], ["OX40 ligand", "PROTEIN", 126, 137], ["OX40L", "PROTEIN", 139, 144], ["activated T cells", "PROBLEM", 34, 51]]], ["OX40 ligation also directly blunts the suppressive effects of Tregs [28, 94] .", [["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["Tregs", "CELL", 62, 67], ["OX40", "PROTEIN", 0, 4], ["Tregs", "CELL_TYPE", 62, 67], ["OX40 ligation", "TREATMENT", 0, 13]]], ["Arming of OV with OX40L has been described once: adenovirus expressing OX40L led to suppression of melanoma, lung and colon tumor growth in mice.", [["melanoma", "ANATOMY", 99, 107], ["lung", "ANATOMY", 109, 113], ["colon tumor", "ANATOMY", 118, 129], ["melanoma", "DISEASE", 99, 107], ["lung and colon tumor", "DISEASE", 109, 129], ["OV", "MULTI-TISSUE_STRUCTURE", 10, 12], ["OX40L", "GENE_OR_GENE_PRODUCT", 18, 23], ["adenovirus", "ORGANISM", 49, 59], ["OX40L", "GENE_OR_GENE_PRODUCT", 71, 76], ["melanoma", "CANCER", 99, 107], ["lung", "ORGAN", 109, 113], ["colon tumor", "CANCER", 118, 129], ["mice", "ORGANISM", 140, 144], ["OX40L", "PROTEIN", 18, 23], ["OX40L", "PROTEIN", 71, 76], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 140, 144], ["OX40L", "TREATMENT", 18, 23], ["adenovirus", "PROBLEM", 49, 59], ["melanoma", "PROBLEM", 99, 107], ["lung and colon tumor growth", "PROBLEM", 109, 136], ["OV", "ANATOMY", 10, 12], ["OX40L", "ANATOMY", 18, 23], ["melanoma", "OBSERVATION", 99, 107], ["lung", "ANATOMY", 109, 113], ["colon", "ANATOMY", 118, 123], ["tumor", "OBSERVATION", 124, 129]]], ["This effect was mediated by Th1 cells and CTLs and an increase in Th1 rather than Th2 cytokine expression [95] .", [["Th1 cells", "ANATOMY", 28, 37], ["CTLs", "ANATOMY", 42, 46], ["Th1 cells", "CELL", 28, 37], ["CTLs", "CELL", 42, 46], ["Th1 cells", "CELL_TYPE", 28, 37], ["CTLs", "CELL_TYPE", 42, 46], ["Th2 cytokine", "PROTEIN", 82, 94], ["CTLs", "TEST", 42, 46], ["Th2 cytokine expression", "TREATMENT", 82, 105], ["Th1 cells", "OBSERVATION", 28, 37], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["Th1", "OBSERVATION", 66, 69]]], ["A study combining systemic OX40L therapy with systemic 4-1BBL therapy and IL-12 expressing adenovirus, revealed increased expression of Th1 cytokines. thereby the antitumor CTL response were enhanced leading to tumor rejection in a colorectal cancer model involving liver metastases compared to OX40L monotherapy and combined 4-1BBL and IL-12 armed OV treatment [96] .", [["antitumor", "ANATOMY", 163, 172], ["tumor", "ANATOMY", 211, 216], ["colorectal cancer", "ANATOMY", 232, 249], ["liver metastases", "ANATOMY", 266, 282], ["4-1BBL", "CHEMICAL", 55, 61], ["tumor", "DISEASE", 211, 216], ["colorectal cancer", "DISEASE", 232, 249], ["liver metastases", "DISEASE", 266, 282], ["OX40L", "CHEMICAL", 295, 300], ["4-1BBL", "CHEMICAL", 326, 332], ["OX40L", "GENE_OR_GENE_PRODUCT", 27, 32], ["4-1BBL", "SIMPLE_CHEMICAL", 55, 61], ["IL-12", "GENE_OR_GENE_PRODUCT", 74, 79], ["adenovirus", "ORGANISM", 91, 101], ["Th1", "GENE_OR_GENE_PRODUCT", 136, 139], ["antitumor", "CANCER", 163, 172], ["tumor", "CANCER", 211, 216], ["colorectal cancer", "CANCER", 232, 249], ["liver", "ORGAN", 266, 271], ["OX40L", "GENE_OR_GENE_PRODUCT", 295, 300], ["4-1BBL", "SIMPLE_CHEMICAL", 326, 332], ["IL-12", "SIMPLE_CHEMICAL", 337, 342], ["OV", "SIMPLE_CHEMICAL", 349, 351], ["OX40L", "PROTEIN", 27, 32], ["Th1 cytokines", "PROTEIN", 136, 149], ["OX40L", "PROTEIN", 295, 300], ["A study", "TEST", 0, 7], ["systemic OX40L therapy", "TREATMENT", 18, 40], ["systemic 4-1BBL therapy", "TREATMENT", 46, 69], ["IL", "TREATMENT", 74, 76], ["adenovirus", "PROBLEM", 91, 101], ["increased expression of Th1 cytokines", "PROBLEM", 112, 149], ["tumor rejection", "PROBLEM", 211, 226], ["a colorectal cancer", "PROBLEM", 230, 249], ["liver metastases", "PROBLEM", 266, 282], ["OX40L monotherapy", "TREATMENT", 295, 312], ["IL", "TREATMENT", 337, 339], ["armed OV treatment", "TREATMENT", 343, 361], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["Th1 cytokines", "OBSERVATION", 136, 149], ["tumor rejection", "OBSERVATION", 211, 226], ["colorectal", "ANATOMY", 232, 242], ["cancer", "OBSERVATION", 243, 249], ["liver", "ANATOMY", 266, 271], ["metastases", "OBSERVATION", 272, 282]]], ["This makes OX40 an interesting transgene, but more research needs to be performed to elucidate its beneficial effects in other tumor models and OVs.GITRGITR is a stimulatory receptor expressed on activated T cells, but it is also constitutively expressed on Tregs [28, 94] .", [["tumor", "ANATOMY", 127, 132], ["OVs", "ANATOMY", 144, 147], ["T cells", "ANATOMY", 206, 213], ["Tregs", "ANATOMY", 258, 263], ["tumor", "DISEASE", 127, 132], ["OX40", "GENE_OR_GENE_PRODUCT", 11, 15], ["tumor", "CANCER", 127, 132], ["OVs", "CANCER", 144, 147], ["T cells", "CELL", 206, 213], ["Tregs", "CELL", 258, 263], ["OX40", "PROTEIN", 11, 15], ["GITRGITR", "PROTEIN", 148, 156], ["activated T cells", "CELL_TYPE", 196, 213], ["Tregs", "CELL_TYPE", 258, 263], ["a stimulatory receptor", "TREATMENT", 160, 182], ["activated T cells", "TREATMENT", 196, 213]]], ["Activation of the receptor promotes proliferation and cytokine production in T effector cells, whereas it inhibits Tregs [28, 94] .", [["T effector cells", "ANATOMY", 77, 93], ["Tregs", "ANATOMY", 115, 120], ["T effector cells", "CELL", 77, 93], ["Tregs", "CELL", 115, 120], ["cytokine", "PROTEIN", 54, 62], ["T effector cells", "CELL_TYPE", 77, 93], ["Tregs", "CELL_TYPE", 115, 120], ["the receptor promotes proliferation", "TREATMENT", 14, 49], ["cytokine production in T effector cells", "PROBLEM", 54, 93], ["Tregs", "TEST", 115, 120]]], ["Expression of GITR ligand itself by an adenoviral vector resulted in increased infiltration of T helper cells and CTLs and suppression of tumor growth, leading to prolonged survival [31] .", [["T helper cells", "ANATOMY", 95, 109], ["CTLs", "ANATOMY", 114, 118], ["tumor", "ANATOMY", 138, 143], ["tumor", "DISEASE", 138, 143], ["GITR ligand", "GENE_OR_GENE_PRODUCT", 14, 25], ["adenoviral", "ORGANISM", 39, 49], ["T helper cells", "CELL", 95, 109], ["CTLs", "CELL", 114, 118], ["tumor", "CANCER", 138, 143], ["GITR ligand", "PROTEIN", 14, 25], ["T helper cells", "CELL_TYPE", 95, 109], ["CTLs", "CELL_TYPE", 114, 118], ["an adenoviral vector", "TREATMENT", 36, 56], ["increased infiltration", "PROBLEM", 69, 91], ["T helper cells", "TREATMENT", 95, 109], ["CTLs", "PROBLEM", 114, 118], ["tumor growth", "PROBLEM", 138, 150], ["prolonged survival", "PROBLEM", 163, 181], ["GITR", "ANATOMY", 14, 18], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["infiltration", "OBSERVATION", 79, 91], ["tumor", "OBSERVATION", 138, 143]]], ["Systemic administration of a stimulating GITR antibody together with intratumoral injection of an adenoviral vector armed with IFN-\u03b1 resulted in enhanced tumor growth inhibition in injected and distant tumors compared to single treatment in colon and pancreatic murine cancer models [97] .", [["intratumoral", "ANATOMY", 69, 81], ["tumor", "ANATOMY", 154, 159], ["tumors", "ANATOMY", 202, 208], ["colon", "ANATOMY", 241, 246], ["pancreatic murine cancer", "ANATOMY", 251, 275], ["IFN-\u03b1", "CHEMICAL", 127, 132], ["tumor", "DISEASE", 154, 159], ["tumors", "DISEASE", 202, 208], ["colon and pancreatic murine cancer", "DISEASE", 241, 275], ["GITR", "GENE_OR_GENE_PRODUCT", 41, 45], ["adenoviral", "ORGANISM", 98, 108], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["tumor", "CANCER", 154, 159], ["tumors", "CANCER", 202, 208], ["colon", "CANCER", 241, 246], ["pancreatic murine cancer", "CANCER", 251, 275], ["GITR antibody", "PROTEIN", 41, 54], ["IFN-\u03b1", "PROTEIN", 127, 132], ["murine", "SPECIES", 262, 268], ["a stimulating GITR antibody", "TREATMENT", 27, 54], ["intratumoral injection", "TREATMENT", 69, 91], ["an adenoviral vector", "TREATMENT", 95, 115], ["IFN", "TREATMENT", 127, 130], ["enhanced tumor growth inhibition", "PROBLEM", 145, 177], ["distant tumors", "PROBLEM", 194, 208], ["single treatment in colon", "TREATMENT", 221, 246], ["pancreatic murine cancer models", "PROBLEM", 251, 282], ["enhanced", "OBSERVATION_MODIFIER", 145, 153], ["tumor", "OBSERVATION", 154, 159], ["distant", "OBSERVATION_MODIFIER", 194, 201], ["tumors", "OBSERVATION", 202, 208], ["colon", "ANATOMY", 241, 246], ["pancreatic", "ANATOMY", 251, 261], ["murine cancer", "OBSERVATION", 262, 275]]], ["This makes GITR ligand attractive as a transgene, but similar to OX40L, more research needs to be performed.", [["GITR", "GENE_OR_GENE_PRODUCT", 11, 15], ["OX40L", "GENE_OR_GENE_PRODUCT", 65, 70], ["GITR ligand", "PROTEIN", 11, 22], ["OX40L", "PROTEIN", 65, 70]]], ["More research needs to be done towards these targets, just like for the newly discovered LIGHT and CD27 anti-tumor targets [98, 99] , (Table 1) .Prostaglandin E2 blockadeProstaglandin E2 (PGE2) is a principal mediator of inflammation expressed by tumor cells and immune cells and stimulates accumulation of MDSCs in the TME.", [["tumor cells", "ANATOMY", 247, 258], ["immune cells", "ANATOMY", 263, 275], ["MDSCs", "ANATOMY", 307, 312], ["Prostaglandin E2", "CHEMICAL", 145, 161], ["Prostaglandin E2", "CHEMICAL", 170, 186], ["PGE2", "CHEMICAL", 188, 192], ["inflammation", "DISEASE", 221, 233], ["tumor", "DISEASE", 247, 252], ["Prostaglandin E2", "CHEMICAL", 145, 161], ["Prostaglandin E2", "CHEMICAL", 170, 186], ["PGE2", "CHEMICAL", 188, 192], ["LIGHT", "GENE_OR_GENE_PRODUCT", 89, 94], ["CD27", "GENE_OR_GENE_PRODUCT", 99, 103], ["Prostaglandin E2", "GENE_OR_GENE_PRODUCT", 145, 161], ["Prostaglandin E2", "GENE_OR_GENE_PRODUCT", 170, 186], ["PGE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["tumor cells", "CELL", 247, 258], ["immune cells", "CELL", 263, 275], ["MDSCs", "CELL", 307, 312], ["LIGHT", "PROTEIN", 89, 94], ["CD27", "PROTEIN", 99, 103], ["tumor cells", "CELL_TYPE", 247, 258], ["immune cells", "CELL_TYPE", 263, 275], ["MDSCs", "CELL_TYPE", 307, 312], ["Prostaglandin E2 blockade", "TREATMENT", 145, 170], ["Prostaglandin E2 (PGE2", "TREATMENT", 170, 192], ["inflammation", "PROBLEM", 221, 233], ["tumor cells", "PROBLEM", 247, 258], ["immune cells", "PROBLEM", 263, 275], ["stimulates accumulation of MDSCs", "TREATMENT", 280, 312], ["inflammation", "OBSERVATION", 221, 233], ["tumor cells", "OBSERVATION", 247, 258], ["immune cells", "OBSERVATION", 263, 275]]], ["Moreover, PGE2 induces IDO and IL-10 expression in DCs, whereas it reduces IL-12 expression, which is necessary to induce a Th1 response [7, 10] .", [["DCs", "ANATOMY", 51, 54], ["PGE2", "CHEMICAL", 10, 14], ["PGE2", "CHEMICAL", 10, 14], ["PGE2", "SIMPLE_CHEMICAL", 10, 14], ["IDO", "GENE_OR_GENE_PRODUCT", 23, 26], ["IL-10", "GENE_OR_GENE_PRODUCT", 31, 36], ["DCs", "CELL", 51, 54], ["IL-12", "GENE_OR_GENE_PRODUCT", 75, 80], ["IDO", "PROTEIN", 23, 26], ["DCs", "CELL_TYPE", 51, 54], ["IL", "PROTEIN", 75, 77], ["IDO and IL", "TREATMENT", 23, 33]]], ["A recent study, revealed PGE2 as an important mediator of resistance to OV therapy and other immunotherapies [100] .", [["PGE2", "CHEMICAL", 25, 29], ["PGE2", "CHEMICAL", 25, 29], ["PGE2", "SIMPLE_CHEMICAL", 25, 29], ["A recent study", "TEST", 0, 14], ["PGE2", "TREATMENT", 25, 29], ["OV therapy", "TREATMENT", 72, 82], ["other immunotherapies", "TREATMENT", 87, 108]]], ["Treatment of mice with VV expressing a PGE2 inactivating enzyme named hydroxyprostaglandin dehydrogenase (HPGD), resulted in a decreased number of MDSCs in the tumor and yielded a better response than other PGE2 blocking agents [100] .", [["MDSCs", "ANATOMY", 147, 152], ["tumor", "ANATOMY", 160, 165], ["PGE2", "CHEMICAL", 39, 43], ["tumor", "DISEASE", 160, 165], ["PGE2", "CHEMICAL", 207, 211], ["PGE2", "CHEMICAL", 39, 43], ["hydroxyprostaglandin", "CHEMICAL", 70, 90], ["PGE2", "CHEMICAL", 207, 211], ["mice", "ORGANISM", 13, 17], ["VV", "ORGANISM", 23, 25], ["PGE2", "SIMPLE_CHEMICAL", 39, 43], ["hydroxyprostaglandin dehydrogenase", "GENE_OR_GENE_PRODUCT", 70, 104], ["HPGD", "SIMPLE_CHEMICAL", 106, 110], ["MDSCs", "CELL", 147, 152], ["tumor", "CANCER", 160, 165], ["PGE2", "SIMPLE_CHEMICAL", 207, 211], ["PGE2 inactivating enzyme", "PROTEIN", 39, 63], ["hydroxyprostaglandin dehydrogenase", "PROTEIN", 70, 104], ["HPGD", "PROTEIN", 106, 110], ["MDSCs", "CELL_TYPE", 147, 152], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["VV", "SPECIES", 23, 25], ["VV", "TREATMENT", 23, 25], ["a PGE2 inactivating enzyme", "TEST", 37, 63], ["hydroxyprostaglandin dehydrogenase", "PROBLEM", 70, 104], ["the tumor", "PROBLEM", 156, 165], ["other PGE2 blocking agents", "TREATMENT", 201, 227], ["decreased", "OBSERVATION_MODIFIER", 127, 136], ["number", "OBSERVATION_MODIFIER", 137, 143], ["MDSCs", "OBSERVATION", 147, 152], ["tumor", "OBSERVATION", 160, 165]]], ["The virus was also shown to sensitize an otherwise resistant renal tumor to anti-PD-1 treatment [100] .", [["renal tumor", "ANATOMY", 61, 72], ["renal tumor", "DISEASE", 61, 72], ["anti-PD-1", "CHEMICAL", 76, 85], ["renal tumor", "CANCER", 61, 72], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 76, 85], ["The virus", "PROBLEM", 0, 9], ["an otherwise resistant renal tumor", "PROBLEM", 38, 72], ["anti-PD", "TREATMENT", 76, 83], ["virus", "OBSERVATION", 4, 9], ["resistant", "OBSERVATION_MODIFIER", 51, 60], ["renal", "ANATOMY", 61, 66], ["tumor", "OBSERVATION", 67, 72]]], ["Thus, blockade of PGE2 showed promising results but this approach needs further validation in other tumor models and with other OVs.Pathogen receptorsToll like receptors (TLRs) are part of the innate immune system and recognize pathogenic molecules such as bacterial lipids and proteins or viral DNA and RNA [101] .", [["tumor", "ANATOMY", 100, 105], ["PGE2", "CHEMICAL", 18, 22], ["tumor", "DISEASE", 100, 105], ["PGE2", "CHEMICAL", 18, 22], ["PGE2", "SIMPLE_CHEMICAL", 18, 22], ["tumor", "CANCER", 100, 105], ["OVs", "CANCER", 128, 131], ["Toll like receptors", "GENE_OR_GENE_PRODUCT", 150, 169], ["TLRs", "GENE_OR_GENE_PRODUCT", 171, 175], ["DNA", "CELLULAR_COMPONENT", 296, 299], ["Pathogen receptors", "PROTEIN", 132, 150], ["Toll like receptors", "PROTEIN", 150, 169], ["TLRs", "PROTEIN", 171, 175], ["viral DNA", "DNA", 290, 299], ["blockade of PGE2", "TREATMENT", 6, 22], ["further validation", "TEST", 72, 90], ["Pathogen receptors", "PROBLEM", 132, 150], ["pathogenic molecules", "PROBLEM", 228, 248], ["bacterial lipids", "TEST", 257, 273], ["viral DNA and RNA", "PROBLEM", 290, 307], ["viral DNA", "OBSERVATION", 290, 299]]], ["The type of TLR that is activated upon infection is an important determinant for the skewing of the subsequent adaptive immune response [101] .", [["infection", "DISEASE", 39, 48], ["TLR", "GENE_OR_GENE_PRODUCT", 12, 15], ["TLR", "PROTEIN", 12, 15], ["TLR", "TREATMENT", 12, 15], ["infection", "PROBLEM", 39, 48], ["infection", "OBSERVATION", 39, 48]]], ["Manipulation of TLR signaling can therefore switch the induced immune response from Th2 to Th1.Pathogen receptorsTRIF mediates TLR3 signaling, whereas other TLRs signal viaPathogen receptorsMyD88 [101] .", [["TLR", "GENE_OR_GENE_PRODUCT", 16, 19], ["Th2", "GENE_OR_GENE_PRODUCT", 84, 87], ["Th1", "GENE_OR_GENE_PRODUCT", 91, 94], ["receptorsTRIF", "GENE_OR_GENE_PRODUCT", 104, 117], ["TLR3", "GENE_OR_GENE_PRODUCT", 127, 131], ["MyD88", "GENE_OR_GENE_PRODUCT", 190, 195], ["TLR", "PROTEIN", 16, 19], ["Th1", "CELL_TYPE", 91, 94], ["Pathogen receptorsTRIF", "PROTEIN", 95, 117], ["TLR3", "PROTEIN", 127, 131], ["TLRs", "PROTEIN", 157, 161], ["viaPathogen receptors", "PROTEIN", 169, 190], ["MyD88", "PROTEIN", 190, 195], ["TLR signaling", "TREATMENT", 16, 29], ["TLR3 signaling", "PROBLEM", 127, 141], ["MyD88", "TEST", 190, 195], ["TLR3 signaling", "OBSERVATION", 127, 141]]], ["Moreover, this pathway induces the production of Th1 cytokines instead of Th2 cytokines.", [["Th1", "GENE_OR_GENE_PRODUCT", 49, 52], ["Th2", "GENE_OR_GENE_PRODUCT", 74, 77], ["Th1 cytokines", "PROTEIN", 49, 62], ["Th2 cytokines", "PROTEIN", 74, 87], ["Th1 cytokines", "TREATMENT", 49, 62], ["Th2 cytokines", "TREATMENT", 74, 87]]], ["To manipulate TLR3 signaling, a VV was engineered to express TRIF to increase TLR3 signaling [102] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 14, 18], ["VV", "ORGANISM", 32, 34], ["TRIF", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR3", "GENE_OR_GENE_PRODUCT", 78, 82], ["TLR3", "PROTEIN", 14, 18], ["TRIF", "PROTEIN", 61, 65], ["TLR3", "PROTEIN", 78, 82], ["VV", "SPECIES", 32, 34], ["a VV", "TREATMENT", 30, 34]]], ["In addition, the viral particle was deglycosylated, resulting in reduced Th2 responses.", [["the viral particle", "TEST", 13, 31], ["reduced Th2 responses", "PROBLEM", 65, 86], ["viral particle", "OBSERVATION", 17, 31], ["reduced", "OBSERVATION_MODIFIER", 65, 72], ["Th2 responses", "OBSERVATION", 73, 86]]], ["Treatment of mice with deglycosylated VV-TRIF resulted in increased production of Th1 but not Th2 cytokines in the TME.", [["mice", "ORGANISM", 13, 17], ["VV-TRIF", "GENE_OR_GENE_PRODUCT", 38, 45], ["Th1", "GENE_OR_GENE_PRODUCT", 82, 85], ["TRIF", "PROTEIN", 41, 45], ["Th2 cytokines", "PROTEIN", 94, 107], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["VV", "SPECIES", 38, 40], ["deglycosylated VV", "TREATMENT", 23, 40], ["TRIF", "TREATMENT", 41, 45], ["increased production of Th1", "PROBLEM", 58, 85], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["production", "OBSERVATION_MODIFIER", 68, 78]]], ["Also, the virus induced infiltration of T helper cells and CTLs.", [["T helper cells", "ANATOMY", 40, 54], ["CTLs", "ANATOMY", 59, 63], ["T helper cells", "CELL", 40, 54], ["CTLs", "CELL", 59, 63], ["T helper cells", "CELL_TYPE", 40, 54], ["CTLs", "CELL_TYPE", 59, 63], ["the virus induced infiltration of T helper cells", "PROBLEM", 6, 54], ["CTLs", "TEST", 59, 63], ["virus", "OBSERVATION", 10, 15], ["infiltration", "OBSERVATION", 24, 36]]], ["These CTLs were both virus and tumor cell specific.", [["CTLs", "ANATOMY", 6, 10], ["tumor cell", "ANATOMY", 31, 41], ["tumor", "DISEASE", 31, 36], ["CTLs", "CELL", 6, 10], ["tumor cell", "CELL", 31, 41], ["CTLs", "CELL_TYPE", 6, 10], ["These CTLs", "TEST", 0, 10], ["tumor cell", "OBSERVATION", 31, 41]]], ["VV-TRIF showed improved antitumor efficacy in colon and renal tumor models compared to VV-GM-CSF (Pexa-Vec).", [["antitumor", "ANATOMY", 24, 33], ["colon", "ANATOMY", 46, 51], ["renal tumor", "ANATOMY", 56, 67], ["colon and renal tumor", "DISEASE", 46, 67], ["VV-GM", "CHEMICAL", 87, 92], ["VV-TRIF", "GENE_OR_GENE_PRODUCT", 0, 7], ["antitumor", "CANCER", 24, 33], ["colon", "CANCER", 46, 51], ["renal tumor", "CANCER", 56, 67], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 90, 96], ["Pexa-Vec", "GENE_OR_GENE_PRODUCT", 98, 106], ["TRIF", "PROTEIN", 3, 7], ["CSF", "PROTEIN", 93, 96], ["Pexa", "PROTEIN", 98, 102], ["VV", "SPECIES", 0, 2], ["VV", "SPECIES", 87, 89], ["VV", "TEST", 0, 2], ["improved antitumor efficacy in colon and renal tumor models", "PROBLEM", 15, 74], ["VV", "TEST", 87, 89], ["CSF", "TEST", 93, 96], ["Pexa", "TEST", 98, 102], ["colon", "ANATOMY", 46, 51], ["renal", "ANATOMY", 56, 61], ["tumor", "OBSERVATION", 62, 67]]], ["Similar results were obtained using intracellular pattern recognition receptor DNA-dependent activator of IFN-regulatory factors (DAI) as an vectorized immune modulator [103] .", [["intracellular", "ANATOMY", 36, 49], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["IFN-regulatory factors", "GENE_OR_GENE_PRODUCT", 106, 128], ["intracellular pattern recognition receptor DNA-dependent activator of IFN-regulatory factors", "PROTEIN", 36, 128], ["DAI", "PROTEIN", 130, 133], ["an vectorized immune modulator", "TREATMENT", 138, 168]]], ["These studies show that the antitumor immune response can be switched from Th2 to Th1 by manipulating intracellular pathogen receptor signaling pathways in tumor cells.BiTEsBiTEs (bispecific T cell engagers) are a class of bispecific monoclonal antibodies that have shown promising anti-tumor effects [104] .", [["antitumor", "ANATOMY", 28, 37], ["intracellular", "ANATOMY", 102, 115], ["tumor cells", "ANATOMY", 156, 167], ["T cell", "ANATOMY", 191, 197], ["anti-tumor", "ANATOMY", 282, 292], ["tumor", "DISEASE", 156, 161], ["BiTEsBiTEs", "CHEMICAL", 168, 178], ["antitumor", "CANCER", 28, 37], ["Th2", "GENE_OR_GENE_PRODUCT", 75, 78], ["Th1", "GENE_OR_GENE_PRODUCT", 82, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["tumor cells", "CELL", 156, 167], ["BiTEsBiTEs", "SIMPLE_CHEMICAL", 168, 178], ["T cell", "CELL", 191, 197], ["anti-tumor", "CANCER", 282, 292], ["Th1", "CELL_TYPE", 82, 85], ["tumor cells", "CELL_TYPE", 156, 167], ["BiTEsBiTEs", "PROTEIN", 168, 178], ["bispecific T cell engagers", "PROTEIN", 180, 206], ["bispecific monoclonal antibodies", "PROTEIN", 223, 255], ["These studies", "TEST", 0, 13], ["Th2 to Th1", "TREATMENT", 75, 85], ["tumor cells", "PROBLEM", 156, 167], ["BiTEsBiTEs", "TEST", 168, 178], ["bispecific monoclonal antibodies", "TEST", 223, 255], ["tumor cells", "OBSERVATION", 156, 167]]], ["However, they have a very short half-life and therefore require continuous infusion.", [["continuous infusion", "TREATMENT", 64, 83]]], ["Vaccinia virus (VV) armed with a BiTE with specificity for the TCR and a TAA was tested in a xenograft lung cancer mouse model.", [["xenograft lung cancer", "ANATOMY", 93, 114], ["BiTE", "CHEMICAL", 33, 37], ["TCR", "CHEMICAL", 63, 66], ["TAA", "DISEASE", 73, 76], ["lung cancer", "DISEASE", 103, 114], ["Vaccinia virus", "ORGANISM", 0, 14], ["VV", "ORGANISM", 16, 18], ["BiTE", "SIMPLE_CHEMICAL", 33, 37], ["TCR", "GENE_OR_GENE_PRODUCT", 63, 66], ["TAA", "SIMPLE_CHEMICAL", 73, 76], ["xenograft lung cancer", "CANCER", 93, 114], ["mouse", "ORGANISM", 115, 120], ["TCR", "PROTEIN", 63, 66], ["Vaccinia virus", "SPECIES", 0, 14], ["mouse", "SPECIES", 115, 120], ["Vaccinia virus", "SPECIES", 0, 14], ["VV", "SPECIES", 16, 18], ["mouse", "SPECIES", 115, 120], ["Vaccinia virus", "PROBLEM", 0, 14], ["the TCR", "PROBLEM", 59, 66], ["a TAA", "TREATMENT", 71, 76], ["a xenograft lung cancer mouse model", "TREATMENT", 91, 126], ["xenograft", "OBSERVATION", 93, 102], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114]]], ["The study showed increased tumor cell killing through T cell activation and skewing towards Th1 responses [105] .", [["tumor cell", "ANATOMY", 27, 37], ["T cell", "ANATOMY", 54, 60], ["tumor", "DISEASE", 27, 32], ["tumor cell", "CELL", 27, 37], ["T cell", "CELL", 54, 60], ["The study", "TEST", 0, 9], ["increased tumor cell killing", "PROBLEM", 17, 45], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["tumor cell killing", "OBSERVATION", 27, 45], ["cell activation", "OBSERVATION", 56, 71]]], ["A disadvantage of BiTEs is that they target only one TAA and therefore stimulate the immune response directed to only that TAA, while other immunemodulatory transgenes induce immunity to multiple TAAs that are released by dying tumor cells.Combining different immune modulatorsTo further improve the efficacy of OV treatment, different combinations of therapies are being exploited.", [["tumor cells", "ANATOMY", 228, 239], ["BiTEs", "CHEMICAL", 18, 23], ["TAA", "DISEASE", 53, 56], ["TAA", "DISEASE", 123, 126], ["tumor", "DISEASE", 228, 233], ["BiTEs", "SIMPLE_CHEMICAL", 18, 23], ["TAA", "SIMPLE_CHEMICAL", 53, 56], ["TAA", "SIMPLE_CHEMICAL", 123, 126], ["TAAs", "GENE_OR_GENE_PRODUCT", 196, 200], ["tumor cells", "CELL", 228, 239], ["OV", "SIMPLE_CHEMICAL", 312, 314], ["immunemodulatory transgenes", "DNA", 140, 167], ["dying tumor cells", "CELL_TYPE", 222, 239], ["TAA", "TREATMENT", 123, 126], ["other immunemodulatory transgenes", "TREATMENT", 134, 167], ["multiple TAAs", "PROBLEM", 187, 200], ["Combining different immune modulators", "TREATMENT", 240, 277], ["OV treatment", "TREATMENT", 312, 324], ["therapies", "TREATMENT", 352, 361], ["tumor cells", "OBSERVATION", 228, 239], ["immune modulators", "OBSERVATION", 260, 277]]], ["OVs armed with several cytokine combinations have been tested with promising results.", [["cytokine", "PROTEIN", 23, 31], ["several cytokine combinations", "TREATMENT", 15, 44]]], ["Adenovirus expressing both GM-CSF and IL-12 induced infiltration of effector T cells, NK cells and activated APCs combined with DC vaccination in a melanoma mouse model, as well as long-term protection to re-challenge with tumor cells [106] .", [["effector T cells", "ANATOMY", 68, 84], ["NK cells", "ANATOMY", 86, 94], ["APCs", "ANATOMY", 109, 113], ["DC", "ANATOMY", 128, 130], ["melanoma", "ANATOMY", 148, 156], ["tumor cells", "ANATOMY", 223, 234], ["GM", "CHEMICAL", 27, 29], ["melanoma", "DISEASE", 148, 156], ["tumor", "DISEASE", 223, 228], ["Adenovirus", "ORGANISM", 0, 10], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 27, 33], ["IL-12", "GENE_OR_GENE_PRODUCT", 38, 43], ["effector T cells", "CELL", 68, 84], ["NK cells", "CELL", 86, 94], ["APCs", "CELL", 109, 113], ["DC", "CELL", 128, 130], ["melanoma", "CANCER", 148, 156], ["mouse", "ORGANISM", 157, 162], ["tumor cells", "CELL", 223, 234], ["GM-CSF and IL-12", "PROTEIN", 27, 43], ["effector T cells", "CELL_TYPE", 68, 84], ["NK cells", "CELL_TYPE", 86, 94], ["APCs", "CELL_TYPE", 109, 113], ["DC", "CELL_TYPE", 128, 130], ["tumor cells", "CELL_TYPE", 223, 234], ["mouse", "SPECIES", 157, 162], ["Adenovirus", "SPECIES", 0, 10], ["mouse", "SPECIES", 157, 162], ["Adenovirus", "PROBLEM", 0, 10], ["IL", "TEST", 38, 40], ["effector T cells", "PROBLEM", 68, 84], ["NK cells", "PROBLEM", 86, 94], ["activated APCs", "PROBLEM", 99, 113], ["DC vaccination", "TREATMENT", 128, 142], ["a melanoma mouse model", "TREATMENT", 146, 168], ["long-term protection", "TREATMENT", 181, 201], ["tumor cells", "PROBLEM", 223, 234], ["CSF", "ANATOMY", 30, 33], ["infiltration", "OBSERVATION", 52, 64], ["effector T cells", "OBSERVATION", 68, 84], ["NK cells", "OBSERVATION", 86, 94]]], ["Moreover, viral expression of GM-CSF and IL-12 in the TME shifted the intratumoral cytokine profile from a Th2 to a preferred Th1 response and improved DC migration to the tumor site [106, 107] .", [["intratumoral", "ANATOMY", 70, 82], ["DC", "ANATOMY", 152, 154], ["tumor site", "ANATOMY", 172, 182], ["GM", "CHEMICAL", 30, 32], ["tumor", "DISEASE", 172, 177], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 30, 36], ["IL-12", "GENE_OR_GENE_PRODUCT", 41, 46], ["DC", "CELL", 152, 154], ["tumor", "CANCER", 172, 177], ["GM-CSF and IL-12", "PROTEIN", 30, 46], ["cytokine", "PROTEIN", 83, 91], ["DC", "CELL_TYPE", 152, 154], ["IL", "TEST", 41, 43], ["tumor", "OBSERVATION", 172, 177]]], ["Similarly, viral co-expression of IL-12 and IL-18 showed enhanced therapeutic efficacy and increased infiltration of DCs and effector T cells compared to mono-expression of IL-12 in murine models [41, 42, 108] .", [["DCs", "ANATOMY", 117, 120], ["effector T cells", "ANATOMY", 125, 141], ["IL-12", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-18", "GENE_OR_GENE_PRODUCT", 44, 49], ["DCs", "CELL", 117, 120], ["effector T cells", "CELL", 125, 141], ["IL-12", "GENE_OR_GENE_PRODUCT", 173, 178], ["murine", "ORGANISM", 182, 188], ["IL-12", "PROTEIN", 34, 39], ["IL-18", "PROTEIN", 44, 49], ["DCs", "CELL_TYPE", 117, 120], ["effector T cells", "CELL_TYPE", 125, 141], ["IL-12", "PROTEIN", 173, 178], ["murine", "SPECIES", 182, 188], ["IL", "TEST", 34, 36], ["IL", "TEST", 44, 46], ["enhanced therapeutic efficacy", "PROBLEM", 57, 86], ["increased infiltration of DCs", "PROBLEM", 91, 120], ["effector T cells", "PROBLEM", 125, 141], ["IL", "TEST", 173, 175], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["infiltration", "OBSERVATION", 101, 113]]], ["The combination of IL-12 and IL-18 showed to have synergistic effects on IFN-\u03b3 production, an important Th1 effector cytokine, by T cells and NK cells and polarization towards a Th1 response [28, 109] .", [["T cells", "ANATOMY", 130, 137], ["NK cells", "ANATOMY", 142, 150], ["IL-12", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-18", "GENE_OR_GENE_PRODUCT", 29, 34], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 73, 78], ["T cells", "CELL", 130, 137], ["NK cells", "CELL", 142, 150], ["IL", "PROTEIN", 19, 21], ["IL-18", "PROTEIN", 29, 34], ["IFN", "PROTEIN", 73, 76], ["Th1 effector cytokine", "PROTEIN", 104, 125], ["T cells", "CELL_TYPE", 130, 137], ["NK cells", "CELL_TYPE", 142, 150], ["IL", "TEST", 19, 21], ["IL", "TEST", 29, 31], ["synergistic effects", "PROBLEM", 50, 69], ["IFN", "TEST", 73, 76], ["a Th1 response", "TEST", 176, 190]]], ["Combining IL-12 expression with CCL2, an important T-cell chemokine, resulted in enhanced neuroblastoma growth inhibition compared to administration of armed HSV alone demonstrating the potential of combining different cytokines and chemokines in mice [67] .Combining different immune modulatorsIn addition, cytokines have also been combined with immune stimulatory receptor ligands.", [["T-cell", "ANATOMY", 51, 57], ["neuroblastoma", "ANATOMY", 90, 103], ["neuroblastoma", "DISEASE", 90, 103], ["IL-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["CCL2", "GENE_OR_GENE_PRODUCT", 32, 36], ["T-cell", "CELL", 51, 57], ["neuroblastoma", "CANCER", 90, 103], ["HSV", "ORGANISM", 158, 161], ["mice", "ORGANISM", 247, 251], ["IL-12", "PROTEIN", 10, 15], ["CCL2", "PROTEIN", 32, 36], ["T-cell chemokine", "PROTEIN", 51, 67], ["cytokines", "PROTEIN", 219, 228], ["chemokines", "PROTEIN", 233, 243], ["cytokines", "PROTEIN", 308, 317], ["mice", "SPECIES", 247, 251], ["HSV", "SPECIES", 158, 161], ["mice", "SPECIES", 247, 251], ["CCL2", "TREATMENT", 32, 36], ["enhanced neuroblastoma growth inhibition", "PROBLEM", 81, 121], ["armed HSV", "TREATMENT", 152, 161], ["combining different cytokines", "TREATMENT", 199, 228], ["Combining different immune modulators", "TREATMENT", 258, 295], ["cytokines", "TREATMENT", 308, 317], ["immune stimulatory receptor ligands", "TREATMENT", 347, 382], ["neuroblastoma", "OBSERVATION", 90, 103], ["immune modulators", "OBSERVATION", 278, 295]]], ["Treatment with adenovirus armed with GM-CSF and B7-1 in a melanoma mouse model resulted in prolonged survival and resistance to tumor re-challenge compared to treatment with unarmed adenovirus [85] .", [["melanoma", "ANATOMY", 58, 66], ["tumor", "ANATOMY", 128, 133], ["GM", "CHEMICAL", 37, 39], ["melanoma", "DISEASE", 58, 66], ["tumor", "DISEASE", 128, 133], ["adenovirus", "ORGANISM", 15, 25], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 37, 43], ["B7-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["melanoma", "CANCER", 58, 66], ["mouse", "ORGANISM", 67, 72], ["tumor", "CANCER", 128, 133], ["adenovirus", "ORGANISM", 182, 192], ["GM", "PROTEIN", 37, 39], ["CSF", "PROTEIN", 40, 43], ["B7", "PROTEIN", 48, 50], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["adenovirus", "TREATMENT", 15, 25], ["B7", "TREATMENT", 48, 50], ["a melanoma mouse model", "TREATMENT", 56, 78], ["prolonged survival", "PROBLEM", 91, 109], ["tumor re-challenge", "TREATMENT", 128, 146], ["treatment with unarmed adenovirus", "TREATMENT", 159, 192], ["melanoma", "OBSERVATION", 58, 66], ["tumor", "OBSERVATION", 128, 133]]], ["Similarly, treatment with oncolytic adenovirus armed with IL-12 as well as B7-1 resulted more often in complete regression in a melanoma mouse model compared to adenovirus armed with IL-12 alone [41] .", [["melanoma", "ANATOMY", 128, 136], ["melanoma", "DISEASE", 128, 136], ["adenovirus", "ORGANISM", 36, 46], ["IL-12", "GENE_OR_GENE_PRODUCT", 58, 63], ["B7-1", "GENE_OR_GENE_PRODUCT", 75, 79], ["melanoma", "CANCER", 128, 136], ["mouse", "ORGANISM", 137, 142], ["adenovirus", "ORGANISM", 161, 171], ["IL-12", "GENE_OR_GENE_PRODUCT", 183, 188], ["IL-12", "PROTEIN", 58, 63], ["B7", "PROTEIN", 75, 77], ["IL", "PROTEIN", 183, 185], ["mouse", "SPECIES", 137, 142], ["mouse", "SPECIES", 137, 142], ["adenovirus", "SPECIES", 161, 171], ["oncolytic adenovirus armed with IL", "TREATMENT", 26, 60], ["a melanoma mouse model", "TREATMENT", 126, 148], ["IL", "TREATMENT", 183, 185], ["melanoma", "OBSERVATION", 128, 136]]], ["Combination of three armed OVs with IL-12, IL-18, and B7-1 yielded significant better results in inhibition of local and distant tumor growth in a neuroblastoma mouse model, compared to single vector treatment demonstrating the possible synergistic effects between cytokines and co-stimulatory receptors [30] .Combining different immune modulatorsThe combination of checkpoint inhibitors and cytokines work equally well.", [["tumor", "ANATOMY", 129, 134], ["neuroblastoma", "ANATOMY", 147, 160], ["tumor", "DISEASE", 129, 134], ["neuroblastoma", "DISEASE", 147, 160], ["IL-12", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-18", "GENE_OR_GENE_PRODUCT", 43, 48], ["B7-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["tumor", "CANCER", 129, 134], ["neuroblastoma", "CANCER", 147, 160], ["mouse", "ORGANISM", 161, 166], ["IL", "PROTEIN", 36, 38], ["IL", "PROTEIN", 43, 45], ["B7", "PROTEIN", 54, 56], ["cytokines", "PROTEIN", 265, 274], ["co-stimulatory receptors", "PROTEIN", 279, 303], ["cytokines", "PROTEIN", 392, 401], ["mouse", "SPECIES", 161, 166], ["mouse", "SPECIES", 161, 166], ["IL", "TEST", 36, 38], ["IL", "TEST", 43, 45], ["B7", "TEST", 54, 56], ["local and distant tumor growth", "PROBLEM", 111, 141], ["a neuroblastoma mouse model", "TREATMENT", 145, 172], ["single vector treatment", "TREATMENT", 186, 209], ["synergistic effects", "PROBLEM", 237, 256], ["cytokines and co-stimulatory receptors", "TREATMENT", 265, 303], ["Combining different immune modulators", "TREATMENT", 310, 347], ["checkpoint inhibitors", "TREATMENT", 366, 387], ["cytokines work", "TREATMENT", 392, 406], ["distant", "OBSERVATION_MODIFIER", 121, 128], ["tumor", "OBSERVATION", 129, 134], ["growth", "OBSERVATION_MODIFIER", 135, 141], ["neuroblastoma mouse", "OBSERVATION", 147, 166], ["possible", "UNCERTAINTY", 228, 236], ["synergistic", "OBSERVATION_MODIFIER", 237, 248], ["immune modulators", "OBSERVATION", 330, 347], ["checkpoint inhibitors", "OBSERVATION", 366, 387]]], ["Co-administration of oncolytic adenovirus expressing GM-CSF and oncolytic adenovirus expressing anti-CTLA-4 has been shown to yield additive antitumor activity in a lung cancer mouse model [110] .", [["antitumor", "ANATOMY", 141, 150], ["lung cancer", "ANATOMY", 165, 176], ["GM", "CHEMICAL", 53, 55], ["anti-CTLA-4", "CHEMICAL", 96, 107], ["lung cancer", "DISEASE", 165, 176], ["adenovirus", "ORGANISM", 31, 41], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 53, 59], ["oncolytic adenovirus", "ORGANISM", 64, 84], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 96, 107], ["antitumor", "CANCER", 141, 150], ["lung cancer", "CANCER", 165, 176], ["mouse", "ORGANISM", 177, 182], ["CSF", "PROTEIN", 56, 59], ["anti-CTLA-4", "PROTEIN", 96, 107], ["mouse", "SPECIES", 177, 182], ["mouse", "SPECIES", 177, 182], ["oncolytic adenovirus", "TREATMENT", 21, 41], ["oncolytic adenovirus", "TREATMENT", 64, 84], ["a lung cancer mouse model", "PROBLEM", 163, 188], ["antitumor activity", "OBSERVATION", 141, 159], ["lung", "ANATOMY", 165, 169], ["cancer", "OBSERVATION", 170, 176]]], ["Furthermore, T-VEC in combination with systemic treatment with anti-CTLA-4 resulted in significantly improved tumor growth control rates in patients with advanced melanoma compared to both monotherapies alone [73] .", [["T-VEC", "ANATOMY", 13, 18], ["tumor", "ANATOMY", 110, 115], ["melanoma", "ANATOMY", 163, 171], ["anti-CTLA-4", "CHEMICAL", 63, 74], ["tumor", "DISEASE", 110, 115], ["melanoma", "DISEASE", 163, 171], ["T-VEC", "CELL", 13, 18], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 63, 74], ["tumor", "CANCER", 110, 115], ["patients", "ORGANISM", 140, 148], ["melanoma", "CANCER", 163, 171], ["T-VEC", "CELL_LINE", 13, 18], ["anti-CTLA-4", "PROTEIN", 63, 74], ["patients", "SPECIES", 140, 148], ["T-VEC", "TREATMENT", 13, 18], ["systemic treatment", "TREATMENT", 39, 57], ["anti-CTLA", "TREATMENT", 63, 72], ["significantly improved tumor growth control rates", "PROBLEM", 87, 136], ["advanced melanoma", "PROBLEM", 154, 171], ["improved", "OBSERVATION_MODIFIER", 101, 109], ["tumor", "OBSERVATION", 110, 115], ["advanced", "OBSERVATION_MODIFIER", 154, 162], ["melanoma", "OBSERVATION", 163, 171]]], ["Currently T-VEC in combination with anti-PD-1 is being evaluated in clinical trials [111] , but the results are still unknown.", [["T-VEC", "ANATOMY", 10, 15], ["T-VEC", "CHEMICAL", 10, 15], ["anti-PD-1", "CHEMICAL", 36, 45], ["T-VEC", "CELL", 10, 15], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 36, 45], ["anti-PD", "PROTEIN", 36, 43], ["anti-PD", "TREATMENT", 36, 43]]], ["In addition, Sorensen et al. engineered a replication deficient adenovirus expressing a TAA.", [["TAA", "DISEASE", 88, 91], ["adenovirus", "ORGANISM", 64, 74], ["a replication deficient adenovirus", "TREATMENT", 40, 74]]], ["By combining administration of this virus with systemic administration of CD40 stimulatory antibodies and CTLA-4 blockage, tumor growth of melanoma was reduced and long term survival was observed in 30-40% of mice in contrast to the monotherapies [112] .", [["tumor", "ANATOMY", 123, 128], ["melanoma", "ANATOMY", 139, 147], ["tumor", "DISEASE", 123, 128], ["melanoma", "DISEASE", 139, 147], ["CD40", "GENE_OR_GENE_PRODUCT", 74, 78], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 106, 112], ["tumor", "CANCER", 123, 128], ["melanoma", "CANCER", 139, 147], ["mice", "ORGANISM", 209, 213], ["CD40 stimulatory antibodies", "PROTEIN", 74, 101], ["CTLA-4", "PROTEIN", 106, 112], ["mice", "SPECIES", 209, 213], ["mice", "SPECIES", 209, 213], ["this virus", "TREATMENT", 31, 41], ["systemic administration", "TREATMENT", 47, 70], ["CD40 stimulatory antibodies", "TREATMENT", 74, 101], ["CTLA", "TEST", 106, 110], ["4 blockage", "PROBLEM", 111, 121], ["tumor growth of melanoma", "PROBLEM", 123, 147], ["long term survival", "TREATMENT", 164, 182], ["tumor", "OBSERVATION_MODIFIER", 123, 128], ["growth", "OBSERVATION_MODIFIER", 129, 135], ["melanoma", "OBSERVATION", 139, 147]]], ["Thus, stimulation of both DCs and T cells is necessary for long term anti-tumor immune response.", [["DCs", "ANATOMY", 26, 29], ["T cells", "ANATOMY", 34, 41], ["DCs", "CELL", 26, 29], ["T cells", "CELL", 34, 41], ["anti-tumor", "CANCER", 69, 79], ["DCs", "CELL_TYPE", 26, 29], ["T cells", "CELL_TYPE", 34, 41], ["stimulation of both DCs and T cells", "TREATMENT", 6, 41], ["long term anti-tumor immune response", "TREATMENT", 59, 95]]], ["Therefore, these (pre-) clinical trials with combination-therapies demonstrate the potential to improve current therapies.Combining different immune modulatorsTaken together, these studies provide a strong rationale for further evaluation of OVs as a local delivery vector for immunotherapies targeting co-stimulatory and co-inhibitory receptors on anti-tumor effector cells or other parts of the TME.Discussion and future directionsOVs represent a class of promising agents to treat cancer.", [["anti-tumor effector cells", "ANATOMY", 349, 374], ["cancer", "ANATOMY", 484, 490], ["cancer", "DISEASE", 484, 490], ["OVs", "SIMPLE_CHEMICAL", 242, 245], ["anti-tumor effector cells", "CELL", 349, 374], ["cancer", "CANCER", 484, 490], ["co-stimulatory and co-inhibitory receptors", "PROTEIN", 303, 345], ["anti-tumor effector cells", "CELL_TYPE", 349, 374], ["therapies", "TREATMENT", 57, 66], ["current therapies", "TREATMENT", 104, 121], ["Combining different immune modulators", "TREATMENT", 122, 159], ["these studies", "TEST", 175, 188], ["further evaluation", "TEST", 220, 238], ["OVs", "TREATMENT", 242, 245], ["a local delivery vector", "TREATMENT", 249, 272], ["immunotherapies targeting co-stimulatory and co-inhibitory receptors", "TREATMENT", 277, 345], ["anti-tumor effector cells", "TREATMENT", 349, 374], ["cancer", "PROBLEM", 484, 490], ["immune modulators", "OBSERVATION", 142, 159], ["cancer", "OBSERVATION", 484, 490]]], ["Besides their direct oncolytic effects, they can function as a 'kick-start' for antitumor immunity.", [["antitumor", "ANATOMY", 80, 89], ["antitumor", "CANCER", 80, 89], ["antitumor immunity", "TREATMENT", 80, 98]]], ["Combining OV therapy with existing immune therapies enhances the potential of both therapies by synergizing their effects.", [["OV", "MULTI-TISSUE_STRUCTURE", 10, 12], ["Combining OV therapy", "TREATMENT", 0, 20], ["existing immune therapies", "TREATMENT", 26, 51], ["both therapies", "TREATMENT", 78, 92]]], ["These studies have broadened our understanding of the strengths of OV immune therapies, but also of its limitations.", [["These studies", "TEST", 0, 13], ["OV immune therapies", "TREATMENT", 67, 86]]], ["As a result, these learning lessons enable us to discuss the potential future directions and further considerations in deciding on effective immune modulators and viral combinations and reducing risks.Effective immune modulatorsOne of the greatest advantages of OVs armed with immune modulators is that this therapy often induces safer systemic and/or more effective localized concentrations of the modulator than systemic monotherapy [58, 86, 92] .", [["OVs", "SIMPLE_CHEMICAL", 262, 265], ["effective immune modulators", "TREATMENT", 131, 158], ["viral combinations", "TREATMENT", 163, 181], ["Effective immune modulators", "TREATMENT", 201, 228], ["immune modulators", "TREATMENT", 277, 294], ["this therapy", "TREATMENT", 303, 315], ["systemic monotherapy", "TREATMENT", 414, 434], ["greatest", "OBSERVATION_MODIFIER", 239, 247]]], ["Nevertheless, vectorization of checkpoint inhibitors can also limit the potency of the immune therapies by incorrect localization and timing and no resilience in case of tumor resistance.", [["tumor", "ANATOMY", 170, 175], ["tumor", "DISEASE", 170, 175], ["tumor", "CANCER", 170, 175], ["vectorization of checkpoint inhibitors", "TREATMENT", 14, 52], ["the immune therapies", "TREATMENT", 83, 103], ["incorrect localization", "TEST", 107, 129], ["tumor resistance", "PROBLEM", 170, 186], ["tumor resistance", "OBSERVATION", 170, 186]]], ["With regard to localization, a checkpoint receptor, such as CTLA-4, is mainly functional in the lymph node and requires systemic delivery of the blocking antibodies [72] .", [["lymph node", "ANATOMY", 96, 106], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 60, 66], ["lymph node", "MULTI-TISSUE_STRUCTURE", 96, 106], ["checkpoint receptor", "PROTEIN", 31, 50], ["CTLA-4", "PROTEIN", 60, 66], ["a checkpoint receptor", "TREATMENT", 29, 50], ["CTLA", "TEST", 60, 64], ["systemic delivery", "TREATMENT", 120, 137], ["the blocking antibodies", "TEST", 141, 164], ["mainly", "OBSERVATION_MODIFIER", 71, 77], ["functional", "OBSERVATION_MODIFIER", 78, 88], ["lymph node", "OBSERVATION", 96, 106], ["systemic", "OBSERVATION_MODIFIER", 120, 128]]], ["For instance, the anti-CTLA-4 armed MV proved to be less effective than monotherapy with CTLA-4 inhibitors [75] .", [["CTLA-4 inhibitors", "CHEMICAL", 89, 106], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 18, 29], ["MV", "ORGANISM", 36, 38], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 89, 95], ["MV", "SPECIES", 36, 38], ["the anti-CTLA-4 armed MV", "TREATMENT", 14, 38], ["monotherapy", "TREATMENT", 72, 83], ["CTLA", "TREATMENT", 89, 93]]], ["Similar results were found for PD-L1 inhibitors delivered by MV and VV [75, 83] , illustrating the second disadvantage of OVs armed with checkpoint inhibitors: the timing of administration of combined therapies.", [["PD-L1", "GENE_OR_GENE_PRODUCT", 31, 36], ["OVs", "SIMPLE_CHEMICAL", 122, 125], ["MV", "SPECIES", 61, 63], ["VV", "SPECIES", 68, 70], ["PD-L1 inhibitors", "TREATMENT", 31, 47], ["MV", "TEST", 61, 63], ["VV", "TEST", 68, 70], ["checkpoint inhibitors", "TREATMENT", 137, 158], ["combined therapies", "TREATMENT", 192, 210]]], ["Rojas et al. and Gao et al. demonstrated that systemic administration of immune therapeutics given shortly (1-3 days) after OV therapy resulted in additive efficacy of the combination therapy in contrast to immune therapeutics given prior to OV administration [71, 113] .", [["immune therapeutics", "TREATMENT", 73, 92], ["OV therapy", "TREATMENT", 124, 134], ["the combination therapy", "TREATMENT", 168, 191], ["immune therapeutics", "TREATMENT", 207, 226], ["OV administration", "TREATMENT", 242, 259]]], ["However, timing strategies may differ per virus as was seen with the armed MYXV where vectorization of anti-PD-1 did result in additive effects [81] .", [["anti-PD-1", "GENE_OR_GENE_PRODUCT", 103, 112], ["anti-PD", "PROTEIN", 103, 110], ["anti-PD", "TREATMENT", 103, 110]]], ["In addition to localization and timing, multiple studies have shown the development of resistance towards these checkpoint inhibitors over time in which new inhibitory molecules were upregulated on the cancer cells rendering the therapy ineffective [27] .", [["cancer cells", "ANATOMY", 202, 214], ["cancer", "DISEASE", 202, 208], ["cancer cells", "CELL", 202, 214], ["inhibitory molecules", "PROTEIN", 157, 177], ["cancer cells", "CELL_TYPE", 202, 214], ["multiple studies", "TEST", 40, 56], ["these checkpoint inhibitors", "TREATMENT", 106, 133], ["the cancer cells", "TREATMENT", 198, 214], ["the therapy", "TREATMENT", 225, 236]]], ["Systemic administration of checkpoint inhibitors would allow for an easier transition between checkpoint therapies if necessary.", [["checkpoint inhibitors", "TREATMENT", 27, 48], ["checkpoint therapies", "TREATMENT", 94, 114]]], ["Therefore, we think that arming viruses with checkpoint inhibitors might not be the most effective combination strategy.Effective immune modulatorsAn alternative approach to consider would be the targeting of APCs, NK cells and CTLs by arming viruses with immune stimulating agonists and cytokines.", [["APCs", "ANATOMY", 209, 213], ["NK cells", "ANATOMY", 215, 223], ["CTLs", "ANATOMY", 228, 232], ["APCs", "CELL", 209, 213], ["NK cells", "CELL", 215, 223], ["CTLs", "CELL", 228, 232], ["APCs", "CELL_TYPE", 209, 213], ["NK cells", "CELL_TYPE", 215, 223], ["CTLs", "CELL_TYPE", 228, 232], ["cytokines", "PROTEIN", 288, 297], ["arming viruses", "PROBLEM", 25, 39], ["checkpoint inhibitors", "TREATMENT", 45, 66], ["Effective immune modulators", "TREATMENT", 120, 147], ["CTLs", "TEST", 228, 232], ["immune stimulating agonists", "TREATMENT", 256, 283], ["cytokines", "PROBLEM", 288, 297]]], ["These immune cells express a known and stable subset of cytokine and co-stimulatory receptors and hence circumvent the treatment resistance as is seen with checkpoint inhibitors.", [["immune cells", "ANATOMY", 6, 18], ["immune cells", "CELL", 6, 18], ["immune cells", "CELL_TYPE", 6, 18], ["cytokine", "PROTEIN", 56, 64], ["co-stimulatory receptors", "PROTEIN", 69, 93], ["cytokine and co-stimulatory receptors", "TREATMENT", 56, 93], ["the treatment resistance", "TREATMENT", 115, 139], ["checkpoint inhibitors", "TREATMENT", 156, 177], ["stable", "OBSERVATION_MODIFIER", 39, 45]]], ["Several studies have shown the additive effects of OVs armed with these agonistic agents compared to OV therapy alone (Table 1 ).", [["OVs", "SIMPLE_CHEMICAL", 51, 54], ["Several studies", "TEST", 0, 15], ["OVs", "TREATMENT", 51, 54], ["these agonistic agents", "TREATMENT", 66, 88], ["OV therapy", "TREATMENT", 101, 111]]], ["In addition, the localized expression of agonistic agents reduces adverse effects in contrast to systemic administration and still allow combination therapy with checkpoint inhibitors [58, 114, 115] .", [["agonistic agents", "TREATMENT", 41, 57], ["systemic administration", "TREATMENT", 97, 120], ["combination therapy", "TREATMENT", 137, 156], ["checkpoint inhibitors", "TREATMENT", 162, 183]]], ["Based on the reviewed studies, we reason that both cytokines and agonists targeting co-stimulatory receptors are very promising as immune modulators in the OV treatment against solid tumors.Viral combinationsAnother point of consideration is the combination of the virus and the immune modulator.", [["solid tumors", "ANATOMY", 177, 189], ["solid tumors", "DISEASE", 177, 189], ["solid tumors", "CANCER", 177, 189], ["cytokines", "PROTEIN", 51, 60], ["co-stimulatory receptors", "PROTEIN", 84, 108], ["the reviewed studies", "TEST", 9, 29], ["both cytokines", "TREATMENT", 46, 60], ["agonists targeting co-stimulatory receptors", "TREATMENT", 65, 108], ["immune modulators", "TREATMENT", 131, 148], ["the OV treatment", "TREATMENT", 152, 168], ["solid tumors", "PROBLEM", 177, 189], ["Viral combinations", "TREATMENT", 190, 208], ["the virus", "PROBLEM", 261, 270], ["the immune modulator", "TREATMENT", 275, 295], ["tumors", "OBSERVATION", 183, 189]]], ["The virus determines both the 'kick-start' effect, which initiates the inflammation, and the concentration and duration of expression of the vectorized immune modulators.", [["inflammation", "DISEASE", 71, 83], ["The virus", "PROBLEM", 0, 9], ["the inflammation", "PROBLEM", 67, 83], ["the vectorized immune modulators", "TREATMENT", 137, 169], ["virus", "OBSERVATION", 4, 9], ["inflammation", "OBSERVATION", 71, 83]]], ["However, viruses differ in the effectiveness in killing the target cell or in expressing the immune modulator.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["target cell", "CELL_TYPE", 60, 71], ["viruses", "PROBLEM", 9, 16], ["viruses", "OBSERVATION", 9, 16], ["target cell", "OBSERVATION", 60, 71], ["immune modulator", "OBSERVATION", 93, 109]]], ["For example, in a study comparing VSV with a replication defective adeno virus, both expressing CD40L, it was shown that the replication defective virus was superior in increasing survival rates over the replicative virus [116] .", [["VSV", "ORGANISM", 34, 37], ["adeno virus", "ORGANISM", 67, 78], ["CD40L", "GENE_OR_GENE_PRODUCT", 96, 101], ["CD40L", "PROTEIN", 96, 101], ["VSV", "SPECIES", 34, 37], ["adeno virus", "SPECIES", 67, 78], ["a study", "TEST", 16, 23], ["a replication defective adeno virus", "PROBLEM", 43, 78], ["the replication defective virus", "PROBLEM", 121, 152], ["the replicative virus", "PROBLEM", 200, 221], ["adeno virus", "OBSERVATION", 67, 78], ["defective virus", "OBSERVATION", 137, 152], ["increasing", "OBSERVATION_MODIFIER", 169, 179], ["survival", "OBSERVATION_MODIFIER", 180, 188]]], ["This is probably because of the low immunogenicity of the replication defective virus resulting in reduced viral clearance by the immune system and hence more immune modulator secretion.", [["immune system", "ANATOMY", 130, 143], ["the low immunogenicity", "PROBLEM", 28, 50], ["the replication defective virus", "PROBLEM", 54, 85], ["reduced viral clearance", "PROBLEM", 99, 122], ["more immune modulator secretion", "PROBLEM", 154, 185], ["probably because of", "UNCERTAINTY", 8, 27], ["low immunogenicity", "OBSERVATION_MODIFIER", 32, 50], ["replication defective virus", "OBSERVATION", 58, 85], ["reduced", "OBSERVATION_MODIFIER", 99, 106], ["viral clearance", "OBSERVATION", 107, 122]]], ["However, whether the benefits of a weaker immune response hold true for all therapies remains unknown and probably depends on the virus.Viral combinationsIn addition to oncolytic activity, the efficacy of the OV immune therapy is influenced by the efficiency of a virus to express the immune modulators.", [["OV", "ORGANISM", 209, 211], ["a weaker immune response", "PROBLEM", 33, 57], ["all therapies", "TREATMENT", 72, 85], ["the virus", "PROBLEM", 126, 135], ["Viral combinations", "TREATMENT", 136, 154], ["oncolytic activity", "TREATMENT", 169, 187], ["the OV immune therapy", "TREATMENT", 205, 226], ["a virus", "PROBLEM", 262, 269], ["the immune modulators", "TREATMENT", 281, 302], ["oncolytic activity", "OBSERVATION", 169, 187]]], ["For instance, for NDV it has been shown that the insertion site in the virus determines the expression levels of the transgene [56] .", [["NDV", "ORGANISM", 18, 21], ["insertion site", "DNA", 49, 63], ["NDV", "SPECIES", 18, 21], ["NDV", "SPECIES", 18, 21], ["NDV", "PROBLEM", 18, 21], ["the insertion site", "PROBLEM", 45, 63], ["the virus", "PROBLEM", 67, 76]]], ["The effect of the insertion site may also hold true for other OVs, but is often not discussed.", [["OVs", "PATHOLOGICAL_FORMATION", 62, 65], ["insertion site", "DNA", 18, 32], ["the insertion site", "TREATMENT", 14, 32]]], ["In addition, the size of the immune modulators is also of importance.", [["size", "OBSERVATION_MODIFIER", 17, 21], ["immune modulators", "OBSERVATION", 29, 46]]], ["Studies using a complete monoclonal antibody, only the light chain or a single-chain variable fragment showed that smaller proteins were more effectively produced than the larger proteins by cells infected with VV.", [["cells", "ANATOMY", 191, 196], ["cells", "CELL", 191, 196], ["monoclonal antibody", "PROTEIN", 25, 44], ["light chain", "PROTEIN", 55, 66], ["single-chain variable fragment", "PROTEIN", 72, 102], ["VV", "SPECIES", 211, 213], ["Studies", "TEST", 0, 7], ["a complete monoclonal antibody", "TEST", 14, 44], ["a single-chain variable fragment", "PROBLEM", 70, 102], ["smaller proteins", "PROBLEM", 115, 131], ["fragment", "OBSERVATION", 94, 102], ["smaller", "OBSERVATION_MODIFIER", 115, 122], ["more effectively", "OBSERVATION_MODIFIER", 137, 153]]], ["However, the single chain fragment without an IgG domain was degraded faster in the TME, resulting in similar antitumor activity as the monoclonal antibody [83] .", [["antitumor", "ANATOMY", 110, 119], ["antitumor", "CANCER", 110, 119], ["IgG domain", "PROTEIN", 46, 56], ["monoclonal antibody", "PROTEIN", 136, 155], ["the single chain fragment", "PROBLEM", 9, 34], ["an IgG domain", "PROBLEM", 43, 56], ["the monoclonal antibody", "TEST", 132, 155], ["chain", "OBSERVATION_MODIFIER", 20, 25], ["fragment", "OBSERVATION", 26, 34], ["IgG", "OBSERVATION", 46, 49], ["antitumor activity", "OBSERVATION", 110, 128]]], ["As not all viruses tolerate large insertions, this information should be considered when deciding which modulator to incorporate.", [["large insertions", "TREATMENT", 28, 44]]], ["However, predicting the efficiency of the modulator expression remains difficult, because differences in expression levels can occur between tumors independent of the virus [110] .Reducing risksWhile moving forward with OV immune therapies to the clinic, safety ought to be considered once more.", [["tumors", "ANATOMY", 141, 147], ["tumors", "DISEASE", 141, 147], ["tumors", "CANCER", 141, 147], ["expression levels", "PROBLEM", 105, 122], ["tumors", "PROBLEM", 141, 147], ["the virus", "PROBLEM", 163, 172], ["OV immune therapies", "TREATMENT", 220, 239], ["efficiency", "OBSERVATION_MODIFIER", 24, 34], ["modulator expression", "OBSERVATION", 42, 62]]], ["So far, no adverse effects have been reported on the therapies combining OV with immune therapies in murine models or clinical trials.", [["OV", "MULTI-TISSUE_STRUCTURE", 73, 75], ["murine", "ORGANISM", 101, 107], ["murine", "SPECIES", 101, 107], ["adverse effects", "PROBLEM", 11, 26], ["the therapies", "TREATMENT", 49, 62], ["immune therapies", "TREATMENT", 81, 97]]], ["Nevertheless, adverse effects of the viral infection, such as excessive viral replication or expression of the immune modulators leading to an overreaction of the immune system cannot be excluded yet.", [["immune system", "ANATOMY", 163, 176], ["viral infection", "DISEASE", 37, 52], ["the viral infection", "PROBLEM", 33, 52], ["excessive viral replication", "PROBLEM", 62, 89], ["the immune modulators", "PROBLEM", 107, 128], ["an overreaction of the immune system", "PROBLEM", 140, 176], ["viral", "OBSERVATION_MODIFIER", 37, 42], ["infection", "OBSERVATION", 43, 52], ["immune modulators", "OBSERVATION", 111, 128], ["cannot be excluded", "UNCERTAINTY", 177, 195]]], ["A possibility to reduce the risks on adverse effects would be the incorporation of a fail-safe mechanism into the OV therapy to abort viral replication if necessary.", [["adverse effects", "PROBLEM", 37, 52], ["the OV therapy", "TREATMENT", 110, 124], ["viral replication", "TREATMENT", 134, 151]]], ["Only for HSV, drugs are available to inhibit viral replication [117] .", [["HSV", "ORGANISM", 9, 12], ["HSV", "SPECIES", 9, 12], ["HSV", "PROBLEM", 9, 12], ["drugs", "TREATMENT", 14, 19]]], ["Alternatively, virus with attenuated virulence or viruses with a different host range may be used.", [["virus", "PROBLEM", 15, 20], ["attenuated virulence", "PROBLEM", 26, 46], ["viruses", "PROBLEM", 50, 57], ["attenuated", "OBSERVATION_MODIFIER", 26, 36], ["virulence", "OBSERVATION_MODIFIER", 37, 46], ["viruses", "OBSERVATION", 50, 57]]], ["In addition, incorporation of suicide genes, such as thymidine kinase [117] , rat cytochrome P450 [118] or cytosine deaminase [119] , would allow inhibition of viral replication by using drugs as well.", [["thymidine", "CHEMICAL", 53, 62], ["cytosine", "CHEMICAL", 107, 115], ["thymidine", "CHEMICAL", 53, 62], ["cytosine", "CHEMICAL", 107, 115], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 53, 69], ["rat", "ORGANISM", 78, 81], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 82, 97], ["cytosine deaminase", "GENE_OR_GENE_PRODUCT", 107, 125], ["suicide genes", "DNA", 30, 43], ["thymidine kinase", "PROTEIN", 53, 69], ["rat cytochrome P450", "PROTEIN", 78, 97], ["cytosine deaminase", "PROTEIN", 107, 125], ["rat", "SPECIES", 78, 81], ["suicide genes", "PROBLEM", 30, 43], ["thymidine kinase", "TEST", 53, 69], ["rat cytochrome P450", "TEST", 78, 97], ["cytosine deaminase", "TREATMENT", 107, 125], ["viral replication", "TREATMENT", 160, 177]]], ["Moreover, it could add to the tumor lytic efficacy of the therapy [120] .", [["tumor", "ANATOMY", 30, 35], ["tumor", "DISEASE", 30, 35], ["tumor", "CANCER", 30, 35], ["the therapy", "TREATMENT", 54, 65], ["tumor", "OBSERVATION", 30, 35], ["lytic", "OBSERVATION_MODIFIER", 36, 41]]], ["During OV therapy, the immune modulator is not incorporated into the host genome and therefore expression levels are dependent on viral replication which is usually transient.", [["host genome", "DNA", 69, 80], ["OV therapy", "TREATMENT", 7, 17], ["the immune modulator", "TREATMENT", 19, 39], ["expression levels", "PROBLEM", 95, 112], ["viral replication", "TREATMENT", 130, 147], ["host genome", "OBSERVATION", 69, 80], ["dependent", "OBSERVATION_MODIFIER", 117, 126], ["viral replication", "OBSERVATION", 130, 147], ["transient", "OBSERVATION_MODIFIER", 165, 174]]], ["Thus, controlling the viral replication would reduce the risks on severe adverse effects of the immune modulators.Reducing risksIn conclusion, the overall effect of the oncolytic immune therapy depends on the interplay between virus, immune modulator and tumor.", [["tumor", "ANATOMY", 255, 260], ["tumor", "DISEASE", 255, 260], ["tumor", "CANCER", 255, 260], ["the viral replication", "TREATMENT", 18, 39], ["severe adverse effects", "PROBLEM", 66, 88], ["the immune modulators", "TREATMENT", 92, 113], ["the oncolytic immune therapy", "TREATMENT", 165, 193], ["virus", "PROBLEM", 227, 232], ["immune modulator", "TREATMENT", 234, 250], ["tumor", "PROBLEM", 255, 260], ["viral replication", "OBSERVATION", 22, 39], ["immune modulators", "OBSERVATION", 96, 113], ["tumor", "OBSERVATION", 255, 260]]], ["Not only tumors develop over time, but the immune system as well.", [["tumors", "ANATOMY", 9, 15], ["immune system", "ANATOMY", 43, 56], ["tumors", "DISEASE", 9, 15], ["tumors", "CANCER", 9, 15], ["tumors", "PROBLEM", 9, 15], ["tumors", "OBSERVATION", 9, 15]]], ["This means that every stage of immune activation should be considered while deciding on the incorporation of an immune modulator (Fig. 2) .", [["immune activation", "PROBLEM", 31, 48], ["an immune modulator (Fig", "TREATMENT", 109, 133]]], ["Weak immunogenic tumors in an immunosuppressive TME will likely benefit from potent oncolytic viruses, cytokines and innate stimulating agonists to activate the initial innate immune response.", [["tumors", "ANATOMY", 17, 23], ["tumors", "DISEASE", 17, 23], ["tumors", "CANCER", 17, 23], ["cytokines", "PROTEIN", 103, 112], ["Weak immunogenic tumors", "PROBLEM", 0, 23], ["an immunosuppressive TME", "TREATMENT", 27, 51], ["potent oncolytic viruses", "TREATMENT", 77, 101], ["cytokines", "TREATMENT", 103, 112], ["innate stimulating agonists", "TREATMENT", 117, 144], ["immunogenic", "OBSERVATION_MODIFIER", 5, 16], ["tumors", "OBSERVATION", 17, 23], ["immunosuppressive TME", "OBSERVATION", 30, 51]]], ["If eventually the tumor is inflamed, effector T cells and NK cells responses can be improved by immune activating agonists, such as 4-1BBL, and checkpoint inhibitors.", [["tumor", "ANATOMY", 18, 23], ["effector T cells", "ANATOMY", 37, 53], ["NK cells", "ANATOMY", 58, 66], ["tumor", "DISEASE", 18, 23], ["tumor", "CANCER", 18, 23], ["effector T cells", "CELL", 37, 53], ["NK cells", "CELL", 58, 66], ["4-1BBL", "SIMPLE_CHEMICAL", 132, 138], ["effector T cells", "CELL_TYPE", 37, 53], ["NK cells", "CELL_TYPE", 58, 66], ["the tumor", "PROBLEM", 14, 23], ["inflamed", "PROBLEM", 27, 35], ["effector T cells", "PROBLEM", 37, 53], ["immune activating agonists", "TREATMENT", 96, 122], ["1BBL", "TREATMENT", 134, 138], ["checkpoint inhibitors", "TREATMENT", 144, 165], ["tumor", "OBSERVATION", 18, 23], ["inflamed", "OBSERVATION_MODIFIER", 27, 35]]], ["The vectorization of both cytokines and immune activating agonists could reduce possible adverse effects compared to systemic administration, whereas systemic delivery of checkpoint inhibitors improves the timing and localization of the treatment.", [["cytokines", "PROTEIN", 26, 35], ["both cytokines", "TREATMENT", 21, 35], ["immune activating agonists", "TREATMENT", 40, 66], ["adverse effects", "PROBLEM", 89, 104], ["systemic administration", "TREATMENT", 117, 140], ["systemic delivery of checkpoint inhibitors", "TREATMENT", 150, 192], ["the treatment", "TREATMENT", 233, 246]]], ["Future directions will have to explore multiple combinations of dually armed OVs allowing to overcome tumor heterogeneity or at least to use both OVs and immune modulators to their full potential.Conflicts of interestThe authors declare no conflict of interest.", [["tumor", "ANATOMY", 102, 107], ["tumor", "DISEASE", 102, 107], ["tumor", "CANCER", 102, 107], ["dually armed OVs", "TREATMENT", 64, 80], ["tumor heterogeneity", "PROBLEM", 102, 121], ["both OVs", "TREATMENT", 141, 149], ["immune modulators", "TREATMENT", 154, 171], ["tumor", "OBSERVATION", 102, 107]]], ["The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.FundingThis work was supported by Stichting Technische Wetenschappen, [#15414] and the foundation \"overleven met alvleesklierkanker\" (www.supportcasper.nl).", [["the study", "TEST", 51, 60]]], ["Tumor cells start secreting viral induced cytokines and chemokines, but also the immune modulators, which improves the immune activation.", [["Tumor cells", "ANATOMY", 0, 11], ["Tumor cells", "CELL", 0, 11], ["Tumor cells", "CELL_TYPE", 0, 11], ["viral induced cytokines", "PROTEIN", 28, 51], ["chemokines", "PROTEIN", 56, 66], ["Tumor cells", "PROBLEM", 0, 11], ["secreting viral induced cytokines", "PROBLEM", 18, 51], ["chemokines", "TREATMENT", 56, 66], ["the immune modulators", "PROBLEM", 77, 98], ["secreting viral induced cytokines", "OBSERVATION", 18, 51], ["immune activation", "OBSERVATION", 119, 136]]], ["As a result, immune cells start to infiltrate the TME.", [["immune cells", "ANATOMY", 13, 25], ["immune cells", "CELL", 13, 25], ["immune cells", "CELL_TYPE", 13, 25], ["immune cells", "PROBLEM", 13, 25], ["infiltrate the TME", "PROBLEM", 35, 53]]], ["(C) Occasionally, the virus will induce an immunogenic cell death.", [["cell", "ANATOMY", 55, 59], ["death", "DISEASE", 60, 65], ["cell", "CELL", 55, 59], ["the virus", "PROBLEM", 18, 27], ["an immunogenic cell death", "PROBLEM", 40, 65], ["immunogenic cell death", "OBSERVATION", 43, 65]]], ["The TAAs and immune stimulating environment will result in the maturation of APCs.", [["APCs", "ANATOMY", 77, 81], ["TAAs", "GENE_OR_GENE_PRODUCT", 4, 8], ["APCs", "CELL", 77, 81], ["APCs", "CELL_TYPE", 77, 81], ["The TAAs", "TREATMENT", 0, 8], ["immune stimulating environment", "TREATMENT", 13, 43]]], ["(D) The APCs will activate the adaptive immune system upon which T cells will start infiltrating the tumor attracted by the secreted chemokines.", [["APCs", "ANATOMY", 8, 12], ["immune system", "ANATOMY", 40, 53], ["T cells", "ANATOMY", 65, 72], ["tumor", "ANATOMY", 101, 106], ["tumor", "DISEASE", 101, 106], ["APCs", "CELL", 8, 12], ["T cells", "CELL", 65, 72], ["tumor", "CANCER", 101, 106], ["APCs", "CELL_TYPE", 8, 12], ["T cells", "CELL_TYPE", 65, 72], ["secreted chemokines", "PROTEIN", 124, 143], ["the adaptive immune system", "TREATMENT", 27, 53], ["infiltrating the tumor", "PROBLEM", 84, 106], ["the secreted chemokines", "TREATMENT", 120, 143], ["tumor", "OBSERVATION", 101, 106]]], ["Possible activity of immune suppressive ligands, such as PD-L1, will be prevented by the circulating immune checkpoint inhibitors resulting in clearance of the tumor.FundingMs.", [["tumor", "ANATOMY", 160, 165], ["tumor", "DISEASE", 160, 165], ["PD-L1", "GENE_OR_GENE_PRODUCT", 57, 62], ["tumor", "CANCER", 160, 165], ["immune suppressive ligands", "PROBLEM", 21, 47], ["PD-L1", "TREATMENT", 57, 62], ["the circulating immune checkpoint inhibitors", "TREATMENT", 85, 129], ["the tumor", "PROBLEM", 156, 165], ["L1", "ANATOMY", 60, 62], ["tumor", "OBSERVATION", 160, 165]]], ["Lisanne de Vor received her Master's degree in Infection and Immunity in Utrecht, The Netherlands, and followed research training at the Viroscience Department of Erasmus MC Rotterdam, The Netherlands and the Karolinska Institute, Sweden.She currently works at the department of Microbiology at Utrecht Medical Institute, The Netherlands.", [["Lisanne", "CHEMICAL", 0, 7], ["Infection", "PROBLEM", 47, 56], ["Infection", "OBSERVATION", 47, 56]]], ["Dr. Bernadette G. van den Hoogen started research training in the group of Prof. S. Ross, at the Pennsylvania School of Medicine in Philadelphia from 1995 to 1998.", [["research training", "TREATMENT", 41, 58], ["Ross", "OBSERVATION", 84, 88]]], ["Subsequently, Bernadette obtained her PhD at the department of Viroscience, Erasmus MC, Rotterdam, The Netherlands on \"the Discovery and Characterization of the Human Metapneumovirus (HMPV)\".", [["Human", "ORGANISM", 161, 166], ["HMPV", "ORGANISM", 184, 188], ["Human", "SPECIES", 161, 166], ["HMPV", "SPECIES", 184, 188], ["the Human Metapneumovirus", "PROBLEM", 157, 182]]], ["Since then, Bernadette has been investigating the interaction between HMPV and the human immune system, but the use of paramyxoviruses as oncolytic viruses.", [["immune system", "ANATOMY", 89, 102], ["HMPV", "ORGANISM", 70, 74], ["human", "ORGANISM", 83, 88], ["immune system", "ANATOMICAL_SYSTEM", 89, 102], ["oncolytic viruses", "ORGANISM", 138, 155], ["human", "SPECIES", 83, 88], ["HMPV", "SPECIES", 70, 74], ["human", "SPECIES", 83, 88], ["HMPV", "PROBLEM", 70, 74], ["the human immune system", "TREATMENT", 79, 102], ["paramyxoviruses", "TREATMENT", 119, 134], ["oncolytic viruses", "TREATMENT", 138, 155]]], ["Her oncolytic research focuses on avian paramyxoviruses and their application in oncolytic viro-immunotherapy for treatment of pancreatic cancer patients.", [["pancreatic cancer", "ANATOMY", 127, 144], ["pancreatic cancer", "DISEASE", 127, 144], ["avian paramyxoviruses", "ORGANISM", 34, 55], ["pancreatic cancer", "CANCER", 127, 144], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["avian paramyxoviruses", "TREATMENT", 34, 55], ["oncolytic viro-immunotherapy", "TREATMENT", 81, 109], ["pancreatic cancer", "PROBLEM", 127, 144], ["pancreatic", "ANATOMY", 127, 137], ["cancer", "OBSERVATION", 138, 144]]]], "0008c57de475138d903f2cca7003cf1e1ad93cf4": [["IntroductionThe effect on the cell membrane of inclusions (membrane proteins, antimicrobial peptides etc.) is a highly active field of study in biophysics [1] .", [["cell membrane", "ANATOMY", 30, 43], ["inclusions", "ANATOMY", 47, 57], ["membrane", "ANATOMY", 59, 67], ["cell membrane", "CELLULAR_COMPONENT", 30, 43], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["membrane proteins", "PROTEIN", 59, 76], ["the cell membrane of inclusions (membrane proteins", "TREATMENT", 26, 76], ["antimicrobial peptides", "TREATMENT", 78, 100]]], ["A very powerful principle employed in describing the interaction between proteins and membranes is that of hydrophobic matching [2, 3] .", [["membranes", "ANATOMY", 86, 95], ["membranes", "CELLULAR_COMPONENT", 86, 95]]], ["It states that proteins with a given hydrophobic length insert preferentially into membranes with a similar hydrophobic thickness [4] .IntroductionMany studies of the interaction used as inclusion the antimicrobial peptide (AMP) Gramicidin A (GramA), which is known [5, 6] to deform (stretch or compress) host membranes to bring them closer to its own hydrophobic length, so the hydrophobic matching mechanism is likely relevant.", [["membranes", "ANATOMY", 83, 92], ["membranes", "ANATOMY", 310, 319], ["AMP", "CHEMICAL", 224, 227], ["Gramicidin A", "CHEMICAL", 229, 241], ["GramA", "CHEMICAL", 243, 248], ["Gramicidin A", "CHEMICAL", 229, 241], ["membranes", "CELLULAR_COMPONENT", 83, 92], ["AMP", "SIMPLE_CHEMICAL", 224, 227], ["Gramicidin A", "SIMPLE_CHEMICAL", 229, 241], ["GramA", "SIMPLE_CHEMICAL", 243, 248], ["a given hydrophobic length insert", "TREATMENT", 29, 62], ["the antimicrobial peptide (AMP) Gramicidin A (GramA)", "TREATMENT", 197, 249], ["stretch or compress) host membranes", "TREATMENT", 284, 319], ["the hydrophobic matching mechanism", "TREATMENT", 375, 409], ["host membranes", "OBSERVATION", 305, 319], ["is likely relevant", "UNCERTAINTY", 410, 428]]], ["This perturbation of the membrane profile induces a repulsive interaction between the GramA pores in bilayers with various compositions [7] that can be explained based on a complete elastic model [8] .IntroductionThis large-scale description raises however fundamental questions about the \"microscopic effect\" of the inclusion, at the scale of the lipid or surfactant molecules composing the membrane.", [["membrane", "ANATOMY", 25, 33], ["membrane", "ANATOMY", 392, 400], ["GramA", "CHEMICAL", 86, 91], ["membrane", "CELLULAR_COMPONENT", 25, 33], ["lipid", "SIMPLE_CHEMICAL", 348, 353], ["membrane", "CELLULAR_COMPONENT", 392, 400], ["the membrane profile", "PROBLEM", 21, 41], ["surfactant molecules", "TREATMENT", 357, 377], ["repulsive", "OBSERVATION", 52, 61], ["surfactant molecules", "OBSERVATION", 357, 377]]], ["Is the continuous elastic model employed for bare membranes still valid?IntroductionIn this paper, our goal is to investigate the influence of GramA inclusions on the local order of the lipid or surfactant chains.", [["membranes", "ANATOMY", 50, 59], ["membranes", "CELLULAR_COMPONENT", 50, 59], ["GramA", "SIMPLE_CHEMICAL", 143, 148], ["lipid", "SIMPLE_CHEMICAL", 186, 191], ["surfactant chains", "SIMPLE_CHEMICAL", 195, 212], ["the continuous elastic model", "TREATMENT", 3, 31], ["bare membranes", "TREATMENT", 45, 59], ["GramA inclusions", "PROBLEM", 143, 159], ["the lipid or surfactant chains", "TREATMENT", 182, 212]]], ["We combine two complementary techniques: wide-angle X-ray scattering (WAXS) gives access Supplementary material in the form of a .pdf file available from the Journal web page at https://doi.org/10.1140/epje/i2018-11644-5 a e-mail: doru.constantin@u-psud.fr to the positional order between neighboring chains, while nuclear magnetic resonance (NMR) is sensitive to the orientational order of chain segments, thus yielding a comprehensive picture of the state of the membrane as a function of the concentration of inclusions.", [["membrane", "ANATOMY", 465, 473], ["membrane", "CELLULAR_COMPONENT", 465, 473], ["chain segments", "PROTEIN", 391, 405], ["wide-angle X-ray scattering (WAXS)", "TREATMENT", 41, 75], ["nuclear magnetic resonance", "TEST", 315, 341], ["inclusions", "PROBLEM", 512, 522], ["inclusions", "OBSERVATION", 512, 522]]], ["We study GramA inserted within bilayers composed of lipids with phosphocholine heads and saturated lipid chains: 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or of single-chain surfactants with zwitterionic or nonionic head groups: dodecyl dimethyl amine oxide (DDAO) and tetraethyleneglycol monododecyl ether (C 12 EO 4 ), respectively, the hydrophobic length of DLPC (20.8\u00c5) [5] DDAO (18.4\u00c5) [6] and C 12 EO 4 (18.8\u00c5) [7] is shorter than that of GramA (22\u00c5) [9] , while DMPC (25.3\u00c5) [5] is longer.", [["GramA", "CHEMICAL", 9, 14], ["phosphocholine", "CHEMICAL", 64, 78], ["1,2-dilauroyl-sn-glycero-3-phosphocholine", "CHEMICAL", 113, 154], ["DLPC", "CHEMICAL", 156, 160], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 166, 209], ["DMPC", "CHEMICAL", 211, 215], ["dodecyl dimethyl amine oxide", "CHEMICAL", 291, 319], ["DDAO", "CHEMICAL", 321, 325], ["tetraethyleneglycol monododecyl ether", "CHEMICAL", 331, 368], ["C 12 EO 4", "CHEMICAL", 370, 379], ["DLPC", "CHEMICAL", 423, 427], ["DMPC", "CHEMICAL", 531, 535], ["phosphocholine", "CHEMICAL", 64, 78], ["1,2-dilauroyl-sn-glycero-3-phosphocholine", "CHEMICAL", 113, 154], ["DLPC", "CHEMICAL", 156, 160], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 166, 209], ["DMPC", "CHEMICAL", 211, 215], ["dodecyl dimethyl amine oxide", "CHEMICAL", 291, 319], ["DDAO", "CHEMICAL", 321, 325], ["tetraethyleneglycol monododecyl ether", "CHEMICAL", 331, 368], ["C 12 EO 4", "CHEMICAL", 370, 379], ["DLPC", "CHEMICAL", 423, 427], ["[5] DDAO", "CHEMICAL", 436, 444], ["GramA", "CHEMICAL", 507, 512], ["DMPC", "CHEMICAL", 531, 535], ["GramA", "SIMPLE_CHEMICAL", 9, 14], ["lipids", "SIMPLE_CHEMICAL", 52, 58], ["phosphocholine heads", "SIMPLE_CHEMICAL", 64, 84], ["saturated lipid chains", "SIMPLE_CHEMICAL", 89, 111], ["1,2-dilauroyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 113, 154], ["DLPC", "SIMPLE_CHEMICAL", 156, 160], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 166, 209], ["DMPC", "SIMPLE_CHEMICAL", 211, 215], ["single-chain surfactants", "SIMPLE_CHEMICAL", 223, 247], ["zwitterionic", "SIMPLE_CHEMICAL", 253, 265], ["nonionic head groups", "SIMPLE_CHEMICAL", 269, 289], ["dodecyl dimethyl amine oxide", "SIMPLE_CHEMICAL", 291, 319], ["DDAO", "SIMPLE_CHEMICAL", 321, 325], ["tetraethyleneglycol monododecyl ether", "SIMPLE_CHEMICAL", 331, 368], ["C 12 EO 4", "SIMPLE_CHEMICAL", 370, 379], ["DLPC", "SIMPLE_CHEMICAL", 423, 427], ["C 12 EO 4", "SIMPLE_CHEMICAL", 461, 470], ["DMPC", "SIMPLE_CHEMICAL", 531, 535], ["GramA", "PROTEIN", 9, 14], ["lipids with phosphocholine heads", "TREATMENT", 52, 84], ["saturated lipid chains", "TREATMENT", 89, 111], ["dilauroyl", "TREATMENT", 117, 126], ["glycero", "TREATMENT", 130, 137], ["phosphocholine (DLPC)", "TREATMENT", 140, 161], ["dimyristoyl", "TREATMENT", 170, 181], ["glycero", "TREATMENT", 185, 192], ["phosphocholine (DMPC)", "TREATMENT", 195, 216], ["single-chain surfactants", "TREATMENT", 223, 247], ["zwitterionic or nonionic head groups", "TREATMENT", 253, 289], ["dodecyl dimethyl amine oxide (DDAO)", "TREATMENT", 291, 326], ["tetraethyleneglycol monododecyl ether", "TREATMENT", 331, 368], ["DLPC", "TEST", 423, 427], ["DDAO", "TEST", 440, 444], ["C 12 EO", "TEST", 461, 468], ["GramA", "TEST", 507, 512], ["DMPC", "TEST", 531, 535]]], ["Since all these molecules form bilayers, and their hydrophobic length is close to that of GramA, the latter is expected to adopt the native helical dimer configuration described by Ketchem et al. [10] , and not the intertwined double helices observed in methanol [11] or in SDS micelles [12] .IntroductionAs for many molecules containing hydrocarbon chains, the WAXS signal of lipid bilayers exhibits a distinctive peak with position q 0 \u223c 14 nm \u22121 , indicative of the packing of these chains in the core of the membrane.", [["membrane", "ANATOMY", 512, 520], ["methanol [11]", "CHEMICAL", 254, 267], ["methanol", "CHEMICAL", 254, 262], ["hydrocarbon", "CHEMICAL", 338, 349], ["GramA", "GENE_OR_GENE_PRODUCT", 90, 95], ["methanol [11]", "SIMPLE_CHEMICAL", 254, 267], ["SDS micelles [12]", "SIMPLE_CHEMICAL", 274, 291], ["membrane", "CELLULAR_COMPONENT", 512, 520], ["GramA", "PROTEIN", 90, 95], ["hydrocarbon chains", "PROTEIN", 338, 356], ["WAXS", "PROTEIN", 362, 366], ["the intertwined double helices", "TREATMENT", 211, 241], ["many molecules containing hydrocarbon chains", "PROBLEM", 312, 356], ["the WAXS signal of lipid bilayers", "TEST", 358, 391], ["hydrophobic length", "OBSERVATION_MODIFIER", 51, 69], ["helical dimer", "OBSERVATION_MODIFIER", 140, 153], ["hydrocarbon chains", "OBSERVATION", 338, 356], ["lipid bilayers", "OBSERVATION", 377, 391], ["distinctive", "OBSERVATION_MODIFIER", 403, 414], ["peak", "OBSERVATION_MODIFIER", 415, 419], ["packing", "OBSERVATION", 469, 476], ["chains", "ANATOMY_MODIFIER", 486, 492], ["core", "ANATOMY_MODIFIER", 500, 504], ["membrane", "ANATOMY_MODIFIER", 512, 520]]], ["Although a full description of the scattered intensity would require an involved model based on liquid state theory [13] , the width of the peak provides a quantitative measurement for the positional order of the lipid chains: the longer the range of order, the narrower the peak.IntroductionThe effect of peptide inclusions on the chain peak has been studied for decades [14] .", [["the scattered intensity", "PROBLEM", 31, 54], ["peptide inclusions", "PROBLEM", 306, 324], ["scattered", "OBSERVATION_MODIFIER", 35, 44], ["narrower", "OBSERVATION_MODIFIER", 262, 270], ["peak", "OBSERVATION_MODIFIER", 275, 279]]], ["Systematic investigations have shown that some AMPs (e.g., magainin) have a very strong disrupting effect on the local order of the chains: the chain signal disappears almost completely for a modest concentration of inclusions [15] [16] [17] .", [["magainin", "CHEMICAL", 59, 67], ["magainin", "CHEMICAL", 59, 67], ["AMPs", "GENE_OR_GENE_PRODUCT", 47, 51], ["magainin", "SIMPLE_CHEMICAL", 59, 67], ["Systematic investigations", "TEST", 0, 25], ["some AMPs (e.g., magainin)", "PROBLEM", 42, 68]]], ["With other peptides, the changes in peak position and width are more subtle [18] and can even lead to a sharper chain peak (as for the SARS coronavirus E protein [19] ).IntroductionTo our knowledge, however, no WAXS studies of the effect of GramA on the chain signal have been published.IntroductionNMR can probe global and local order parameters in various lipid phases and along the lipid chain.", [["GramA", "CHEMICAL", 241, 246], ["GramA", "GENE_OR_GENE_PRODUCT", 241, 246], ["SARS coronavirus E protein", "PROTEIN", 135, 161], ["GramA", "PROTEIN", 241, 246], ["SARS coronavirus", "SPECIES", 135, 151], ["other peptides", "TREATMENT", 5, 19], ["the changes in peak position and width", "PROBLEM", 21, 59], ["a sharper chain peak", "TEST", 102, 122], ["the SARS coronavirus E protein", "TEST", 131, 161], ["WAXS studies", "TEST", 211, 223], ["the chain signal", "TEST", 250, 266], ["various lipid phases", "TEST", 350, 370], ["peptides", "OBSERVATION", 11, 19], ["peak", "OBSERVATION_MODIFIER", 36, 40], ["position", "OBSERVATION_MODIFIER", 41, 49], ["width", "OBSERVATION_MODIFIER", 54, 59], ["more subtle", "OBSERVATION_MODIFIER", 64, 75], ["lipid chain", "OBSERVATION", 385, 396]]], ["Deuterium ( 2 H) NMR has been the method of choice since the 1970s and has proven very successful until today [20] [21] [22] [23] .", [["Deuterium", "CHEMICAL", 0, 9], ["2 H", "CHEMICAL", 12, 15], ["Deuterium ( 2 H)", "CHEMICAL", 0, 16], ["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 110, 129], ["NMR", "TEST", 17, 20]]], ["The effect of GramA on the order parameter of the lipid (or surfactant) chains has already been studied by deuterium ( 2 H) NMR in membranes composed of DMPC [21, [24] [25] [26] , DLPC [26] and DDAO [6] , but not necessarily at the same temperature, concentration or lipid position as studied here.IntroductionHere, we use a novel application of solid-state NMR under magic-angle spinning (MAS) and dipolar recoupling, called the Dipolar Recoupling On-Axis with Scaling and Shape Preservation (DROSS) [27] .", [["membranes", "ANATOMY", 131, 140], ["GramA", "CHEMICAL", 14, 19], ["H", "CHEMICAL", 121, 122], ["DMPC [21, [24] [25] [26] , DLPC [26]", "CHEMICAL", 153, 189], ["GramA", "CHEMICAL", 14, 19], ["deuterium ( 2 H)", "CHEMICAL", 107, 123], ["DMPC", "CHEMICAL", 153, 157], ["DLPC", "CHEMICAL", 180, 184], ["DDAO", "CHEMICAL", 194, 198], ["GramA", "SIMPLE_CHEMICAL", 14, 19], ["lipid", "SIMPLE_CHEMICAL", 50, 55], ["membranes", "CELLULAR_COMPONENT", 131, 140], ["DMPC [21, [24] [25] [26]", "SIMPLE_CHEMICAL", 153, 177], ["DLPC [26]", "SIMPLE_CHEMICAL", 180, 189], ["DDAO [6]", "SIMPLE_CHEMICAL", 194, 202], ["GramA", "PROTEIN", 14, 19], ["GramA", "TREATMENT", 14, 19], ["the lipid (or surfactant) chains", "TREATMENT", 46, 78], ["NMR in membranes", "TEST", 124, 140], ["DMPC", "TEST", 153, 157], ["DLPC", "TEST", 180, 184], ["DDAO", "TEST", 194, 198], ["a novel application of solid", "TREATMENT", 323, 351], ["magic-angle spinning", "TREATMENT", 368, 388], ["dipolar recoupling", "TREATMENT", 399, 417]]], ["It provides similar information as 2 H NMR, by recording simultaneously the isotropic 13 C chemical shifts (at natural abundance) and the 13 C-1 H dipolar couplings at each carbon position along the lipid or surfactant chain and head group regions.", [["head", "ANATOMY", 229, 233], ["H", "CHEMICAL", 37, 38], ["C", "CHEMICAL", 89, 90], ["C-1 H", "CHEMICAL", 141, 146], ["carbon", "CHEMICAL", 173, 179], ["lipid", "SIMPLE_CHEMICAL", 199, 204], ["head group regions", "PROTEIN", 229, 247], ["1 H dipolar couplings at each carbon position", "TREATMENT", 143, 188], ["the lipid or surfactant chain and head group regions", "TREATMENT", 195, 247], ["surfactant chain", "OBSERVATION", 208, 224], ["head", "ANATOMY", 229, 233]]], ["The (absolute value of the) 13 C-1 H orientation order parameter S CH = 3 cos 2 \u03b8 \u2212 1 /2, with \u03b8 the angle between the internuclear vector and the motional axis, is extracted from those dipolar couplings, and the variation of order profiles with temperature or cholesterol content has already been probed, with lipids that were difficult to deuterate [28, 29] .", [["cholesterol", "CHEMICAL", 261, 272], ["C-1 H", "CHEMICAL", 31, 36], ["cholesterol", "CHEMICAL", 261, 272], ["cholesterol", "SIMPLE_CHEMICAL", 261, 272], ["lipids", "SIMPLE_CHEMICAL", 311, 317], ["C", "TEST", 31, 32], ["S CH", "TEST", 65, 69], ["cos", "TEST", 74, 77], ["those dipolar couplings", "TREATMENT", 180, 203], ["temperature or cholesterol content", "PROBLEM", 246, 280], ["lipids", "TREATMENT", 311, 317], ["angle", "ANATOMY_MODIFIER", 101, 106], ["internuclear vector", "ANATOMY", 119, 138], ["motional axis", "OBSERVATION", 147, 160], ["dipolar couplings", "OBSERVATION", 186, 203]]], ["Using the same approach, we monitor the lipid or surfactant order profile when membranes are doped with different concentrations of gramicidin.IntroductionThe main advantages of 13 C over 2 H are: the possibility to study natural lipids, with no isotopic labeling, and the high spectral resolution provided by 13 C-NMR, allowing the observation of all carbons along the lipid in a single 2D experiment.", [["membranes", "ANATOMY", 79, 88], ["gramicidin", "CHEMICAL", 132, 142], ["C", "CHEMICAL", 313, 314], ["carbons", "CHEMICAL", 352, 359], ["lipid", "SIMPLE_CHEMICAL", 40, 45], ["surfactant", "SIMPLE_CHEMICAL", 49, 59], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["gramicidin", "SIMPLE_CHEMICAL", 132, 142], ["lipids", "SIMPLE_CHEMICAL", 230, 236], ["lipid", "SIMPLE_CHEMICAL", 370, 375], ["gramicidin", "TREATMENT", 132, 142], ["isotopic labeling", "TEST", 246, 263], ["all carbons", "TREATMENT", 348, 359], ["main", "OBSERVATION_MODIFIER", 159, 163]]], ["Segmental order parameters are deduced, via a simple equation, from the doublet splittings in the second dimension of the 2D spectra.", [["Segmental order parameters", "TEST", 0, 26], ["a simple equation", "TEST", 44, 61], ["the doublet splittings", "TREATMENT", 68, 90], ["doublet splittings", "OBSERVATION", 72, 90]]], ["The data treatment is simple for nonspecialists and the sample preparation is very easy since there is no need for isotopic enrichment.", [["the sample preparation", "TREATMENT", 52, 74], ["isotopic enrichment", "TREATMENT", 115, 134], ["no need for", "UNCERTAINTY", 103, 114], ["isotopic enrichment", "OBSERVATION", 115, 134]]], ["All these facts make this technique ideal to probe and study new molecules and to be able to compare the results with the ones obtained with other similar particles.IntroductionThe downsides are the reduced precision in the measurement and the impossibility to extract data from lipids in the gel phase.", [["lipids", "SIMPLE_CHEMICAL", 279, 285], ["this technique", "TREATMENT", 21, 35], ["lipids in the gel phase", "TEST", 279, 302], ["reduced", "OBSERVATION_MODIFIER", 199, 206]]], ["In particular, carbons at the interfacial region of the lipids (at the glycerol backbone and at the top of the acyl chains) are less sensitive to changes in membrane rigidity, and while subtle changes can be detected with 2 H-NMR, they are difficult to interpret with 13 C-NMR at these positions.", [["membrane", "ANATOMY", 157, 165], ["glycerol", "CHEMICAL", 71, 79], ["rigidity", "DISEASE", 166, 174], ["carbons", "CHEMICAL", 15, 22], ["glycerol", "CHEMICAL", 71, 79], ["acyl", "CHEMICAL", 111, 115], ["H", "CHEMICAL", 224, 225], ["C", "CHEMICAL", 271, 272], ["carbons", "SIMPLE_CHEMICAL", 15, 22], ["lipids", "SIMPLE_CHEMICAL", 56, 62], ["glycerol", "SIMPLE_CHEMICAL", 71, 79], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["carbons", "TREATMENT", 15, 22], ["the glycerol backbone", "TREATMENT", 67, 88], ["changes in membrane rigidity", "PROBLEM", 146, 174], ["interfacial", "ANATOMY_MODIFIER", 30, 41], ["lipids", "ANATOMY", 56, 62], ["acyl chains", "ANATOMY", 111, 122], ["membrane rigidity", "OBSERVATION", 157, 174]]], ["Furthermore, the inefficiency of the DROSS method in the gel phase would theoretically allow measuring the lipid order in fluid phases coexisting with gel phases and quantifying the amount of lipids in each phase.", [["lipids", "SIMPLE_CHEMICAL", 192, 198], ["the DROSS method in the gel phase", "TREATMENT", 33, 66], ["the lipid order in fluid phases", "TEST", 103, 134], ["gel phases", "TEST", 151, 161]]], ["In our measurements, lipids in the gel phase were not abundant enough to be detected.Sample preparationThe samples were prepared from stock solutions of lipid or surfactant and, respectively, Gram A in isopropanol.", [["samples", "ANATOMY", 107, 114], ["isopropanol", "CHEMICAL", 202, 213], ["isopropanol", "CHEMICAL", 202, 213], ["lipids", "SIMPLE_CHEMICAL", 21, 27], ["lipid", "SIMPLE_CHEMICAL", 153, 158], ["surfactant", "SIMPLE_CHEMICAL", 162, 172], ["Gram A", "SIMPLE_CHEMICAL", 192, 198], ["isopropanol", "SIMPLE_CHEMICAL", 202, 213], ["lipids", "TREATMENT", 21, 27], ["Sample preparation", "TREATMENT", 85, 103], ["lipid or surfactant", "TREATMENT", 153, 172]]], ["We mix the two solutions at the desired concentration and briefly stir the vials using a tabletop vortexer.", [["a tabletop vortexer", "TREATMENT", 87, 106]]], ["The resulting solutions are then left to dry under vacuum at room temperature until all the solvent evaporates, as verified by repeated weighing.", [["The resulting solutions", "TREATMENT", 0, 23]]], ["The absence of residual isopropanol was cheked by 1 H NMR.Sample preparationWe then add the desired amount of water and mix the sample thoroughly using the vortexer and then by centrifuging the vials back and forth.", [["isopropanol", "CHEMICAL", 24, 35], ["isopropanol", "CHEMICAL", 24, 35], ["1 H", "CHEMICAL", 50, 53], ["isopropanol", "SIMPLE_CHEMICAL", 24, 35], ["residual isopropanol", "PROBLEM", 15, 35], ["the vortexer", "TREATMENT", 152, 164]]], ["Phases containing DMPC and DLPC were prepared at full hydration (in contact with excess water).", [["DMPC", "CHEMICAL", 18, 22], ["DLPC", "CHEMICAL", 27, 31], ["DMPC", "CHEMICAL", 18, 22], ["DLPC", "CHEMICAL", 27, 31], ["DMPC", "SIMPLE_CHEMICAL", 18, 22], ["DLPC", "SIMPLE_CHEMICAL", 27, 31], ["DMPC", "TREATMENT", 18, 22], ["DLPC", "TREATMENT", 27, 31], ["DMPC", "OBSERVATION_MODIFIER", 18, 22]]], ["C 12 EO 4 systems contained between 47 and 50 vol.% D 2 O (for NMR) and between 46 and 47 vol.% H 2 O (for WAXS).", [["H 2 O", "CHEMICAL", 96, 101], ["D 2 O", "SIMPLE_CHEMICAL", 52, 57], ["H 2 O", "SIMPLE_CHEMICAL", 96, 101], ["C 12 EO 4 systems", "TEST", 0, 17], ["NMR", "TEST", 63, 66], ["vol", "TEST", 90, 93], ["WAXS", "TEST", 107, 111]]], ["DDAO systems contained between 17 and 18 vol.% D 2 O (for NMR) and between 18 and 25 vol.% H 2 O (for WAXS with and without cholesterol).", [["cholesterol", "CHEMICAL", 124, 135], ["H 2 O", "CHEMICAL", 91, 96], ["cholesterol", "CHEMICAL", 124, 135], ["DDAO", "SIMPLE_CHEMICAL", 0, 4], ["D 2 O", "SIMPLE_CHEMICAL", 47, 52], ["H 2 O", "SIMPLE_CHEMICAL", 91, 96], ["cholesterol", "SIMPLE_CHEMICAL", 124, 135], ["DDAO systems", "TEST", 0, 12], ["NMR", "TEST", 58, 61], ["WAXS", "TEST", 102, 106]]], ["The GramA concentration is quantified by the molar ratio P/L (peptide to lipid or surfactant) to be consistent with the literature.", [["GramA", "CHEMICAL", 4, 9], ["GramA", "CHEMICAL", 4, 9], ["GramA", "SIMPLE_CHEMICAL", 4, 9], ["lipid", "SIMPLE_CHEMICAL", 73, 78], ["surfactant", "SIMPLE_CHEMICAL", 82, 92], ["The GramA concentration", "TREATMENT", 0, 23], ["the molar ratio P/L (peptide to lipid or surfactant", "TREATMENT", 41, 92]]], ["Note, however, that a same P/L corresponds to twice as many inclusions per chain in membranes composed of single-chain surfactants than in lipid bilayers.Sample preparationFor WAXS, we used a microspatula to deposit small amounts of sample in the opening of a glass X-ray capillary (WJM-Glas M\u00fcller GmbH, Berlin), 1.5 or 2 mm in diameter and we centrifuged the capillary until the sample moved to the bottom.", [["membranes", "ANATOMY", 84, 93], ["lipid bilayers", "ANATOMY", 139, 153], ["sample", "ANATOMY", 233, 239], ["capillary", "ANATOMY", 361, 370], ["sample", "ANATOMY", 381, 387], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["single-chain surfactants", "SIMPLE_CHEMICAL", 106, 130], ["lipid bilayers", "SIMPLE_CHEMICAL", 139, 153], ["capillary", "TISSUE", 361, 370], ["P/L", "DNA", 27, 30], ["many inclusions per chain in membranes", "PROBLEM", 55, 93], ["single-chain surfactants", "TREATMENT", 106, 130], ["WAXS", "TEST", 176, 180], ["a microspatula", "TREATMENT", 190, 204], ["inclusions", "OBSERVATION", 60, 70], ["small", "OBSERVATION_MODIFIER", 216, 221], ["amounts", "OBSERVATION_MODIFIER", 222, 229], ["bottom", "ANATOMY_MODIFIER", 401, 407]]], ["We repeated the process until reaching a sample height of about 1.5 cm.", [["a sample height", "TEST", 39, 54], ["about 1.5 cm", "OBSERVATION_MODIFIER", 58, 70]]], ["The capillary was then either flame-sealed or closed using a glue gun.", [["capillary", "ANATOMY", 4, 13], ["capillary", "TISSUE", 4, 13], ["a glue gun", "TEST", 59, 69], ["capillary", "ANATOMY", 4, 13], ["glue gun", "OBSERVATION", 61, 69]]], ["For NMR, approximately 100 mg of GramA/lipid or GramA/surfactant dispersion in deuterated water were introduced in a 4 mm diameter rotor for solid-state NMR.NMRNMR experiments with DMPC, DLPC and C 12 EO 4 were performed with a Bruker AVANCE 400 WB NMR spectrometer ( 1 H resonance at 400 MHz, 13 C resonance at 100 MHz) using a Bruker 4 mm MAS probe.", [["GramA", "CHEMICAL", 33, 38], ["GramA", "CHEMICAL", 48, 53], ["DMPC", "CHEMICAL", 181, 185], ["DMPC", "CHEMICAL", 181, 185], ["GramA", "SIMPLE_CHEMICAL", 33, 38], ["GramA", "SIMPLE_CHEMICAL", 48, 53], ["water", "SIMPLE_CHEMICAL", 90, 95], ["DMPC", "SIMPLE_CHEMICAL", 181, 185], ["NMR", "TEST", 4, 7], ["GramA/lipid", "TREATMENT", 33, 44], ["GramA/surfactant dispersion in deuterated water", "TREATMENT", 48, 95], ["a 4 mm diameter rotor", "TREATMENT", 115, 136], ["DMPC", "PROBLEM", 181, 185], ["DLPC", "TEST", 187, 191], ["a Bruker AVANCE", "TEST", 226, 241], ["NMR spectrometer", "TEST", 249, 265], ["a Bruker 4 mm MAS probe", "TREATMENT", 327, 350]]], ["NMR experiments with DDAO were performed with a Bruker AVANCE 300 WB NMR spectrometer ( 1 H resonance at 300 MHz, 13 C resonance at 75 MHz) using a Bruker 4 mm MAS probe.", [["DDAO", "CHEMICAL", 21, 25], ["DDAO", "SIMPLE_CHEMICAL", 21, 25], ["NMR experiments", "TEST", 0, 15], ["a Bruker AVANCE", "TEST", 46, 61], ["NMR spectrometer", "TEST", 69, 85], ["a Bruker 4 mm MAS probe", "TREATMENT", 146, 169]]], ["All experiments were performed at 30 \u2022 C.NMRThe DROSS pulse sequence [27] with a scaling factor \u03c7 = 0.393 was used with carefully set pulse lengths and refocused insensitive nuclei enhanced by polarization transfer (RINEPT) with delays set to 1/8 J and 1/4 J and a J value of 125 Hz.", [["nuclei", "ANATOMY", 174, 180], ["DROSS pulse sequence", "TEST", 48, 68], ["a scaling factor \u03c7", "TEST", 79, 97], ["a J value", "TEST", 263, 272]]], ["The spinning rate was set at 5 kHz, typical pulse lengths were 13 C (90 \u2022 ) = 3 \u03bcs, 1 H (90 \u2022 ) = 2.5 \u03bcs and 1 H two-pulse phase-modulation (TPPM) decoupling was performed at 50 kHz with a phase-modulation angle of 15 \u2022 .NMR1D spectra were acquired using the simple 13 C-RINEPT sequence with the same parameters.", [["13 C-RINEPT sequence", "DNA", 266, 286], ["The spinning rate", "TEST", 0, 17], ["typical pulse lengths", "TEST", 36, 57], ["\u03bcs", "TEST", 102, 104], ["a phase-modulation angle", "TEST", 187, 211], ["the simple 13 C-RINEPT sequence", "TREATMENT", 255, 286]]], ["For the 2D spectra, 64 free induction decays were acquired, with 64 to 512 scans summed, a recycle delay of 3 s, a spectral width of 32 kHz and 8000 complex points.", [["a recycle delay", "TEST", 89, 104], ["a spectral width", "TEST", 113, 129]]], ["The total acquisition time was between 2 and 14 h.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The data were treated using the Bruker TopSpin 3.2 software.NMRResonance assignments followed that of previously published data [22, 24, 27, 30, 31] , using the C \u03c9\u2212n convention, where n is the total number of segments, decreasing from the terminal methyl segment, C \u03c9 , to the upper carbonyl segment C 1 .", [["methyl", "CHEMICAL", 249, 255], ["methyl", "CHEMICAL", 249, 255], ["C", "CHEMICAL", 265, 266], ["carbonyl", "CHEMICAL", 284, 292], ["C \u03c9", "SIMPLE_CHEMICAL", 265, 268], ["terminal methyl segment", "PROTEIN", 240, 263], ["C \u03c9", "PROTEIN", 265, 268], ["upper carbonyl segment C 1", "PROTEIN", 278, 304], ["the Bruker TopSpin", "TREATMENT", 28, 46], ["the C \u03c9\u2212n convention", "TREATMENT", 157, 177], ["total", "OBSERVATION_MODIFIER", 194, 199], ["segments", "ANATOMY_MODIFIER", 210, 218], ["decreasing", "OBSERVATION_MODIFIER", 220, 230], ["terminal", "ANATOMY_MODIFIER", 240, 248], ["methyl", "ANATOMY_MODIFIER", 249, 255], ["segment", "ANATOMY_MODIFIER", 256, 263], ["upper", "ANATOMY_MODIFIER", 278, 283], ["carbonyl segment", "ANATOMY_MODIFIER", 284, 300]]], ["This representation permits a segmentby-segment comparison of the chain regions.", [["chain regions", "PROTEIN", 66, 79], ["segment", "ANATOMY_MODIFIER", 40, 47], ["chain", "ANATOMY_MODIFIER", 66, 71], ["regions", "ANATOMY_MODIFIER", 72, 79]]], ["Backbone regions are assigned according to the stereospecific nomenclature (sn) convention for the glycerol moiety.", [["glycerol", "CHEMICAL", 99, 107], ["glycerol", "CHEMICAL", 99, 107], ["glycerol moiety", "SIMPLE_CHEMICAL", 99, 114], ["the glycerol moiety", "TREATMENT", 95, 114]]], ["Phosphocholine head group carbons are given Greek (\u03b1, \u03b2, \u03b3) letter designations.", [["Phosphocholine", "CHEMICAL", 0, 14], ["Phosphocholine", "CHEMICAL", 0, 14], ["carbons", "CHEMICAL", 26, 33], ["Phosphocholine head group carbons", "SIMPLE_CHEMICAL", 0, 33], ["Phosphocholine head group carbons", "TREATMENT", 0, 33]]], ["The internal reference was chosen to be the acyl chain terminal 13 CH 3 resonance assigned to 14 ppm for all lipids and surfactants studied here.NMROrder parameters were extracted from the 2D DROSS spectra by measuring the dipolar splittings of the Pake doublet at each carbon site.", [["acyl", "CHEMICAL", 44, 48], ["CH", "CHEMICAL", 67, 69], ["carbon", "CHEMICAL", 270, 276], ["Pake doublet", "PROTEIN", 249, 261], ["all lipids", "TREATMENT", 105, 115], ["surfactants", "TREATMENT", 120, 131], ["the 2D DROSS spectra", "TREATMENT", 185, 205], ["the dipolar splittings", "TREATMENT", 219, 241], ["the Pake doublet at each carbon site", "TREATMENT", 245, 281], ["dipolar splittings", "OBSERVATION", 223, 241], ["carbon site", "OBSERVATION", 270, 281]]], ["This splitting was converted into a dipolar coupling by taking the scaling factor \u03c7 into account.", [["scaling factor \u03c7", "PROTEIN", 67, 83], ["a dipolar coupling", "TREATMENT", 34, 52]]], ["The absolute value of the segmental order parameter is an additional \"scaling factor\" \u03c7 of the static dipolar coupling into the measured dipolar coupling.", [["the static dipolar coupling", "TREATMENT", 91, 118], ["the measured dipolar coupling", "PROBLEM", 124, 153], ["absolute", "OBSERVATION_MODIFIER", 4, 12], ["segmental", "ANATOMY_MODIFIER", 26, 35], ["dipolar coupling", "OBSERVATION", 137, 153]]], ["Since the static dipolar coupling, on the order of 20 kHz, is not known with high precision for each carbon, we have adjusted it empirically in the case of DMPC, by comparing it to previously determined values [22, 27, 30 ].WAXSWe recorded the scattered intensity I as a function of the scattering vector q = 4\u03c0 \u03bb sin(\u03b8), where \u03bb is the X-ray wavelength and 2\u03b8 is the angle between the incident and the scattered beams.WAXSLipids.", [["DMPC", "CHEMICAL", 156, 160], ["carbon", "CHEMICAL", 101, 107], ["DMPC", "CHEMICAL", 156, 160], ["carbon", "SIMPLE_CHEMICAL", 101, 107], ["DMPC", "SIMPLE_CHEMICAL", 156, 160], ["\u03bb", "PROTEIN", 328, 329], ["X", "PROTEIN", 337, 338], ["WAXSLipids", "TREATMENT", 419, 429], ["scattered", "OBSERVATION_MODIFIER", 244, 253], ["intensity", "OBSERVATION_MODIFIER", 254, 263], ["scattered", "OBSERVATION_MODIFIER", 403, 412], ["beams", "OBSERVATION_MODIFIER", 413, 418]]], ["X-ray scattering measurements on the GramA/ DLPC and GramA/DMPC systems were performed at the ID02 beamline (ESRF, Grenoble), in a SAXS+WAXS configuration, at an X-ray energy of 12.4 keV (\u03bb = 1\u00c5).", [["GramA/DMPC", "SIMPLE_CHEMICAL", 53, 63], ["GramA", "PROTEIN", 53, 58], ["X-ray scattering measurements", "TEST", 0, 29], ["the GramA/ DLPC", "TEST", 33, 48], ["GramA/DMPC systems", "TEST", 53, 71], ["a SAXS", "TEST", 129, 135], ["an X-ray energy", "TEST", 159, 174], ["DLPC", "ANATOMY", 44, 48], ["WAXS configuration", "OBSERVATION", 136, 154]]], ["The WAXS range was from 5 to 53 nm \u22121 .", [["The WAXS range", "TEST", 0, 14]]], ["We recorded the integrated intensity I(q) and subtracted the scattering signal of an empty capillary, as well as that of a water sample (weighted by the water volume fraction in the lipid samples).", [["capillary", "ANATOMY", 91, 100], ["lipid samples", "ANATOMY", 182, 195], ["capillary", "TISSUE", 91, 100], ["I(q)", "PROTEIN", 37, 41], ["a water sample", "TREATMENT", 121, 135], ["the water volume fraction", "TEST", 149, 174], ["the lipid samples", "TEST", 178, 195], ["empty capillary", "OBSERVATION", 85, 100]]], ["We used nine peptide-to-lipid molar ratios P/L ranging from 0 to 1/5 and three temperature points: 20, 30 and 40 \u2022 C. The chain peak was fitted with a Lorentzian function:WAXSWe are mainly interested in the parameter \u03b3, the halfwidth at half-maximum (HWHM) of the peak.WAXSSurfactants.", [["WAXSSurfactants", "SIMPLE_CHEMICAL", 269, 284], ["nine peptide", "TEST", 8, 20], ["lipid molar ratios", "TEST", 24, 42], ["WAXSSurfactants", "TREATMENT", 269, 284]]], ["The GramA/DDAO and GramA/C 12 EO 4 systems were studied using an in-house setup using as source a molybdenum rotating anode [32] .", [["molybdenum", "CHEMICAL", 98, 108], ["molybdenum", "CHEMICAL", 98, 108], ["GramA", "GENE_OR_GENE_PRODUCT", 4, 9], ["The GramA/DDAO", "TEST", 0, 14], ["GramA/C 12 EO 4 systems", "TEST", 19, 42], ["a molybdenum rotating anode", "TREATMENT", 96, 123]]], ["The X-ray energy is 17.4 keV (\u03bb = 0.71\u00c5) and the sample-to-detector distance is 75 cm, yielding an accessible q-range of 0.3 to 30 nm \u22121 .", [["The X-ray energy", "TEST", 0, 16], ["the sample", "TEST", 45, 55], ["17.4 keV", "OBSERVATION_MODIFIER", 20, 28], ["75 cm", "OBSERVATION_MODIFIER", 80, 85]]], ["We used five peptide-to-surfactant molar ratios (also denoted by P/L) ranging from 0 to 1/5.5 and eight temperature points, from 0 to 60 \u2022 C. The best fit for the peak was obtained using a Gaussian function:WAXSFor coherence with the measurements on lipid systems, we present the results in terms of the HWHM \u03b3 = \u221a 2 ln 2 \u03c3.", [["five peptide", "TREATMENT", 8, 20], ["lipid systems", "TREATMENT", 250, 263], ["the HWHM", "TEST", 300, 308]]], ["We emphasize that the difference in peak shape (Lorentzian vs. Gaussian) is intrinsic to the systems (double-chain lipids vs. single-chain surfactants) and not due to the resolution of the experimental setups, which is much better than the typical HWHM values measured.NMRWe acquired twelve 2D spectra for various surfactants and GramA concentration.", [["GramA", "CHEMICAL", 330, 335], ["GramA", "CHEMICAL", 330, 335], ["HWHM", "SIMPLE_CHEMICAL", 248, 252], ["GramA", "SIMPLE_CHEMICAL", 330, 335], ["HWHM", "PROTEIN", 248, 252], ["the difference in peak shape", "PROBLEM", 18, 46], ["double-chain lipids", "TREATMENT", 102, 121], ["single-chain surfactants", "TREATMENT", 126, 150], ["the experimental setups", "PROBLEM", 185, 208], ["the typical HWHM values", "TEST", 236, 259], ["various surfactants", "TREATMENT", 306, 325], ["GramA concentration", "TREATMENT", 330, 349], ["peak shape", "OBSERVATION_MODIFIER", 36, 46], ["experimental setups", "OBSERVATION", 189, 208]]], ["Figure 1 shows the 2D DROSS NMR spectrum of C 12 EO 4 with a molar GramA concentration P/L = 0.118.NMRFor each 2D spectrum, slices were extracted at each carbon position and order parameters were deduced.", [["slices", "ANATOMY", 124, 130], ["GramA", "CHEMICAL", 67, 72], ["carbon", "CHEMICAL", 154, 160]]], ["Figure 2 shows a set of such representative slices (at the position C \u03c9\u22122 ).NMRAs already explained, carbons at the glycerol backbone and at the first two positions along the acyl chains were discarded.", [["slices", "ANATOMY", 44, 50], ["glycerol", "CHEMICAL", 116, 124], ["carbons", "CHEMICAL", 101, 108], ["glycerol", "CHEMICAL", 116, 124], ["acyl", "CHEMICAL", 175, 179], ["NMRAs", "SIMPLE_CHEMICAL", 76, 81], ["carbons", "SIMPLE_CHEMICAL", 101, 108], ["glycerol", "SIMPLE_CHEMICAL", 116, 124], ["carbons at the glycerol backbone", "TREATMENT", 101, 133], ["the acyl chains", "TREATMENT", 171, 186], ["acyl chains", "OBSERVATION", 175, 186]]], ["Figure 3 shows the order profiles determined for each lipid and surfactant, with variable amounts of GramA.NMRAs shown in fig. 3 , there is hardly any change for the head group region (C \u03b1 , C \u03b2 and C \u03b3 ), which is expected, considering the high mobility of this region, except in DDAO (CH 3 , C 2 and C 3 ).", [["head", "ANATOMY", 166, 170], ["GramA", "CHEMICAL", 101, 106], ["DDAO", "CHEMICAL", 281, 285], ["CH 3 , C 2 and C 3", "CHEMICAL", 287, 305], ["lipid", "SIMPLE_CHEMICAL", 54, 59], ["surfactant", "SIMPLE_CHEMICAL", 64, 74], ["GramA", "GENE_OR_GENE_PRODUCT", 101, 106], ["head", "ORGANISM_SUBDIVISION", 166, 170], ["C \u03b3", "SIMPLE_CHEMICAL", 199, 202], ["DDAO", "SIMPLE_CHEMICAL", 281, 285], ["GramA", "PROTEIN", 101, 106], ["head group region", "PROTEIN", 166, 183], ["C \u03b1", "PROTEIN", 185, 188], ["C \u03b2", "PROTEIN", 191, 194], ["C \u03b3", "PROTEIN", 199, 202], ["each lipid and surfactant", "TREATMENT", 49, 74], ["the head group region", "TEST", 162, 183], ["C", "TEST", 185, 186], ["\u03b1 , C \u03b2 and C \u03b3 )", "PROBLEM", 187, 204], ["the high mobility of this region", "PROBLEM", 237, 269], ["fig", "OBSERVATION", 122, 125], ["change", "OBSERVATION", 151, 157], ["head", "ANATOMY", 166, 170], ["high mobility", "OBSERVATION_MODIFIER", 241, 254]]], ["In the aliphatic region, in DMPC ( fig. 3(a) ), the order parameter increases for a ratio of P/L = 0.06 and then decreases for the P/L = 0.115.", [["DMPC", "CHEMICAL", 28, 32], ["DMPC", "SIMPLE_CHEMICAL", 28, 32], ["a ratio", "TEST", 82, 89], ["aliphatic", "ANATOMY_MODIFIER", 7, 16], ["region", "ANATOMY_MODIFIER", 17, 23], ["DMPC", "OBSERVATION_MODIFIER", 28, 32]]], ["In DLPC and C 12 EO 4 mixtures (figs.", [["DLPC", "ANATOMY", 3, 7], ["DLPC and C 12 EO 4 mixtures", "TREATMENT", 3, 30]]], ["3(b) and (c)), the order parameter slightly increases when adding the peptide compared to the pure lipids with no significant dependence on P/L, reaching almost the same values for both P/L = 0.053 and P/L = 0.112.", [["lipids", "SIMPLE_CHEMICAL", 99, 105], ["the peptide", "TREATMENT", 66, 77], ["the pure lipids", "TEST", 90, 105], ["significant dependence", "PROBLEM", 114, 136], ["no", "UNCERTAINTY", 111, 113], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["dependence", "OBSERVATION", 126, 136]]], ["For DDAO ( fig. 3(d) ) we observe a remarkable increase in the order parameter profile with increasing P/L all along the molecule but especially in the acyl chain region.NMROverall, we conclude that the order profiles significantly increase along the acyl chains with the concentration of gramicidin, except in the case of DMPC where the order profile globally increases with the addition of P/L = 0.05 of gramicidin and then decreases at P/L = 0.11.", [["DDAO", "CHEMICAL", 4, 8], ["acyl", "CHEMICAL", 251, 255], ["gramicidin", "CHEMICAL", 289, 299], ["DMPC", "CHEMICAL", 323, 327], ["gramicidin", "CHEMICAL", 406, 416], ["DDAO", "CHEMICAL", 4, 8], ["acyl", "CHEMICAL", 152, 156], ["acyl", "CHEMICAL", 251, 255], ["DMPC", "CHEMICAL", 323, 327], ["DDAO", "SIMPLE_CHEMICAL", 4, 8], ["gramicidin", "SIMPLE_CHEMICAL", 289, 299], ["DMPC", "SIMPLE_CHEMICAL", 323, 327], ["gramicidin", "SIMPLE_CHEMICAL", 406, 416], ["P", "PROTEIN", 103, 104], ["acyl chain region", "PROTEIN", 152, 169], ["DDAO", "PROBLEM", 4, 8], ["increasing P/L", "TREATMENT", 92, 106], ["the acyl chains", "TREATMENT", 247, 262], ["gramicidin", "TREATMENT", 289, 299], ["DMPC", "TREATMENT", 323, 327], ["P/L", "TREATMENT", 392, 395], ["gramicidin", "TREATMENT", 406, 416], ["remarkable", "OBSERVATION_MODIFIER", 36, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["acyl", "ANATOMY_MODIFIER", 152, 156], ["chain", "ANATOMY_MODIFIER", 157, 162]]], ["This peculiar effect was already qualitatively observed by Rice and Oldfield, at the \u03c9 position by 2 H NMR [24] , and by Cornell and Keniry, measuring the carbonyl CSA by 13 C NMR [33] .", [["carbonyl", "CHEMICAL", 155, 163], ["2 H", "CHEMICAL", 99, 102], ["carbonyl", "CHEMICAL", 155, 163], ["13 C", "CHEMICAL", 171, 175], ["carbonyl CSA", "SIMPLE_CHEMICAL", 155, 167], ["the carbonyl CSA", "TEST", 151, 167], ["NMR", "TEST", 176, 179]]], ["The increase is larger in DLPC than in DMPC, as already observed by De Planque by 2 H NMR with P/L = 0.03 gramicidin [26] .", [["DMPC", "CHEMICAL", 39, 43], ["gramicidin", "CHEMICAL", 106, 116], ["DMPC", "CHEMICAL", 39, 43], ["2 H", "CHEMICAL", 82, 85], ["DMPC", "SIMPLE_CHEMICAL", 39, 43], ["P/L", "TREATMENT", 95, 98], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["larger", "OBSERVATION_MODIFIER", 16, 22], ["DLPC", "OBSERVATION_MODIFIER", 26, 30]]], ["The increase is also significant in DDAO, as observed by Or\u00e4dd et al. by 2 H NMR [6] .", [["DDAO", "CHEMICAL", 36, 40], ["2 H", "CHEMICAL", 73, 76], ["DDAO", "SIMPLE_CHEMICAL", 36, 40], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["In the head group region, effects are generally smaller, within the error bar, except for DDAO where we show that gramicidin has the same effect as on the acyl chains.NMRConsequently, we show that gramicidin generally rigidifies the acyl chains of DLPC, C 12 EO 4 and DDAO, as well as the head group region of DDAO.", [["head", "ANATOMY", 7, 11], ["head", "ANATOMY", 289, 293], ["gramicidin", "CHEMICAL", 114, 124], ["gramicidin", "CHEMICAL", 197, 207], ["DLPC", "CHEMICAL", 248, 252], ["C 12 EO 4", "CHEMICAL", 254, 263], ["DDAO", "CHEMICAL", 268, 272], ["DDAO", "CHEMICAL", 310, 314], ["DDAO", "CHEMICAL", 90, 94], ["acyl", "CHEMICAL", 155, 159], ["acyl", "CHEMICAL", 233, 237], ["DLPC", "CHEMICAL", 248, 252], ["DDAO", "CHEMICAL", 268, 272], ["DDAO", "CHEMICAL", 310, 314], ["head", "ORGANISM_SUBDIVISION", 7, 11], ["gramicidin", "SIMPLE_CHEMICAL", 114, 124], ["gramicidin", "SIMPLE_CHEMICAL", 197, 207], ["DLPC", "SIMPLE_CHEMICAL", 248, 252], ["DDAO", "SIMPLE_CHEMICAL", 268, 272], ["DDAO", "SIMPLE_CHEMICAL", 310, 314], ["DDAO", "PROTEIN", 90, 94], ["DDAO", "PROTEIN", 268, 272], ["head group region", "PROTEIN", 289, 306], ["DDAO", "PROTEIN", 310, 314], ["gramicidin", "TREATMENT", 114, 124], ["the acyl chains", "TREATMENT", 151, 166], ["gramicidin", "TREATMENT", 197, 207], ["DDAO", "TREATMENT", 268, 272], ["head", "ANATOMY", 7, 11], ["generally", "OBSERVATION_MODIFIER", 38, 47], ["smaller", "OBSERVATION_MODIFIER", 48, 55], ["head", "ANATOMY", 289, 293]]], ["In the case of DMPC, gramicidin first rigidifies the acyl chains, but more peptides tend to return the membrane to its original fluidity.WAXSThe chain peak has long been used as a marker for the ordered or disordered state of the hydrocarbon chains within the bilayer [34] .", [["membrane", "ANATOMY", 103, 111], ["DMPC", "CHEMICAL", 15, 19], ["gramicidin", "CHEMICAL", 21, 31], ["DMPC", "CHEMICAL", 15, 19], ["acyl", "CHEMICAL", 53, 57], ["hydrocarbon", "CHEMICAL", 230, 241], ["DMPC", "SIMPLE_CHEMICAL", 15, 19], ["gramicidin", "SIMPLE_CHEMICAL", 21, 31], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["hydrocarbon chains", "PROTEIN", 230, 248], ["DMPC", "TREATMENT", 15, 19], ["gramicidin", "TREATMENT", 21, 31], ["the acyl chains", "TREATMENT", 49, 64], ["hydrocarbon chains", "OBSERVATION", 230, 248]]], ["For lipids, an important parameter is the main transition (or \"chain melting\") temperature, at which the chains go from a gel to a liquid crystalline (in short, \"liquid\") phase [35] .", [["lipids", "SIMPLE_CHEMICAL", 4, 10], ["lipids", "TREATMENT", 4, 10], ["a gel to a liquid crystalline (in short, \"liquid", "TREATMENT", 120, 168]]], ["The main transition temperature of pure DLPC is at about \u22121 \u2022 C [36] [37] [38] [39] and that of pure DMPC is between 23 \u2022 C and 24 \u2022 C [36] [37] [38] [39] [40] .WAXSFor the lipids, in the liquid phase the peak width increases slightly with P/L for all temperatures ( fig. 4 ).", [["DLPC", "CHEMICAL", 40, 44], ["DMPC", "CHEMICAL", 101, 105], ["DLPC", "CHEMICAL", 40, 44], ["DMPC", "CHEMICAL", 101, 105], ["DLPC", "SIMPLE_CHEMICAL", 40, 44], ["DMPC", "SIMPLE_CHEMICAL", 101, 105], ["23 \u2022 C", "SIMPLE_CHEMICAL", 117, 123], ["24 \u2022 C [36] [37] [38] [39] [40]", "SIMPLE_CHEMICAL", 128, 159], ["lipids", "SIMPLE_CHEMICAL", 173, 179], ["pure DLPC", "TEST", 35, 44], ["pure DMPC", "TEST", 96, 105], ["C", "TEST", 122, 123], ["the lipids", "TEST", 169, 179], ["all temperatures", "TEST", 248, 264], ["main", "OBSERVATION_MODIFIER", 4, 8], ["transition temperature", "OBSERVATION_MODIFIER", 9, 31], ["pure DLPC", "OBSERVATION", 35, 44], ["peak", "OBSERVATION_MODIFIER", 205, 209], ["width", "OBSERVATION_MODIFIER", 210, 215]]], ["In the gel phase of DMPC at 20 \u2022 C ( fig. 4 (right) and fig. 5 ) this disordering effect is very pronounced, in agreement with the results of several different techniques, reviewed in ref.", [["DMPC", "CHEMICAL", 20, 24], ["DMPC", "CHEMICAL", 20, 24], ["DMPC", "SIMPLE_CHEMICAL", 20, 24], ["DMPC", "TEST", 20, 24], ["right", "ANATOMY_MODIFIER", 45, 50]]], ["V-A).", [["V-A", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["The linear increase in HWHM with P/L can be interpreted as a broadening (rather than a shift) of the transition.", [["The linear increase in HWHM", "PROBLEM", 0, 27], ["P/L", "TREATMENT", 33, 36], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["broadening", "OBSERVATION_MODIFIER", 61, 71]]], ["The liquid crystalline phase value of the HWHM is reached only at the highest investigated P/L, amounting to one GramA molecule per 5 or six lipids.WAXSFor surfactants, which we only studied in the liquid crystalline phase, changes to the chain peak are slight.", [["HWHM", "CHEMICAL", 42, 46], ["WAXSFor surfactants", "CHEMICAL", 148, 167], ["GramA", "CHEMICAL", 113, 118], ["HWHM", "SIMPLE_CHEMICAL", 42, 46], ["WAXSFor", "SIMPLE_CHEMICAL", 148, 155], ["GramA molecule", "PROTEIN", 113, 127], ["The liquid crystalline phase value", "TEST", 0, 34], ["surfactants", "TREATMENT", 156, 167], ["the chain peak", "TEST", 235, 249], ["liquid crystalline", "OBSERVATION_MODIFIER", 4, 22], ["slight", "OBSERVATION_MODIFIER", 254, 260]]], ["In C 12 EO 4 membranes, the peak position q 0 decreases very slightly with temperature ( fig. 6 ), while the peak width is almost unchanged by temperature or gramicidin content ( fig. 7 (right) ).", [["EO 4 membranes", "ANATOMY", 8, 22], ["gramicidin", "CHEMICAL", 158, 168], ["gramicidin", "SIMPLE_CHEMICAL", 158, 168], ["the peak position", "TEST", 24, 41], ["temperature ( fig.", "TEST", 75, 93], ["the peak width", "TEST", 105, 119], ["gramicidin content", "TEST", 158, 176], ["12 EO 4 membranes", "OBSERVATION_MODIFIER", 5, 22], ["unchanged", "OBSERVATION_MODIFIER", 130, 139], ["right", "ANATOMY_MODIFIER", 187, 192]]], ["As an example, we observe a small decrease of q 0 with the temperature at P/L = 0.073 ( fig. 6 (left) ), as well as a very slight increase with P/L at 20 \u2022 C, as seen in fig. 6 (right) .", [["a small decrease", "PROBLEM", 26, 42], ["the temperature", "TEST", 55, 70], ["P/L", "TREATMENT", 144, 147], ["small", "OBSERVATION_MODIFIER", 28, 33], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["left", "ANATOMY_MODIFIER", 96, 100], ["very", "OBSERVATION_MODIFIER", 118, 122], ["slight", "OBSERVATION_MODIFIER", 123, 129], ["increase", "OBSERVATION_MODIFIER", 130, 138], ["right", "ANATOMY_MODIFIER", 178, 183]]], ["If we take the overall WAXS peak position shift as a function of temperature and for all inclusions concentration (data not shown) we have a small temperature dependence for each P/L. Comparing the value in absence of inclusion, the peak position slightly shifts after adding gramicidin at a P/L = 0.015 but remains almost the same for the different gramicidin content, showing no significant influence of the inclusions on the C 12 EO 4 membranes.", [["gramicidin", "CHEMICAL", 276, 286], ["gramicidin", "CHEMICAL", 350, 360], ["gramicidin", "SIMPLE_CHEMICAL", 276, 286], ["gramicidin", "SIMPLE_CHEMICAL", 350, 360], ["all inclusions concentration", "PROBLEM", 85, 113], ["a small temperature dependence", "PROBLEM", 139, 169], ["gramicidin", "TREATMENT", 276, 286], ["a P/L", "TREATMENT", 290, 295], ["the different gramicidin content", "TEST", 336, 368], ["the inclusions", "PROBLEM", 406, 420], ["small", "OBSERVATION_MODIFIER", 141, 146], ["no", "UNCERTAINTY", 378, 380], ["significant", "OBSERVATION_MODIFIER", 381, 392], ["influence", "OBSERVATION_MODIFIER", 393, 402], ["inclusions", "OBSERVATION", 410, 420]]], ["This conclusion is confirmed by the very modest change in the HWHM values presented in fig. 7 (right).", [["the very modest change", "PROBLEM", 32, 54], ["the HWHM values", "TEST", 58, 73], ["very", "OBSERVATION_MODIFIER", 36, 40], ["modest", "OBSERVATION_MODIFIER", 41, 47], ["change", "OBSERVATION", 48, 54], ["right", "ANATOMY_MODIFIER", 95, 100]]], ["At P/L = 0, the HWHM is very close to 2.6 nm \u22121 for all temperatures.", [["the HWHM", "TEST", 12, 20], ["all temperatures", "TEST", 52, 68]]], ["As the gramicidin content increases, we observe a small gap between the different temperatures: the width stays constant or increases for the lower temperatures (up to about 40 \u2022 C) and decreases for the higher ones.", [["gramicidin", "CHEMICAL", 7, 17], ["gramicidin", "SIMPLE_CHEMICAL", 7, 17], ["the gramicidin content", "TEST", 3, 25], ["a small gap", "PROBLEM", 48, 59], ["the lower temperatures", "PROBLEM", 138, 160], ["small", "OBSERVATION_MODIFIER", 50, 55], ["gap", "OBSERVATION_MODIFIER", 56, 59], ["width", "OBSERVATION_MODIFIER", 100, 105], ["increases", "OBSERVATION_MODIFIER", 124, 133], ["lower temperatures", "OBSERVATION_MODIFIER", 142, 160]]], ["This gap widens at high gramicidin content (P/L > 0.07).WAXSIn the case of DDAO, the influence of gramicidin content is more notable than for C 12 EO 4 and the behavior is richer, especially in the presence of cholesterol.WAXSWithout cholesterol, the DDAO WAXS peaks coincide for the different temperatures at a given inclusion concentration (e.g., in fig. 8 (left) at P/L = 0.178) whereas the profiles differ according to the gramicidin concentration for a given temperature (see fig. 8 (right) ).WAXSThese observations differ in presence of cholesterol where for one concentration of gramicidin inclusions (e.g., case of P/L = 0.082 in fig. 9 (left) ) at different temperatures, we observe two families in which the spectra are quasi identical: one group at low temperatures (0-30 \u2022 C) and another distinct group at higher temperatures (40-60 \u2022 C).", [["gramicidin", "CHEMICAL", 24, 34], ["DDAO", "CHEMICAL", 75, 79], ["gramicidin", "CHEMICAL", 98, 108], ["cholesterol", "CHEMICAL", 210, 221], ["cholesterol", "CHEMICAL", 234, 245], ["DDAO", "CHEMICAL", 251, 255], ["gramicidin", "CHEMICAL", 427, 437], ["cholesterol", "CHEMICAL", 543, 554], ["gramicidin", "CHEMICAL", 586, 596], ["DDAO", "CHEMICAL", 75, 79], ["cholesterol", "CHEMICAL", 210, 221], ["cholesterol", "CHEMICAL", 234, 245], ["DDAO", "CHEMICAL", 251, 255], ["cholesterol", "CHEMICAL", 543, 554], ["gramicidin", "SIMPLE_CHEMICAL", 24, 34], ["DDAO", "SIMPLE_CHEMICAL", 75, 79], ["gramicidin", "SIMPLE_CHEMICAL", 98, 108], ["cholesterol", "SIMPLE_CHEMICAL", 210, 221], ["WAXSWithout", "SIMPLE_CHEMICAL", 222, 233], ["cholesterol", "SIMPLE_CHEMICAL", 234, 245], ["DDAO", "SIMPLE_CHEMICAL", 251, 255], ["gramicidin", "SIMPLE_CHEMICAL", 427, 437], ["cholesterol", "SIMPLE_CHEMICAL", 543, 554], ["gramicidin", "SIMPLE_CHEMICAL", 586, 596], ["This gap widens", "PROBLEM", 0, 15], ["high gramicidin content", "PROBLEM", 19, 42], ["DDAO", "PROBLEM", 75, 79], ["gramicidin content", "TEST", 98, 116], ["the DDAO WAXS peaks", "PROBLEM", 247, 266], ["the different temperatures", "PROBLEM", 280, 306], ["inclusion concentration", "TREATMENT", 318, 341], ["the gramicidin concentration", "TREATMENT", 423, 451], ["gramicidin inclusions", "PROBLEM", 586, 607], ["widens", "OBSERVATION_MODIFIER", 9, 15], ["high", "OBSERVATION_MODIFIER", 19, 23], ["gramicidin content", "OBSERVATION", 24, 42], ["left", "ANATOMY_MODIFIER", 360, 364], ["right", "ANATOMY_MODIFIER", 489, 494]]], ["At 20 \u2022 C, the peaks for DDAO cholesterol tend to superpose for P/L > 0.028 (data not shown), whereas at 50 \u2022 C ( fig. 9 (right) ) the peak profiles differ and vary with P/L. For the DDAO system, the peak occurs at much lower q 0 with cholesterol than without: q 0 = 12.77 nm \u22121 at 20 \u2022 C, 12.62 nm \u22121 at 30 \u2022 C and 12.28 nm \u22121 at 50 \u2022 C. Thus, the cholesterol expands DDAO bilayers, in contrast with the condensing effect observed in lipid membranes [42, 43] .", [["lipid membranes", "ANATOMY", 435, 450], ["cholesterol", "CHEMICAL", 30, 41], ["cholesterol", "CHEMICAL", 235, 246], ["cholesterol", "CHEMICAL", 349, 360], ["cholesterol", "CHEMICAL", 30, 41], ["cholesterol", "CHEMICAL", 235, 246], ["cholesterol", "CHEMICAL", 349, 360], ["DDAO", "CHEMICAL", 369, 373], ["DDAO cholesterol", "SIMPLE_CHEMICAL", 25, 41], ["cholesterol", "SIMPLE_CHEMICAL", 235, 246], ["cholesterol", "SIMPLE_CHEMICAL", 349, 360], ["DDAO bilayers", "SIMPLE_CHEMICAL", 369, 382], ["lipid membranes", "CELLULAR_COMPONENT", 435, 450], ["DDAO cholesterol", "TEST", 25, 41], ["P/L", "TEST", 64, 67], ["the peak profiles", "TEST", 131, 148], ["the DDAO system", "TEST", 179, 194], ["cholesterol", "TEST", 235, 246], ["C", "TEST", 287, 288], ["C", "TEST", 310, 311], ["nm", "TEST", 322, 324], ["C.", "TEST", 336, 338], ["the cholesterol", "TEST", 345, 360], ["right", "ANATOMY_MODIFIER", 122, 127], ["lipid membranes", "OBSERVATION", 435, 450]]], ["More detailed molecular-scale studies would be needed to understand this phenomenon.WAXSWithout cholesterol, the width of the main peak in DDAO membranes is little affected by a temperature change, at least between 0 \u2022 C and 60 \u2022 C. Without gramicidin, we observe two distinct HWHM values: \u223c 2.38 nm \u22121 at the lower temperatures (between 0 \u2022 C and room temperature) and \u223c 2.5 nm \u22121 for higher temperatures (between 30 \u2022 C and 60 \u2022 C), but this gap closes with the addition of gramicidin, and at high P/L only an insignificant difference of 0.05 nm \u22121 persists ( fig. 7 (left) ).WAXSOn the other hand, at a given temperature the HWHM does vary as a function of P/L. This change is sigmoidal, with an average HWHM of \u223c 2.4 nm \u22121 for P/L < 0.05 and \u223c 2.7 nm \u22121 for P/L > 0.11.", [["DDAO membranes", "ANATOMY", 139, 153], ["cholesterol", "CHEMICAL", 96, 107], ["gramicidin", "CHEMICAL", 241, 251], ["gramicidin", "CHEMICAL", 476, 486], ["cholesterol", "CHEMICAL", 96, 107], ["WAXSWithout", "SIMPLE_CHEMICAL", 84, 95], ["cholesterol", "SIMPLE_CHEMICAL", 96, 107], ["DDAO membranes", "CELLULAR_COMPONENT", 139, 153], ["gramicidin", "SIMPLE_CHEMICAL", 241, 251], ["gramicidin", "SIMPLE_CHEMICAL", 476, 486], ["scale studies", "TEST", 24, 37], ["this phenomenon", "PROBLEM", 68, 83], ["cholesterol", "TEST", 96, 107], ["a temperature change", "PROBLEM", 176, 196], ["gramicidin", "TREATMENT", 241, 251], ["the lower temperatures", "TEST", 306, 328], ["room temperature", "TEST", 348, 364], ["\u223c", "TEST", 370, 371], ["higher temperatures", "PROBLEM", 386, 405], ["gramicidin", "TREATMENT", 476, 486], ["an average HWHM", "TEST", 696, 711], ["P", "TEST", 731, 732], ["\u223c", "TEST", 746, 747], ["P/L", "TEST", 762, 765], ["width", "OBSERVATION_MODIFIER", 113, 118], ["main", "OBSERVATION_MODIFIER", 126, 130], ["peak", "OBSERVATION_MODIFIER", 131, 135], ["DDAO membranes", "OBSERVATION", 139, 153], ["little", "OBSERVATION_MODIFIER", 157, 163], ["insignificant", "OBSERVATION_MODIFIER", 512, 525], ["difference", "OBSERVATION_MODIFIER", 526, 536], ["left", "ANATOMY_MODIFIER", 570, 574], ["sigmoidal", "OBSERVATION_MODIFIER", 680, 689]]], ["Thus, above this concentration, the gramicidin decreases slightly the positional order of the chains.WAXSAn opposite effect is observed in the presence of cholesterol ( fig. 10) , where at high temperature (40-60 \u2022 C) the HWHM drops with the P/L: for instance, from 2.37 nm \u22121 to 2.08 nm \u22121 at 60 \u2022 C. At low temperature (0-30 \u2022 C) there is no systematic dependence on P/L. Overall we can conclude that gramicidin addition has an effect that differs according to the membrane composition.", [["membrane", "ANATOMY", 467, 475], ["gramicidin", "CHEMICAL", 36, 46], ["cholesterol", "CHEMICAL", 155, 166], ["gramicidin", "CHEMICAL", 403, 413], ["cholesterol", "CHEMICAL", 155, 166], ["gramicidin", "SIMPLE_CHEMICAL", 36, 46], ["WAXSAn", "SIMPLE_CHEMICAL", 101, 107], ["cholesterol", "SIMPLE_CHEMICAL", 155, 166], ["HWHM", "SIMPLE_CHEMICAL", 222, 226], ["gramicidin", "SIMPLE_CHEMICAL", 403, 413], ["membrane", "CELLULAR_COMPONENT", 467, 475], ["the gramicidin", "TREATMENT", 32, 46], ["the HWHM drops", "PROBLEM", 218, 232], ["systematic dependence on P/L.", "PROBLEM", 344, 373], ["gramicidin", "TREATMENT", 403, 413], ["chains", "ANATOMY_MODIFIER", 94, 100], ["no", "UNCERTAINTY", 341, 343]]], ["The temperature has a significant influence only in the presence of cholesterol.", [["cholesterol", "CHEMICAL", 68, 79], ["cholesterol", "CHEMICAL", 68, 79], ["cholesterol", "SIMPLE_CHEMICAL", 68, 79], ["The temperature", "TEST", 0, 15], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["cholesterol", "OBSERVATION", 68, 79]]], ["In all surfactant systems and over the temperature range from 0 to 60 \u2022 C, the peak is broad, indicating that the alkyl chains are in the liquid crystalline state.", [["alkyl", "CHEMICAL", 114, 119], ["alkyl chains", "SIMPLE_CHEMICAL", 114, 126], ["all surfactant systems", "TREATMENT", 3, 25], ["the temperature range", "TEST", 35, 56], ["the alkyl chains", "PROBLEM", 110, 126], ["broad", "OBSERVATION_MODIFIER", 87, 92], ["alkyl chains", "OBSERVATION", 114, 126], ["liquid crystalline", "OBSERVATION", 138, 156]]], ["There are, however, subtle differences between the different compositions, as detailed below.WAXSIn C 12 EO 4 membranes, the peak position q 0 decreases very slightly with temperature, while the HWHM is almost unchanged by temperature or gramicidin content.WAXSFor DDAO (without cholesterol), q 0 also decreases with temperature at a given P/L, but increases with P/L at fixed temperature.", [["gramicidin", "CHEMICAL", 238, 248], ["DDAO", "CHEMICAL", 265, 269], ["cholesterol", "CHEMICAL", 279, 290], ["DDAO", "CHEMICAL", 265, 269], ["cholesterol", "CHEMICAL", 279, 290], ["gramicidin", "SIMPLE_CHEMICAL", 238, 248], ["WAXSFor", "SIMPLE_CHEMICAL", 257, 264], ["DDAO", "SIMPLE_CHEMICAL", 265, 269], ["cholesterol", "SIMPLE_CHEMICAL", 279, 290], ["the peak position", "TEST", 121, 138], ["temperature", "TEST", 172, 183], ["P/L at fixed temperature", "TREATMENT", 364, 388], ["subtle", "OBSERVATION_MODIFIER", 20, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38], ["different compositions", "OBSERVATION_MODIFIER", 51, 73], ["12 EO 4 membranes", "OBSERVATION_MODIFIER", 102, 119], ["unchanged", "OBSERVATION_MODIFIER", 210, 219]]], ["On adding gramicidin, the HWHM increases slightly with a sigmoidal dependence on P/L. Thus, a high gramicidin concentration P/L \u2265 0.1 reduces the positional order of the chains in DDAO bilayers.WAXSThe opposite behavior is measured in DDAO membranes with cholesterol.", [["DDAO membranes", "ANATOMY", 235, 249], ["gramicidin", "CHEMICAL", 10, 20], ["gramicidin", "CHEMICAL", 99, 109], ["cholesterol", "CHEMICAL", 255, 266], ["DDAO", "CHEMICAL", 180, 184], ["cholesterol", "CHEMICAL", 255, 266], ["gramicidin", "SIMPLE_CHEMICAL", 10, 20], ["HWHM", "SIMPLE_CHEMICAL", 26, 30], ["gramicidin", "SIMPLE_CHEMICAL", 99, 109], ["DDAO bilayers", "SIMPLE_CHEMICAL", 180, 193], ["DDAO membranes", "CELLULAR_COMPONENT", 235, 249], ["cholesterol", "SIMPLE_CHEMICAL", 255, 266], ["gramicidin", "TREATMENT", 10, 20], ["a sigmoidal dependence", "PROBLEM", 55, 77], ["P/L", "TREATMENT", 81, 84], ["a high gramicidin concentration P/L \u2265", "TREATMENT", 92, 129], ["sigmoidal dependence", "OBSERVATION", 57, 77]]], ["Adding gramicidin inclusions have two distinct behaviors depending on the temperature.", [["gramicidin", "CHEMICAL", 7, 17], ["gramicidin inclusions", "SIMPLE_CHEMICAL", 7, 28], ["gramicidin inclusions", "TREATMENT", 7, 28], ["the temperature", "TEST", 70, 85], ["two distinct", "OBSERVATION_MODIFIER", 34, 46]]], ["For low temperatures (between 0 \u2022 C and 30 \u2022 C) we have a small peptide concentration dependence and a clear temperature correlation, whereas at high temperatures (between 40 \u2022 C and 60 \u2022 C) we have a strong decrease in the HWHM in presence of inclusions depending only with the P/L content without any variation with the temperature rise.", [["HWHM", "SIMPLE_CHEMICAL", 224, 228], ["low temperatures", "PROBLEM", 4, 20], ["a small peptide concentration dependence", "PROBLEM", 56, 96], ["high temperatures", "TEST", 145, 162], ["a strong decrease in the HWHM", "PROBLEM", 199, 228], ["inclusions", "PROBLEM", 244, 254], ["the P/L content", "TREATMENT", 275, 290], ["the temperature rise", "PROBLEM", 318, 338], ["low temperatures", "OBSERVATION_MODIFIER", 4, 20], ["small peptide concentration dependence", "OBSERVATION_MODIFIER", 58, 96], ["strong", "OBSERVATION_MODIFIER", 201, 207], ["decrease", "OBSERVATION_MODIFIER", 208, 216], ["inclusions", "OBSERVATION", 244, 254]]], ["Since at P/L = 0 the HWHM value is very close for the different temperatures then we can conclude that adding gramicidin to a membrane containing cholesterol helps rigidify it.Comparing the NMR and WAXS resultsAlthough the orientational and positional order parameters are distinct physical parameters, one would expect them to be correlated (e.g., straighter molecules can be more tightly packed, as in the gel phase with respect to the fluid phase.)", [["membrane", "ANATOMY", 126, 134], ["gramicidin", "CHEMICAL", 110, 120], ["cholesterol", "CHEMICAL", 146, 157], ["cholesterol", "CHEMICAL", 146, 157], ["gramicidin", "SIMPLE_CHEMICAL", 110, 120], ["membrane", "CELLULAR_COMPONENT", 126, 134], ["cholesterol", "SIMPLE_CHEMICAL", 146, 157], ["straighter molecules", "PROTEIN", 349, 369], ["the HWHM value", "TEST", 17, 31], ["gramicidin", "TREATMENT", 110, 120], ["a membrane containing cholesterol", "TREATMENT", 124, 157], ["the NMR", "TEST", 186, 193], ["the fluid phase", "TEST", 434, 449]]], ["This tendency is indeed observed in our measurements, with the exception of DDAO.Comparing the NMR and WAXS resultsWe measured by NMR that the orientational order parameter for DMPC increases when adding P/L = 0.05 and slightly decreases at P/L = 0.1 ( fig. 3(a) ).", [["DDAO", "CHEMICAL", 76, 80], ["DMPC", "CHEMICAL", 177, 181], ["DDAO", "CHEMICAL", 76, 80], ["DMPC", "CHEMICAL", 177, 181], ["DDAO", "SIMPLE_CHEMICAL", 76, 80], ["DMPC", "SIMPLE_CHEMICAL", 177, 181], ["DDAO", "TREATMENT", 76, 80], ["the NMR", "TEST", 91, 98], ["DMPC", "TEST", 177, 181], ["P", "TEST", 204, 205], ["slightly decreases", "PROBLEM", 219, 237]]], ["This behavior was also measured by WAXS for the positional order parameter at both P/L values ( fig. 4 (right) ).", [["P/L values", "TEST", 83, 93], ["right", "ANATOMY_MODIFIER", 104, 109]]], ["Similarly, we measured for DLPC acyl chains the same orientational and positional order profiles where the order increases for P/L = 0.05 and remains the same when adding P/L = 0.1 gramicidin (figs.", [["gramicidin", "CHEMICAL", 181, 191], ["acyl", "CHEMICAL", 32, 36], ["gramicidin", "SIMPLE_CHEMICAL", 181, 191], ["DLPC acyl chains", "TREATMENT", 27, 43], ["P/L", "TREATMENT", 127, 130], ["gramicidin", "TREATMENT", 181, 191]]], ["3(b) and 4 (left)).Comparing the NMR and WAXS resultsAs for the C 12 EO 4 surfactant acyl chains, we found a modest raise in both the orientational and the positional order parameters when adding the gramicidin peptide with no dependence on the P/L molar ratio (figs.", [["gramicidin", "CHEMICAL", 200, 210], ["acyl", "CHEMICAL", 85, 89], ["gramicidin peptide", "SIMPLE_CHEMICAL", 200, 218], ["the NMR", "TEST", 29, 36], ["the C 12 EO 4 surfactant acyl chains", "TREATMENT", 60, 96], ["the gramicidin peptide", "TREATMENT", 196, 218], ["the P/L molar ratio", "TREATMENT", 241, 260], ["left", "ANATOMY_MODIFIER", 12, 16], ["modest", "OBSERVATION_MODIFIER", 109, 115]]], ["3(c) and 7 (right)).Comparing the NMR and WAXS resultsIn the case of DDAO we found that adding gramicidin significantly increases the orientational order ( fig. 3(d) ) and decreases the positional order ( fig. 7 (left) ).", [["gramicidin", "CHEMICAL", 95, 105], ["DDAO", "CHEMICAL", 69, 73], ["DDAO", "SIMPLE_CHEMICAL", 69, 73], ["gramicidin", "SIMPLE_CHEMICAL", 95, 105], ["the NMR", "TEST", 30, 37], ["gramicidin", "TREATMENT", 95, 105], ["right", "ANATOMY_MODIFIER", 12, 17], ["left", "ANATOMY_MODIFIER", 213, 217]]], ["Solidstate NMR also shows an abrupt change in the head group region when little GramA is added, followed by a more gradual ordering of the acyl chain when more GramA is added.", [["head", "ANATOMY", 50, 54], ["GramA", "CHEMICAL", 80, 85], ["GramA", "CHEMICAL", 160, 165], ["Solidstate", "CHEMICAL", 0, 10], ["GramA", "CHEMICAL", 80, 85], ["acyl", "CHEMICAL", 139, 143], ["GramA", "CHEMICAL", 160, 165], ["Solidstate", "SIMPLE_CHEMICAL", 0, 10], ["GramA", "SIMPLE_CHEMICAL", 80, 85], ["GramA", "SIMPLE_CHEMICAL", 160, 165], ["head group region", "PROTEIN", 50, 67], ["GramA", "PROTEIN", 80, 85], ["acyl chain", "PROTEIN", 139, 149], ["GramA", "PROTEIN", 160, 165], ["Solidstate NMR", "TEST", 0, 14], ["an abrupt change in the head group region", "PROBLEM", 26, 67], ["the acyl chain", "TREATMENT", 135, 149], ["abrupt", "OBSERVATION_MODIFIER", 29, 35], ["change", "OBSERVATION", 36, 42], ["head", "ANATOMY", 50, 54]]], ["This may imply a particular geometrical reorganisation of DDAO around the GramA inclusion that could be tested with molecular models.ConclusionsUsing solid-state NMR and wide-angle X-ray scattering, we showed that inserting Gramicidin A in lipid and surfactant bilayers modifies the local order of the constituent acyl chains depending on multiple factors.", [["DDAO", "CHEMICAL", 58, 62], ["Gramicidin A", "CHEMICAL", 224, 236], ["DDAO", "CHEMICAL", 58, 62], ["Gramicidin A", "CHEMICAL", 224, 236], ["acyl", "CHEMICAL", 314, 318], ["DDAO", "SIMPLE_CHEMICAL", 58, 62], ["GramA", "SIMPLE_CHEMICAL", 74, 79], ["Gramicidin A", "SIMPLE_CHEMICAL", 224, 236], ["lipid", "SIMPLE_CHEMICAL", 240, 245], ["surfactant bilayers", "SIMPLE_CHEMICAL", 250, 269], ["DDAO", "PROBLEM", 58, 62], ["the GramA inclusion", "TREATMENT", 70, 89], ["NMR", "TEST", 162, 165], ["wide-angle X-ray scattering", "TEST", 170, 197], ["inserting Gramicidin A in lipid and surfactant bilayers", "TREATMENT", 214, 269], ["the constituent acyl chains", "TREATMENT", 298, 325], ["acyl chains", "OBSERVATION", 314, 325]]], ["In particular, we studied the influence of membrane composition and temperature on the local order.ConclusionsThe behavior of this local order is quite rich, with significant differences between lipids, on the one hand, and single-tail surfactants, on the other, but also between DDAO and all the other systems.ConclusionsWe showed that adding gramicidin influences the orientational order of the acyl chains and we find a similar behavior for the orientational order and the positional order, except in the particular case of DDAO.ConclusionsIn this system, GramA content seems to notably influence the DDAO acyl chains by decreasing their positional order and increasing their orientational order.", [["membrane", "ANATOMY", 43, 51], ["gramicidin", "CHEMICAL", 344, 354], ["DDAO", "CHEMICAL", 527, 531], ["GramA", "CHEMICAL", 559, 564], ["DDAO acyl", "CHEMICAL", 604, 613], ["DDAO", "CHEMICAL", 280, 284], ["acyl", "CHEMICAL", 397, 401], ["DDAO", "CHEMICAL", 527, 531], ["GramA", "CHEMICAL", 559, 564], ["DDAO acyl", "CHEMICAL", 604, 613], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["lipids", "SIMPLE_CHEMICAL", 195, 201], ["DDAO", "SIMPLE_CHEMICAL", 280, 284], ["gramicidin", "SIMPLE_CHEMICAL", 344, 354], ["DDAO", "SIMPLE_CHEMICAL", 527, 531], ["GramA", "SIMPLE_CHEMICAL", 559, 564], ["DDAO acyl chains", "SIMPLE_CHEMICAL", 604, 620], ["DDAO", "PROTEIN", 527, 531], ["DDAO acyl chains", "PROTEIN", 604, 620], ["membrane composition", "TREATMENT", 43, 63], ["lipids", "TREATMENT", 195, 201], ["single-tail surfactants", "TREATMENT", 224, 247], ["gramicidin", "TREATMENT", 344, 354], ["the acyl chains", "TREATMENT", 393, 408], ["the DDAO acyl chains", "TREATMENT", 600, 620]]], ["GramA also influences the orientational order of the head groups.", [["head", "ANATOMY", 53, 57], ["GramA", "CHEMICAL", 0, 5], ["GramA", "CHEMICAL", 0, 5], ["GramA", "GENE_OR_GENE_PRODUCT", 0, 5], ["head", "ORGANISM_SUBDIVISION", 53, 57], ["GramA", "PROTEIN", 0, 5], ["head", "ANATOMY", 53, 57]]], ["Also in DDAO, we showed by WAXS that the temperature has a significant influence on the positional order only in the presence of cholesterol.ConclusionsIn the gel phase of DMPC, GramA addition leads to a linear decrease in positional order, saturating at the liquid phase value for a molar ratio P/L between 1/6 and 1/5.", [["cholesterol", "CHEMICAL", 129, 140], ["DMPC", "CHEMICAL", 172, 176], ["GramA", "CHEMICAL", 178, 183], ["cholesterol", "CHEMICAL", 129, 140], ["DMPC", "CHEMICAL", 172, 176], ["GramA", "CHEMICAL", 178, 183], ["DDAO", "SIMPLE_CHEMICAL", 8, 12], ["cholesterol", "SIMPLE_CHEMICAL", 129, 140], ["DMPC", "SIMPLE_CHEMICAL", 172, 176], ["GramA", "SIMPLE_CHEMICAL", 178, 183], ["the temperature", "TEST", 37, 52], ["DMPC", "TREATMENT", 172, 176], ["a linear decrease in positional order", "PROBLEM", 202, 239], ["a molar ratio", "TEST", 282, 295], ["cholesterol", "OBSERVATION", 129, 140], ["linear", "OBSERVATION_MODIFIER", 204, 210], ["decrease", "OBSERVATION_MODIFIER", 211, 219]]], ["In the liquid phase, we measure relatively small modifications in the local order in terms of position and orientation when adding Gramicidin A, especially in the case of DMPC, DLPC and C 12 EO 4 .", [["Gramicidin A", "CHEMICAL", 131, 143], ["DMPC", "CHEMICAL", 171, 175], ["Gramicidin A", "CHEMICAL", 131, 143], ["DMPC", "CHEMICAL", 171, 175], ["DLPC", "CHEMICAL", 177, 181], ["Gramicidin A", "SIMPLE_CHEMICAL", 131, 143], ["DMPC", "SIMPLE_CHEMICAL", 171, 175], ["Gramicidin A", "TREATMENT", 131, 143], ["liquid phase", "OBSERVATION_MODIFIER", 7, 19], ["small", "OBSERVATION_MODIFIER", 43, 48], ["modifications", "OBSERVATION", 49, 62]]], ["This is a very significant result, which allows further elaboration of elastic models in the presence of inclusions by using the same elastic constants obtained for bare membranes.ConclusionsAs seen above for DDAO, in some membranes the presence of inclusions influences differently the positional and orientational order of the acyl chains.", [["membranes", "ANATOMY", 170, 179], ["membranes", "ANATOMY", 223, 232], ["DDAO", "CHEMICAL", 209, 213], ["DDAO", "CHEMICAL", 209, 213], ["acyl", "CHEMICAL", 329, 333], ["membranes", "CELLULAR_COMPONENT", 170, 179], ["DDAO", "SIMPLE_CHEMICAL", 209, 213], ["membranes", "CELLULAR_COMPONENT", 223, 232], ["acyl chains", "PROTEIN", 329, 340], ["bare membranes", "TREATMENT", 165, 179], ["ConclusionsAs", "TEST", 180, 193], ["DDAO", "PROBLEM", 209, 213], ["inclusions influences", "PROBLEM", 249, 270], ["the acyl chains", "TREATMENT", 325, 340], ["elastic models", "OBSERVATION", 71, 85], ["inclusions", "OBSERVATION", 105, 115], ["inclusions", "OBSERVATION", 249, 259]]], ["Consequently, combining both techniques (NMR and WAXS) on the same system is very useful in obtaining a full image of the local order.", [["combining both techniques (NMR and WAXS)", "TEST", 14, 54]]], ["A more detailed analysis could be performed by comparing our results with molecular dynamics simulations.", [["A more detailed analysis", "TEST", 0, 24]]], ["The correlation between changes in the chain order and larger-scale parameters of the bilayer (e.g., the elastic properties) could be established by using dynamic techniques, such as neutron spin echo.", [["dynamic techniques", "TEST", 155, 173], ["neutron spin echo", "TEST", 183, 200], ["larger", "OBSERVATION_MODIFIER", 55, 61], ["bilayer", "ANATOMY_MODIFIER", 86, 93]]]]}